{"meta":{"query_hash":"35fb7377424e","filters":{"venue":"HemaSphere"},"cohort_total":321,"direct_labels_cover":0,"predictions_cover":321,"exported":321,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/35fb7377424e","api":"https://metacan.xera.ac/api/v1/cohort?venue=HemaSphere"},"results":[{"id":"W2793129204","doi":"10.1097/hs9.0000000000000033","title":"Identifying Educational Needs and Practice Gaps of European Hematologists and Hematology Nurses in the Treatment and Management of Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Axdev Group (Canada)","funders":"","keywords":"Medicine; Medical education","score_opus":0.048800714674720316,"score_gpt":0.3674418180071542,"score_spread":0.3186411033324339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793129204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98357844,0.004882742,0.000014053303,0.0011791377,0.000037849582,0.00057341944,0.0000067160645,0.000006488551,0.0097211385],"genre_scores_gemma":[0.99353284,0.0018504036,0.0040622307,0.00004522201,0.000024434545,0.000034101642,0.000012018754,0.000010379416,0.00042839145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990996,0.00016830943,0.00023056625,0.00018944297,0.00014644917,0.00016563052],"domain_scores_gemma":[0.9990402,0.00050599594,0.000104305516,0.00020762134,0.0000713296,0.000070583206],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022726918,0.000118486845,0.00024530478,0.00007163483,0.00005719128,0.000012675723,0.000049330032,0.000031811098,0.000040497536],"category_scores_gemma":[0.00015080239,0.00007704745,0.000022991182,0.0001458849,0.00035972538,0.00007085777,0.00005029034,0.000048826878,0.000005145138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015210247,0.0025836497,0.90853894,0.0023603188,0.0007740916,0.00048757688,0.01270615,2.3090163e-7,0.0021951348,0.015956808,0.00064406317,0.052232016],"study_design_scores_gemma":[0.0066854544,0.0013178444,0.95861447,0.0006906852,0.00025368558,0.002102121,0.019734154,0.00007114108,0.005725809,0.000326882,0.004343339,0.00013441907],"about_ca_topic_score_codex":0.00013435596,"about_ca_topic_score_gemma":0.00010348108,"teacher_disagreement_score":0.052097596,"about_ca_system_score_codex":0.000020281423,"about_ca_system_score_gemma":0.000023360688,"threshold_uncertainty_score":0.3141904},"labels":[],"label_agreement":null},{"id":"W2802748326","doi":"10.1097/hs9.0000000000000044","title":"Clinical Utility of Next‐generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single‐Center Experience","year":2018,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"European Hematology Association; Bristol-Myers Squibb","keywords":"Medicine; Myeloid; Oncology; Internal medicine; Myelofibrosis; DNA sequencing; Bioinformatics; Gene; Biology; Genetics; Bone marrow","score_opus":0.1708202741207578,"score_gpt":0.36932847587103346,"score_spread":0.19850820175027567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802748326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878242,0.0002688657,0.00028909458,0.00030544947,0.00014456939,0.00083863316,0.0000079283145,0.000012430983,0.010308806],"genre_scores_gemma":[0.9929632,0.0001710355,0.0060333107,0.00040379225,0.00016341379,0.0001339718,0.00001719484,0.000011931599,0.00010214883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807304,0.00018530244,0.0007632547,0.00037166517,0.00038863212,0.00021812905],"domain_scores_gemma":[0.9989189,0.0001235872,0.00021441965,0.00045652466,0.00022197214,0.00006460037],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045001548,0.00018427239,0.00044538057,0.00003523217,0.00006347735,0.000015611507,0.000121019584,0.00009227573,0.00049832347],"category_scores_gemma":[0.000060646194,0.00011914203,0.00012816314,0.00028174015,0.00030229613,0.000114571136,0.000054343178,0.00013709211,0.000014517723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008228398,0.0033449403,0.9203704,0.0005350121,0.00050158653,0.00017507604,0.024856877,0.000007659661,0.0069471155,0.006017476,0.001470758,0.034950253],"study_design_scores_gemma":[0.0139137935,0.0076322607,0.5448128,0.003388029,0.00056825037,0.00025527924,0.045763247,0.013116232,0.364021,0.00066601805,0.005114896,0.00074819976],"about_ca_topic_score_codex":0.000062773965,"about_ca_topic_score_gemma":0.00029167303,"teacher_disagreement_score":0.3755576,"about_ca_system_score_codex":0.000092664406,"about_ca_system_score_gemma":0.00010001836,"threshold_uncertainty_score":0.54562926},"labels":[],"label_agreement":null},{"id":"W2903296906","doi":"10.1097/hs9.0000000000000159","title":"Maintenance Therapy With Interleukin‐2 for Childhood AML","year":2018,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Assistance publique-Hôpitaux de Paris; Institut National Du Cancer; Fondation ARC pour la Recherche sur le Cancer; CNIB; Société Française de lutte contre les Cancers et les leucémies de l'Enfant et de l'Adolescent; Association Laurette Fugain","keywords":"Medicine; Cytarabine; Internal medicine; Mitoxantrone; Maintenance therapy; Acute myeloblastic leukemia; Population; Randomized controlled trial; Leukemia; Chemotherapy; Surgery; Oncology","score_opus":0.019421724370781965,"score_gpt":0.2944160902014198,"score_spread":0.2749943658306378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903296906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9227957,0.0009874717,0.008773375,0.006055968,0.0001790909,0.002358342,0.000021165872,0.00026716935,0.05856173],"genre_scores_gemma":[0.9596288,0.00011853716,0.016254283,0.0021767926,0.00095734757,0.00018149734,0.000017339265,0.000085523454,0.020579845],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987662,0.000017636718,0.00016182727,0.0003462934,0.00023456253,0.00047346734],"domain_scores_gemma":[0.9989161,0.00006429962,0.000052029285,0.0004799944,0.00032221913,0.00016536156],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015288679,0.00017624786,0.00027078608,0.000036242494,0.00009943518,0.000022974571,0.00016590659,0.00009096072,0.0009859445],"category_scores_gemma":[0.00008027049,0.00011278143,0.00008423054,0.00020900872,0.00023841533,0.000072434246,0.000038192524,0.00021550493,0.00024555039],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011861512,0.0012342553,0.015662262,0.0004737468,0.0010195326,0.00028253198,0.004884251,0.000001709473,0.019550316,0.004850725,0.6592826,0.2808965],"study_design_scores_gemma":[0.02119614,0.010225945,0.02894916,0.0008172078,0.00006681666,0.000786183,0.0015257599,0.0005430922,0.076645024,0.00077701616,0.8579211,0.0005465139],"about_ca_topic_score_codex":0.000025398118,"about_ca_topic_score_gemma":0.000034432345,"teacher_disagreement_score":0.28035,"about_ca_system_score_codex":0.0001580953,"about_ca_system_score_gemma":0.0003842227,"threshold_uncertainty_score":0.9999273},"labels":[],"label_agreement":null},{"id":"W2924768710","doi":"10.1097/hs9.0000000000000233","title":"AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor Cells","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"Blood Cancer UK; Medical Research Council; Bloodwise; Cancer Research UK","keywords":"Myeloproliferative neoplasm; Essential thrombocythemia; Polycythemia vera; Myeloid leukemia; Cancer research; Thrombopoietin receptor; Janus kinase 2; Myeloproliferative Disorders; Myelofibrosis; Tyrosine kinase; Stem cell; Haematopoiesis; Myeloid; Medicine; Polycythaemia; Biology; Immunology; Internal medicine; Receptor; Bone marrow; Thrombopoietin; Genetics","score_opus":0.0072144557509660635,"score_gpt":0.23445714613808136,"score_spread":0.22724269038711528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924768710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9526554,0.00033454134,0.000036445523,0.00071502937,0.0004217694,0.002757211,0.00004387188,0.0002208653,0.04281488],"genre_scores_gemma":[0.9875635,0.000079258476,0.0033259545,0.00079133897,0.0003976319,0.00046625076,0.00018087146,0.000082831124,0.0071123526],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99753976,0.00011591275,0.00049963914,0.0007655511,0.00052393664,0.0005551742],"domain_scores_gemma":[0.9983717,0.0002055468,0.00021427404,0.00042036688,0.00048401504,0.00030409356],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015359379,0.00048300583,0.0007053919,0.00007982283,0.00016177437,0.0000734248,0.000068629066,0.00023523533,0.002859322],"category_scores_gemma":[0.00010945392,0.00038797487,0.0002245085,0.00032889144,0.000089738285,0.00018787042,0.000067850066,0.0003484827,0.0024731932],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033170448,0.007183152,0.5788128,0.0020256424,0.0030245369,0.003002899,0.01595476,0.000161229,0.3210686,0.006892093,0.026914403,0.03164286],"study_design_scores_gemma":[0.00641612,0.0015606978,0.03548733,0.0007089083,0.00026219836,0.00024802875,0.0016314508,0.00030435744,0.94199485,0.0001866689,0.010606715,0.0005926678],"about_ca_topic_score_codex":0.00003809988,"about_ca_topic_score_gemma":0.000038915325,"teacher_disagreement_score":0.62092626,"about_ca_system_score_codex":0.00026998634,"about_ca_system_score_gemma":0.00030655906,"threshold_uncertainty_score":0.9998572},"labels":[],"label_agreement":null},{"id":"W2926447864","doi":"10.1097/hs9.0000000000000185","title":"CAR‐T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; Therakos; Celgene; Mallinckrodt Pharmaceuticals; Gilead Sciences; Sanofi; AOP Orphan; GlaxoSmithKline; Amgen","keywords":"Medicine; Chimeric antigen receptor; Cytokine release syndrome; Lymphoma; Hematopoietic stem cell transplantation; Cell therapy; Clinical trial; Oncology; Transplantation; Immunotherapy; Adverse effect; Blinatumomab; Immunology; Internal medicine; Stem cell; CD19; Antigen; Immune system; Biology","score_opus":0.05290399143292113,"score_gpt":0.3387629218292847,"score_spread":0.28585893039636356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2926447864","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035693434,0.9563654,0.0000016113712,0.000031314834,0.00021047094,0.002761345,0.000051564497,0.00006391559,0.036945023],"genre_scores_gemma":[0.00025602605,0.902877,0.000075574106,0.0001595306,0.00029333032,0.00015312292,0.00013273601,0.00024830134,0.09580443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966037,0.00029146307,0.00068005413,0.0009294572,0.0006045221,0.0008907802],"domain_scores_gemma":[0.9977859,0.0003353217,0.00022216169,0.0012477601,0.00008548494,0.00032332842],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00048521403,0.00073868094,0.0027852408,0.00021967014,0.00005583873,0.00006497814,0.0003341393,0.00076035666,0.0044196974],"category_scores_gemma":[0.00002753116,0.0005622981,0.0005514665,0.00059585104,0.000086488035,0.00006733076,0.00021158856,0.0007973171,0.00079722906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001364988,0.002843291,0.00017726839,0.03250128,0.00010859561,0.00038860567,0.00022047642,2.7476702e-8,0.00014366534,0.000016154214,0.003465016,0.95999914],"study_design_scores_gemma":[0.014862964,0.0003916089,0.000025576439,0.0043094587,0.00021898824,0.00011898431,0.00009912381,0.0000063374223,0.00010155037,0.0000073882634,0.9793566,0.0005014124],"about_ca_topic_score_codex":0.00012671588,"about_ca_topic_score_gemma":0.000050147322,"teacher_disagreement_score":0.9758916,"about_ca_system_score_codex":0.0003497485,"about_ca_system_score_gemma":0.00081952516,"threshold_uncertainty_score":0.99998075},"labels":[],"label_agreement":null},{"id":"W2947040488","doi":"10.1097/hs9.0000000000000250","title":"A Simple RNA Target Capture NGS Strategy for Fusion Genes Assessment in the Diagnostics of Pediatric B‐cell Acute Lymphoblastic Leukemia","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Associazione Italiana per la Ricerca sul Cancro; Canadian Thoracic Society","keywords":"Fusion gene; Computational biology; Gold standard (test); Gene; Fusion transcript; Fluorescence in situ hybridization; Molecular diagnostics; Biology; Bioinformatics; Medicine; Genetics; Internal medicine","score_opus":0.015764705861514582,"score_gpt":0.2963564559634752,"score_spread":0.28059175010196064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947040488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888364,0.0019662485,0.0023609719,0.00024489878,0.00017693419,0.0022305753,0.00013581343,0.00003748056,0.0040106485],"genre_scores_gemma":[0.99376124,0.0009889338,0.0031430002,0.0002649401,0.00035069988,0.0001775964,0.00017286107,0.000066843226,0.0010738684],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9973828,0.00010009997,0.0005697202,0.00046503078,0.00083893817,0.000643403],"domain_scores_gemma":[0.996828,0.0018854203,0.00021917441,0.00064917986,0.0002594392,0.00015876815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044529728,0.00031695343,0.0005870553,0.000117197254,0.00006740767,0.000032555305,0.00038920782,0.0002797641,0.00062900514],"category_scores_gemma":[0.00022079414,0.00021445149,0.00018625808,0.0005722733,0.00006811077,0.0000958833,0.00013314372,0.00037662944,0.00006573799],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050051548,0.0050205444,0.4400915,0.01734923,0.0010851243,0.002298074,0.007857784,0.025838083,0.13007173,0.005454456,0.3447693,0.01515904],"study_design_scores_gemma":[0.12639369,0.015512538,0.31138644,0.0013869851,0.005665294,0.0010221637,0.03792769,0.3804762,0.06763406,0.00822146,0.040042043,0.00433143],"about_ca_topic_score_codex":0.00018007404,"about_ca_topic_score_gemma":0.000043605796,"teacher_disagreement_score":0.35463813,"about_ca_system_score_codex":0.00091133843,"about_ca_system_score_gemma":0.0030489136,"threshold_uncertainty_score":0.8745078},"labels":[],"label_agreement":null},{"id":"W2949123848","doi":"10.1097/01.hs9.0000562148.00155.2f","title":"PS961 PATIENTS WITH RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA HAVE SHORT REMISSION DURATION WITH RE‐INDUCTION: A SINGLE CENTER EXPERIENCE","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Single Center; Immunophenotyping; Chemotherapy; Induction chemotherapy; Oncology; Gastroenterology; Immunology; Antigen","score_opus":0.014677957396985113,"score_gpt":0.2547064270067543,"score_spread":0.24002846960976917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949123848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876848,0.000026440355,0.00091202033,0.0003168004,0.00019858858,0.0011965744,0.000007829984,0.000173901,0.009483067],"genre_scores_gemma":[0.9877477,0.0000076382075,0.0042352136,0.00020211795,0.0001518405,0.00006746594,0.00017961625,0.00010424216,0.007304139],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99729526,0.00005419009,0.00036185927,0.00067917013,0.0011058586,0.00050366117],"domain_scores_gemma":[0.99830276,0.00005167598,0.00013099382,0.0007582584,0.00045689114,0.00029940295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009408527,0.00031768758,0.00039096863,0.00006420746,0.00013420843,0.00005020885,0.00015577281,0.00021234334,0.0008735015],"category_scores_gemma":[0.000063695144,0.00021091133,0.000058309895,0.00035275356,0.00013448205,0.0003931554,0.00007768471,0.00036531058,0.00020171239],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02819305,0.0019293858,0.80097467,0.00068501243,0.00082193635,0.0007179953,0.008077355,0.00014757016,0.10713425,0.00009275867,0.035006464,0.016219536],"study_design_scores_gemma":[0.12216395,0.033843324,0.3665773,0.010336972,0.0015763484,0.0027169962,0.020876694,0.014031942,0.35063568,0.00009320801,0.0722362,0.0049113645],"about_ca_topic_score_codex":0.000041790678,"about_ca_topic_score_gemma":0.000037532354,"teacher_disagreement_score":0.43439737,"about_ca_system_score_codex":0.0015956432,"about_ca_system_score_gemma":0.00064999337,"threshold_uncertainty_score":0.9564229},"labels":[],"label_agreement":null},{"id":"W2949128311","doi":"10.1097/01.hs9.0000567464.22478.55","title":"PB2247 ADJUSTED INDIRECT COMPARISON OF ELTROMBOPAG RELATIVE TO RITUXIMAB OR SPLENECTOMY IN SECOND LINE TREATMENT FOR CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Eltrombopag; Splenectomy; Medicine; Romiplostim; Rituximab; Thrombocytopenic purpura; Internal medicine; Thrombopoietin; Immune thrombocytopenia; Surgery; Gastroenterology; Platelet; Lymphoma; Spleen","score_opus":0.048526908402695745,"score_gpt":0.3407681379589744,"score_spread":0.2922412295562787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949128311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878459,0.005004257,0.0000349765,0.000245974,0.00012407043,0.00371335,0.000101383084,0.00004516744,0.002884917],"genre_scores_gemma":[0.9894943,0.00010959226,0.0016496871,0.000049135644,0.000036817466,0.00029115184,0.00023198279,0.000054725475,0.008082605],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820167,0.00004219952,0.0006308122,0.00047189067,0.00019983076,0.00045362514],"domain_scores_gemma":[0.9989156,0.00019647463,0.00020947418,0.00046349582,0.000087496315,0.00012746175],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000068951995,0.00034284196,0.0016793188,0.00012065164,0.000043029984,0.000010633893,0.00011059894,0.00017690628,0.0032395108],"category_scores_gemma":[0.00003816343,0.00024954655,0.00021280459,0.00041968672,0.00003287696,0.00012694721,0.00004461997,0.00015846621,0.00025208446],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042714674,0.048502605,0.3463153,0.007372175,0.011451672,0.0016744423,0.020522837,0.00082429784,0.28139862,0.0014729167,0.0054192943,0.23233116],"study_design_scores_gemma":[0.17829052,0.057562966,0.27093703,0.0033687453,0.0015905683,0.00025432487,0.003807809,0.0034751368,0.44707885,0.00046033584,0.031598695,0.0015750424],"about_ca_topic_score_codex":0.00019871928,"about_ca_topic_score_gemma":0.0030086027,"teacher_disagreement_score":0.23075612,"about_ca_system_score_codex":0.0006487195,"about_ca_system_score_gemma":0.00034427078,"threshold_uncertainty_score":0.99999565},"labels":[],"label_agreement":null},{"id":"W2949134677","doi":"10.1097/01.hs9.0000562560.17744.f0","title":"PS1066 AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN REFRACTORY LARGE B CELL LYMPHOMA: OUTCOMES IN PATIENTS ≥ OR < 65 YEARS OF AGE IN THE PIVOTAL PHASE 1/2 ZUMA‐1 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Leukapheresis; Lymphoma; Adverse effect; Gastroenterology; Phases of clinical research; Clinical endpoint; Oncology; Surgery; Chemotherapy; Clinical trial; Stem cell; CD34","score_opus":0.01893548555659678,"score_gpt":0.31333592288334955,"score_spread":0.29440043732675275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949134677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350935,0.00018922555,0.0000014015403,0.000081614366,0.00010795088,0.0022454641,0.00003642799,0.000021305466,0.0038072357],"genre_scores_gemma":[0.99493724,0.000032985758,0.00008854831,0.0002686058,0.000034064145,0.00008702492,0.000045891265,0.000056783138,0.004448834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680144,0.0003434559,0.0007417792,0.0005092434,0.00094421755,0.00065985933],"domain_scores_gemma":[0.9983939,0.00034784578,0.00015959307,0.0009094499,0.00007105456,0.00011813883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009184244,0.00028096169,0.0007971461,0.0002587881,0.000024959458,0.000017214601,0.0004510107,0.00019387374,0.00075105525],"category_scores_gemma":[0.0002662126,0.00019929075,0.000113770235,0.0008072819,0.00006570518,0.0001420625,0.0002199846,0.00055182393,0.00021219159],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020577966,0.028938137,0.9503882,0.00026033146,0.000049354658,0.0019236262,0.007067134,0.0000041384146,0.002326692,0.000012595592,0.0014135876,0.0055584405],"study_design_scores_gemma":[0.07196912,0.0028845107,0.9137741,0.00014529817,0.00002862822,0.0000052890728,0.007958993,0.00007652056,0.0007113544,0.000008929234,0.002185342,0.00025196376],"about_ca_topic_score_codex":0.0005447033,"about_ca_topic_score_gemma":0.0016924716,"teacher_disagreement_score":0.06991133,"about_ca_system_score_codex":0.0006126746,"about_ca_system_score_gemma":0.0004105758,"threshold_uncertainty_score":0.8223528},"labels":[],"label_agreement":null},{"id":"W2949201926","doi":"10.1097/01.hs9.0000561740.44478.b8","title":"S865 CHANGE IN CLONE SIZE DOES NOT PREDICT RISK OF MAJOR ADVERSE VASCULAR EVENTS: RESULTS FROM THE INTERNATIONAL PNH REGISTRY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"clone (Java method); Medicine; Logistic regression; Paroxysmal nocturnal hemoglobinuria; Lactate dehydrogenase; Poisson regression; Internal medicine; Biology; Population; Environmental health; Genetics","score_opus":0.012555608972821776,"score_gpt":0.2373896514976666,"score_spread":0.22483404252484485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949201926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99241436,0.0012845455,0.000004085093,0.0005941353,0.0012827495,0.00062140566,0.003076748,0.000034022472,0.0006879469],"genre_scores_gemma":[0.99673826,0.00013040921,0.00005452001,0.0001440713,0.000115339746,0.000065017666,0.00039354165,0.000013868768,0.0023449578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986359,0.00025678086,0.00046442848,0.0003356634,0.00010555597,0.00020169445],"domain_scores_gemma":[0.9982023,0.0006742563,0.00033900875,0.00070916093,0.000059343627,0.00001590989],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035066946,0.00014917502,0.00025821323,0.000019660783,0.00003736967,0.0000046106575,0.0005236277,0.0001313555,0.0062623275],"category_scores_gemma":[0.00047051167,0.00009717928,0.00015044698,0.00007292244,0.00006760847,0.0000895605,0.00021912776,0.0001940846,0.00044100924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013078441,0.0003219042,0.9536699,0.00006580449,0.0009013745,0.00000863018,0.001503264,0.000014900047,0.033169303,0.00017938482,0.008217938,0.0006397716],"study_design_scores_gemma":[0.0075307935,0.00007324043,0.94558537,0.0005131976,0.00012638954,0.000003896027,0.0020464843,0.00001861074,0.0101157315,0.00022098808,0.03356077,0.00020453586],"about_ca_topic_score_codex":0.0040970803,"about_ca_topic_score_gemma":0.0012442679,"teacher_disagreement_score":0.025342835,"about_ca_system_score_codex":0.000053871663,"about_ca_system_score_gemma":0.00003743531,"threshold_uncertainty_score":0.9946461},"labels":[],"label_agreement":null},{"id":"W2949220394","doi":"10.1097/01.hs9.0000561568.20578.1a","title":"S822 NIVOLUMAB AND BRENTUXIMAB VEDOTIN‐BASED, RESPONSE‐ADAPTED TREATMENT IN PRIMARY REFRACTORY AND IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN CHECKMATE 744","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Nivolumab; Refractory (planetary science); Cohort; Oncology; Salvage therapy; Regimen; Bendamustine; Surgery; Lymphoma; Chemotherapy; Rituximab; Cancer; Hodgkin lymphoma; Immunotherapy","score_opus":0.007223904925934763,"score_gpt":0.21527984959316313,"score_spread":0.20805594466722838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949220394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945047,0.0026434318,4.8340803e-7,0.0002906815,0.00007317557,0.0013647613,0.000021996384,0.00004206699,0.0010587337],"genre_scores_gemma":[0.998124,0.00047651798,0.00033584423,0.00019420794,0.000033798617,0.00018093074,0.000089019835,0.000060011465,0.0005056444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975625,0.00022924665,0.00053218025,0.00076402636,0.00040399408,0.0005080082],"domain_scores_gemma":[0.9987141,0.0003945341,0.00017317531,0.0004500549,0.000046095058,0.00022204807],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021718952,0.00043757775,0.0008029004,0.00030816364,0.000037076814,0.000028053906,0.000066030836,0.0002558246,0.00010109124],"category_scores_gemma":[0.000051842002,0.00033702556,0.00006388775,0.0004252423,0.00007896701,0.00018621987,0.00006178701,0.00017999606,0.00003652453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011548406,0.006463546,0.9611192,0.00020709637,0.00003564586,0.0005470249,0.00034716973,0.000008232826,0.00009866482,0.0000066053576,0.00010617189,0.019512288],"study_design_scores_gemma":[0.061002534,0.0033847329,0.93275404,0.0003916173,0.00008916572,0.000017715387,0.00013073572,0.00015286801,0.0001350851,0.000005615484,0.0016223199,0.0003135756],"about_ca_topic_score_codex":0.00034762183,"about_ca_topic_score_gemma":0.0008099673,"teacher_disagreement_score":0.04945413,"about_ca_system_score_codex":0.0018786045,"about_ca_system_score_gemma":0.00058930303,"threshold_uncertainty_score":0.99990815},"labels":[],"label_agreement":null},{"id":"W2949266517","doi":"10.1097/01.hs9.0000560668.77636.9b","title":"PF595 POMALIDOMIDE + BORTEZOMIB + LOW‐DOSE DEXAMETHASONE AFTER ONE PRIOR LINE OF THERAPY IN PATIENTS WITH LENALIDOMIDE‐PRETREATED MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 OPTIMISMM TRIAL","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Fleurimont; Centre Hospitalier Universitaire de Sherbrooke; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Dexamethasone; Bortezomib; Internal medicine; Population; Refractory (planetary science); Multiple myeloma; Phases of clinical research; Oncology; Surgery; Clinical trial","score_opus":0.018447104509424005,"score_gpt":0.2828985369928948,"score_spread":0.2644514324834708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949266517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947609,0.00044652063,0.00004400835,0.000085811545,0.000059615817,0.004252481,0.0001937133,0.000025799503,0.00013118667],"genre_scores_gemma":[0.9970156,0.00006736797,0.0018398484,0.00007028863,0.000037871527,0.00018475775,0.00023016555,0.000060139893,0.0004939525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99668294,0.00027589916,0.0008998054,0.0005778322,0.00102508,0.00053842476],"domain_scores_gemma":[0.99735767,0.00037381085,0.00046091064,0.0011560518,0.00042053475,0.0002309962],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036444928,0.0003955156,0.0014663227,0.00032718293,0.000041061317,0.000016296883,0.00024693945,0.00019829976,0.0016282802],"category_scores_gemma":[0.0002748414,0.00023996047,0.00048910076,0.0018500544,0.0001853254,0.00014153552,0.00009162814,0.00030904292,0.000015582411],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28270623,0.0077539915,0.69397235,0.00014310301,0.003396748,0.0000381481,0.0002655059,0.00023579488,0.004440411,0.0000022957,0.000012214218,0.0070332],"study_design_scores_gemma":[0.3162293,0.004155325,0.6523708,0.00032859677,0.00086438307,0.0000013198355,0.00007607182,0.0022653274,0.023488894,0.0000024732383,0.000017677783,0.00019978534],"about_ca_topic_score_codex":0.0007052034,"about_ca_topic_score_gemma":0.0004699089,"teacher_disagreement_score":0.041601546,"about_ca_system_score_codex":0.00016074763,"about_ca_system_score_gemma":0.00022457483,"threshold_uncertainty_score":0.9992844},"labels":[],"label_agreement":null},{"id":"W2949279564","doi":"10.1097/01.hs9.0000561604.66251.2e","title":"S831 CPI‐0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) INHIBITOR, REDUCES PRO‐INFLAMMATORY CYTOKINES, BONE MARROW FIBROSIS AND THE NUMBER OF TRANSFUSIONS IN MYELOFIBROSIS PATIENTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Myeloproliferative neoplasm; Ruxolitinib; Bone marrow; Anemia; Internal medicine; Cancer research","score_opus":0.0057436719220246395,"score_gpt":0.22666235977413904,"score_spread":0.2209186878521144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949279564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940589,0.0011449317,0.0000020441485,0.00037795486,0.00008665022,0.0016733714,0.00003513505,0.000032986696,0.0025880313],"genre_scores_gemma":[0.99640596,0.00026675622,0.0016640733,0.000058468548,0.000061741026,0.00013708281,0.00002992883,0.000050798502,0.001325172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978751,0.00015990288,0.00061452657,0.000517987,0.00044056363,0.0003919145],"domain_scores_gemma":[0.99893665,0.00019982764,0.00018501013,0.0004412843,0.000071353505,0.00016589307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030019463,0.0003413877,0.0007146267,0.00006380912,0.00008645154,0.000027022414,0.00009492421,0.00021346664,0.00056893186],"category_scores_gemma":[0.000042964046,0.00023710227,0.00012080289,0.00025329666,0.0003708327,0.00017410691,0.00009178545,0.00026384552,0.000026569041],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042401673,0.00058912655,0.8706703,0.0015940279,0.00019002918,0.00009515046,0.0046028555,0.0000020310977,0.107264176,0.00058520195,0.0009035854,0.009263345],"study_design_scores_gemma":[0.068672456,0.00089340145,0.8905321,0.0038026716,0.00044610695,0.00055427005,0.002458025,0.00018477296,0.028235834,0.0014084477,0.002026658,0.00078530796],"about_ca_topic_score_codex":0.00028256187,"about_ca_topic_score_gemma":0.00014277341,"teacher_disagreement_score":0.07902834,"about_ca_system_score_codex":0.00022937068,"about_ca_system_score_gemma":0.00023659214,"threshold_uncertainty_score":0.966875},"labels":[],"label_agreement":null},{"id":"W2949283805","doi":"10.1097/01.hs9.0000564528.96696.2c","title":"PS1570 PENTRAXIN-3 LEVEL AS A NOVEL VASCULAR ENDOTHELIAL MARKER IN NEWLY DIAGNOSED AND MULTI-TRANSFUSED PATIENTS WITH B-THALASSEMIA MAJOR: RELATION TO OXIDATIVE STRESS AND SUB-CLINICAL ATHEROSCLEROSIS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Biomarkers in Disease Mechanisms","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Internal medicine; Oxidative stress; Gastroenterology; Endothelial dysfunction; Coronary artery disease; Thalassemia; Ferritin; Disease; Inflammation; Lipid profile; Biomarker; Cardiology; Immunology; Cholesterol","score_opus":0.01603195702708122,"score_gpt":0.24188225008250025,"score_spread":0.22585029305541904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949283805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631786,0.0003451136,0.0011543545,0.000054463584,0.00028110505,0.0013966559,0.0003064554,0.00004126394,0.000102706836],"genre_scores_gemma":[0.9967484,0.000088909466,0.0024492638,0.00016593566,0.000011309822,0.00007957872,0.00011291072,0.00004222987,0.0003014834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816644,0.00025352516,0.00039249475,0.00070008857,0.00009902616,0.00038842543],"domain_scores_gemma":[0.99897593,0.00038331343,0.000120393306,0.00034859174,0.00007473658,0.00009704214],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026369968,0.00030432583,0.00042421164,0.00006286104,0.00008347395,0.000028776105,0.00014536553,0.00042142707,0.00050215994],"category_scores_gemma":[0.00014807805,0.00026432506,0.000077282006,0.00014990677,0.00015068661,0.00017276137,0.000096245254,0.0003243035,0.00014729788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012095375,0.00084963744,0.8994011,0.00006166744,0.0002887377,0.0000041761245,0.0005986614,0.0000030692784,0.095167466,0.00008747824,0.00007569578,0.0022527336],"study_design_scores_gemma":[0.018275281,0.00043877622,0.9623119,0.00030492927,0.00009197392,0.0000033400133,0.00038442118,0.000019217461,0.017608475,0.000020172349,0.00020721466,0.00033429338],"about_ca_topic_score_codex":0.00025422825,"about_ca_topic_score_gemma":0.00069560757,"teacher_disagreement_score":0.07755899,"about_ca_system_score_codex":0.00005634101,"about_ca_system_score_gemma":0.000059439106,"threshold_uncertainty_score":0.99998087},"labels":[],"label_agreement":null},{"id":"W2949315927","doi":"10.1097/01.hs9.0000563256.18006.bf","title":"PS1244 REAL‐WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) OF PATIENTS DIAGNOSED WITH CLASSICAL HODGKIN LYMPHOMA (CHL) TREATED WITH ANTI‐PD1 CHECKPOINT INHIBITORS IN THE UNITED STATES (US)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Pembrolizumab; Nivolumab; Pediatrics; Internal medicine; Retrospective cohort study; Cancer; Immunotherapy","score_opus":0.01748511497946377,"score_gpt":0.25687475519915653,"score_spread":0.23938964021969278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949315927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994825,0.00017609417,0.0000022904676,0.0011434613,0.000025286543,0.0016868977,0.00004636877,0.00006798121,0.0020266299],"genre_scores_gemma":[0.99723953,0.00021543122,0.000114231436,0.0006105087,0.00003664874,0.00013396589,0.0012722417,0.000059105605,0.00031832373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99768794,0.00021847185,0.00053360395,0.00048338837,0.0006637358,0.00041288225],"domain_scores_gemma":[0.9984228,0.00026305634,0.00030294355,0.0006089635,0.00024277202,0.00015946855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016106287,0.0003548286,0.00061268156,0.0001837151,0.000072000854,0.000027638558,0.00012479011,0.00012824319,0.00010000399],"category_scores_gemma":[0.00003162806,0.00019359041,0.0000866435,0.0014562956,0.00013042132,0.0000864634,0.00003460504,0.00012890087,0.000020040483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012345207,0.0023112954,0.9887163,0.00026167874,0.000109448825,0.0001574063,0.0013226644,0.00011651688,0.000020562557,0.00018631828,0.0011411855,0.0044221263],"study_design_scores_gemma":[0.013092466,0.0027090851,0.9681856,0.0012461476,0.00014454497,0.000013554883,0.0020541386,0.00039882853,0.003487175,0.000008452409,0.008430016,0.00022997695],"about_ca_topic_score_codex":0.0062327846,"about_ca_topic_score_gemma":0.004097967,"teacher_disagreement_score":0.020530662,"about_ca_system_score_codex":0.00036465653,"about_ca_system_score_gemma":0.00017848719,"threshold_uncertainty_score":0.9422147},"labels":[],"label_agreement":null},{"id":"W2949392892","doi":"10.1097/01.hs9.0000559456.76601.13","title":"PF311 ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) ‐ AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Adrenal and Paraganglionic Tumors","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; Adrenal gland; Malignancy; Retrospective cohort study; Pathological; Internal medicine; Pathology","score_opus":0.012245290450787902,"score_gpt":0.26510805859907816,"score_spread":0.25286276814829023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949392892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871009,0.00024990478,0.000039736817,0.00007803736,0.00029699408,0.001054466,0.00003986863,0.000121696685,0.011018415],"genre_scores_gemma":[0.9935338,0.0000056572444,0.00035880913,0.0001673894,0.00016231937,0.00001681294,0.00008638576,0.000051623436,0.0056172223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99756616,0.00011474554,0.00066979206,0.0006342304,0.00058988424,0.00042520522],"domain_scores_gemma":[0.9984023,0.000053067186,0.00030840037,0.00073815085,0.0002704032,0.00022765536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030547025,0.00030679372,0.0006921024,0.00010258225,0.00007983613,0.000019032872,0.00019079504,0.00012815227,0.0008663218],"category_scores_gemma":[0.00007779609,0.00025706348,0.00018393842,0.00045476275,0.0000693856,0.00024636334,0.00012014705,0.00014170978,0.00023984832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026339136,0.015508524,0.8962337,0.00089643855,0.0013841348,0.0063084085,0.02201779,0.00008085448,0.007841806,0.00027980463,0.0026848412,0.02042459],"study_design_scores_gemma":[0.0271154,0.003565228,0.9574699,0.00047248142,0.00026542624,0.00052716304,0.004915339,0.0016175841,0.0030219757,0.00004617876,0.00056864007,0.0004146879],"about_ca_topic_score_codex":0.0004778254,"about_ca_topic_score_gemma":0.00014593886,"teacher_disagreement_score":0.06123622,"about_ca_system_score_codex":0.00023432232,"about_ca_system_score_gemma":0.0001860274,"threshold_uncertainty_score":0.99998814},"labels":[],"label_agreement":null},{"id":"W2949420727","doi":"10.1097/01.hs9.0000564700.06449.e7","title":"S1613 ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION CAN ABROGATE INCREASING RISK OF RELAPSE FROM PERSISTENT MUTATIONS MEASURED BY TARGETED SEQUENCING AT REMISSION IN NORMAL KARYOTYPE ACUTE MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Oncology; Cumulative incidence; Medicine; Internal medicine; Hazard ratio; Minimal residual disease; Myeloid leukemia; Proportional hazards model; Hematopoietic stem cell transplantation; Transplantation; Myeloid; Leukemia; Immunology; Confidence interval","score_opus":0.011044685027055674,"score_gpt":0.2357432481250833,"score_spread":0.22469856309802763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949420727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99477637,0.0016121096,0.00008476891,0.0001787603,0.000092948496,0.00090170157,0.00027816894,0.00007527033,0.0019998932],"genre_scores_gemma":[0.9916031,0.000848123,0.0037391149,0.000084390456,0.00003314738,0.000029542285,0.0013787311,0.00008181693,0.0022020726],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969289,0.0003671334,0.0007205624,0.00061827665,0.00079670426,0.00056846556],"domain_scores_gemma":[0.99831474,0.00025124685,0.0003273019,0.0005653007,0.0002170495,0.00032435465],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005827409,0.00034290718,0.0006334048,0.00015412287,0.0001444727,0.000018112518,0.00021025863,0.00034300267,0.00087491487],"category_scores_gemma":[0.00013315165,0.000323554,0.00024356709,0.00052639656,0.00009799665,0.00016886408,0.000072451454,0.0006860589,0.00010939568],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015369635,0.00006490703,0.1307629,0.0004496969,0.00022129208,0.00019223399,0.0043130624,0.0013890222,0.8603316,0.0000028075108,0.00036397853,0.0003715593],"study_design_scores_gemma":[0.011241551,0.00059753325,0.071602345,0.0013778387,0.0013230364,0.00042962458,0.006442792,0.008536645,0.89738494,0.00005969678,0.0002834679,0.0007205581],"about_ca_topic_score_codex":0.008813262,"about_ca_topic_score_gemma":0.0007171648,"teacher_disagreement_score":0.059160557,"about_ca_system_score_codex":0.0031204,"about_ca_system_score_gemma":0.0010467017,"threshold_uncertainty_score":0.9999217},"labels":[],"label_agreement":null},{"id":"W2949444368","doi":"10.1097/01.hs9.0000561592.51072.9b","title":"S828 A RANDOMIZED, DOUBLE BLIND PHASE 2 STUDY OF 3 DIFFERENT DOSES OF PRM‐151 IN PATIENTS WITH MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH OR INELIGIBLE FOR RUXOLITINIB","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Essential thrombocythemia; Internal medicine; Randomization; Bone marrow; Polycythemia vera; Gastroenterology; Randomized controlled trial; Anemia","score_opus":0.031235462883460782,"score_gpt":0.3296657506900283,"score_spread":0.2984302878065675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949444368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98188585,0.0001348473,0.000012124741,0.000029009962,0.000019247751,0.016455403,0.000033372857,0.000029175097,0.00140094],"genre_scores_gemma":[0.98883843,0.000041200667,0.00016588645,0.000013555251,0.000028399247,0.00089735,0.00008452416,0.00008081189,0.009849867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997447,0.00013486133,0.0007398194,0.00047809753,0.00073595723,0.0004642553],"domain_scores_gemma":[0.99800646,0.00037448332,0.0003316171,0.0006615399,0.0004655835,0.00016030484],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032623994,0.00034802422,0.0018759411,0.00018304716,0.000029380792,0.000018238443,0.00016204463,0.00010937077,0.0021442124],"category_scores_gemma":[0.00005312975,0.00018875452,0.00014890893,0.000515019,0.0001296993,0.000098377095,0.000053953525,0.0001900488,0.0000043678638],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69073164,0.0072963284,0.2959671,0.00126226,0.0004859821,0.000006857167,0.0015579554,0.000010965511,0.0011711885,0.00001568151,0.00008123071,0.001412789],"study_design_scores_gemma":[0.93853724,0.026462601,0.008935053,0.0018013589,0.00040308328,0.000003967467,0.0018775786,0.00011347451,0.021509368,0.0000088704855,0.000097068754,0.00025031142],"about_ca_topic_score_codex":0.00046183597,"about_ca_topic_score_gemma":0.00042347505,"teacher_disagreement_score":0.28703204,"about_ca_system_score_codex":0.00009242212,"about_ca_system_score_gemma":0.00019288994,"threshold_uncertainty_score":0.998768},"labels":[],"label_agreement":null},{"id":"W2949456808","doi":"10.1097/01.hs9.0000566328.51622.ab","title":"PB1958 SUDDEN ONSET HEARING AND VISUAL LOSS: AN UNUSUAL PRESENTATION OF CHRONIC PHASE CHRONIC MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Hearing loss; Sensorineural hearing loss; Tinnitus; Vertigo; Chronic myelogenous leukemia; Pediatrics; Audiology; Surgery; Leukemia; Internal medicine","score_opus":0.01761472004695952,"score_gpt":0.3226365060866205,"score_spread":0.30502178603966096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949456808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99401593,0.002876875,0.00007171827,0.0000821399,0.0001649566,0.0010283915,0.000025262014,0.00010510507,0.0016296197],"genre_scores_gemma":[0.9959463,0.0002668086,0.00030450904,0.000052973563,0.00037116124,0.000037798123,0.00025807152,0.00007372625,0.002688663],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99786395,0.00007743591,0.00048437927,0.0006017213,0.0004709778,0.00050156016],"domain_scores_gemma":[0.9988121,0.00010091184,0.0002015166,0.0005150175,0.000093599,0.00027690225],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017721928,0.00032451432,0.00059229136,0.00009385812,0.000071284936,0.00002862364,0.00011084377,0.00020659858,0.0018053561],"category_scores_gemma":[0.00003801988,0.00030957587,0.00010819813,0.00024601258,0.00015588805,0.00034240392,0.0001072058,0.00029956794,0.00019274635],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00426147,0.0040528825,0.27774712,0.008449307,0.0017806242,0.0008401483,0.0037848656,0.0007846051,0.39964992,0.0006699131,0.00356929,0.29440984],"study_design_scores_gemma":[0.1426731,0.03268188,0.19933096,0.0041132285,0.0016877488,0.0028635017,0.0037731943,0.112478055,0.4877296,0.00027832435,0.010072928,0.002317471],"about_ca_topic_score_codex":0.0006799405,"about_ca_topic_score_gemma":0.0003014803,"teacher_disagreement_score":0.29209235,"about_ca_system_score_codex":0.002749033,"about_ca_system_score_gemma":0.0019523137,"threshold_uncertainty_score":0.9999356},"labels":[],"label_agreement":null},{"id":"W2949508612","doi":"10.1097/01.hs9.0000567684.54373.e5","title":"PB2304 CRIZANLIZUMAB DOSE CONFIRMATION IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE: SOLACE‐KIDS TRIAL DESIGN","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation","funders":"","keywords":"Medicine; Acute chest syndrome; Dosing; Placebo; Sickle cell anemia; Inflammation; Disease; Adverse effect; Internal medicine; Immunology; Gastroenterology; Pathology","score_opus":0.006921737993898245,"score_gpt":0.2106317121253292,"score_spread":0.20370997413143094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949508612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98856896,0.0010724602,0.00031526684,0.00018625958,0.00032675627,0.0024259274,0.000007244113,0.00007642769,0.0070207035],"genre_scores_gemma":[0.9967613,0.00009749799,0.00041889356,0.00017715516,0.00010342627,0.000044922654,0.00009009272,0.000044015535,0.002262674],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9985135,0.00007999041,0.00033683545,0.00032338404,0.00039939312,0.00034685744],"domain_scores_gemma":[0.99915713,0.0000612103,0.00012291885,0.00033572552,0.00009639549,0.00022663482],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012233674,0.0002184051,0.00032424336,0.000076897544,0.000046623594,0.000022615804,0.000080326434,0.00016789538,0.001002691],"category_scores_gemma":[0.00004482851,0.0001634297,0.000076729826,0.0003709598,0.000029760211,0.00013984539,0.000025626478,0.00027603196,0.0004990639],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25431365,0.009040806,0.6932665,0.003646028,0.00014926054,0.0003160442,0.003095139,0.004668443,0.00024473353,0.00032827136,0.022674987,0.008256139],"study_design_scores_gemma":[0.6751129,0.010663959,0.28750548,0.0007513131,0.0011208255,0.000009148156,0.0016669692,0.007007777,0.0003689192,0.00028419716,0.013723752,0.0017847391],"about_ca_topic_score_codex":0.00002481683,"about_ca_topic_score_gemma":0.0000045423326,"teacher_disagreement_score":0.42079926,"about_ca_system_score_codex":0.00009316418,"about_ca_system_score_gemma":0.00032241223,"threshold_uncertainty_score":0.99991053},"labels":[],"label_agreement":null},{"id":"W2949512078","doi":"10.1097/01.hs9.0000563628.38037.c3","title":"PS1337 IVOSIDENIB (AG‐120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1‐MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME IN A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Isocitrate dehydrogenase; Medicine; IDH1; Internal medicine; Myelodysplastic syndromes; Refractory (planetary science); Myeloid leukemia; Bone marrow; Gastroenterology; Oncology; Pharmacodynamics; Pharmacokinetics; International Prognostic Scoring System; Mutant; Chemistry; Biology; Gene","score_opus":0.011476636537717237,"score_gpt":0.26962185674816475,"score_spread":0.2581452202104475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949512078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967327,0.00019712851,0.000016113128,0.00013009243,0.00005345433,0.0026165268,0.000007055497,0.00003821689,0.00020872826],"genre_scores_gemma":[0.9992294,0.0001462151,0.00017742494,0.000032483873,0.00001286473,0.000066296634,0.000024616218,0.000047620273,0.0002631042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973524,0.00017337644,0.00049710594,0.00071528857,0.0008287158,0.00043309198],"domain_scores_gemma":[0.9988619,0.00023690729,0.00011063708,0.00039690608,0.00011832143,0.00027532782],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047089,0.00029383943,0.0005442764,0.00028772323,0.00009644003,0.000037473288,0.00010156811,0.00027013215,0.00041421867],"category_scores_gemma":[0.00018015278,0.00022493552,0.000023661358,0.00064439717,0.0000796114,0.0004884906,0.00009299112,0.00096506695,0.000021541133],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040648854,0.0022624661,0.92361915,0.00029628866,0.000033043187,0.00064023794,0.0030446134,0.000029988718,0.060457636,0.0000062933477,0.000020599924,0.0055247694],"study_design_scores_gemma":[0.031478286,0.004720445,0.9567696,0.0014980384,0.000054979035,0.00013656908,0.00309686,0.0009280376,0.0009846793,0.000026730864,0.00001824354,0.00028754372],"about_ca_topic_score_codex":0.0004515342,"about_ca_topic_score_gemma":0.00045094785,"teacher_disagreement_score":0.059472956,"about_ca_system_score_codex":0.00032059863,"about_ca_system_score_gemma":0.00032692906,"threshold_uncertainty_score":0.91726047},"labels":[],"label_agreement":null},{"id":"W2949669015","doi":"10.1097/01.hs9.0000562584.48238.c8","title":"PS1073 PRELIMINARY RESULTS OF ASTX660, A NOVEL NON‐PEPTIDOMIMETIC CIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphoma; Mycosis fungoides; Internal medicine; Refractory (planetary science); Adverse effect; Peripheral T-cell lymphoma; Cutaneous T-cell lymphoma; Brentuximab vedotin; Oncology; Gastroenterology; T cell; Immunology; Hodgkin lymphoma; Immune system","score_opus":0.010926125519944384,"score_gpt":0.2491841757747903,"score_spread":0.23825805025484592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949669015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547735,0.0035213185,0.00000940207,0.00015061973,0.00013791931,0.0012742354,0.00005424823,0.00004860329,0.04003015],"genre_scores_gemma":[0.94295025,0.0006622133,0.00115912,0.00014797675,0.0001180129,0.000030375133,0.000032736454,0.000117840835,0.054781478],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99677795,0.00011068261,0.00079724955,0.0009265444,0.00066446955,0.0007231284],"domain_scores_gemma":[0.99791807,0.00040427034,0.00025870636,0.0009019497,0.00015077772,0.00036622965],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043071204,0.0004665877,0.00094731024,0.00019030795,0.000075386626,0.000046639463,0.00022016357,0.00039452408,0.0010327926],"category_scores_gemma":[0.00007979331,0.00044166262,0.00015372632,0.000399345,0.00032701693,0.00011911754,0.00024828987,0.00032303226,0.00006416282],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023766695,0.0032674135,0.0104048345,0.0019221911,0.00009066265,0.00068366725,0.0034671838,0.000036813228,0.923413,0.0000118159,0.001188073,0.03174767],"study_design_scores_gemma":[0.23333423,0.028843489,0.088538356,0.0028724498,0.00044355562,0.0075263404,0.010326814,0.018469142,0.56149715,0.00013679692,0.045404278,0.002607384],"about_ca_topic_score_codex":0.00047519436,"about_ca_topic_score_gemma":0.0000673755,"teacher_disagreement_score":0.3619158,"about_ca_system_score_codex":0.00033590192,"about_ca_system_score_gemma":0.0004550919,"threshold_uncertainty_score":0.9998804},"labels":[],"label_agreement":null},{"id":"W2949673037","doi":"10.1097/01.hs9.0000558628.70462.93","title":"S102 POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) AND LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): INTERIM ANALYSIS OF A PHASE IB/II TRIAL","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Internal medicine; Tolerability; Regimen; Follicular lymphoma; Interim analysis; Gastroenterology; Rituximab; Adverse effect; Lymphoma; Clinical trial","score_opus":0.01006676472665592,"score_gpt":0.25852921532171413,"score_spread":0.24846245059505823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949673037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544936,0.0014669898,0.0000072579696,0.00006354825,0.00015851433,0.001398675,0.000049510258,0.00003907076,0.0013670631],"genre_scores_gemma":[0.99853426,0.00010864067,0.00030222832,0.00013870923,0.00005130354,0.00009679116,0.00019141355,0.00004893179,0.00052771997],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99753743,0.00010693078,0.0007298122,0.0006643144,0.00055186154,0.00040964497],"domain_scores_gemma":[0.9984018,0.00013505053,0.00037763413,0.000713316,0.00013934699,0.0002328409],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015915016,0.00041161,0.0013353392,0.00032834386,0.00006500047,0.000024763185,0.000121552366,0.00021184271,0.00059520506],"category_scores_gemma":[0.00007011849,0.00030707082,0.00035370124,0.00086080766,0.00009045954,0.00019190292,0.00010692671,0.00012804226,0.000030235964],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1827724,0.026048196,0.723432,0.0005365716,0.010251862,0.00049897196,0.0034462698,0.000094379844,0.0020452952,0.00047326396,0.00096498674,0.049435783],"study_design_scores_gemma":[0.72674745,0.025979958,0.22746566,0.0011070097,0.006003597,0.000026824118,0.0010135808,0.0013718166,0.0044571944,0.000028073851,0.0050571696,0.00074166706],"about_ca_topic_score_codex":0.0009013801,"about_ca_topic_score_gemma":0.0002677297,"teacher_disagreement_score":0.54397506,"about_ca_system_score_codex":0.0010398881,"about_ca_system_score_gemma":0.00038336802,"threshold_uncertainty_score":0.99993813},"labels":[],"label_agreement":null},{"id":"W2949689749","doi":"10.1097/01.hs9.0000566416.30505.81","title":"PB1980 IMPROVING HEALTHCARE PROVIDERS’ KNOWLEDGE REGARDING THE PRINCIPLES OF GENE THERAPY FOR HEMOPHILIA THROUGH ONLINE EDUCATION","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Biomedical and Engineering Education","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Hemophilia Society","funders":"","keywords":"Haemophilia; Medicine; Curriculum; Continuing medical education; Certification; Test (biology); Health care; Family medicine; Multiple choice; Medical education; Continuing education; Internal medicine; Pediatrics; Psychology; Significant difference","score_opus":0.02563213125077249,"score_gpt":0.2677342574249516,"score_spread":0.24210212617417912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949689749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.961692,0.01935851,0.008597146,0.0025937536,0.0033781533,0.0016908522,0.000037398517,0.00035527474,0.0022969404],"genre_scores_gemma":[0.98644185,0.00025519825,0.010883766,0.000110384266,0.0005522895,0.0001351909,0.000075074444,0.000056128367,0.0014901357],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992381,0.000012614163,0.000255067,0.000173151,0.00010408147,0.00021700094],"domain_scores_gemma":[0.99941415,0.0000767356,0.000053595886,0.00030948617,0.00009686658,0.00004917642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001250656,0.00014390315,0.00017615783,0.000022668044,0.000048993003,0.000016137063,0.00016605521,0.00010449176,0.000028097227],"category_scores_gemma":[0.000032809792,0.00010456822,0.00007680085,0.00017532361,0.000024988836,0.00011827987,0.000015615691,0.00013588685,0.000008963704],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001221213,0.0010494227,0.0029408324,0.022236636,0.00033657867,4.824142e-7,0.018437225,0.007991156,0.18186378,0.024318162,0.015608731,0.72509485],"study_design_scores_gemma":[0.002935996,0.0006587912,0.012907511,0.0016728186,0.00008288096,0.000033930097,0.009367241,0.12303844,0.1526432,0.0028805602,0.6923756,0.0014030114],"about_ca_topic_score_codex":0.00005776637,"about_ca_topic_score_gemma":0.000026757858,"teacher_disagreement_score":0.7236919,"about_ca_system_score_codex":0.00008235316,"about_ca_system_score_gemma":0.00015871013,"threshold_uncertainty_score":0.42641684},"labels":[],"label_agreement":null},{"id":"W2949734536","doi":"10.1097/01.hs9.0000560652.54765.fe","title":"PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D‐RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research; Leukemia & Lymphoma Society of Canada; University of British Columbia; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Internal medicine; Medicine; Lenalidomide; Tolerability; Oncology; Multiple myeloma; Gastroenterology; Adverse effect","score_opus":0.01260982214245829,"score_gpt":0.25760121233349176,"score_spread":0.24499139019103347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949734536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99671084,0.0015336593,0.00001878384,0.00009058476,0.000034423596,0.0008075919,0.00010624706,0.000020673428,0.00067717436],"genre_scores_gemma":[0.9977999,0.00045884823,0.0012599082,0.00008664292,0.000011971438,0.000021106809,0.000113426344,0.000030099178,0.00021810162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980694,0.00017952011,0.0006497117,0.0005124067,0.0003312576,0.0002576778],"domain_scores_gemma":[0.9978008,0.00095414126,0.00036002923,0.00063923333,0.000084863226,0.0001609193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031455042,0.00028123494,0.0011334426,0.0002911736,0.000041178642,0.000008592253,0.000070076545,0.00018429449,0.0007703587],"category_scores_gemma":[0.00022185719,0.00020395782,0.00015639329,0.0009190376,0.000119742195,0.000038953833,0.00004447037,0.00014717922,0.000007749096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011581976,0.0015402946,0.9658266,0.00018066466,0.0012152183,0.000076947246,0.0002945716,0.0006645621,0.0058937795,0.000024013463,0.0001027828,0.012598645],"study_design_scores_gemma":[0.033167966,0.0015733456,0.94083416,0.0003932341,0.0018696567,0.0000066139933,0.00024618543,0.007735862,0.013682701,0.0000035670448,0.0002931225,0.00019360485],"about_ca_topic_score_codex":0.0009119796,"about_ca_topic_score_gemma":0.0010308607,"teacher_disagreement_score":0.024992405,"about_ca_system_score_codex":0.00013162469,"about_ca_system_score_gemma":0.00012177829,"threshold_uncertainty_score":0.84348875},"labels":[],"label_agreement":null},{"id":"W2949752825","doi":"10.1097/01.hs9.0000561220.73976.40","title":"PF734 PATIENT PREFERENCES FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS OF A PATIENT SURVEY OF RAVULIZUMAB (ALXN1210) AND ECULIZUMAB","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Eculizumab; Paroxysmal nocturnal hemoglobinuria; Medicine; Dosing; Clinical trial; Pediatrics; Internal medicine; Immunology; Antibody","score_opus":0.023483692159303005,"score_gpt":0.25275744604142786,"score_spread":0.22927375388212484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949752825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869622,0.00914872,0.000014345654,0.000029792325,0.0003850297,0.0014806965,0.001602724,0.000009772699,0.0003667435],"genre_scores_gemma":[0.99931204,0.00011547505,0.00007963227,0.000006013891,0.0000076068673,0.00008152038,0.00017298483,0.000011410371,0.00021332575],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983506,0.0002682808,0.00078165194,0.0002832025,0.000086144246,0.00023007885],"domain_scores_gemma":[0.9976741,0.00094713416,0.0006598057,0.00045465605,0.00024120686,0.000023075561],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015692993,0.00020343576,0.0005533846,0.000030539286,0.000057722104,0.0000049791684,0.00016906718,0.00010547869,0.0004368544],"category_scores_gemma":[0.00009680048,0.00012528787,0.00014469055,0.00009305623,0.00017775537,0.00003543917,0.00006314974,0.000046685098,0.000008734321],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055506002,0.009003799,0.5594094,0.0027316741,0.006906722,0.000006983844,0.027672864,0.00071911374,0.0986963,0.0015829076,0.022182476,0.21558177],"study_design_scores_gemma":[0.028434306,0.025932034,0.4099069,0.000750097,0.0006087648,0.000049151768,0.008766051,0.00009678418,0.49642244,0.0003111694,0.028064135,0.00065817166],"about_ca_topic_score_codex":0.0014965563,"about_ca_topic_score_gemma":0.0005240756,"teacher_disagreement_score":0.39772612,"about_ca_system_score_codex":0.000041897583,"about_ca_system_score_gemma":0.000115976785,"threshold_uncertainty_score":0.51090914},"labels":[],"label_agreement":null},{"id":"W2949761811","doi":"10.1097/01.hs9.0000559724.11537.93","title":"PF378 TREATMENT EMERGENT ADVERSE EVENTS VARY WITH DIFFERENT PI3K INHIBITORS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cardiac pacing and defibrillation studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"","keywords":"Medicine; Adverse effect; Idelalisib; Incidence (geometry); Internal medicine; Leukemia","score_opus":0.013331003188037302,"score_gpt":0.2542559222531651,"score_spread":0.2409249190651278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949761811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91790354,0.0006156134,0.00002678669,0.00014630874,0.00036071776,0.00044108686,0.000007329691,0.00009270769,0.08040591],"genre_scores_gemma":[0.9798849,0.00014379607,0.000120399716,0.000082727616,0.00019758193,0.000025746682,0.000021187045,0.000026085545,0.019497523],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99900424,0.000020891186,0.00018539255,0.00027621983,0.0002993536,0.00021390566],"domain_scores_gemma":[0.9994015,0.000029527015,0.00006316907,0.00031923136,0.00005593227,0.00013062941],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0000285908,0.00020824309,0.00045534252,0.00003251617,0.00005776682,0.0000025851207,0.000009709892,0.000050956525,0.00040421277],"category_scores_gemma":[0.000006677361,0.000129454,0.00018996693,0.000110837886,0.000019445935,0.000034806922,0.00002801268,0.00005807496,0.0003874539],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045702475,0.00025038538,0.98694944,0.000119935954,0.0006746573,0.000029254334,0.0007472553,0.00014912005,0.00081245136,0.00006348666,0.006877946,0.0028690288],"study_design_scores_gemma":[0.012325959,0.0033726147,0.76080495,0.0008716312,0.000885911,0.0004517916,0.0059673963,0.000078760015,0.009268662,0.000044339165,0.2051428,0.0007852128],"about_ca_topic_score_codex":0.00004537262,"about_ca_topic_score_gemma":0.000017886063,"teacher_disagreement_score":0.22614454,"about_ca_system_score_codex":0.00014487526,"about_ca_system_score_gemma":0.000040976847,"threshold_uncertainty_score":0.5278981},"labels":[],"label_agreement":null},{"id":"W2949764170","doi":"10.1097/01.hs9.0000564104.83392.dc","title":"PS1460 LONG-TERM FOLLOW UP OF JAK INHIBITOR (JAKI) TREATED PATIENTS WITH MYELOFIBROSIS: IMPACT OF MOLECULAR ENHANCED INTEGRATED SCORING SYSTEMS AND TYPE OF JAKI THERAPY FAILURE ON SURVIVAL","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Term (time); Medicine; Ruxolitinib; Internal medicine; Oncology; Physics","score_opus":0.014467297131724972,"score_gpt":0.26835723356450547,"score_spread":0.2538899364327805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949764170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99721223,0.00074835593,0.000015599851,0.000011013479,0.00012466812,0.0014342936,0.00005941135,0.000021679725,0.00037275304],"genre_scores_gemma":[0.9993646,0.00011581491,0.00010445851,0.000007027845,0.00001839452,0.00004099827,0.000116987016,0.000048603826,0.00018308958],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984468,0.00008478881,0.00045403407,0.0003599983,0.00042343602,0.00023094041],"domain_scores_gemma":[0.9984584,0.00008645688,0.00036217575,0.00039804305,0.0005753469,0.00011960604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000074482676,0.00034433036,0.0009547302,0.00008599595,0.00002229372,0.000012324605,0.000057126123,0.00013899527,0.00018308897],"category_scores_gemma":[0.000029934743,0.00020998507,0.00015014739,0.00034754348,0.000064702785,0.00007370159,0.00002026746,0.000120373355,0.000006619134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00392768,0.0007720687,0.87775695,0.00045081344,0.0009214592,0.00001149707,0.00032381725,0.000055559507,0.11430757,0.000048980124,0.00002873023,0.001394875],"study_design_scores_gemma":[0.009203213,0.008938112,0.5293247,0.002949358,0.00013101129,0.0000033139204,0.00016557684,0.000022320779,0.44909528,0.0000010499906,0.00000465376,0.00016139138],"about_ca_topic_score_codex":0.00030606473,"about_ca_topic_score_gemma":0.00004167091,"teacher_disagreement_score":0.34843224,"about_ca_system_score_codex":0.00009337033,"about_ca_system_score_gemma":0.0001307302,"threshold_uncertainty_score":0.8562943},"labels":[],"label_agreement":null},{"id":"W2949825634","doi":"10.1097/01.hs9.0000567788.99221.f8","title":"PB2331 IMPACT OF PRETRANSPLANT CHEMOTHERAPY, GRAFT VERSUS HOST DISEASE PROPHYLAXIS, GENDER AND RISK GROUP ON ALLOGENEIC REDUCED INTENSITY CONDITIONING TRANSPLANTS FOR ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Busulfan; Internal medicine; Fludarabine; Population; Transplantation; Myeloid leukemia; Chemotherapy; Surgery; Graft-versus-host disease; Regimen; Oncology; Hematopoietic stem cell transplantation; Cyclophosphamide","score_opus":0.01376130337854467,"score_gpt":0.27589634943856917,"score_spread":0.26213504606002447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949825634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99544233,0.00017323674,0.00033529114,0.000023579782,0.00019401654,0.002271939,0.0012752245,0.000056729627,0.00022764597],"genre_scores_gemma":[0.9977774,0.00047119096,0.0005941545,0.000063287735,0.00008099988,0.00007423786,0.00069375685,0.00008203536,0.00016294314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977692,0.00006562916,0.00039520249,0.0006218047,0.0005802773,0.00056791556],"domain_scores_gemma":[0.9983451,0.00026428307,0.00019371715,0.00047600493,0.0002690144,0.00045187902],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001716931,0.0003827161,0.00061679573,0.000097277996,0.00011602758,0.000024546092,0.0001563491,0.00023154546,0.0002331811],"category_scores_gemma":[0.00008312587,0.00029546727,0.00029392893,0.00017378991,0.00015555054,0.00012653253,0.000025998772,0.00035450584,0.000022040367],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16586168,0.0013785041,0.64184403,0.0037835035,0.006361564,0.0002419081,0.0024480645,0.00015690942,0.16822174,0.00010805916,0.0022821722,0.007311831],"study_design_scores_gemma":[0.042667177,0.013692728,0.9183666,0.00072964694,0.0010201548,0.00004802349,0.00014869927,0.0017411604,0.02089226,0.0000732603,0.00006492222,0.0005553385],"about_ca_topic_score_codex":0.00017436704,"about_ca_topic_score_gemma":0.000010210268,"teacher_disagreement_score":0.27652258,"about_ca_system_score_codex":0.00079928053,"about_ca_system_score_gemma":0.0006237943,"threshold_uncertainty_score":0.99994975},"labels":[],"label_agreement":null},{"id":"W2949973349","doi":"10.1097/01.hs9.0000562776.32990.9f","title":"PS1123 IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"IGHV@; Venetoclax; Rituximab; Chronic lymphocytic leukemia; Chemoimmunotherapy; Neuroblastoma RAS viral oncogene homolog; Bendamustine; Oncology; KRAS; Internal medicine; Medicine; Lenalidomide; Somatic evolution in cancer; CDKN2A; Lymphocytosis; Leukemia; Lymphoma; Multiple myeloma; Cancer","score_opus":0.02167245289051603,"score_gpt":0.33282394885288435,"score_spread":0.31115149596236835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949973349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946154,0.00028953943,0.000004268445,0.000007723931,0.00004830639,0.0034308776,0.000052343854,0.000028229862,0.0015233329],"genre_scores_gemma":[0.9988671,0.000016520074,0.000028736102,0.00003878234,0.000053398642,0.00011462199,0.00009272172,0.0000672647,0.0007208432],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972112,0.0002146546,0.000806726,0.00047432084,0.0007811989,0.0005118716],"domain_scores_gemma":[0.9977924,0.00033784265,0.00030920666,0.0012407438,0.00018720304,0.0001325775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035260848,0.0003524105,0.0008930404,0.00018559565,0.000055972785,0.000018625713,0.00034961058,0.00014204076,0.0007069795],"category_scores_gemma":[0.00008927688,0.00021376286,0.00021323487,0.00058464764,0.00014221789,0.000116751675,0.000064403685,0.00037286946,0.00017814344],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03815796,0.0138389645,0.83969545,0.003510362,0.0028135718,0.0010051265,0.0136263035,0.06389342,0.017474826,0.0001480312,0.0016434656,0.0041925143],"study_design_scores_gemma":[0.6507887,0.04760444,0.22535378,0.0011539717,0.0006015996,0.00014509256,0.0018805688,0.06864335,0.0030064187,0.000011551599,0.00016107838,0.0006494346],"about_ca_topic_score_codex":0.008367278,"about_ca_topic_score_gemma":0.0006006289,"teacher_disagreement_score":0.6143417,"about_ca_system_score_codex":0.13313265,"about_ca_system_score_gemma":0.028025024,"threshold_uncertainty_score":0.99823606},"labels":[],"label_agreement":null},{"id":"W2949991172","doi":"10.1097/01.hs9.0000567032.31064.27","title":"PB2137 SUBGROUP ANALYSIS OF PATIENTS FROM CANADA AND THE UNITED STATES IN THE PHASE 3 FIRST TRIAL IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Leukemia & Lymphoma Society of Canada; McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Lenalidomide; Medicine; Thalidomide; Multiple myeloma; Internal medicine; Melphalan; Prednisone; Progression-free survival; Surgery; Gastroenterology; Chemotherapy","score_opus":0.014403361998694684,"score_gpt":0.26546221435834677,"score_spread":0.2510588523596521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949991172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970607,0.00026551582,0.0000041418334,0.0004056229,0.00003970854,0.0016159514,0.0005103159,0.0000060250295,0.00009198168],"genre_scores_gemma":[0.99733645,0.00026121174,0.00003068178,0.0001837904,0.000017928085,0.00009467996,0.0020131497,0.000012053642,0.00005005604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983712,0.00020609364,0.00039572926,0.0002531295,0.00047940892,0.00029443178],"domain_scores_gemma":[0.99753356,0.0018542814,0.00009154897,0.00036620104,0.00005836059,0.00009607364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022434107,0.0001678758,0.00054241647,0.00015424647,0.000044957007,0.000017455295,0.00014985043,0.00005856633,0.00032258473],"category_scores_gemma":[0.00018232998,0.000089951565,0.00009471841,0.001158378,0.00007454893,0.000045699795,0.000021553824,0.00018263272,0.000003155508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044339582,0.0007953633,0.9504197,0.000051720115,0.0005444105,0.00013431998,0.0023724602,0.00022985699,0.000015410273,0.0000066389225,0.00021649747,0.0008739913],"study_design_scores_gemma":[0.24788786,0.00030545914,0.73341924,0.00007925761,0.0003406222,4.7076807e-7,0.0011646381,0.016101092,0.0001521176,0.000014126008,0.00044237805,0.00009271876],"about_ca_topic_score_codex":0.8897249,"about_ca_topic_score_gemma":0.94353074,"teacher_disagreement_score":0.2170005,"about_ca_system_score_codex":0.000085199,"about_ca_system_score_gemma":0.0001328699,"threshold_uncertainty_score":0.36681184},"labels":[],"label_agreement":null},{"id":"W2949995351","doi":"10.1097/01.hs9.0000562472.96992.e6","title":"PS1044 THE PROGNOSTIC SIGNIFICANCE OF BCR‐1 AND BCR‐3 ISOFORM OF PML‐RARA AND FLT3‐ITD IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group; University of Calgary","funders":"","keywords":"Medicine; Acute promyelocytic leukemia; breakpoint cluster region; Internal medicine; Regimen; Oncology; Gastroenterology; Biology; Gene","score_opus":0.005892820207575328,"score_gpt":0.2284704105657468,"score_spread":0.22257759035817146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949995351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487454,0.00041317416,0.000013979046,0.00022081855,0.00002206789,0.0024136368,0.000017688797,0.000016428588,0.0020076553],"genre_scores_gemma":[0.9977157,0.000078977995,0.00089518825,0.00006622396,0.000019705643,0.0000636413,0.000014892001,0.000036779715,0.0011089056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983489,0.00005303572,0.0003707422,0.00035712295,0.0005047182,0.00036549018],"domain_scores_gemma":[0.9987957,0.0002343762,0.0001745241,0.00047014025,0.00020812945,0.00011714387],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025146757,0.00021111053,0.000522064,0.00006797533,0.000034646207,0.000012383849,0.00014769277,0.00012038773,0.00013977182],"category_scores_gemma":[0.00011609439,0.0001275018,0.000035476874,0.00032716242,0.00035749108,0.00012060916,0.00012368387,0.00037229707,0.0000130072785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015323905,0.00013017727,0.9859519,0.0013148432,0.00017451594,0.00003152368,0.0011354169,0.00001203743,0.0029491044,0.00014011086,0.0003102988,0.006317689],"study_design_scores_gemma":[0.007448867,0.001922637,0.9824455,0.000638604,0.00014448189,0.00003943531,0.0006630196,0.0008079567,0.0053591873,0.00008832183,0.0002501684,0.00019183473],"about_ca_topic_score_codex":0.0001709832,"about_ca_topic_score_gemma":0.000056055826,"teacher_disagreement_score":0.0061258543,"about_ca_system_score_codex":0.00022764443,"about_ca_system_score_gemma":0.0006399576,"threshold_uncertainty_score":0.5199372},"labels":[],"label_agreement":null},{"id":"W2950158180","doi":"10.1097/01.hs9.0000563624.30413.c3","title":"PS1336 DISCREPANCE OF ALLELIC BURDEN CHANGES AND CLINICAL RESPONSE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME TREATED WITH HYPOMETHYLATING AGENTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Decitabine; Azacitidine; Medicine; Internal medicine; Myelodysplastic syndromes; International Prognostic Scoring System; Hypomethylating agent; Allele; Gastroenterology; Myeloid; Oncology; Bone marrow; Gene; Genetics; DNA methylation; Biology","score_opus":0.015556206433921428,"score_gpt":0.2852610328947903,"score_spread":0.2697048264608689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950158180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980566,0.0001512186,0.0000075307917,0.00025784914,0.000026239264,0.000992539,0.00002232702,0.000035391844,0.0004503],"genre_scores_gemma":[0.99503934,0.00006961652,0.0014466038,0.000043264554,0.000030486877,0.000025173837,0.000023638466,0.000060151924,0.0032617177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978129,0.000317625,0.0003946203,0.0005178599,0.0005492059,0.0004077775],"domain_scores_gemma":[0.9982202,0.0006883219,0.00023918289,0.00049600494,0.00015129967,0.00020497508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005643492,0.00024332953,0.0006781132,0.00012471352,0.000036144404,0.00001251762,0.00011681369,0.00016314608,0.00039465254],"category_scores_gemma":[0.0003059758,0.00015983249,0.000039286555,0.000496756,0.00018824151,0.000087843044,0.00010061942,0.00048403844,0.000042820204],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015666539,0.00019144724,0.9807756,0.00018911307,0.0002138797,0.00018011355,0.00019844247,0.000027475171,0.00018809664,0.0000038158537,0.0000515237,0.002313971],"study_design_scores_gemma":[0.011297602,0.006441697,0.98014873,0.0007735773,0.000112472575,0.0000270089,0.00018619801,0.0005060429,0.00008302382,0.0000036216834,0.0002322381,0.00018777471],"about_ca_topic_score_codex":0.00035066996,"about_ca_topic_score_gemma":0.000093110306,"teacher_disagreement_score":0.0062502497,"about_ca_system_score_codex":0.00014447833,"about_ca_system_score_gemma":0.00014634864,"threshold_uncertainty_score":0.651778},"labels":[],"label_agreement":null},{"id":"W2950165149","doi":"10.1097/01.hs9.0000566236.65976.7d","title":"PB1935 REAL LIFE EXPERIENCE IN CML PATIENTS IN CANARY ISLAND","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Utilities Corporation","funders":"","keywords":"Medicine; Imatinib; Internal medicine; Cumulative incidence; Myeloid leukemia; Incidence (geometry); Dasatinib; Gastroenterology; Cohort","score_opus":0.013506230120531003,"score_gpt":0.2677709842224399,"score_spread":0.2542647541019089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950165149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96782666,0.00020549414,6.1444115e-7,0.000093973234,0.00014862466,0.0005370488,0.0000060090533,0.000024442066,0.031157117],"genre_scores_gemma":[0.9958448,0.000094360155,0.00011152597,0.0002827313,0.00004237166,0.000047506124,0.000041549283,0.000023540206,0.0035116517],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987731,0.000028373239,0.0002784695,0.00032890795,0.00025699515,0.00033415403],"domain_scores_gemma":[0.9993757,0.00004139937,0.000051984403,0.00036301924,0.000025847683,0.00014203542],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000052623014,0.00015511457,0.0003081323,0.000054479453,0.000013231038,0.0000058985506,0.000082207145,0.0001074778,0.002098243],"category_scores_gemma":[0.00006134595,0.00013711509,0.000037533468,0.00023843124,0.000026355443,0.00009124079,0.000049939074,0.00018458047,0.00032989442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014562998,0.0002375468,0.9950233,0.0000718946,0.000010515271,0.0001448401,0.0018866006,0.000012235241,0.00011697992,0.000023178129,0.0013250922,0.0010021504],"study_design_scores_gemma":[0.009148682,0.00025072592,0.98635256,0.0003268611,0.0000091679085,0.000010147798,0.0010179151,0.00035398177,0.00032877014,0.000015181037,0.0020182522,0.00016773587],"about_ca_topic_score_codex":0.011411833,"about_ca_topic_score_gemma":0.012814908,"teacher_disagreement_score":0.028018089,"about_ca_system_score_codex":0.0009169813,"about_ca_system_score_gemma":0.0004085505,"threshold_uncertainty_score":0.998814},"labels":[],"label_agreement":null},{"id":"W2950218799","doi":"10.1097/01.hs9.0000558992.23463.e7","title":"PF194 EVALUATION OF TELOMERE LENGTH AND TELOMERASE ACTIVITY AS PROGNOSTIC MARKERS IN A PEDIATRIC PATIENT COHORT WITH ACUTE LYMPHOBLASTIC LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Telomeres, Telomerase, and Senescence","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Telomerase; Telomere; Medicine; clone (Java method); Cohort; Oncology; Cancer; Pediatric cancer; Internal medicine; Stem cell; Acute lymphocytic leukemia; Immunology; Leukemia; Cancer research; Biology; Lymphoblastic Leukemia; Genetics; Gene","score_opus":0.008302490414296315,"score_gpt":0.2426752915722549,"score_spread":0.23437280115795858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950218799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928097,0.0008434413,0.000009926344,0.00006207401,0.0001096453,0.0024110854,0.000011181118,0.00005438522,0.0036885748],"genre_scores_gemma":[0.99864227,0.00036036945,0.0004021071,0.00007672986,0.000047377005,0.00013456734,0.000021239473,0.00005074587,0.00026461884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715835,0.00016422087,0.00044403155,0.00065062,0.0011341107,0.00044867024],"domain_scores_gemma":[0.9984217,0.0002579072,0.0002728094,0.00048681078,0.00032306934,0.00023765575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049591943,0.00035287952,0.0006618944,0.00020961654,0.000050912124,0.000019846731,0.000093574476,0.00017223161,0.0004525466],"category_scores_gemma":[0.00029487238,0.00028595864,0.00007248704,0.0007564125,0.000115279,0.00022020518,0.00006139645,0.00028188163,0.000056573237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016103266,0.0003539315,0.9601337,0.0006950131,0.00016979134,0.0001481478,0.0005269201,0.0001220967,0.002564896,0.000026855287,0.00010569611,0.03354268],"study_design_scores_gemma":[0.005522589,0.0016250636,0.9826877,0.0004583926,0.0010479839,0.00031592406,0.0006096455,0.0038471133,0.003396819,0.000035824363,0.000063440675,0.00038950887],"about_ca_topic_score_codex":0.00031002393,"about_ca_topic_score_gemma":0.00014382094,"teacher_disagreement_score":0.033153173,"about_ca_system_score_codex":0.00045799676,"about_ca_system_score_gemma":0.0013651686,"threshold_uncertainty_score":0.99995923},"labels":[],"label_agreement":null},{"id":"W2950269753","doi":"10.1097/01.hs9.0000560680.23378.f5","title":"PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT‐ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D‐VTD): PHASE 3 CASSIOPEIA STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Plerixafor; Multiple myeloma; Autologous stem-cell transplantation; Internal medicine; Daratumumab; Transplantation; Surgery; Bortezomib; Oncology; CXCR4","score_opus":0.024670295667957722,"score_gpt":0.2923307548691387,"score_spread":0.267660459201181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950269753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926932,0.0005941908,0.00007260168,0.000058248697,0.00015966248,0.0038582361,0.00013446818,0.000087543915,0.0023418663],"genre_scores_gemma":[0.99751544,0.00043972867,0.0003663528,0.00005406475,0.000045195404,0.00021780464,0.0002320455,0.00007612684,0.0010532513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689525,0.00019402706,0.0006576535,0.0008344343,0.000698253,0.00072035386],"domain_scores_gemma":[0.9980833,0.0006996681,0.00014905205,0.00052097894,0.000110956375,0.00043602518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032809548,0.00045115204,0.00079106615,0.0002042845,0.00013876984,0.00007254967,0.00014962272,0.00020071892,0.00038898585],"category_scores_gemma":[0.00006131583,0.00038705944,0.00011517819,0.0004322496,0.00004951534,0.0003409107,0.00003486427,0.00045116586,0.00013598816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006026858,0.0047539226,0.94037616,0.0007096437,0.00014011702,0.0017142266,0.0051974473,0.00002489694,0.008369297,0.0000013289698,0.00013421227,0.032551907],"study_design_scores_gemma":[0.10694544,0.004199419,0.850735,0.0010146125,0.00024823053,0.00006721719,0.003946245,0.0015148597,0.03060257,0.0000049596706,0.00016925683,0.0005521806],"about_ca_topic_score_codex":0.0014336511,"about_ca_topic_score_gemma":0.0032446682,"teacher_disagreement_score":0.10091858,"about_ca_system_score_codex":0.00016643881,"about_ca_system_score_gemma":0.00012507784,"threshold_uncertainty_score":0.99985814},"labels":[],"label_agreement":null},{"id":"W2950296737","doi":"10.1097/01.hs9.0000563780.03390.ca","title":"PS1376 LENALIDOMIDE MAINTENANCE POSITIVELY IMPACTS OUTCOMES IN MULTIPLE MYELOMA WITHOUT NEGATIVE IMPACTS IN RELAPSE: AN ANALYSIS OF REAL WORLD DATA FROM THE MYELOMA CANADA RESEARCH NETWORK NATIONAL DATABASE","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; Vancouver General Hospital; Princess Margaret Cancer Centre; Ottawa Hospital; Dalhousie University; Université de Montréal; University of Saskatchewan; Queen Elizabeth II Health Sciences Centre; University of Alberta","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Bortezomib; Oncology; Internal medicine; Maintenance therapy; Chemotherapy","score_opus":0.0944339017398557,"score_gpt":0.38919401619865,"score_spread":0.2947601144587943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950296737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921947,0.0002576532,0.000010431093,0.0013233079,0.000060904633,0.0013971863,0.0033056543,0.000017436016,0.001432732],"genre_scores_gemma":[0.9933221,0.00011400336,0.001737744,0.00027472508,0.000110161374,0.000054148328,0.0034939982,0.000045498895,0.00084764854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941339,0.00091813493,0.0007620436,0.0009362511,0.002028201,0.0012214712],"domain_scores_gemma":[0.99283063,0.0041162716,0.00028222258,0.0017384446,0.0005519996,0.0004804554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023861714,0.00035378765,0.0010983198,0.00039378775,0.00014940483,0.000054679003,0.0007963875,0.00009096882,0.00046845313],"category_scores_gemma":[0.0030094488,0.00023916384,0.00011243201,0.0032717232,0.00026755792,0.00053905445,0.0005568229,0.0008630039,0.000027081214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034899286,0.00037219838,0.9883671,0.000042097745,0.0013059512,0.00040933266,0.00037918924,0.0007768494,0.000690011,0.0001292422,0.0034888065,0.00054933975],"study_design_scores_gemma":[0.0059942575,0.00017278154,0.96147686,0.0005486856,0.0001358524,0.0000046566743,0.0015346841,0.029318986,0.00041945654,0.00006484713,0.00012190158,0.0002070361],"about_ca_topic_score_codex":0.8824545,"about_ca_topic_score_gemma":0.9938038,"teacher_disagreement_score":0.111349255,"about_ca_system_score_codex":0.0013898065,"about_ca_system_score_gemma":0.002754711,"threshold_uncertainty_score":0.97528183},"labels":[],"label_agreement":null},{"id":"W2950319468","doi":"10.1097/01.hs9.0000565876.04604.d2","title":"PB1843 EFFECT OF ADHERENCE TO PHYSICAL THERPY REGIMEN ON JOINTS OUTCOMES FOR HEMOPHILIAC CHILDREN AT ZAGAZIG UNIVERSITY HOSPITALS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Physical therapy; Regimen; Outpatient clinic; Attendance; Test (biology); Joint pain; Clotting factor; Internal medicine","score_opus":0.013227288999329902,"score_gpt":0.2962124569902549,"score_spread":0.282985167990925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950319468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883117,0.00004264575,0.0000023616465,0.00072760595,0.000073991294,0.002542443,0.000041949108,0.000046897425,0.0082104225],"genre_scores_gemma":[0.9499794,0.000010887043,0.00015313424,0.000074346244,0.00007211528,0.000014836055,0.000029460463,0.00002979814,0.04963599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99865556,0.000060639122,0.00013899706,0.00040785334,0.00038762792,0.0003493138],"domain_scores_gemma":[0.9987505,0.00035764516,0.00006492748,0.0005370954,0.00007661775,0.00021322051],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015212529,0.00022929854,0.0006389299,0.00005476335,0.00006603527,0.000005742902,0.00016287819,0.000103827704,0.00048702827],"category_scores_gemma":[0.00009242851,0.00015415254,0.0003105001,0.00017833582,0.00006032821,0.000047606063,0.00011001174,0.00012891386,0.0010928846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025532946,0.0004814854,0.96483636,0.00038169438,0.00043960215,0.000023682214,0.000385678,0.0000061161595,0.016354661,0.00023848943,0.0075467317,0.0067522177],"study_design_scores_gemma":[0.0117537165,0.019911151,0.7388693,0.0005823592,0.000256782,0.000012039217,0.00013455124,0.000064619984,0.22584803,0.00010760537,0.0020439941,0.0004158391],"about_ca_topic_score_codex":0.000031180316,"about_ca_topic_score_gemma":0.0000045962915,"teacher_disagreement_score":0.22596705,"about_ca_system_score_codex":0.00016990665,"about_ca_system_score_gemma":0.000053539068,"threshold_uncertainty_score":0.9996849},"labels":[],"label_agreement":null},{"id":"W2950360095","doi":"10.1097/01.hs9.0000566660.48019.07","title":"PB2043 UPPER AND LOWER GASTROINTESTINAL ENDOSCOPY FINDINGS IN PATIENTS WITH ISOLATED FERRITIN DEFICIENCY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Esophageal and GI Pathology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Iron-deficiency anemia; Endoscopy; Iron deficiency; Ferritin; Hepatology; Anemia; Helicobacter pylori; Gastritis","score_opus":0.004365030723828843,"score_gpt":0.21130576093141065,"score_spread":0.2069407302075818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950360095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933458,0.00014292348,0.000036852514,0.00013401256,0.000042664225,0.0003217502,0.0000047808508,0.00003135154,0.0059398734],"genre_scores_gemma":[0.99568,0.0000020841082,0.0026128395,0.00029393405,0.000014507169,0.0000060548527,0.000017837876,0.000018803106,0.0013539799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991005,0.00002313647,0.00016028661,0.0002811169,0.00014082933,0.00029410663],"domain_scores_gemma":[0.9996187,0.000046540747,0.00003376662,0.00015484956,0.00005611843,0.00009002486],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007344273,0.00013982349,0.00023517008,0.000043742162,0.000025043784,0.000008644386,0.000042040952,0.00005644398,0.0011705915],"category_scores_gemma":[0.000045237437,0.00010325305,0.000022100494,0.00013929613,0.00005861057,0.00006515247,0.000045467783,0.00020819307,0.00019636251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070064625,0.00021785716,0.99721694,0.00007427528,0.00000283782,0.00014954197,0.00011174805,0.0000012249374,0.0010111403,0.00007591015,0.00012385102,0.0003140356],"study_design_scores_gemma":[0.0042021493,0.0027724367,0.9918129,0.00035257195,0.00001549243,0.00032680624,0.00011444113,0.000063713625,0.00012816205,0.000042682666,0.000054625405,0.000114037386],"about_ca_topic_score_codex":0.000023806346,"about_ca_topic_score_gemma":0.000012873107,"teacher_disagreement_score":0.0054040505,"about_ca_system_score_codex":0.00002668313,"about_ca_system_score_gemma":0.000034205772,"threshold_uncertainty_score":0.99974245},"labels":[],"label_agreement":null},{"id":"W2950383245","doi":"10.1097/01.hs9.0000562228.80333.3e","title":"PS982 THE ROLE OF STAT3 ISOFORMS IN ACUTE MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"STAT3; Myeloid leukemia; Cancer research; STAT protein; Transactivation; Biology; Myeloid; Leukemia; Medicine; Immunology; Transcription factor; Signal transduction; Cell biology; Gene; Genetics","score_opus":0.00818188320902069,"score_gpt":0.2644259495847453,"score_spread":0.2562440663757246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950383245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93499124,0.00089915725,0.0000152228495,0.00073576526,0.000063416664,0.00077258586,0.000015674826,0.000037140773,0.06246979],"genre_scores_gemma":[0.9827173,0.0002333919,0.0006549496,0.0003745202,0.00007188335,0.000033246422,0.00001762871,0.000043645126,0.015853472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983293,0.000045071065,0.00035569025,0.00028430973,0.0005027516,0.00048291875],"domain_scores_gemma":[0.99880975,0.00013141132,0.00009225443,0.0007450352,0.000106072934,0.0001154443],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003672256,0.00017552439,0.00040616153,0.00007034085,0.000034269848,0.000012616739,0.00029946037,0.00015053042,0.002676054],"category_scores_gemma":[0.00006325049,0.000107332206,0.000116370065,0.00047533345,0.000116060415,0.0001167286,0.00016230896,0.0005892374,0.00087981054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025428438,0.0003587808,0.49006748,0.0008000046,0.00069440395,0.00032232565,0.0054356996,0.00019692109,0.32862908,0.009294236,0.019655272,0.14200296],"study_design_scores_gemma":[0.017855741,0.0023146595,0.3651065,0.0010449025,0.0003007508,0.00063918694,0.022448633,0.014454256,0.3155301,0.0065000723,0.25271988,0.0010853466],"about_ca_topic_score_codex":0.00043144613,"about_ca_topic_score_gemma":0.000093699826,"teacher_disagreement_score":0.2330646,"about_ca_system_score_codex":0.0005318915,"about_ca_system_score_gemma":0.00073661923,"threshold_uncertainty_score":0.99989814},"labels":[],"label_agreement":null},{"id":"W2950542774","doi":"10.1097/01.hs9.0000559388.41193.da","title":"PF294 IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Jewish General Hospital","funders":"","keywords":"Medicine; International Prognostic Index; Internal medicine; Diffuse large B-cell lymphoma; Clinical endpoint; CHOP; Rituximab; Oncology; Lymphoma; Regimen; Gastroenterology; Randomized controlled trial","score_opus":0.01167698582169717,"score_gpt":0.27383872382028873,"score_spread":0.26216173799859155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950542774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99083585,0.00013915182,0.0000067354426,0.00013679158,0.00008923203,0.00546938,0.00041473858,0.00009495323,0.002813183],"genre_scores_gemma":[0.9801942,0.000017669034,0.00008688611,0.0002872711,0.000088521236,0.00017890599,0.000395539,0.00013976355,0.01861121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99635625,0.0003000169,0.00057149836,0.0009494185,0.0009999885,0.0008228254],"domain_scores_gemma":[0.9971785,0.0005050685,0.00024263043,0.0014408466,0.00035628444,0.0002766697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035086562,0.00054137845,0.0009234873,0.000082257735,0.00012927638,0.00007630308,0.000359596,0.00017378911,0.00082813593],"category_scores_gemma":[0.00009538018,0.00030704838,0.00012883538,0.0005575063,0.000108596374,0.00015755939,0.00014128057,0.00046524827,0.00017200045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0661178,0.029249864,0.8825102,0.00006501922,0.0009863044,0.0005424003,0.009445323,0.00002520961,0.0045893565,0.0000030246554,0.0005566457,0.005908879],"study_design_scores_gemma":[0.47824308,0.014174705,0.49176663,0.00036443496,0.0003241776,0.000007831152,0.006578345,0.0012546696,0.0047120675,0.0000037754642,0.0019466291,0.00062367064],"about_ca_topic_score_codex":0.006310521,"about_ca_topic_score_gemma":0.00426797,"teacher_disagreement_score":0.41212526,"about_ca_system_score_codex":0.0010650214,"about_ca_system_score_gemma":0.0005140634,"threshold_uncertainty_score":0.9999382},"labels":[],"label_agreement":null},{"id":"W2950544845","doi":"10.1097/01.hs9.0000559524.28466.13","title":"PF328 PREDICTORS OF TREATMENT RESPONSE TO IMMUNOSUPPRESSANTS IN ACQUIRED HEMOPHILIA A","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Proportional hazards model; Partial thromboplastin time; Population; Single Center; Retrospective cohort study; Coagulation","score_opus":0.020589671907914595,"score_gpt":0.303439360244783,"score_spread":0.2828496883368684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950544845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99257416,0.00039455885,7.322275e-7,0.0010817463,0.00013488186,0.0014199277,0.000020231771,0.000060247938,0.0043135034],"genre_scores_gemma":[0.9732018,0.00006275732,0.00025047353,0.000052507177,0.00004923918,0.00007613405,0.000015112721,0.000042961878,0.026249029],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984368,0.00011111383,0.00034813187,0.00035228342,0.00034493947,0.00040673543],"domain_scores_gemma":[0.9988706,0.00016361524,0.00004641673,0.00063028507,0.00007183657,0.00021721217],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024407123,0.0002069253,0.0005175373,0.00016666221,0.000022708711,0.0000072684247,0.00011517883,0.00013415156,0.0012613406],"category_scores_gemma":[0.0001025549,0.00014909422,0.00013826435,0.00042447392,0.000050641644,0.00005940337,0.000065738546,0.00007430083,0.00059194455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012830559,0.0010971372,0.7451651,0.0002001998,0.00018745451,0.0002700111,0.0020008134,0.000050155424,0.23362924,0.000018269298,0.0010829215,0.0034681398],"study_design_scores_gemma":[0.014501158,0.009506448,0.79240143,0.0008765916,0.00009717463,0.00006812504,0.0011290265,0.00018591865,0.1637219,0.000053562664,0.017116657,0.00034198957],"about_ca_topic_score_codex":0.000120408644,"about_ca_topic_score_gemma":0.000023384386,"teacher_disagreement_score":0.06990734,"about_ca_system_score_codex":0.00038077397,"about_ca_system_score_gemma":0.00030484932,"threshold_uncertainty_score":0.9996517},"labels":[],"label_agreement":null},{"id":"W2950604500","doi":"10.1097/01.hs9.0000562556.40615.f8","title":"PS1065 OPEN‐LABEL STUDY OF GILTERITINIB, GILTERITINIB PLUS AZACITIDINE, OR AZACITIDINE ALONE IN NEWLY DIAGNOSED FLT3‐MUTATED AML PATIENTS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY: RESULTS FROM THE SAFETY COHORT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Cohort; Chemotherapy; Surgery; Internal medicine; Gastroenterology; Adverse effect","score_opus":0.049429120927616754,"score_gpt":0.34203074886872575,"score_spread":0.292601627941109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950604500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822831,0.00016221566,0.000036555648,0.00095002475,0.0002883555,0.013186549,0.0011661872,0.00008056992,0.001846405],"genre_scores_gemma":[0.9921712,0.00024521138,0.0010734898,0.001478842,0.00021209326,0.0007244993,0.0015126643,0.00016915968,0.0024128212],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99471176,0.0002619227,0.0017921135,0.0012498932,0.001029296,0.0009550298],"domain_scores_gemma":[0.99397755,0.0021831095,0.0005043127,0.0016596329,0.0013924384,0.00028293603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008589805,0.00059574214,0.0017950581,0.00012288282,0.00013400879,0.00009984622,0.000994489,0.00028416264,0.0008830403],"category_scores_gemma":[0.0022967102,0.00041624508,0.00014763349,0.0009850125,0.00022072588,0.0002954663,0.00062267605,0.0005192738,0.000084100706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44185844,0.02854323,0.33946732,0.0027381007,0.0049214703,0.0029114888,0.036959868,0.0005647657,0.020289326,0.00016549643,0.09262355,0.028956935],"study_design_scores_gemma":[0.8305521,0.009553534,0.09938964,0.0030488102,0.00035400625,0.000096403295,0.025026904,0.011589513,0.0129582295,0.00011295456,0.006204846,0.0011130403],"about_ca_topic_score_codex":0.014384676,"about_ca_topic_score_gemma":0.0038609884,"teacher_disagreement_score":0.3886937,"about_ca_system_score_codex":0.0034284256,"about_ca_system_score_gemma":0.0029698794,"threshold_uncertainty_score":0.99982893},"labels":[],"label_agreement":null},{"id":"W2950620394","doi":"10.1097/01.hs9.0000561796.30124.a4","title":"S879 RESULTS OF ASTRAL‐1 STUDY, A PHASE 3 RANDOMIZED TRIAL OF GUADECITABINE (G) VS TREATMENT CHOICE (TC) IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN‐AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY (IC)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta Hospital; Alberta Hospital Edmonton","funders":"","keywords":"Medicine; Decitabine; Internal medicine; Clinical endpoint; Cytarabine; Randomized controlled trial; Regimen; Induction chemotherapy; Oncology; Gastroenterology; Chemotherapy; Surgery","score_opus":0.03473661491423022,"score_gpt":0.3619602162914029,"score_spread":0.32722360137717266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950620394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9754093,0.00042704615,0.000059186525,0.0013897073,0.0002562076,0.020902686,0.00033628114,0.000058546826,0.0011609909],"genre_scores_gemma":[0.9821744,0.0010312246,0.0018468635,0.00017611652,0.00029543487,0.0018320341,0.00032924575,0.00012861789,0.0121860625],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951363,0.00033115997,0.0019689803,0.000996525,0.00074390444,0.00082311063],"domain_scores_gemma":[0.9947783,0.002110452,0.0007423189,0.0012852309,0.0008366204,0.00024712677],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011094275,0.00071129977,0.0036530418,0.00033282992,0.000050943425,0.00002181059,0.00031087679,0.00032284055,0.00032130565],"category_scores_gemma":[0.0010108354,0.0004994931,0.0009154184,0.0006398528,0.00022663604,0.00014539267,0.00007619598,0.00030294774,0.00004966025],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9210572,0.0053835865,0.0002517357,0.00017927542,0.00286109,0.000084547246,0.004840673,0.00003663373,0.04688104,0.000021235941,0.0014389926,0.016963974],"study_design_scores_gemma":[0.76774853,0.032661494,0.00015708679,0.00024240618,0.00076266605,0.00001908683,0.0027053668,0.00066443265,0.19170085,0.000021215394,0.003037528,0.0002793244],"about_ca_topic_score_codex":0.0031797274,"about_ca_topic_score_gemma":0.00035234145,"teacher_disagreement_score":0.15330867,"about_ca_system_score_codex":0.0026926112,"about_ca_system_score_gemma":0.0016762469,"threshold_uncertainty_score":0.99974567},"labels":[],"label_agreement":null},{"id":"W2950623518","doi":"10.1097/01.hs9.0000559048.84930.7b","title":"PF208 MN1 IS INDISPENSABLE FOR MLL‐REARRANGED ACUTE MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Biology; Cancer research; Leukemia; Myeloid leukemia; clone (Java method); Cell culture; Myeloid; Cytotoxic T cell; Oncogene; U937 cell; Apoptosis; Cell cycle; Molecular biology; In vitro; Immunology; Genetics; Gene","score_opus":0.020453164644980325,"score_gpt":0.29962421660561406,"score_spread":0.27917105196063374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950623518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9007607,0.00061091926,0.0003611816,0.0035401043,0.00034557763,0.0028839414,0.00011279077,0.00024396753,0.09114082],"genre_scores_gemma":[0.66063523,0.00027920984,0.01055659,0.004700347,0.0007194541,0.0003006866,0.0002654055,0.00024572609,0.32229736],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972264,0.00004063949,0.00040846347,0.0007183671,0.00064311636,0.0009630203],"domain_scores_gemma":[0.9979723,0.00018549651,0.000117812466,0.0010409083,0.0002833376,0.000400164],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00035825718,0.00035834458,0.00070896064,0.00010507213,0.00014318926,0.000059174094,0.0003458213,0.00037691928,0.010939906],"category_scores_gemma":[0.00011217959,0.00031000742,0.00031509952,0.00043500576,0.00010441441,0.00020583629,0.00015903157,0.00062412815,0.005478177],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026340878,0.00020192841,0.019603789,0.0013847145,0.0011875809,0.00035067165,0.0015482822,0.000014450732,0.13775593,0.0011500486,0.8165252,0.017643321],"study_design_scores_gemma":[0.019624382,0.0017147661,0.010256797,0.0005077768,0.0005434689,0.0005324363,0.0014910667,0.004312265,0.116664596,0.00092944026,0.8423727,0.0010503035],"about_ca_topic_score_codex":0.0001643975,"about_ca_topic_score_gemma":0.00003383156,"teacher_disagreement_score":0.24012549,"about_ca_system_score_codex":0.0010098981,"about_ca_system_score_gemma":0.0010554149,"threshold_uncertainty_score":0.9999352},"labels":[],"label_agreement":null},{"id":"W2950630840","doi":"10.1097/01.hs9.0000560636.62389.3a","title":"PF587 SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPD) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SAIT Polytechnic; Alberta Cancer Foundation; Hôpital Maisonneuve-Rosemont; Vancouver General Hospital; CancerCare Manitoba; Royal Victoria Hospital; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Tolerability; Lenalidomide; Medicine; Multiple myeloma; Refractory (planetary science); Dexamethasone; Internal medicine; Oncology; Bortezomib; Pharmacology; Phases of clinical research; Progressive disease; Adverse effect; Gastroenterology; Toxicity; Chemotherapy; Materials science","score_opus":0.01371024063456188,"score_gpt":0.2593603018621555,"score_spread":0.24565006122759359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950630840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568343,0.00039535973,0.000009518778,0.00012667877,0.000055974037,0.0014688502,0.000020767307,0.00006408257,0.0021753612],"genre_scores_gemma":[0.9888133,0.00005796659,0.0045216875,0.00015885309,0.00004147313,0.00003701565,0.00009913544,0.000059760554,0.006210809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807876,0.00008719853,0.00030668444,0.0005124953,0.0005090724,0.0005057963],"domain_scores_gemma":[0.9986251,0.0003168868,0.00009331997,0.00049180276,0.00014112153,0.00033176073],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016239016,0.00027369807,0.00050481054,0.00010396448,0.000050370774,0.000024202793,0.00008208946,0.00015497222,0.0012997966],"category_scores_gemma":[0.0003545302,0.00017600681,0.00004920731,0.00031083098,0.00007301068,0.0001799066,0.000071802824,0.00032717796,0.0002520761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009304892,0.0007439746,0.97269505,0.00019533279,0.000119906734,0.00024335008,0.00014136585,0.0000034455418,0.0004888348,0.000008501399,0.00034266146,0.015712678],"study_design_scores_gemma":[0.036821257,0.0022721798,0.95640796,0.0003725515,0.000039444436,0.000024166786,0.00021037295,0.0005779401,0.00063843315,0.000008056481,0.002396469,0.00023117405],"about_ca_topic_score_codex":0.00022558881,"about_ca_topic_score_gemma":0.00037499965,"teacher_disagreement_score":0.027516363,"about_ca_system_score_codex":0.00014061663,"about_ca_system_score_gemma":0.00015510459,"threshold_uncertainty_score":0.99961317},"labels":[],"label_agreement":null},{"id":"W2950632884","doi":"10.1097/01.hs9.0000564556.92986.0e","title":"PS1577 PLATELET COUNT AND MEAN PLATELET VOLUME IN ACUTE STROKE: A SYSTEMATIC REVIEW AND META‐ANALYSIS","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Strictly standardized mean difference; Meta-analysis; Internal medicine; Stroke (engine); Confidence interval; Mean platelet volume; Inclusion and exclusion criteria; Subgroup analysis; Platelet; Pathology; Alternative medicine","score_opus":0.04291832931752954,"score_gpt":0.3239036019234264,"score_spread":0.28098527260589684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950632884","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031963533,0.99058497,0.000005603428,0.00010597049,0.000048215767,0.008155686,0.00049320504,0.00007821395,0.00049616495],"genre_scores_gemma":[0.00002546915,0.9937103,0.0004262905,0.00046409282,0.000027511034,0.0014328021,0.00028788965,0.00012611071,0.0034995559],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99520177,0.0005517976,0.001938177,0.0010981427,0.0006459191,0.00056421506],"domain_scores_gemma":[0.99685484,0.00027661424,0.001005104,0.0013541303,0.00013999724,0.00036930156],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012122297,0.0010482463,0.014603118,0.00038859947,0.00006410326,0.00008508567,0.00028935657,0.00060410774,0.0012314818],"category_scores_gemma":[0.00014116571,0.0007338732,0.0020980185,0.0010087923,0.00013621307,0.00013531893,0.00023194452,0.0006400427,0.00019887162],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014738322,0.000043131047,0.00004682914,0.7879665,0.2088299,0.0005248939,0.000031489068,5.604099e-8,4.8851437e-8,0.000016239825,0.00082271703,0.0017034751],"study_design_scores_gemma":[0.00043679192,0.000052649502,0.0000068634818,0.1341804,0.8000277,0.0005507562,0.000030438165,0.000025042984,3.5686892e-7,0.0000030106125,0.0641304,0.0005555488],"about_ca_topic_score_codex":0.000023112156,"about_ca_topic_score_gemma":0.000049839233,"teacher_disagreement_score":0.6537861,"about_ca_system_score_codex":0.00022342778,"about_ca_system_score_gemma":0.00030397082,"threshold_uncertainty_score":0.99968153},"labels":[],"label_agreement":null},{"id":"W2950636832","doi":"10.1097/01.hs9.0000561096.37776.87","title":"PF703 LONG‐TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; McMaster University","funders":"","keywords":"Medicine; Discontinuation; Adverse effect; Tolerability; Placebo; Internal medicine; Syk; Nausea; Immune thrombocytopenia; Platelet","score_opus":0.03448255536868397,"score_gpt":0.36925396620834694,"score_spread":0.334771410839663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950636832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910525,0.0010043818,0.0000025422046,0.00014019031,0.00016500008,0.0049421554,0.00002389181,0.00007079804,0.0025985183],"genre_scores_gemma":[0.9969111,0.0002748603,0.00051761256,0.000022232602,0.000103093655,0.00023083328,0.00008500612,0.00003817752,0.0018170695],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99841964,0.000058182504,0.00057428365,0.00035478777,0.00028047207,0.00031262005],"domain_scores_gemma":[0.9988054,0.00009422265,0.00025686363,0.00065992505,0.00006863831,0.00011495354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008145074,0.0002636512,0.0009176447,0.00001889133,0.00007187991,0.000020620739,0.00010389549,0.00011461742,0.000891891],"category_scores_gemma":[0.000017115839,0.0001343757,0.0002716454,0.00013588663,0.00011109189,0.00007138662,0.000030578616,0.00012421091,0.00012656016],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32205403,0.040283866,0.2363432,0.000821039,0.0029418624,0.0017842533,0.0020846804,0.0000029001856,0.001544015,0.000040701092,0.00010700557,0.39199245],"study_design_scores_gemma":[0.70535064,0.060599152,0.2195689,0.00083775533,0.0008481646,0.0003466533,0.0007571686,0.000069849775,0.009785777,0.000013765782,0.0014715558,0.00035061376],"about_ca_topic_score_codex":0.00004544113,"about_ca_topic_score_gemma":0.000085098494,"teacher_disagreement_score":0.39164183,"about_ca_system_score_codex":0.00006171229,"about_ca_system_score_gemma":0.000118724965,"threshold_uncertainty_score":0.9765581},"labels":[],"label_agreement":null},{"id":"W2950646286","doi":"10.1097/01.hs9.0000564672.91201.a6","title":"S1606 SAFETY AND EFFICACY OF COMBINATION OF SELINEXOR, DARATUMUMAB, AND DEXAMETHASONE (SDD) IN PATIENTS WITH MULTIPLE MYELOMA (MM) PREVIOUSLY EXPOSED TO PROTEASOME INHIBITORS AND IMMUNOMODULATORY DRUGS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Vancouver General Hospital; CancerCare Manitoba; Royal Victoria Hospital; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Tolerability; Medicine; Refractory (planetary science); Internal medicine; Oncology; Dexamethasone; Proteasome inhibitor; Phases of clinical research; Carfilzomib; Multiple myeloma; Pharmacology; Lenalidomide; Gastroenterology; Toxicity; Adverse effect; Biology","score_opus":0.006718724720766075,"score_gpt":0.23815034598627274,"score_spread":0.23143162126550668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950646286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973991,0.00052396255,0.000022694565,0.000100826015,0.000010177276,0.0016724383,0.000010522677,0.000013345591,0.00024694938],"genre_scores_gemma":[0.9985924,0.00002706888,0.0011788305,0.000028271985,0.000010585979,0.000028836192,0.00002411088,0.000016198856,0.00009374294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990764,0.00002761438,0.00032388177,0.00026161838,0.0001752644,0.00013520085],"domain_scores_gemma":[0.99932104,0.00012593635,0.00011594026,0.00021236714,0.00009682937,0.00012786865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001451656,0.00013426198,0.00033938244,0.000031691903,0.000028017746,0.0000054192174,0.00003773536,0.00007700458,0.000022772649],"category_scores_gemma":[0.000079354024,0.000113143644,0.00001869827,0.00018743511,0.000103346676,0.00006820127,0.00004226139,0.00013748974,0.0000012950278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037135358,0.0009988432,0.831025,0.0015612304,0.00006878096,0.0000015185562,0.001496672,0.000019509287,0.14173485,0.00012140035,0.000022911363,0.019235732],"study_design_scores_gemma":[0.013465663,0.00060446793,0.8814189,0.00058327476,0.000050225317,0.0000041692474,0.00023978887,0.00032225644,0.10290019,0.000011675599,0.00024730756,0.00015208716],"about_ca_topic_score_codex":0.00001337889,"about_ca_topic_score_gemma":0.000002245055,"teacher_disagreement_score":0.050393876,"about_ca_system_score_codex":0.000029502311,"about_ca_system_score_gemma":0.000031440944,"threshold_uncertainty_score":0.4613864},"labels":[],"label_agreement":null},{"id":"W2950661198","doi":"10.1097/01.hs9.0000559348.09806.86","title":"PF284 OCCUPATIONAL PESTICIDES EXPOSURE IS ASSOCIATED WITH AN INCREASED RISK OF ACUTE MYELOID LEUKEMIA: A META-ANALYSIS OF CASE-CONTROL STUDIES INCLUDING 2981 PATIENTS AND 248705 CONTROLS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Human Health and Disease","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Odds ratio; Medicine; Confidence interval; Meta-analysis; Population; Internal medicine; Leukemia; Myeloid leukemia; Oncology; Environmental health","score_opus":0.05383176886792042,"score_gpt":0.3324609436776316,"score_spread":0.2786291748097112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950661198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99431574,0.0029985437,0.000035087545,0.000044715733,0.000014595718,0.0008383393,0.0016202702,0.000025604346,0.000107080145],"genre_scores_gemma":[0.9984998,0.000039685252,0.0003856909,0.000726235,0.000020828738,0.00005917343,0.00016086231,0.000021348615,0.0000863386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785256,0.00028005886,0.0006840133,0.00037187582,0.0005393295,0.00027213374],"domain_scores_gemma":[0.9967528,0.00094079785,0.0007155736,0.00034551928,0.0009139963,0.00033129245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049935235,0.00025862473,0.0019949751,0.00015342733,0.00011618992,0.0000098381115,0.00005989863,0.00012461175,0.0007579627],"category_scores_gemma":[0.00087809854,0.0001763525,0.000402258,0.0004073398,0.00012252081,0.00013913172,0.000032149117,0.00018267504,0.0000030463443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002299541,0.00029818504,0.8512549,0.00023674741,0.1445025,0.000107731066,0.0008711018,0.00011865904,0.00007905643,0.00002214911,0.00012529407,0.00008413989],"study_design_scores_gemma":[0.008440545,0.0015043984,0.65747154,0.00004675263,0.32927412,0.000013138302,0.0006922508,0.002246843,0.000106471925,0.000041069005,0.000003380909,0.00015949375],"about_ca_topic_score_codex":0.0006390526,"about_ca_topic_score_gemma":0.00036499742,"teacher_disagreement_score":0.19378336,"about_ca_system_score_codex":0.00012093425,"about_ca_system_score_gemma":0.00033117982,"threshold_uncertainty_score":0.829916},"labels":[],"label_agreement":null},{"id":"W2950731790","doi":"10.1097/01.hs9.0000562564.17744.e5","title":"PS1067 AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA: PRELIMINARY RESULTS OF EARLIER STEROID USE","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Adverse effect; Refractory (planetary science); Cohort; Tocilizumab; Lymphoma; Gastroenterology; Clinical endpoint; Surgery; Oncology; Chimeric antigen receptor; Cancer; Disease; Randomized controlled trial; Immunotherapy","score_opus":0.012470315148255274,"score_gpt":0.23937852626221545,"score_spread":0.22690821111396017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950731790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814812,0.00047004112,0.000006701129,0.00006221369,0.00013427538,0.0013752864,0.00009962716,0.00004919868,0.016321437],"genre_scores_gemma":[0.9352751,0.00007897788,0.0004405599,0.00014701969,0.000055559158,0.000028022598,0.00015016364,0.00010513769,0.0637195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689627,0.00014711295,0.0006233001,0.0006562483,0.0009993162,0.00067773374],"domain_scores_gemma":[0.99778265,0.0002173458,0.00023423636,0.0012342759,0.00028167316,0.00024983496],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003928481,0.0003323796,0.00064063317,0.00015921805,0.000039851562,0.000022626902,0.0002307469,0.0002731146,0.0027627524],"category_scores_gemma":[0.000076167235,0.00027237623,0.00013608464,0.0004407562,0.00009317944,0.0002694471,0.00016908841,0.00040358046,0.00032650752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0714377,0.014324846,0.84024423,0.001244084,0.00021765164,0.00030231604,0.0024472189,0.00003469707,0.04955077,0.000018709943,0.008093172,0.012084605],"study_design_scores_gemma":[0.09033931,0.0115288785,0.82125527,0.00079733116,0.00008189966,0.00001285542,0.00063888705,0.00012885552,0.03425743,0.000008360669,0.040389348,0.0005615514],"about_ca_topic_score_codex":0.00016872343,"about_ca_topic_score_gemma":0.000059944352,"teacher_disagreement_score":0.047398064,"about_ca_system_score_codex":0.00025111315,"about_ca_system_score_gemma":0.00026350812,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W2950773020","doi":"10.1097/01.hs9.0000562404.53930.45","title":"PS1027 ASSESSMENT OF MOLECULAR MRD KINETICS BY ERROR‐CORRECTED NEXT‐GENERATION SEQUENCING PROVIDES INDEPENDENT PROGNOSTIC INFORMATION IN ADULT AML PATIENTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Ontario Institute for Cancer Research; University of Alberta; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Minimal residual disease; Induction chemotherapy; Chemotherapy; Proportional hazards model; Stage (stratigraphy); Point mutation; DNA sequencing; Gene; Mutation; Leukemia; Biology; Genetics","score_opus":0.01952076263891619,"score_gpt":0.26385232389323277,"score_spread":0.24433156125431657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950773020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969016,0.00017179978,0.00019629055,0.00009633446,0.00013509621,0.0015717264,0.000014158355,0.00002977394,0.0008832277],"genre_scores_gemma":[0.9969391,0.000027719783,0.0019504145,0.0002484303,0.000014425183,0.00015639537,0.00061554345,0.000017636388,0.000030324258],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985877,0.000048701717,0.0004960543,0.00019373058,0.00047202813,0.00020176398],"domain_scores_gemma":[0.9991179,0.000039354676,0.00022247914,0.00024009819,0.0003071026,0.00007304311],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006876054,0.00017487483,0.00028329284,0.000074459465,0.000017633569,0.000029222567,0.000054932327,0.00010891771,0.0001343985],"category_scores_gemma":[0.00010952778,0.00015062164,0.00006150365,0.00020488078,0.0000149189855,0.000267986,0.00003317746,0.00012901542,0.000025909208],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031084262,0.0008576263,0.9390155,0.00027638196,0.0000538984,0.000011483823,0.00034374426,0.0005629149,0.047206428,0.00009244333,0.0003406197,0.011207883],"study_design_scores_gemma":[0.007884211,0.0018779363,0.80127716,0.0011785814,0.00021440936,0.000014143315,0.0011637078,0.043959517,0.141755,0.00002618591,0.00025971854,0.0003894409],"about_ca_topic_score_codex":0.0002491142,"about_ca_topic_score_gemma":0.00008846869,"teacher_disagreement_score":0.13773835,"about_ca_system_score_codex":0.00038788878,"about_ca_system_score_gemma":0.00013924426,"threshold_uncertainty_score":0.6142172},"labels":[],"label_agreement":null},{"id":"W2950780445","doi":"10.1097/01.hs9.0000562468.89369.69","title":"PS1043 OUTCOMES OF PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA: A POPULATION‐BASED REAL‐WORLD STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary; Western University","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Refractory (planetary science); Myeloid leukemia; Regimen; Population; Chemotherapy regimen; Intensive care; Chemotherapy; Pediatrics; Surgery; Intensive care medicine","score_opus":0.01713439800318669,"score_gpt":0.2992449930988417,"score_spread":0.28211059509565506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950780445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99122745,0.000020257765,0.000016176351,0.00020600951,0.00011713447,0.0027121408,0.000043759657,0.00013639031,0.00552071],"genre_scores_gemma":[0.9631043,0.0000086329865,0.0022603802,0.00030574636,0.000048701124,0.0000799079,0.0002233463,0.00010985072,0.033859152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968224,0.00013834494,0.0006549569,0.00060350256,0.0012708948,0.0005098612],"domain_scores_gemma":[0.9974117,0.00030384678,0.00033686068,0.0012728883,0.0004240244,0.00025066052],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002850291,0.000375221,0.0009881319,0.00024692967,0.00008095634,0.000019023842,0.00027649425,0.00017026113,0.0028579792],"category_scores_gemma":[0.00014147935,0.00024016548,0.00014408494,0.0008958184,0.00006804414,0.00020793546,0.00011536387,0.00063970464,0.00022564766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042914823,0.0009829529,0.9903156,0.00021727191,0.0005204062,0.00009924381,0.0002612961,0.000035709065,0.00019994799,0.000026646661,0.001991274,0.0010581604],"study_design_scores_gemma":[0.016379882,0.0031507853,0.9777107,0.00016323896,0.00032594465,0.0000028327172,0.00045729073,0.00017234668,0.00027152142,0.0000070678966,0.0010775727,0.00028081785],"about_ca_topic_score_codex":0.001281499,"about_ca_topic_score_gemma":0.0010196343,"teacher_disagreement_score":0.028338442,"about_ca_system_score_codex":0.0012187414,"about_ca_system_score_gemma":0.0010522096,"threshold_uncertainty_score":0.99805355},"labels":[],"label_agreement":null},{"id":"W2950809516","doi":"10.1097/hs9.0000000000000205","title":"Screening for cancer in unprovoked venous thromboembolism","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Calgary; University of Ottawa","funders":"Servier; Sanofi; Bayer; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Cancer; Malignancy; Venous thromboembolism; Confidence interval; Incidence (geometry); Occult; Clinical trial; Internal medicine; Randomized controlled trial; Pathology; Thrombosis; Alternative medicine","score_opus":0.02311906044994245,"score_gpt":0.3087215694838521,"score_spread":0.28560250903390966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950809516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707056,0.001981745,0.0004401927,0.0019689729,0.00053758273,0.0026941535,0.000017965625,0.000109731875,0.021544008],"genre_scores_gemma":[0.990817,0.00024754822,0.0026993235,0.001497101,0.00023549894,0.0003929075,0.000020468875,0.000058767135,0.004031349],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987457,0.00001417,0.0002556495,0.00036142723,0.00019894973,0.00042412305],"domain_scores_gemma":[0.9993961,0.000048872473,0.0000708368,0.00033668274,0.00005366249,0.00009385615],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016126943,0.00017404425,0.0006692669,0.000061565275,0.000044820015,0.000019019206,0.00009881209,0.00009841699,0.0020195353],"category_scores_gemma":[0.000021625781,0.00015841256,0.00012444274,0.00018514969,0.000022246755,0.00008070217,0.00005317559,0.0001367024,0.000107877844],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011226131,0.007794802,0.26390192,0.007599178,0.0019066344,0.00025225355,0.007627137,0.0045583188,0.026544694,0.046983615,0.08842315,0.54328567],"study_design_scores_gemma":[0.0112776905,0.0015226551,0.7009516,0.0021658596,0.00050366746,0.000019481511,0.0025975732,0.0041047623,0.0057291863,0.0014816034,0.26875034,0.00089563895],"about_ca_topic_score_codex":0.00048747312,"about_ca_topic_score_gemma":0.00035866478,"teacher_disagreement_score":0.54239005,"about_ca_system_score_codex":0.000092076414,"about_ca_system_score_gemma":0.00007661262,"threshold_uncertainty_score":0.9988927},"labels":[],"label_agreement":null},{"id":"W2950880743","doi":"10.1097/01.hs9.0000560844.39623.aa","title":"PF640 MULTIPLE MYELOMA TREATMENT LANDSCAPE FROM 2011 TO 2017 IN ALBERTA, CANADA: RESULTS FROM THE POPULATION‐BASED “IDENTIFYING OUTCOMES IN REAL‐WORLD MULTIPLE MYELOMA” (INFORMM) STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Multiple myeloma; Lenalidomide; Medicine; Population; Bortezomib; Autologous stem-cell transplantation; Transplantation; Family medicine; Internal medicine; Environmental health","score_opus":0.045912224532869875,"score_gpt":0.3112283706097278,"score_spread":0.26531614607685794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950880743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910524,0.00017144272,0.0000032024673,0.0018288419,0.00033233658,0.0042731497,0.0007161249,0.0000512293,0.0015712657],"genre_scores_gemma":[0.9858081,0.00002188486,0.0009012563,0.00025059583,0.00010880118,0.00037211462,0.0016754719,0.00006436977,0.010797428],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99606276,0.00020756341,0.0009984485,0.00092033506,0.00096202735,0.0008488421],"domain_scores_gemma":[0.9953832,0.0023595353,0.00022242601,0.0015136251,0.00009297157,0.00042826723],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026874425,0.00054454454,0.0010019718,0.00022039964,0.00016604437,0.00008061683,0.00036815688,0.00012995195,0.0010738495],"category_scores_gemma":[0.00057602156,0.0003674372,0.00016783297,0.000457952,0.00002110798,0.000195258,0.00014862245,0.0003305021,0.00075003755],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025570437,0.0009871599,0.9865882,0.000020544103,0.00029596605,0.000417914,0.0017900168,0.00032955283,0.00006426407,0.0000020007597,0.0025050128,0.004442324],"study_design_scores_gemma":[0.02676487,0.0002895921,0.9641754,0.00024036443,0.000073005845,0.0000013096821,0.001765469,0.0042713135,0.0002940699,0.000008303895,0.0017782162,0.00033807638],"about_ca_topic_score_codex":0.99124855,"about_ca_topic_score_gemma":0.9989643,"teacher_disagreement_score":0.024207827,"about_ca_system_score_codex":0.0013502317,"about_ca_system_score_gemma":0.00070180214,"threshold_uncertainty_score":0.99987775},"labels":[],"label_agreement":null},{"id":"W2950895705","doi":"10.1097/01.hs9.0000559856.05874.69","title":"PF411 ENESTOP 192‐WK RESULTS: DURABILITY AND IMPACT ON QUALITY OF LIFE OF TREATMENT‐FREE REMISSION (TFR) FOLLOWING SECOND‐LINE (2L) NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Nilotinib; Internal medicine; Gastroenterology; Imatinib mesylate; Surgery; Myeloid leukemia; Imatinib","score_opus":0.018766925244077012,"score_gpt":0.2870449102057383,"score_spread":0.2682779849616613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950895705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944503,0.0007880774,0.0000026735847,0.00009154116,0.000112306974,0.0018405057,0.0002346119,0.000057462414,0.0024225398],"genre_scores_gemma":[0.9973477,0.00009596095,0.00038977037,0.000045691646,0.00006928312,0.00003551834,0.00027094717,0.00007321791,0.0016718996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961252,0.00024189356,0.0014200892,0.00094767363,0.00068856747,0.0005765404],"domain_scores_gemma":[0.99638635,0.00056179904,0.0007491121,0.0017594226,0.00016330683,0.00038001832],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059740443,0.00061302504,0.0016436265,0.00012632465,0.00005409405,0.00001134651,0.00020614442,0.0003155936,0.00058808026],"category_scores_gemma":[0.0007003965,0.00041840374,0.00033063808,0.0004287875,0.00013813414,0.00019663,0.000115590396,0.00033856713,0.00002076909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012975692,0.0014001274,0.96845824,0.0012924195,0.00048950966,0.00002341887,0.0007646322,0.00029061592,0.0066626305,0.00001988854,0.00019714491,0.007425671],"study_design_scores_gemma":[0.07560471,0.014283875,0.89184326,0.0019205387,0.00020698398,0.000010214236,0.0002904111,0.00025998263,0.014678538,0.000036644695,0.00041881672,0.00044605072],"about_ca_topic_score_codex":0.0040202183,"about_ca_topic_score_gemma":0.0014589488,"teacher_disagreement_score":0.076615006,"about_ca_system_score_codex":0.007962736,"about_ca_system_score_gemma":0.002661047,"threshold_uncertainty_score":0.9998268},"labels":[],"label_agreement":null},{"id":"W2950944873","doi":"10.1097/01.hs9.0000563756.72895.a3","title":"PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW‐UP OF THE PHASE 2, RANDOMIZED ELOQUENT‐3 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Lenalidomide; Medicine; Internal medicine; Dexamethasone; Oncology; Multiple myeloma; Combination therapy; Ixazomib; Refractory (planetary science); Progression-free survival; Bortezomib; Overall survival; Carfilzomib","score_opus":0.025348177318384468,"score_gpt":0.31251581433105274,"score_spread":0.2871676370126683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950944873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865555,0.00097551564,0.000046889953,0.00020784723,0.00025351415,0.008808246,0.0015799701,0.000050314444,0.0015221795],"genre_scores_gemma":[0.98600763,0.000028533408,0.0017849042,0.0000787795,0.0001111356,0.0014417857,0.0004535557,0.00006202002,0.0100316275],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970077,0.00038962622,0.0007398404,0.0006314882,0.0007323264,0.0004990094],"domain_scores_gemma":[0.99460864,0.003738374,0.00030661095,0.0008057432,0.0002610417,0.0002796034],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00072318857,0.0003560147,0.0011073273,0.00007003103,0.00013375524,0.00002803131,0.00017104113,0.00015426832,0.002315227],"category_scores_gemma":[0.0029498222,0.0002244146,0.0004791973,0.00021750692,0.00023823371,0.00011728009,0.00013945751,0.00029095932,0.000068788584],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9584505,0.005636859,0.01093331,0.00036215244,0.002246628,0.00015176472,0.0020335938,0.000008059997,0.0015316074,0.000079130514,0.0071397917,0.0114266],"study_design_scores_gemma":[0.94499725,0.0021030232,0.043532275,0.00039953765,0.0005126579,0.000043385324,0.0010181679,0.0010278949,0.0014678829,0.000050775423,0.0045865476,0.0002605917],"about_ca_topic_score_codex":0.00014963871,"about_ca_topic_score_gemma":0.000105137595,"teacher_disagreement_score":0.032598965,"about_ca_system_score_codex":0.00018410268,"about_ca_system_score_gemma":0.00033929592,"threshold_uncertainty_score":0.9985968},"labels":[],"label_agreement":null},{"id":"W2950949385","doi":"10.1097/01.hs9.0000560700.97828.31","title":"PF603 FASTER & SUSTAINED IMPROVEMENT IN HEALTH‐RELATED QUALITY OF LIFE IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D‐RD) VS RD: MAIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Quality of life (healthcare); Lenalidomide; Health related quality of life; Visual analogue scale; Internal medicine; Multiple myeloma; Daratumumab; Physical therapy; Disease","score_opus":0.1367159433928387,"score_gpt":0.3582859021089189,"score_spread":0.2215699587160802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950949385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837235,0.0023058604,0.0010457652,0.00790072,0.00021128377,0.0029204444,0.00040941703,0.0000776645,0.0014053436],"genre_scores_gemma":[0.99079585,0.00021248596,0.0032743718,0.0023698125,0.000058798225,0.0002588376,0.0003259505,0.00009850712,0.0026053893],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9882109,0.0010164678,0.008236684,0.0011928171,0.00026378324,0.0010793199],"domain_scores_gemma":[0.9927597,0.0019740257,0.0035951005,0.0011353169,0.00012976819,0.0004060965],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.012747431,0.0005428384,0.0029854006,0.00054353534,0.00010403232,0.000064299296,0.0004062472,0.0003954566,0.0016363615],"category_scores_gemma":[0.0016574188,0.00060346146,0.00020857694,0.00087727536,0.00010594275,0.0005357618,0.0000627105,0.0005169841,0.00093644566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015282586,0.0006185173,0.98163056,0.002870596,0.00013894346,0.000007152172,0.0053063924,0.003157632,0.00013373923,0.002176325,0.0021868534,0.00024499875],"study_design_scores_gemma":[0.059356928,0.001033023,0.9009351,0.0026613923,0.00002816882,0.000016973489,0.008522831,0.0063196677,0.0002170451,0.0025418755,0.015864985,0.0025020088],"about_ca_topic_score_codex":0.045426067,"about_ca_topic_score_gemma":0.0622945,"teacher_disagreement_score":0.08069549,"about_ca_system_score_codex":0.0011359386,"about_ca_system_score_gemma":0.0005461758,"threshold_uncertainty_score":0.99984145},"labels":[],"label_agreement":null},{"id":"W2950984087","doi":"10.1097/01.hs9.0000563784.11014.52","title":"PS1377 IMPROVEMENT IN HEALTH‐RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT‐ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont; McGill University; Hotel Dieu Hospital","funders":"","keywords":"Medicine; Daratumumab; Bortezomib; Multiple myeloma; Internal medicine; Autologous stem-cell transplantation; Oncology","score_opus":0.03098393264413396,"score_gpt":0.3156171613640681,"score_spread":0.28463322871993413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950984087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99033695,0.0005998895,0.000021751883,0.00012073405,0.000043471566,0.008371559,0.00021647755,0.000048822843,0.00024032162],"genre_scores_gemma":[0.99763346,0.00008878466,0.00085808925,0.00006885573,0.000012622379,0.00048360915,0.00030196575,0.000060105518,0.0004924872],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996729,0.00024601797,0.001086329,0.0006900923,0.00059433974,0.0006542053],"domain_scores_gemma":[0.9977837,0.00059854,0.0003753782,0.0005343099,0.00021713058,0.000490948],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005844389,0.00037939605,0.0012253738,0.0001349283,0.00009833571,0.000022599494,0.00011212567,0.00014233358,0.00013840973],"category_scores_gemma":[0.0002643642,0.0002737035,0.000107980515,0.00038953792,0.00007404907,0.0001340358,0.000041094525,0.00024079463,0.000010884267],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014331524,0.0037202334,0.97093844,0.0011034753,0.0004830454,0.000064536565,0.0012554512,0.000016103833,0.0010174091,0.000009956775,0.0000855624,0.0069742682],"study_design_scores_gemma":[0.09036678,0.008446173,0.89629143,0.000428196,0.00007029693,0.000004767556,0.0014470874,0.00060390134,0.0020394037,0.0000073187243,0.000049738537,0.00024492908],"about_ca_topic_score_codex":0.013286757,"about_ca_topic_score_gemma":0.0058835163,"teacher_disagreement_score":0.07603525,"about_ca_system_score_codex":0.00018525268,"about_ca_system_score_gemma":0.00031565956,"threshold_uncertainty_score":0.9999715},"labels":[],"label_agreement":null},{"id":"W2951024782","doi":"10.1097/01.hs9.0000565672.55016.07","title":"PB1792 AGE AS AN INDEPENDENT PREDICTIVE FACTOR IN SURVIVAL OUTCOMES OF MULTIMODALITY TREATMENTS FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A REVIEW FROM TERTIARY INSTITUTION","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Primary central nervous system lymphoma; Radiation therapy; Proportional hazards model; Hazard ratio; Internal medicine; Salvage therapy; Survival analysis; Retrospective cohort study; Multivariate analysis; Lymphoma; Log-rank test; Surgery; Chemotherapy; Confidence interval","score_opus":0.05474239867495916,"score_gpt":0.3460365340602778,"score_spread":0.2912941353853186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951024782","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023973223,0.9609314,0.0000290674,0.00001893184,0.00066345755,0.010440079,0.0033080988,0.00009135817,0.0005443573],"genre_scores_gemma":[0.01972958,0.9720733,0.0003078774,0.00008494461,0.00013161547,0.0018431422,0.005522448,0.00011096976,0.00019610813],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957455,0.00036445708,0.0015976129,0.0010769765,0.00066431833,0.000551182],"domain_scores_gemma":[0.99723506,0.00035500547,0.0008772232,0.001108508,0.000111864996,0.00031235444],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019887036,0.0009261257,0.0054927417,0.00011244867,0.00005472265,0.000022139755,0.0002554484,0.0005915767,0.00009383752],"category_scores_gemma":[0.00009262571,0.0006454942,0.0013603171,0.00020752981,0.00008081646,0.00017904422,0.00011565052,0.00017184542,0.000047830647],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001738855,0.003533687,0.043265864,0.11753733,0.00279101,0.0005336209,0.00015215685,0.0000010976871,6.801005e-7,0.00005151513,0.00005159749,0.8319076],"study_design_scores_gemma":[0.009321371,0.0008101489,0.77389926,0.16509056,0.013681585,0.00010336194,0.00015984147,0.000019156343,0.000010293765,0.000009559528,0.036197588,0.00069724914],"about_ca_topic_score_codex":0.0039008248,"about_ca_topic_score_gemma":0.00030785854,"teacher_disagreement_score":0.8312103,"about_ca_system_score_codex":0.0038533548,"about_ca_system_score_gemma":0.0013986961,"threshold_uncertainty_score":0.9999707},"labels":[],"label_agreement":null},{"id":"W2951051106","doi":"10.1097/01.hs9.0000559844.15284.b3","title":"PF408 DASFREE 2‐YEAR UPDATE: DASATINIB DISCONTINUATION IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML‐CP) AND DEEP MOLECULAR RESPONSE (DMR)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Dasatinib; Discontinuation; Medicine; Internal medicine; Clinical endpoint; Oncology; Myeloid leukemia; Imatinib; Gastroenterology; Clinical trial","score_opus":0.005851570532110407,"score_gpt":0.24902571653131772,"score_spread":0.2431741459992073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951051106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942794,0.002048526,0.00006783259,0.00018656979,0.000081982456,0.002197171,0.00002120783,0.000071480725,0.0010458637],"genre_scores_gemma":[0.9973669,0.00016028307,0.00081140915,0.00013779356,0.00007142683,0.00014270938,0.00032570603,0.00010947618,0.000874272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99691963,0.00021697184,0.0006324979,0.00089906005,0.00060079986,0.0007310296],"domain_scores_gemma":[0.9983943,0.0001189456,0.00023156246,0.0009442504,0.00008570366,0.00022525141],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039987318,0.0004867145,0.0007114866,0.00020454092,0.000049063445,0.00004240977,0.00018276733,0.00025877057,0.0010558772],"category_scores_gemma":[0.00013083822,0.0004234954,0.00007804822,0.00056450587,0.00012566011,0.00033477994,0.00013070146,0.00052714336,0.0002895137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029650146,0.0024167565,0.80508864,0.001431083,0.0005340925,0.0014929479,0.0027805502,0.0023824451,0.052113824,0.000539662,0.0006821154,0.10088773],"study_design_scores_gemma":[0.23892553,0.01297415,0.70310783,0.0034645463,0.0003466915,0.00011140299,0.000758032,0.012538692,0.019776266,0.00012270462,0.0062557855,0.0016183333],"about_ca_topic_score_codex":0.00037868955,"about_ca_topic_score_gemma":0.0019014947,"teacher_disagreement_score":0.2092754,"about_ca_system_score_codex":0.011084444,"about_ca_system_score_gemma":0.0022578642,"threshold_uncertainty_score":0.9998573},"labels":[],"label_agreement":null},{"id":"W2951075811","doi":"10.1097/01.hs9.0000562932.11356.53","title":"PS1162 COMBINATION THERAPY TO PREVENT IBRUTINIB WITHDRAWAL: CONTINUED IBRUTINIB WITH THE ADDITION OF VENETOCLAX AT TIME OF PROGRESSION IN IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Ibrutinib; Venetoclax; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Neutropenia; Discontinuation; Leukemia; Chemotherapy","score_opus":0.0057942809302078385,"score_gpt":0.2487847723173081,"score_spread":0.24299049138710027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951075811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920453,0.00039702316,0.000007804001,0.0001104278,0.000041551873,0.0056407475,0.000043234606,0.00007134273,0.0016425912],"genre_scores_gemma":[0.9952617,0.000037320213,0.000177425,0.00007908132,0.000042212854,0.00027836527,0.00039443708,0.00010128674,0.0036281226],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996413,0.00022098245,0.0007030474,0.000647135,0.0013626947,0.0006531274],"domain_scores_gemma":[0.997402,0.00028930124,0.0005793669,0.0009899612,0.00054038595,0.0001989745],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042829048,0.00042586896,0.0008512097,0.0001554793,0.00008096315,0.00002058954,0.00032053958,0.00022655664,0.0013087335],"category_scores_gemma":[0.000070313916,0.0002567763,0.0001128295,0.0010003594,0.00028501754,0.00015581053,0.0001465639,0.0002624647,0.00015487304],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.19409208,0.007880125,0.49145004,0.0109721115,0.0038917733,0.00047680573,0.019483427,0.024634125,0.14070609,0.00078038295,0.03328279,0.07235025],"study_design_scores_gemma":[0.2580231,0.032696944,0.24858539,0.014517703,0.0003747323,0.00018359284,0.0006567771,0.03684725,0.40072745,0.000042456642,0.0058915373,0.0014530689],"about_ca_topic_score_codex":0.0007278146,"about_ca_topic_score_gemma":0.00031433033,"teacher_disagreement_score":0.26002136,"about_ca_system_score_codex":0.032664645,"about_ca_system_score_gemma":0.011099778,"threshold_uncertainty_score":0.99998844},"labels":[],"label_agreement":null},{"id":"W2951076122","doi":"10.1097/01.hs9.0000562392.68284.f5","title":"PS1024 IMPACT OF MINIMAL RESIDUAL DISEASE AND COMPLETE REMISSION (CR)/CR WITH PARTIAL HEMATOLOGIC RECOVERY ON SURVIVAL AFTER GILTERITINIB THERAPY IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY AML","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Adverse effect; Nausea; Refractory (planetary science); Myeloid leukemia; Neutropenia; Chemotherapy","score_opus":0.01674566369118301,"score_gpt":0.27405793809520557,"score_spread":0.25731227440402255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951076122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99745446,0.00024161077,0.0000033293745,0.00021309634,0.000044070766,0.0012516637,0.00013339471,0.00004433921,0.0006140244],"genre_scores_gemma":[0.9988327,0.00007211121,0.0003313994,0.00011678247,0.000053688622,0.000045288223,0.00016640329,0.00007759318,0.0003040179],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99741876,0.000235448,0.00043228202,0.00062402675,0.0007439963,0.0005454954],"domain_scores_gemma":[0.99846023,0.00022586355,0.00018587621,0.0005998071,0.00013422284,0.00039400609],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000227388,0.0003808626,0.0007343503,0.000120636665,0.00004156867,0.000025473402,0.0001229192,0.00017091008,0.00096540933],"category_scores_gemma":[0.000095317744,0.00023300934,0.000095659445,0.00029587498,0.00020559448,0.00018317346,0.000074475596,0.00053128524,0.00003215703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11351246,0.0007510847,0.8805076,0.00027360223,0.00017864347,0.00043210358,0.00019346502,0.000031809654,0.0025184283,0.0000054605025,0.0005498761,0.0010454673],"study_design_scores_gemma":[0.016502503,0.012187598,0.96847975,0.0011090754,0.000048848826,0.000021950402,0.00014252814,0.00012035804,0.00083765475,0.000014295695,0.00021572612,0.0003196898],"about_ca_topic_score_codex":0.000105286235,"about_ca_topic_score_gemma":0.000021838307,"teacher_disagreement_score":0.09700996,"about_ca_system_score_codex":0.00028677547,"about_ca_system_score_gemma":0.000488674,"threshold_uncertainty_score":0.99994785},"labels":[],"label_agreement":null},{"id":"W2951090524","doi":"10.1097/01.hs9.0000564792.15111.43","title":"S1636 FRACTIONATED DOSING OF ARI‐0001 CELLS (A3B1:CD8:4–1BB:CD3Z CAR19) AND EARLY TOCILIZUMAB ADMINISTRATION MAY REDUCE THE INCIDENCE OF SEVERE CYTOKINE RELEASE SYNDROME IN PATIENTS WITH CD19+ MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Apheresis Group","funders":"","keywords":"Medicine; Cytokine release syndrome; Cyclophosphamide; Fludarabine; Internal medicine; Cohort; Cytokine; CD8; Toxicity; Immunology; Dosing; Gastroenterology; Immune system; Cancer; Chemotherapy; Immunotherapy","score_opus":0.012196298858509851,"score_gpt":0.25969541848738176,"score_spread":0.24749911962887192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951090524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967074,0.0002322458,0.0000052909945,0.00020529173,0.00006048919,0.0011652452,0.000027654873,0.000019070556,0.0015773142],"genre_scores_gemma":[0.99562633,0.000049082155,0.00025605125,0.000032846197,0.000018757833,0.000023189828,0.00002379819,0.0000348028,0.0039351354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980628,0.00010556255,0.00044961157,0.00034700814,0.00075304386,0.0002820086],"domain_scores_gemma":[0.99859446,0.00018566618,0.0002596539,0.00050218735,0.00035738136,0.00010065221],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027129575,0.00019996818,0.000440263,0.00008562497,0.00004861876,0.000021717777,0.00013279924,0.00014024242,0.0011275578],"category_scores_gemma":[0.00007522605,0.00014484434,0.00005937872,0.00048316558,0.00018142251,0.00021923656,0.000057205965,0.00034727977,0.000013628738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064312085,0.00063402916,0.6388951,0.0009640692,0.00015225711,0.00012753213,0.0015509477,0.00013396845,0.3469519,0.00012976461,0.00019517151,0.0038340415],"study_design_scores_gemma":[0.005642319,0.0027766544,0.855926,0.001303053,0.00007215733,0.00018074956,0.0011480307,0.000101062986,0.1321613,0.0000519296,0.00038801873,0.00024872913],"about_ca_topic_score_codex":0.0008856234,"about_ca_topic_score_gemma":0.00014479656,"teacher_disagreement_score":0.21703088,"about_ca_system_score_codex":0.00014299393,"about_ca_system_score_gemma":0.00031451392,"threshold_uncertainty_score":0.99978554},"labels":[],"label_agreement":null},{"id":"W2951135883","doi":"10.1097/01.hs9.0000559340.02182.80","title":"PF282 THE EFFECT OF MODERN THERAPEUTICS IN ADULT ACUTE MYELOID LEUKEMIA (AML): POPULATION‐BASED ANALYSIS OF LONG‐TERM OUTCOMES FROM THE MANITOBA CANCER REGISTRY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Medicine; Cancer registry; Relative survival; Population; Cancer; Cohort; Myeloid leukemia; Demography; Internal medicine; Pediatrics; Environmental health","score_opus":0.022140299836415783,"score_gpt":0.31686439306914493,"score_spread":0.29472409323272913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951135883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958967,0.0008864636,0.00015816979,0.0013712933,0.000087550754,0.0010075829,0.00015746779,0.000026450607,0.00040831976],"genre_scores_gemma":[0.9977125,0.00016457855,0.00013290092,0.0007335171,0.00006493231,0.00007451652,0.000212591,0.000047023117,0.000857471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757993,0.00028220328,0.0005821304,0.00038851786,0.0008087661,0.00035847584],"domain_scores_gemma":[0.9967474,0.0011258838,0.00036265847,0.0015087235,0.00018634014,0.00006904591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039913275,0.00029417442,0.0009782468,0.000119681696,0.00005773164,0.000020099216,0.0005636551,0.00021923972,0.0006550132],"category_scores_gemma":[0.00009038704,0.0001526715,0.00044597103,0.0010411429,0.0001423874,0.00007212126,0.0001118349,0.00056919374,0.000016621912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008667027,0.000035238456,0.9794919,0.00016506707,0.0029050973,0.00001986554,0.0003599791,0.0022630012,0.0042649675,0.000012239965,0.00016358067,0.009452348],"study_design_scores_gemma":[0.0031276487,0.00016665009,0.9620057,0.00022312404,0.0027400623,0.0000023268353,0.00018332562,0.023240382,0.00812234,0.000020743651,0.000022782644,0.0001449318],"about_ca_topic_score_codex":0.014698348,"about_ca_topic_score_gemma":0.011844923,"teacher_disagreement_score":0.02097738,"about_ca_system_score_codex":0.0007535434,"about_ca_system_score_gemma":0.00037908548,"threshold_uncertainty_score":0.99186283},"labels":[],"label_agreement":null},{"id":"W2951153020","doi":"10.1097/01.hs9.0000561560.35825.0d","title":"S820 FRONTLINE BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE 3/4 CLASSICAL HODGKIN LYMPHOMA: 3‐YEAR UPDATE OF THE ECHELON‐1 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"ABVD; Dacarbazine; Procarbazine; Medicine; Brentuximab vedotin; Vinblastine; Bleomycin; Vincristine; Internal medicine; Oncology; Population; Chemotherapy; Lymphoma; Cyclophosphamide; Hodgkin lymphoma","score_opus":0.00953334348027245,"score_gpt":0.25238860756793524,"score_spread":0.24285526408766278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951153020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935526,0.0002819267,0.00008813913,0.0018601711,0.00013116308,0.0025721397,0.000050869123,0.00004585661,0.0014171266],"genre_scores_gemma":[0.9922723,0.000025510097,0.0018594015,0.00044972802,0.000091402435,0.0001573033,0.000024081519,0.000056649766,0.0050635906],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99855125,0.000044399618,0.00030438378,0.00039502542,0.00038555666,0.00031940083],"domain_scores_gemma":[0.9988144,0.00008833867,0.00017216077,0.0007205291,0.000108119464,0.00009644569],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014779142,0.00025219464,0.0005583807,0.000021080674,0.000060962266,0.000017152033,0.00015919996,0.000089673085,0.000657254],"category_scores_gemma":[0.000017646085,0.0001379474,0.00018991058,0.00015691911,0.000065696135,0.00004763383,0.000058145655,0.00006609437,0.00007063794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003609193,0.0125889955,0.9539768,0.00031766458,0.00090368214,0.0000397398,0.00082760525,0.00002469341,0.0010802858,0.0011471089,0.008015594,0.017468615],"study_design_scores_gemma":[0.12272718,0.00797488,0.7414531,0.0004978359,0.000862591,0.00004467183,0.0042128996,0.0006918722,0.054059982,0.0000991072,0.066796675,0.00057921547],"about_ca_topic_score_codex":0.000070053386,"about_ca_topic_score_gemma":0.00010263807,"teacher_disagreement_score":0.21252373,"about_ca_system_score_codex":0.00016252192,"about_ca_system_score_gemma":0.00021354774,"threshold_uncertainty_score":0.71964705},"labels":[],"label_agreement":null},{"id":"W2951165653","doi":"10.1097/01.hs9.0000559032.62059.eb","title":"PF204 TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"CD34; CD38; Haematopoiesis; Stem cell; Biology; Cancer research; Myeloid leukemia; Leukemia; Cytotoxic T cell; Cord blood; T-cell receptor; Hematopoietic stem cell; Immunology; T cell; Immune system; Cell biology; In vitro","score_opus":0.02690869596386572,"score_gpt":0.3173762327065463,"score_spread":0.29046753674268055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951165653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93320596,0.0028322786,0.00000827498,0.002230777,0.000107818545,0.0015023533,0.0000036414795,0.000032925374,0.060075942],"genre_scores_gemma":[0.9804209,0.00015054713,0.00022910604,0.0018157373,0.000075037424,0.00013317318,0.000024443021,0.00004141999,0.01710965],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981249,0.00020033585,0.00031551416,0.00031893075,0.0005654245,0.0004748731],"domain_scores_gemma":[0.9988933,0.00019632155,0.000047589056,0.00075870764,0.000037188307,0.00006688507],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00055235403,0.00018924096,0.00038342108,0.0000756838,0.00002904799,0.00003278718,0.00028379966,0.00010187844,0.030585812],"category_scores_gemma":[0.0000201809,0.00013306529,0.00010287926,0.00038583414,0.00006251567,0.00006410043,0.000050849252,0.00048998836,0.0012504428],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003301121,0.0023866352,0.20168811,0.0004924402,0.00022937827,0.0005807037,0.012785714,0.00033329107,0.7475764,0.0015564325,0.007920988,0.021148782],"study_design_scores_gemma":[0.018415043,0.0015391406,0.09282438,0.0006808785,0.000037140366,0.0001433166,0.009291891,0.0021662554,0.06740147,0.0021123195,0.8047481,0.00064003334],"about_ca_topic_score_codex":0.00044532993,"about_ca_topic_score_gemma":0.00014214299,"teacher_disagreement_score":0.79682714,"about_ca_system_score_codex":0.00019024468,"about_ca_system_score_gemma":0.00014305428,"threshold_uncertainty_score":0.9995272},"labels":[],"label_agreement":null},{"id":"W2951223200","doi":"10.1097/01.hs9.0000559496.29967.d6","title":"PF321 REAL‐WORLD TREATMENT PATTERNS OF PATIENTS DIAGNOSED WITH DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) IN THE UNITED STATES (US)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Lymphoma; Internal medicine; International Prognostic Index; Diagnosis code; Medical diagnosis; Oncology; Retrospective cohort study; Population; Radiology","score_opus":0.00875889552529891,"score_gpt":0.23278754855979186,"score_spread":0.22402865303449296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951223200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950271,0.00013448019,0.0000015703578,0.0001798396,0.00005071653,0.0013467814,0.00016199406,0.00003260484,0.003064879],"genre_scores_gemma":[0.9961722,0.0006970152,0.000056154637,0.0005803434,0.000024984343,0.0002158393,0.0008826866,0.000040716703,0.0013300697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998411,0.000094579875,0.00034592167,0.0003490212,0.00040201514,0.00039747608],"domain_scores_gemma":[0.9986916,0.0002791347,0.0001688636,0.0006574901,0.00009044528,0.00011243122],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007695234,0.0003107435,0.0004934627,0.00011189944,0.000042942655,0.000019427796,0.000120391065,0.00006697311,0.00036922022],"category_scores_gemma":[0.000007737314,0.00016502116,0.00011884433,0.0004194791,0.000028111246,0.000057353423,0.000032975397,0.00005067158,0.000085859356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034781737,0.028084,0.9668756,0.00014676867,0.00012629594,0.00024737118,0.0022619166,0.000010620484,0.000005510302,0.00011852125,0.00040828987,0.0013672811],"study_design_scores_gemma":[0.05550247,0.0019491394,0.92718846,0.0002521702,0.00018461904,0.000003995934,0.0017483401,0.00008603672,0.0014364071,0.0000076693095,0.011467957,0.0001727337],"about_ca_topic_score_codex":0.009825624,"about_ca_topic_score_gemma":0.00723986,"teacher_disagreement_score":0.055154655,"about_ca_system_score_codex":0.0003479288,"about_ca_system_score_gemma":0.00008591589,"threshold_uncertainty_score":0.99676806},"labels":[],"label_agreement":null},{"id":"W2951229452","doi":"10.1097/01.hs9.0000562388.60660.bc","title":"PS1023 MUTANT IDH1 INHIBITOR IVOSIDENIB (AG‐120) IN COMBINATION WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Internal medicine; Gastroenterology; Isocitrate dehydrogenase; IDH1; Adverse effect; Azacitidine; Bone marrow; Nausea; Leukemia; Cytarabine; Chemistry; Mutant","score_opus":0.013060103779296627,"score_gpt":0.2728298898142398,"score_spread":0.25976978603494316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951229452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889367,0.00023550799,0.00067745347,0.0023295898,0.00021529806,0.003743912,0.00005226379,0.00017723184,0.003632046],"genre_scores_gemma":[0.98524284,0.0001549545,0.004613773,0.00069729425,0.000319772,0.00037782593,0.00027489333,0.00015985116,0.008158817],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99690634,0.0000750719,0.0005787888,0.0007689355,0.0007842107,0.00088667806],"domain_scores_gemma":[0.99798274,0.00043496865,0.00017744827,0.0007309775,0.00035083105,0.00032300508],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044966364,0.00042699004,0.00079300645,0.00022608244,0.00009449516,0.0000636773,0.0002655979,0.00033169935,0.00083141215],"category_scores_gemma":[0.00020692476,0.00035006998,0.00015976494,0.0007279498,0.00012431934,0.0003565751,0.000115211194,0.00067854417,0.0004611942],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016007336,0.0017425522,0.11639402,0.003452912,0.0011904525,0.004213228,0.0035019233,0.0005686982,0.7460119,0.0058415015,0.07150827,0.0295672],"study_design_scores_gemma":[0.1892884,0.015402959,0.075903505,0.0050054137,0.0009176434,0.0016947836,0.007349467,0.0324975,0.60209244,0.0020968297,0.064503,0.0032480557],"about_ca_topic_score_codex":0.00033771852,"about_ca_topic_score_gemma":0.00039218756,"teacher_disagreement_score":0.17328106,"about_ca_system_score_codex":0.0017793896,"about_ca_system_score_gemma":0.0011753832,"threshold_uncertainty_score":0.99989516},"labels":[],"label_agreement":null},{"id":"W2951250026","doi":"10.1097/01.hs9.0000567584.58810.12","title":"PB2279 EFFECT OF EDUCATIONAL TRAINING PROGRAM ON IMPROVING PEDIATRIC ONCOLOGY NURSES, PRACTICE REGARDING NON PHARMACOLOGICAL PAIN MANAGEMENT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Innovations in Medical Education","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Checklist; Massage; Observational study; Psychological intervention; Reflexology; Physical therapy; Pediatric oncology; Family medicine; Nursing; Alternative medicine; Internal medicine; Psychology; Cancer","score_opus":0.013517080295208006,"score_gpt":0.38406880210148703,"score_spread":0.37055172180627904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951250026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89540756,0.000112370944,0.00014891902,0.004861935,0.0015299332,0.0024908942,8.295049e-7,0.000070946335,0.09537661],"genre_scores_gemma":[0.96682465,0.00002392165,0.027802706,0.0015004916,0.00086982496,0.00047380335,0.000055974975,0.00002853746,0.0024200648],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981715,0.000267626,0.0004319058,0.00035973775,0.0004623522,0.00030685615],"domain_scores_gemma":[0.9980022,0.0011691819,0.00031507493,0.0002448979,0.0001902581,0.00007841624],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021309606,0.00017333876,0.00035529677,0.00013767043,0.00006788013,0.000012062514,0.00011834724,0.00017199865,0.0014417546],"category_scores_gemma":[0.0023175827,0.00014108003,0.00008452438,0.0006020816,0.00005313941,0.000108911205,0.000036257712,0.0004912824,0.0001350025],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006433695,0.0018999507,0.006596164,0.0014146066,0.00014536997,0.000022883212,0.00065862737,0.000031351155,0.0011218368,0.0019247573,0.018676916,0.96686417],"study_design_scores_gemma":[0.048907895,0.07689279,0.090302855,0.0033746178,0.0086282715,0.0009854271,0.042717036,0.029071566,0.013282402,0.00055741396,0.6825389,0.0027408127],"about_ca_topic_score_codex":0.000006749947,"about_ca_topic_score_gemma":2.802329e-7,"teacher_disagreement_score":0.96412337,"about_ca_system_score_codex":0.0003789426,"about_ca_system_score_gemma":0.0002998289,"threshold_uncertainty_score":0.99947107},"labels":[],"label_agreement":null},{"id":"W2951328102","doi":"10.1097/01.hs9.0000561272.36751.47","title":"PF747 DEFIBROTIDE TREATMENT IN ADULTS WITH SEVERE OR VERY SEVERE VENO‐OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC CELL TRANSPLANTATION: DEFIFRANCE STUDY INTERIM RESULTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Defibrotide; Medicine; Hepatic veno-occlusive disease; Transplantation; Interim analysis; Surgery; Population; Hematopoietic stem cell transplantation; Internal medicine; Hematopoietic cell; Clinical trial; Haematopoiesis; Stem cell","score_opus":0.00913459838911086,"score_gpt":0.23552118520770793,"score_spread":0.22638658681859708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951328102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914875,0.00029677423,0.00008069685,0.00012178832,0.00023650353,0.0042528193,0.00020203611,0.00013691641,0.0031849635],"genre_scores_gemma":[0.99566066,0.00014744898,0.001088857,0.00008598958,0.00005658631,0.0004946623,0.00026952184,0.000104465085,0.002091809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99679697,0.00015720431,0.00082267117,0.0009978226,0.00067036145,0.0005549659],"domain_scores_gemma":[0.9983875,0.00020131528,0.00022045085,0.00074620417,0.00012223017,0.00032227396],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012703809,0.00059624884,0.0008262424,0.00015170047,0.00007574975,0.00004353854,0.00013228801,0.00017811227,0.0007495245],"category_scores_gemma":[0.000013627256,0.0004540063,0.00015262155,0.000526734,0.000065536355,0.00032743497,0.000021312078,0.00028232258,0.00042307834],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13304228,0.004266963,0.77379346,0.014530165,0.00038287052,0.027531331,0.043439183,0.0015662384,0.00034637476,0.000021411232,0.00008710683,0.0009926308],"study_design_scores_gemma":[0.053810947,0.008432517,0.88932085,0.0127677275,0.00095166254,0.013931713,0.016746594,0.00016594457,0.0023836868,0.000037786693,0.00015139664,0.0012991538],"about_ca_topic_score_codex":0.00024150634,"about_ca_topic_score_gemma":0.0013708124,"teacher_disagreement_score":0.11552743,"about_ca_system_score_codex":0.00043044076,"about_ca_system_score_gemma":0.00037569783,"threshold_uncertainty_score":0.99979115},"labels":[],"label_agreement":null},{"id":"W2951331135","doi":"10.1097/01.hs9.0000562572.63485.4f","title":"PS1070 THE ECHELON‐2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE‐BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T‐CELL LYMPHOMAS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Brentuximab vedotin; CHOP; Internal medicine; Prednisone; Vincristine; Anaplastic large-cell lymphoma; Cyclophosphamide; Oncology; CD30; Lymphoma; Gastroenterology; Surgery; Chemotherapy","score_opus":0.025085509203232586,"score_gpt":0.2964247673137847,"score_spread":0.2713392581105521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951331135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889536,0.0015205229,6.911819e-7,0.000094475385,0.00016071867,0.0076484242,0.00007423415,0.000012272401,0.0015350597],"genre_scores_gemma":[0.9987113,0.00022773816,0.00013505649,0.000008498878,0.000039086615,0.00032855046,0.00008132672,0.00003214181,0.00043633694],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976652,0.00018040655,0.00095172814,0.00044222688,0.0005104493,0.00024998884],"domain_scores_gemma":[0.9979793,0.00045143452,0.0006456394,0.00063877116,0.00018551231,0.00009937125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030341806,0.00034719566,0.0017053497,0.00007730116,0.000030598316,0.000010518708,0.00009776137,0.00010107646,0.00012847348],"category_scores_gemma":[0.00004803795,0.00018488389,0.00021570666,0.00024486764,0.00013464077,0.00006676751,0.00004154005,0.000058103935,0.0000033584445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8792921,0.041574202,0.07058481,0.00011561422,0.0008112111,0.000022295519,0.0038408146,0.000028567647,0.00004518731,0.000010192524,0.00003933077,0.0036357236],"study_design_scores_gemma":[0.9409545,0.025286932,0.026360426,0.00017666194,0.0010299898,0.0000020069715,0.0022618463,0.00010350905,0.0035343051,0.0000021945705,0.00014211456,0.00014549855],"about_ca_topic_score_codex":0.0018405591,"about_ca_topic_score_gemma":0.000511326,"teacher_disagreement_score":0.061662465,"about_ca_system_score_codex":0.00023613875,"about_ca_system_score_gemma":0.0001920349,"threshold_uncertainty_score":0.7539346},"labels":[],"label_agreement":null},{"id":"W2951347740","doi":"10.1097/01.hs9.0000563296.27415.ad","title":"PS1254 CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA AFTER RETREATMENT WITH SECOND‐LINE RITUXIMAB‐CONTAINING CHEMOTHERAPY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont; University of Toronto","funders":"","keywords":"Medicine; Rituximab; Follicular lymphoma; Chemotherapy; Radiation therapy; Surgery; Internal medicine; CHOP; Lymphoma","score_opus":0.005708754038137033,"score_gpt":0.2138741022099388,"score_spread":0.20816534817180177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951347740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975174,0.00043458422,0.000011715433,0.00015445177,0.00004522712,0.0009496491,0.000056072826,0.000034221117,0.00079667044],"genre_scores_gemma":[0.99620044,0.000038536455,0.0019368371,0.0004879931,0.000031309228,0.000094812,0.000110268054,0.000054680924,0.0010451056],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986805,0.00001852262,0.00034136727,0.00038436704,0.0003159636,0.00025927988],"domain_scores_gemma":[0.99902135,0.000044555713,0.0002032156,0.00044523503,0.00013837744,0.00014727443],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000053227446,0.00030810296,0.0007232567,0.000036472084,0.000032881897,0.000017650056,0.00004188591,0.00009967052,0.00097416877],"category_scores_gemma":[0.000006852305,0.00018711852,0.00007952524,0.000107326305,0.000058417994,0.00008154835,0.000023888548,0.0000516094,0.000032006727],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029638929,0.0016641752,0.9874056,0.00023859105,0.00048662777,0.00015315558,0.00027866804,2.7392383e-7,0.000034511635,0.000042474527,0.000025780919,0.0067062783],"study_design_scores_gemma":[0.03509461,0.0038740605,0.95660794,0.00039501826,0.000298663,0.000032700198,0.00011065663,0.000021612097,0.0016503455,0.0000052994715,0.0016911618,0.0002179569],"about_ca_topic_score_codex":0.000035408637,"about_ca_topic_score_gemma":0.000025571531,"teacher_disagreement_score":0.03213072,"about_ca_system_score_codex":0.00016220789,"about_ca_system_score_gemma":0.00006420234,"threshold_uncertainty_score":0.9999391},"labels":[],"label_agreement":null},{"id":"W2951365685","doi":"10.1097/01.hs9.0000566860.46379.37","title":"PB2094 A SINGLE CENTRE EXPERIENCE WITH AZACITIDINE FOR MDS, AML AND CMML IN RELATION TO CYTOGENETIC RISK AND PERFORMANCE STATUS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Azacitidine; Medicine; Myelodysplastic syndromes; Chronic myelomonocytic leukemia; Internal medicine; International Prognostic Scoring System; Cytogenetics; Oncology; Bone marrow","score_opus":0.014594104408073412,"score_gpt":0.25887850042652266,"score_spread":0.24428439601844926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951365685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968268,0.00053748605,0.00026481628,0.0002269257,0.000015985777,0.0011103448,0.000011355237,0.000021432606,0.0009848041],"genre_scores_gemma":[0.9915062,0.0002059403,0.006187735,0.00010005281,0.000032186414,0.000052922023,0.00001338396,0.000026322408,0.0018752343],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99895525,0.000021353422,0.00015144616,0.0003260164,0.0001865472,0.00035937675],"domain_scores_gemma":[0.9994081,0.00007940945,0.000041929557,0.00021139889,0.00006969169,0.00018943737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010579428,0.00012512112,0.0002027454,0.000055117085,0.000049454946,0.000019962295,0.000037046386,0.00006643271,0.00013463723],"category_scores_gemma":[0.00007838812,0.00010070218,0.000012947733,0.00020957887,0.000054777258,0.00011067428,0.000047112117,0.00014865107,0.000024450495],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012608719,0.000052841224,0.96391135,0.0003101951,0.0000136174085,0.000012864987,0.003955784,0.00008909282,0.012083929,0.000033397646,0.0002458017,0.01803027],"study_design_scores_gemma":[0.009822497,0.0037804574,0.92935073,0.0008493731,0.00005162886,0.00011053123,0.0069245636,0.015013047,0.020925997,0.000028681829,0.012722436,0.00042003227],"about_ca_topic_score_codex":0.000086472086,"about_ca_topic_score_gemma":0.00013889174,"teacher_disagreement_score":0.03456058,"about_ca_system_score_codex":0.00015745658,"about_ca_system_score_gemma":0.00009177857,"threshold_uncertainty_score":0.41065156},"labels":[],"label_agreement":null},{"id":"W2951443426","doi":"10.1097/01.hs9.0000565788.38670.37","title":"PB1821 REAL‐WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) PATIENTS INITIATED ON ANTI‐CANCER THERAPIES IN THE UNITED STATES (US)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Lymphoma; Diagnosis code; Internal medicine; Oncology; Medical diagnosis; Cancer; Retrospective cohort study; Population; Pathology","score_opus":0.030268310438438563,"score_gpt":0.2996516692063359,"score_spread":0.2693833587678973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951443426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948102,0.0014590176,4.484471e-7,0.00077134906,0.00004195043,0.0009052771,0.00012585348,0.00003093064,0.0018549325],"genre_scores_gemma":[0.9930996,0.0035316541,0.000013888061,0.002273655,0.000018046401,0.000062223524,0.0007277322,0.000030575557,0.00024267158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99863285,0.00018626313,0.00030964153,0.00027991273,0.00032352417,0.00026783173],"domain_scores_gemma":[0.9990642,0.00021939562,0.00016658669,0.00034463534,0.00012898742,0.0000762077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013021914,0.00020499136,0.00034287572,0.000121029,0.00006349635,0.000019090854,0.000076098804,0.00008393067,0.00010166678],"category_scores_gemma":[0.000017418904,0.00013071511,0.000048207396,0.0005288458,0.000042879186,0.000052169875,0.00003163593,0.00007087308,0.00001299939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034488674,0.0053955987,0.98381966,0.00023043093,0.000054865308,0.000015610483,0.0026227427,0.000009918825,0.000034530065,0.0004977923,0.0008865054,0.00608747],"study_design_scores_gemma":[0.022084171,0.0006834735,0.96046555,0.0008452087,0.000050101702,0.0000014948123,0.002566729,0.0003232443,0.002323376,0.000019447842,0.010489778,0.00014739732],"about_ca_topic_score_codex":0.0030683689,"about_ca_topic_score_gemma":0.0012762476,"teacher_disagreement_score":0.023354072,"about_ca_system_score_codex":0.00018967649,"about_ca_system_score_gemma":0.000058447793,"threshold_uncertainty_score":0.53304076},"labels":[],"label_agreement":null},{"id":"W2951452128","doi":"10.1097/01.hs9.0000559332.56440.58","title":"PF280 INTENSIVE TREATMENT OF ELDERLY AML PATIENTS IS SAFE AND FEASIBLE, PRINCESS MARGARET CANCER CENTRE EXPERIENCE","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Internal medicine; Acute promyelocytic leukemia; Induction chemotherapy; Hazard ratio; Cumulative incidence; Cancer; Proportional hazards model; Incidence (geometry); Population; Cohort; Oncology; Chemotherapy; Pediatrics; Confidence interval","score_opus":0.02058978345610138,"score_gpt":0.3075071428970854,"score_spread":0.28691735944098407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951452128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99235964,0.0011527451,0.0000046366285,0.0010281559,0.00011359106,0.0009478269,0.00004461383,0.000021486027,0.004327304],"genre_scores_gemma":[0.9849092,0.0009799994,0.00041238565,0.00042569768,0.00004804863,0.000047975944,0.00002362754,0.00003056812,0.013122532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99859256,0.000029287226,0.00024206801,0.00040122773,0.0003851941,0.00034964582],"domain_scores_gemma":[0.9987288,0.000053164094,0.00010413597,0.00040846426,0.000504115,0.00020129753],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000028455564,0.00020201967,0.0004285263,0.000042211464,0.000037293637,0.0000124829185,0.00009669591,0.00010600744,0.003366659],"category_scores_gemma":[0.00004467022,0.00015064304,0.00006888856,0.0001861648,0.00011964145,0.000096816315,0.00007792491,0.00011172708,0.00007820994],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050191965,0.00021436193,0.9561353,0.00027207803,0.0001196245,0.000034526358,0.007223441,0.0000011958784,0.0015505045,0.00004240553,0.004352952,0.02955171],"study_design_scores_gemma":[0.02051959,0.004968476,0.75763077,0.0014154334,0.0002130085,0.00005111829,0.021330336,0.0007099934,0.10990684,0.00005737845,0.08249305,0.00070402527],"about_ca_topic_score_codex":0.00095108734,"about_ca_topic_score_gemma":0.000086502325,"teacher_disagreement_score":0.19850454,"about_ca_system_score_codex":0.00043361407,"about_ca_system_score_gemma":0.00024255522,"threshold_uncertainty_score":0.9975444},"labels":[],"label_agreement":null},{"id":"W2951457160","doi":"10.1097/01.hs9.0000559376.17429.23","title":"PF291 A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL‐2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1‐MUTATED (MIDH1) MYELOID MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Venetoclax; Ven; IDH1; Medicine; Tolerability; Internal medicine; Oncology; Refractory (planetary science); Myeloid; Myeloid leukemia; Gastroenterology; Leukemia; Adverse effect; Chronic lymphocytic leukemia; Chemistry; Biology; Mutation","score_opus":0.016503030005904973,"score_gpt":0.3079110771014915,"score_spread":0.29140804709558654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951457160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909205,0.00007462284,0.00021231317,0.00037612603,0.00005993248,0.008103163,0.00004272061,0.00006764227,0.00014296823],"genre_scores_gemma":[0.9975165,0.000008966067,0.00085789454,0.00015889475,0.00007737512,0.00056561606,0.00029923962,0.00010146571,0.00041404265],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99670345,0.00025553122,0.00076058495,0.0006641327,0.0010740956,0.0005422104],"domain_scores_gemma":[0.9972762,0.00040288916,0.00044388266,0.0006577076,0.0010512565,0.00016807135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007025887,0.00037262152,0.000806548,0.0001570879,0.000110650515,0.000037138223,0.0001812269,0.00019173369,0.00009902704],"category_scores_gemma":[0.00016107138,0.00021399863,0.00007310937,0.0010513763,0.00026447626,0.0002762097,0.000077683384,0.0005899632,0.000021273321],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0627798,0.021829702,0.88465464,0.0011698691,0.0008450484,0.00023618285,0.005416804,0.0004508967,0.014161765,0.0001623786,0.0043594525,0.00393348],"study_design_scores_gemma":[0.44474828,0.15513407,0.3274167,0.0034559383,0.00086741993,0.00008333033,0.026433803,0.0048419284,0.03410788,0.00008016949,0.0014926477,0.0013378378],"about_ca_topic_score_codex":0.00020426906,"about_ca_topic_score_gemma":0.000586343,"teacher_disagreement_score":0.5572379,"about_ca_system_score_codex":0.00047720602,"about_ca_system_score_gemma":0.0009127735,"threshold_uncertainty_score":0.8726611},"labels":[],"label_agreement":null},{"id":"W2951500503","doi":"10.1097/01.hs9.0000564124.13888.22","title":"PS1465 SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB <10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Myelofibrosis; Anemia; Internal medicine; Clinical endpoint; Gastroenterology; Ruxolitinib; Polycythemia vera; Regimen; Dosing; Surgery; Clinical trial; Bone marrow","score_opus":0.01047886968490293,"score_gpt":0.22865220476873951,"score_spread":0.21817333508383657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951500503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991763,0.00026355652,2.1661637e-7,0.00044945866,0.000086048276,0.0019233936,0.00022172743,0.000010858225,0.0052817683],"genre_scores_gemma":[0.9973592,0.00015263144,0.00026020632,0.00006330432,0.0000340165,0.00003087129,0.00009178525,0.000025973337,0.001981993],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998255,0.00010436229,0.0005870368,0.0004144644,0.00039854468,0.00024057936],"domain_scores_gemma":[0.9985446,0.00040709283,0.0003089384,0.00048325877,0.00013265791,0.00012346856],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018245952,0.00024226925,0.0006637515,0.000039421226,0.00005454294,0.000008654042,0.00006764809,0.00012931906,0.00031853383],"category_scores_gemma":[0.00017396317,0.00014252945,0.000076010394,0.00019886323,0.00015529996,0.000056982783,0.00010513749,0.00013013545,0.00000824037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15808028,0.0017262795,0.83126545,0.0004961571,0.00014879736,0.000009997011,0.0017877641,0.000011585169,0.0003011316,0.00031157778,0.0021414775,0.0037195182],"study_design_scores_gemma":[0.12593973,0.0038957167,0.8616565,0.00091579347,0.00015156984,0.00000599877,0.00014812293,0.0000110554965,0.0052106506,0.000015476846,0.0019000848,0.00014934274],"about_ca_topic_score_codex":0.00013399027,"about_ca_topic_score_gemma":0.00019420477,"teacher_disagreement_score":0.032140553,"about_ca_system_score_codex":0.00008438231,"about_ca_system_score_gemma":0.00008817557,"threshold_uncertainty_score":0.58121824},"labels":[],"label_agreement":null},{"id":"W2951608335","doi":"10.1097/01.hs9.0000558816.91319.ce","title":"S149 FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION‐FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Minimal residual disease; Gastroenterology; Venetoclax; Hazard ratio; Clinical endpoint; Obinutuzumab; Population; Surrogate endpoint; Progression-free survival; Oncology; Surgery; Confidence interval; Randomized controlled trial; Chronic lymphocytic leukemia; Bone marrow; Leukemia; Chemotherapy","score_opus":0.0093089771667384,"score_gpt":0.25355556727727147,"score_spread":0.24424659011053307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951608335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99648476,0.0007470135,0.0000020132093,0.00011324548,0.00005340813,0.0018852734,0.000042342766,0.000051956766,0.00062000926],"genre_scores_gemma":[0.99797225,0.00005109461,0.00030518643,0.000029766867,0.00006633217,0.00007662581,0.00014086276,0.000040208583,0.0013176675],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802125,0.00012354697,0.00029398117,0.0004945942,0.000640535,0.00042611838],"domain_scores_gemma":[0.99877316,0.00019749666,0.00011147079,0.0004926405,0.00013232003,0.00029292065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020043459,0.00024971468,0.0004223649,0.000057745172,0.00007284572,0.00006198079,0.00009667171,0.000116736526,0.00011478764],"category_scores_gemma":[0.00024302068,0.000184641,0.00002686503,0.00017914044,0.00024364486,0.00024228779,0.00019090124,0.00022512238,0.000011430485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.025380375,0.00027693095,0.9568065,0.004017008,0.00020617589,0.00044904015,0.0024475923,0.00011015407,0.0005236345,0.0003555486,0.0020122628,0.0074147927],"study_design_scores_gemma":[0.07309794,0.0028485977,0.90322036,0.0015984346,0.00013645597,0.00003304593,0.00082688563,0.016480463,0.0008571938,0.00013002455,0.00030087633,0.0004697413],"about_ca_topic_score_codex":0.00096172956,"about_ca_topic_score_gemma":0.00064754114,"teacher_disagreement_score":0.05358614,"about_ca_system_score_codex":0.007338129,"about_ca_system_score_gemma":0.006947873,"threshold_uncertainty_score":0.9986818},"labels":[],"label_agreement":null},{"id":"W2951773279","doi":"10.1097/01.hs9.0000560744.31107.fc","title":"PF614 PATIENT‐REPORTED OUTCOMES FROM THE INNOVATE™ STUDY: RESULTS OF IBRUTINIB‐RITUXIMAB IN WALDENSTRÖM MACROGLOBULINEMIA (WM)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Royal Victoria Regional Health Centre; Ottawa Hospital; Royal Victoria Hospital; University of Ottawa","funders":"","keywords":"Ibrutinib; Rituximab; Medicine; Internal medicine; Oncology; Waldenstrom macroglobulinemia; Placebo; Lymphoma; Leukemia; Chronic lymphocytic leukemia; Pathology","score_opus":0.027596417593564685,"score_gpt":0.3061365200328294,"score_spread":0.2785401024392647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951773279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98712146,0.00034130266,0.0000016278719,0.0011195954,0.0002670128,0.0019503324,0.00005756211,0.00006431683,0.009076814],"genre_scores_gemma":[0.99675137,0.000016556223,0.0003506375,0.00036231967,0.000078182675,0.000040385796,0.000087733155,0.00004922859,0.002263572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962462,0.00013938274,0.0013053522,0.000642704,0.0011130973,0.000553258],"domain_scores_gemma":[0.9969192,0.00068326655,0.00035967512,0.0016160568,0.00030196874,0.00011978963],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060561666,0.0003007846,0.0008716434,0.000073682204,0.000042634518,0.000025133342,0.00035381655,0.00019237082,0.0011898911],"category_scores_gemma":[0.00097527506,0.00019531419,0.00014379321,0.0008742332,0.00014294274,0.00008340989,0.0003372072,0.00054259674,0.00034543694],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045590564,0.003672469,0.9526989,0.000251976,0.0006731602,0.0020158966,0.0063009392,0.000042233616,0.0026404476,0.000087837674,0.010072507,0.016984584],"study_design_scores_gemma":[0.3302294,0.002607655,0.6063552,0.0013609023,0.0003317681,0.00036233224,0.023787891,0.0030023204,0.015961751,0.00032597734,0.014719664,0.00095511205],"about_ca_topic_score_codex":0.009465441,"about_ca_topic_score_gemma":0.0008033519,"teacher_disagreement_score":0.34634367,"about_ca_system_score_codex":0.002091705,"about_ca_system_score_gemma":0.0027039796,"threshold_uncertainty_score":0.99972314},"labels":[],"label_agreement":null},{"id":"W2951809321","doi":"10.1097/hs9.0000000000000197","title":"Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Chronic lymphocytic leukemia; Leukemia; Medicine; Mathematics; Computational biology; Immunology; Biology","score_opus":0.047759829510846945,"score_gpt":0.3091606406097494,"score_spread":0.26140081109890245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951809321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813633,0.0014377374,0.000014058138,0.00013791346,0.00020557678,0.00103243,0.0000064506635,0.000044800272,0.015757758],"genre_scores_gemma":[0.9876647,0.00012973393,0.000050241328,0.00021193529,0.000118595584,0.000054367327,0.000014607506,0.000058828897,0.01169697],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99758136,0.00006315165,0.0005020162,0.0004382379,0.0007160573,0.0006991645],"domain_scores_gemma":[0.9984954,0.00021087038,0.0001351404,0.0008982006,0.000113091664,0.00014726768],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045664032,0.0002538099,0.0005506762,0.00007993375,0.000048867107,0.000021994249,0.00034956535,0.00020317038,0.0017983421],"category_scores_gemma":[0.00011139784,0.00017401765,0.00015495789,0.00045953575,0.00014468723,0.000110739245,0.00023772889,0.00037138013,0.000758189],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010526459,0.0019515512,0.43529925,0.043076105,0.004343271,0.005130648,0.034675404,0.08690516,0.29137677,0.020832289,0.04651409,0.019369014],"study_design_scores_gemma":[0.1690987,0.0020442018,0.06436932,0.0067835716,0.00033729043,0.0015259086,0.00296633,0.5964736,0.1350959,0.00013787765,0.019946642,0.0012206635],"about_ca_topic_score_codex":0.0012769017,"about_ca_topic_score_gemma":0.00024341147,"teacher_disagreement_score":0.50956845,"about_ca_system_score_codex":0.05336428,"about_ca_system_score_gemma":0.018759314,"threshold_uncertainty_score":0.99911416},"labels":[],"label_agreement":null},{"id":"W2951857323","doi":"10.1097/01.hs9.0000564816.09273.68","title":"S1642 DEVELOPMENT OF A CLINICAL PREDICTION RULE FOR VENOUS THROMBOEMBOLISM IN PATIENTS WITH ACUTE LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Interquartile range; Pulmonary embolism; Internal medicine; Thrombosis; Acute leukemia; Venous thrombosis; Deep vein; Retrospective cohort study; Myeloid leukemia; Logistic regression; Surgery; Leukemia","score_opus":0.016252410817581442,"score_gpt":0.29079610340659334,"score_spread":0.2745436925890119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951857323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356484,0.000050712628,0.00025453378,0.00005367353,0.00030558702,0.0019992965,0.000018998036,0.000039134124,0.003713207],"genre_scores_gemma":[0.98859996,0.000026703125,0.0103663,0.00020153493,0.00007547096,0.00013551308,0.00012548477,0.000039319606,0.00042970406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99832016,0.000021637203,0.0006852393,0.0003535869,0.00033041945,0.00028893846],"domain_scores_gemma":[0.99917495,0.000050853927,0.00020821176,0.00032976072,0.00013953185,0.00009668384],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029269117,0.00016982129,0.0008897896,0.00005636943,0.000037283826,0.000007294835,0.000090788504,0.0001305277,0.00019759504],"category_scores_gemma":[0.000026453943,0.00013392893,0.000100657686,0.00014204964,0.000035705074,0.00008180999,0.000054689248,0.00014283483,0.000051322106],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012577937,0.004976712,0.9407709,0.0009649505,0.0010830173,0.000011512417,0.0016105267,0.00008153787,0.00012629537,0.00060303224,0.0044908575,0.04402283],"study_design_scores_gemma":[0.0073792995,0.0016114863,0.9824352,0.00042372185,0.0002221889,0.0000012471984,0.0001721614,0.00010380181,0.0004672848,0.000053035947,0.0069894693,0.00014109614],"about_ca_topic_score_codex":0.00002457715,"about_ca_topic_score_gemma":0.000036307043,"teacher_disagreement_score":0.043881733,"about_ca_system_score_codex":0.00015498597,"about_ca_system_score_gemma":0.0003770482,"threshold_uncertainty_score":0.54614633},"labels":[],"label_agreement":null},{"id":"W2951897386","doi":"10.1097/01.hs9.0000564396.90858.34","title":"PS1534 EFFICACY AND SAFETY OF STEM CELL MOBILISATION FOLLOWING GDP SALVAGE IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Plerixafor; Salvage therapy; Etoposide; Apheresis; Regimen; Granulocyte colony-stimulating factor; Internal medicine; Neutropenia; Gemcitabine; Surgery; Chemotherapy; Oncology; Urology; Gastroenterology; CXCR4","score_opus":0.007516110765720078,"score_gpt":0.22500030285622663,"score_spread":0.21748419209050654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951897386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372107,0.00013392595,0.0000108839395,0.000021970201,0.000119762655,0.00073230884,0.000004694628,0.000024511033,0.0052308943],"genre_scores_gemma":[0.99734753,0.000019089592,0.00013971407,0.00005891623,0.000017186607,0.000014178388,0.000012411146,0.000024268302,0.002366696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.999195,0.000035445744,0.00023189445,0.00021452949,0.00018753858,0.00013562503],"domain_scores_gemma":[0.9994702,0.00008033726,0.000094440176,0.0002528358,0.000042257478,0.000059962556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000080829355,0.00011250311,0.00027137122,0.000038539103,0.000028854474,0.000005692255,0.000032580985,0.00007090095,0.00024641247],"category_scores_gemma":[0.0000063673433,0.000081106984,0.000039889426,0.00019176528,0.000023152346,0.000117032134,0.000018692788,0.00008693608,0.000019910953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032500336,0.0006181748,0.97694886,0.0003225418,0.00004748197,0.000012657022,0.00077531266,0.000034761462,0.0036609143,0.000021008133,0.00016531628,0.0141429575],"study_design_scores_gemma":[0.019191498,0.0015405422,0.9726977,0.00046791582,0.00008322107,0.000003448629,0.0005741885,0.000012235142,0.0029444548,0.0000025871227,0.002343705,0.00013849948],"about_ca_topic_score_codex":0.000058705427,"about_ca_topic_score_gemma":0.000067459376,"teacher_disagreement_score":0.015941465,"about_ca_system_score_codex":0.00011558016,"about_ca_system_score_gemma":0.00010491753,"threshold_uncertainty_score":0.33074468},"labels":[],"label_agreement":null},{"id":"W2952050362","doi":"10.1097/01.hs9.0000567332.39511.c6","title":"PB2213 SPLANCHNIC VEIN THROMBOSIS IN MYELOPROLOFERATIVE NEOPLASMS; A PROSPECTIVE ANALYSIS OF THROMBOSIS OUTCOME","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Thrombosis; Thrombocytosis; Thrombus; Portal vein thrombosis; Prospective cohort study; Polycythaemia; Internal medicine; Budd–Chiari syndrome; Myelofibrosis; Polycythemia vera; Radiology; Splenic vein; Surgery; Gastroenterology; Portal hypertension; Bone marrow; Platelet; Inferior vena cava; Cirrhosis","score_opus":0.027074326728748103,"score_gpt":0.3238680065348369,"score_spread":0.2967936798060888,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952050362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97882354,0.0003145949,0.000030740743,0.00062243885,0.00012564416,0.0018364701,0.00007552348,0.00006479434,0.018106256],"genre_scores_gemma":[0.9962104,0.00014542733,0.0015848922,0.0003356401,0.00004017553,0.00035316072,0.00009765651,0.00004623556,0.0011864173],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971188,0.000117737254,0.0008730302,0.00081719545,0.0005699418,0.00050330744],"domain_scores_gemma":[0.99822974,0.0003259132,0.0003095846,0.0007061102,0.00025894758,0.00016972242],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026480234,0.00046337786,0.0019672927,0.00042259626,0.00005888416,0.000024865503,0.00014470478,0.00024301282,0.0043844567],"category_scores_gemma":[0.00010838576,0.0003647468,0.00051499676,0.0020911728,0.000105874555,0.00017402461,0.00008490817,0.00036461418,0.00027200175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021606004,0.0011658779,0.9877219,0.000186005,0.0035883375,0.000027393886,0.002033933,0.00018145028,0.0019896699,0.002468935,0.00020522173,0.00021520127],"study_design_scores_gemma":[0.0033219988,0.0009922591,0.98033535,0.00022245952,0.0019494252,0.0000063911307,0.00096355774,0.0007373969,0.010847047,0.00012991087,0.00017270217,0.00032149817],"about_ca_topic_score_codex":0.0003202258,"about_ca_topic_score_gemma":0.0015112879,"teacher_disagreement_score":0.017386857,"about_ca_system_score_codex":0.0004002824,"about_ca_system_score_gemma":0.00017703777,"threshold_uncertainty_score":0.99988043},"labels":[],"label_agreement":null},{"id":"W2952131264","doi":"10.1097/01.hs9.0000558648.00957.de","title":"S107 FIVE‐YEAR FOLLOW‐UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Chlorambucil; Internal medicine; Hazard ratio; Adverse effect; Neutropenia; Progression-free survival; Bendamustine; Clinical endpoint; Oncology; Leukemia; Randomized controlled trial; Confidence interval; Toxicity; Chemotherapy","score_opus":0.021839086168430458,"score_gpt":0.28791569770824105,"score_spread":0.2660766115398106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952131264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919594,0.001183224,0.00013145123,0.000034552544,0.00037711553,0.0022852558,0.000075558295,0.0000509526,0.0039025089],"genre_scores_gemma":[0.9819427,0.00036903072,0.000746652,0.000023180395,0.00019288732,0.00011171735,0.00015322655,0.00008179917,0.0163788],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974713,0.000037225975,0.00072354294,0.0005163992,0.00063426467,0.00061728305],"domain_scores_gemma":[0.99767303,0.00051038066,0.00030531327,0.0009153064,0.0003957951,0.00020017284],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018391329,0.00031641187,0.0009415816,0.00009676751,0.00005479909,0.000009114897,0.00020598083,0.0002277658,0.0014172752],"category_scores_gemma":[0.00027287315,0.0002608434,0.00040694798,0.0003233656,0.00012262262,0.000087610606,0.00008996471,0.00008644443,0.0001684886],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06780622,0.00964883,0.28928596,0.085629545,0.0105759995,0.0003322294,0.026207276,0.02933939,0.032592993,0.0040475824,0.051456068,0.3930779],"study_design_scores_gemma":[0.57978487,0.034181952,0.01331924,0.004770201,0.0011800089,0.00008260559,0.0013716591,0.17038481,0.1521685,0.00044029774,0.040981717,0.0013341493],"about_ca_topic_score_codex":0.0007247493,"about_ca_topic_score_gemma":0.00021383564,"teacher_disagreement_score":0.5119786,"about_ca_system_score_codex":0.05752987,"about_ca_system_score_gemma":0.015609111,"threshold_uncertainty_score":0.9999844},"labels":[],"label_agreement":null},{"id":"W2952140490","doi":"10.1097/01.hs9.0000564652.16751.86","title":"S1601 NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM THE PHASE 2 CHECKMATE 436 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Brentuximab vedotin; Nivolumab; Medicine; CD30; Lymphoma; Anaplastic large-cell lymphoma; Oncology; Internal medicine; Cancer research; Immune system; Immunology; Immunotherapy","score_opus":0.011245016612673695,"score_gpt":0.25012934407963827,"score_spread":0.23888432746696459,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952140490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898826,0.0016818672,0.000021649623,0.0006509678,0.0002217793,0.0038315665,0.00050606264,0.000105433726,0.0030981104],"genre_scores_gemma":[0.99594504,0.000119641016,0.0005876618,0.00042673174,0.00018664336,0.00018997928,0.0007782206,0.00007358184,0.0016925267],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99759835,0.0001073979,0.00054927845,0.00075722486,0.0004875923,0.00050015294],"domain_scores_gemma":[0.99741477,0.0010951945,0.0002892869,0.00084092456,0.00012619111,0.00023362861],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036422964,0.00041952886,0.0007338319,0.000026350239,0.00023436613,0.000052781947,0.0001665925,0.00012233596,0.00020478347],"category_scores_gemma":[0.00009833811,0.00025254657,0.000119911725,0.00015114855,0.00008155134,0.00011208087,0.00011716127,0.0001419006,0.00010817307],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28323585,0.22977862,0.30718696,0.0011271588,0.003647916,0.0015467698,0.017789183,0.000013846919,0.0030519795,0.00025355787,0.043126985,0.10924118],"study_design_scores_gemma":[0.5323206,0.013945077,0.42744654,0.0004900461,0.0010734184,0.00005017051,0.0028014078,0.00021909982,0.0012325706,0.000015008856,0.019974537,0.00043151932],"about_ca_topic_score_codex":0.00021522971,"about_ca_topic_score_gemma":0.00013193405,"teacher_disagreement_score":0.24908476,"about_ca_system_score_codex":0.00026688486,"about_ca_system_score_gemma":0.00030480462,"threshold_uncertainty_score":0.99999267},"labels":[],"label_agreement":null},{"id":"W2952175842","doi":"10.1097/01.hs9.0000559784.51441.da","title":"PF393 A RANDOMISED JOINT AUSTRALASIAN (ALLG) AND FRENCH (FILO) STUDY OF LENALIDOMIDE CONSOLIDATION IN PATIENTS WITH RESIDUAL CLL AFTER FRONT‐LINE TREATMENT WITH FC/FCR (THE CLL6 TRIAL)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"","keywords":"Lenalidomide; Medicine; Minimal residual disease; Fludarabine; Internal medicine; Oncology; Progression-free survival; Cyclophosphamide; Chronic lymphocytic leukemia; Surgery; Leukemia; Chemotherapy; Multiple myeloma","score_opus":0.015111516384380777,"score_gpt":0.2572424225864546,"score_spread":0.2421309062020738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952175842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909625,0.00012609772,0.000005403729,0.00015652049,0.000036119007,0.008061647,0.00001631007,0.000018254817,0.00061716116],"genre_scores_gemma":[0.9969039,0.000014876353,0.00021255402,0.000035417994,0.00006279556,0.0004622172,0.000055958306,0.000039162613,0.002213098],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976218,0.00024460748,0.00058587216,0.00046908442,0.00071045384,0.0003681945],"domain_scores_gemma":[0.998613,0.00021469666,0.0002118392,0.0006494832,0.00017238925,0.00013859934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003743651,0.00028910994,0.0008094824,0.000087781875,0.00003848224,0.000026083491,0.000084180814,0.0001031206,0.0007088637],"category_scores_gemma":[0.00006487866,0.00015304351,0.000052941064,0.00019784798,0.00014046286,0.00009493089,0.000048087295,0.00019956856,0.000031719785],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7629007,0.0053757406,0.21872276,0.0003636868,0.0009661145,0.0002240982,0.008820239,0.00014355205,0.000198358,0.000005989738,0.00031668256,0.001962059],"study_design_scores_gemma":[0.90304893,0.02196024,0.07040588,0.00039450015,0.00033907822,0.000018897554,0.0024228243,0.0003159278,0.0008085508,0.0000063283974,0.00008633892,0.00019248122],"about_ca_topic_score_codex":0.0023050553,"about_ca_topic_score_gemma":0.0039255,"teacher_disagreement_score":0.14831689,"about_ca_system_score_codex":0.002087268,"about_ca_system_score_gemma":0.0015481662,"threshold_uncertainty_score":0.776156},"labels":[],"label_agreement":null},{"id":"W2952177114","doi":"10.1097/01.hs9.0000562400.45413.a7","title":"PS1026 ENASIDENIB ASSOCIATED WITH IMPROVED SURVIVAL COMPARED WITH STANDARD OF CARE FOR R/R AML PATIENTS WITH AN IDH2 MUTATION BASED ON DATA FROM STUDY AG221‐C‐001 AND A REVIEW OF PATIENT CHARTS IN FRANCE","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Alberta","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Oncology; Propensity score matching; IDH2; Hematopoietic stem cell transplantation; Transplantation; Confidence interval; Mutation; IDH1; Biology","score_opus":0.050355798225258826,"score_gpt":0.351584830850553,"score_spread":0.30122903262529416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952177114","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11781187,0.8522387,0.000044178512,0.000018073517,0.00004986813,0.021640552,0.008098611,0.000033435233,0.000064689775],"genre_scores_gemma":[0.12882479,0.7844436,0.0034934168,0.00019811334,0.00009264632,0.0017862056,0.08048149,0.0005852947,0.00009440844],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9956249,0.0005157005,0.0010785788,0.001063445,0.00132559,0.00039178904],"domain_scores_gemma":[0.9948433,0.0006266857,0.0014108032,0.0016740204,0.0012716596,0.0001735047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005334418,0.0006206797,0.0041563367,0.00013580002,0.000046372355,0.00001892642,0.0003769543,0.00020600903,0.00007193658],"category_scores_gemma":[0.0003839992,0.0003847266,0.000089721594,0.0005932547,0.000116183415,0.00015943575,0.000109083725,0.00052178156,0.000001282391],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016453251,0.006503774,0.09026384,0.52125263,0.003304891,0.00022229475,0.0030134951,0.00002455722,0.0000023999905,0.0000022487827,0.00055327645,0.35840333],"study_design_scores_gemma":[0.06272616,0.06960344,0.01790899,0.8119684,0.007242257,0.0000063643865,0.0033699882,0.0009798784,0.00001961446,0.0000012037412,0.024716286,0.0014574204],"about_ca_topic_score_codex":0.00057178846,"about_ca_topic_score_gemma":0.0021373972,"teacher_disagreement_score":0.3569459,"about_ca_system_score_codex":0.00064244267,"about_ca_system_score_gemma":0.0018606992,"threshold_uncertainty_score":0.99986047},"labels":[],"label_agreement":null},{"id":"W2952260994","doi":"10.1097/01.hs9.0000563768.57648.ea","title":"PS1373 A TWENTY‐FOUR YEAR EXPERIENCE OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LIGHT CHAIN AMYLOIDOSIS PATIENTS IN THE UNITED KINGDOM","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Univariate analysis; Internal medicine; Proportional hazards model; Cohort; AL amyloidosis; Amyloidosis; Survival analysis; Transplantation; Log-rank test; Oncology; Multivariate analysis; Surgery; Immunology; Immunoglobulin light chain","score_opus":0.028762564540519484,"score_gpt":0.2877169989745835,"score_spread":0.258954434434064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952260994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668574,0.000045617053,0.00011734648,0.00015452623,0.000090590685,0.0013879492,0.000015841624,0.00002114547,0.0014812195],"genre_scores_gemma":[0.99852914,0.00003175557,0.000268961,0.0001358761,0.000028414224,0.000121244564,0.0000490366,0.000023027475,0.0008125532],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99862057,0.00008142199,0.0003018543,0.0002483711,0.00044147813,0.00030627585],"domain_scores_gemma":[0.99913365,0.00023986994,0.000099121266,0.00036016136,0.000110365385,0.000056840425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002303689,0.00012737325,0.00025425715,0.00008843545,0.000030807656,0.000010695598,0.0001978366,0.00011167201,0.00015251848],"category_scores_gemma":[0.000026394968,0.000089292,0.00008093712,0.00042312295,0.000043669206,0.000054742864,0.000020334088,0.00013433506,0.00004278112],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01426478,0.005185885,0.6086251,0.022860857,0.00037057148,0.0006039622,0.24298953,0.0013047471,0.068287544,0.0061534713,0.009536429,0.01981714],"study_design_scores_gemma":[0.23697603,0.0077558914,0.23376545,0.0044717663,0.0005592834,0.00032276488,0.049986016,0.06765819,0.36061394,0.000242433,0.035827704,0.0018205428],"about_ca_topic_score_codex":0.0007088562,"about_ca_topic_score_gemma":0.0000571636,"teacher_disagreement_score":0.37485963,"about_ca_system_score_codex":0.0008978615,"about_ca_system_score_gemma":0.0005225928,"threshold_uncertainty_score":0.3641222},"labels":[],"label_agreement":null},{"id":"W2952276066","doi":"10.1097/01.hs9.0000564512.99374.a4","title":"PS1566 HEMATOPOIETIC STEM CELL GRAFTS AS A SOURCE FOR RECONSTITUTING INNATE LYMPHOID CELLS FOLLOWING STEM CELL TRANSPLANTATION","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Mesenchymal stem cell research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Stem cell; Innate lymphoid cell; Interleukin-7 receptor; Stromal cell; Immunology; CD34; Biology; Haematopoiesis; Stem cell factor; Progenitor cell; Lymphopoiesis; Bone marrow; Transplantation; Hematopoietic stem cell transplantation; Cancer research; Medicine; Cell biology; T cell; Immune system; Innate immune system; Internal medicine","score_opus":0.01976166850489929,"score_gpt":0.26874222606698317,"score_spread":0.24898055756208387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952276066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9211455,0.0013335444,0.0023705799,0.00010086596,0.00052408583,0.0025569107,0.000013268286,0.00016830162,0.07178697],"genre_scores_gemma":[0.9237308,0.0000918559,0.0009774265,0.00018391441,0.00011268468,0.00011703218,0.000036698617,0.0001061959,0.07464337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99672633,0.0001225406,0.0006795556,0.0007782103,0.00078662,0.0009067391],"domain_scores_gemma":[0.9980965,0.0004983086,0.00021688029,0.0005995169,0.00019235486,0.00039641268],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007583736,0.00039906963,0.00069897017,0.000117762036,0.00020940768,0.000085568354,0.0002548837,0.00029026,0.0006577036],"category_scores_gemma":[0.000012618592,0.0003725075,0.00034752945,0.0004931151,0.0000520642,0.0001903361,0.000057772842,0.0003401177,0.0016081333],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001769804,0.0006527383,0.030493952,0.0265677,0.00029252912,0.00093918527,0.011960273,0.0007036783,0.89595914,0.0004924774,0.0030900901,0.027078424],"study_design_scores_gemma":[0.007863046,0.000719207,0.0000785004,0.0014522562,0.00029590985,0.0003585943,0.007021947,0.0022017586,0.9618773,0.000056773246,0.017414136,0.0006605705],"about_ca_topic_score_codex":0.00009136693,"about_ca_topic_score_gemma":0.000014008125,"teacher_disagreement_score":0.065918155,"about_ca_system_score_codex":0.00023627374,"about_ca_system_score_gemma":0.0005259226,"threshold_uncertainty_score":0.9998727},"labels":[],"label_agreement":null},{"id":"W2952294434","doi":"10.1097/01.hs9.0000561352.05716.6c","title":"PF767 PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF ONE OR TWO DOSES OF DONOR LYMPHOCYTES DEPLETED OF HOST ALLOREACTIVE T‐CELLS (ATIR101) FOLLOWING T‐CELL‐DEPLETED HAPLOIDENTICAL HSCT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Graft-versus-host disease; Immunosuppression; Immune system; T cell; Immunology; Ex vivo; CD34; Stem cell; Transplantation; Haematopoiesis; Clinical endpoint; Internal medicine; Gastroenterology; In vivo; Clinical trial; Biology","score_opus":0.05400656725039787,"score_gpt":0.3857418889832553,"score_spread":0.3317353217328574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952294434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355096,0.0008432067,0.00004798903,0.00006893215,0.00010047033,0.0033571771,0.0000303481,0.00003432334,0.0019665814],"genre_scores_gemma":[0.9975143,0.000069273745,0.0007551824,0.000035554796,0.00006648757,0.000033141605,0.000016998983,0.00007798863,0.0014310556],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99619514,0.000448305,0.0010386492,0.0005411802,0.0013293631,0.00044734447],"domain_scores_gemma":[0.99509364,0.0029587923,0.00045072823,0.0009039987,0.0004232746,0.00016955734],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014300185,0.00033058083,0.0012279307,0.00011459885,0.00009102823,0.00002296382,0.0002966238,0.000114647184,0.0023833818],"category_scores_gemma":[0.0007866406,0.00022495075,0.00031099308,0.00063617143,0.00027995434,0.000115631214,0.00022978176,0.00033226004,0.00001510562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01586554,0.0031297961,0.017552575,0.00047006964,0.0010558203,0.0000303826,0.0038287898,0.000020178086,0.9482834,0.000024056711,0.000018994762,0.0097204],"study_design_scores_gemma":[0.06852896,0.01294674,0.023960864,0.0008706689,0.001223924,0.000025156623,0.013344185,0.0036328218,0.87498945,0.000024406532,0.0000972741,0.00035557194],"about_ca_topic_score_codex":0.00063540315,"about_ca_topic_score_gemma":0.000085657804,"teacher_disagreement_score":0.07329397,"about_ca_system_score_codex":0.00014578378,"about_ca_system_score_gemma":0.00045556528,"threshold_uncertainty_score":0.9985286},"labels":[],"label_agreement":null},{"id":"W2952375224","doi":"10.1097/01.hs9.0000562928.03733.42","title":"PS1161 EFFICACY AND SAFETY OF IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS PREVIOUSLY TREATED WITH VENETOCLAX IN THE MURANO STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Venetoclax; Medicine; Bendamustine; Ibrutinib; Internal medicine; Rituximab; Hazard ratio; Chronic lymphocytic leukemia; Population; Oncology; Refractory (planetary science); Clinical endpoint; Confidence interval; Leukemia; Randomized controlled trial; Lymphoma","score_opus":0.010360389187044253,"score_gpt":0.2625796229925551,"score_spread":0.25221923380551087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952375224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99128324,0.0012729692,5.8756484e-7,0.000014672158,0.00003157797,0.0045028813,0.0000042003835,0.00003037545,0.0028594742],"genre_scores_gemma":[0.99892867,0.00014520963,0.000027077194,0.00004690632,0.000036140722,0.000097647404,0.000024611836,0.00005394739,0.00063977495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99714196,0.00029104177,0.00064092444,0.0005648741,0.0007734498,0.00058773346],"domain_scores_gemma":[0.9981674,0.00052560447,0.00017176534,0.0009169158,0.000095044335,0.00012327504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060456234,0.00030812225,0.000704158,0.00012616096,0.0000414531,0.000017824566,0.00027226636,0.00016867915,0.0002649604],"category_scores_gemma":[0.00014506998,0.00019681241,0.000057183628,0.00073217787,0.00017065533,0.000087507484,0.00010575246,0.0004299679,0.00006109837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013684084,0.0015622752,0.9563089,0.0021417846,0.00029506048,0.00072901626,0.011126265,0.0035518259,0.00065740093,0.00004991256,0.0002970289,0.009596421],"study_design_scores_gemma":[0.21362355,0.008736153,0.7645611,0.002019324,0.00014798134,0.00012318234,0.0023018562,0.0071354266,0.00034889724,0.0000066941343,0.0006316154,0.00036423025],"about_ca_topic_score_codex":0.0034724497,"about_ca_topic_score_gemma":0.0011686955,"teacher_disagreement_score":0.19993946,"about_ca_system_score_codex":0.049165208,"about_ca_system_score_gemma":0.015525805,"threshold_uncertainty_score":0.99005526},"labels":[],"label_agreement":null},{"id":"W2952463147","doi":"10.1097/01.hs9.0000561068.22529.45","title":"PF696 SAFETY AND EFFICACY OF SELF‐ADMINISTERED ROMIPLOSTIM IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP): RESULTS OF AN INTEGRATED ANALYSIS OF FIVE CLINICAL TRIALS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Romiplostim; Medicine; Clinical trial; Subgroup analysis; Immune thrombocytopenia; Placebo; Internal medicine; Pediatrics; Platelet; Confidence interval; Alternative medicine; Thrombopoietin","score_opus":0.0475940576395064,"score_gpt":0.3800442237727957,"score_spread":0.33245016613328926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952463147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99668115,0.00016668138,0.000009740055,0.00003431133,0.00005048556,0.0019072922,0.00021078378,0.000017371904,0.00092215353],"genre_scores_gemma":[0.99777377,0.000055145596,0.0014315029,0.0000074076424,0.00001394654,0.000006526283,0.00027200623,0.000030131958,0.0004095657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943238,0.0011579654,0.0030627965,0.00050820445,0.0006909615,0.0002562687],"domain_scores_gemma":[0.99451315,0.0023341973,0.0013113305,0.0010481256,0.0006269521,0.00016626394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004292172,0.00023249352,0.0035970404,0.0002889746,0.000014378577,0.00000693929,0.00021837921,0.00025034708,0.0003177421],"category_scores_gemma":[0.00259783,0.00015464022,0.00028768997,0.0011636894,0.00019187083,0.000094911964,0.00010762749,0.0002870408,0.0000075558273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047003843,0.0023060679,0.94083035,0.00093846075,0.003201246,0.000011928749,0.0026136576,0.000055808083,0.0012060829,0.000021105838,0.000039434555,0.0017720186],"study_design_scores_gemma":[0.053780667,0.004813011,0.93015087,0.0020691487,0.0016269835,0.000017635253,0.0023950825,0.0018681824,0.003040607,0.0000030508083,0.00004966969,0.00018510419],"about_ca_topic_score_codex":0.00037530047,"about_ca_topic_score_gemma":0.00017438564,"teacher_disagreement_score":0.010679489,"about_ca_system_score_codex":0.00007859806,"about_ca_system_score_gemma":0.0003508913,"threshold_uncertainty_score":0.6306045},"labels":[],"label_agreement":null},{"id":"W2952482267","doi":"10.1097/01.hs9.0000558668.31452.51","title":"S112 MLL FUSIONS AFFECT SPLICING TO INDUCE EXPLOITABLE METABOLIC DEPENDENCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Genetics","funders":"","keywords":"PKM2; Biology; Cell biology; Warburg effect; Small hairpin RNA; Alternative splicing; Glycolysis; Cell growth; RNA splicing; Cancer research; Exon; Chemistry; Pyruvate kinase; Gene; Biochemistry; RNA; Metabolism","score_opus":0.027358971629896298,"score_gpt":0.30676860134906336,"score_spread":0.27940962971916705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952482267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93607265,0.0010126437,0.00020214815,0.0013872607,0.00020633616,0.00119968,0.0000067775204,0.00017708894,0.059735395],"genre_scores_gemma":[0.9462743,0.00008775344,0.0035509337,0.0013492972,0.0002805923,0.000102224345,0.00001462841,0.00007427268,0.048266005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977094,0.000066032546,0.00026583887,0.00052421866,0.00066272763,0.0007717896],"domain_scores_gemma":[0.9982193,0.00018700228,0.000051495444,0.0008909793,0.00016728468,0.00048395398],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004021848,0.00026058668,0.0005597712,0.00014791168,0.00012713211,0.000045513254,0.0002702301,0.00017557593,0.0063411533],"category_scores_gemma":[0.00032175804,0.00021598769,0.00014417915,0.00077017315,0.00003360528,0.00019491711,0.0003458356,0.0005705233,0.00652185],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000309281,0.00027277358,0.08937641,0.00042366493,0.0002724923,0.0004035573,0.0020246566,0.00012232551,0.8283958,0.0033606235,0.06152896,0.013509446],"study_design_scores_gemma":[0.0070393016,0.0013998955,0.13958412,0.0011569934,0.00037998654,0.00078436924,0.01166056,0.0008650949,0.46692112,0.00024106535,0.3685885,0.0013789788],"about_ca_topic_score_codex":0.0007868311,"about_ca_topic_score_gemma":0.00019284754,"teacher_disagreement_score":0.3614747,"about_ca_system_score_codex":0.00023963534,"about_ca_system_score_gemma":0.00054516405,"threshold_uncertainty_score":0.99456716},"labels":[],"label_agreement":null},{"id":"W2952497968","doi":"10.1097/01.hs9.0000563764.80519.69","title":"PS1372 B‐CELL MATURATION ANTIGEN ANTIBODY‐DRUG CONJUGATE (ADC), GSK2857916, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL SAFETY, EFFICACY AND PHARMACOKINETIC (PK) ANALYSES FROM A PHASE I STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Interim analysis; Pharmacokinetics; Antibody; Pharmacology; Immunology; Clinical trial","score_opus":0.045145304319847965,"score_gpt":0.3849031199403042,"score_spread":0.3397578156204562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952497968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99138254,0.0033430785,0.000052086863,0.00016852864,0.00017291644,0.0029596596,0.0001803693,0.00010302164,0.0016378224],"genre_scores_gemma":[0.99592733,0.0006240415,0.0007885822,0.000103714745,0.0001630134,0.000057632897,0.00070316147,0.00007257874,0.0015599492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996765,0.00027463958,0.000698334,0.00090892334,0.0006983085,0.00065477163],"domain_scores_gemma":[0.9980865,0.0004979989,0.00021424158,0.0006525279,0.00013148967,0.00041721883],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002735479,0.00048730406,0.00085291074,0.00021512576,0.00013981627,0.00007801344,0.00018358298,0.00014104437,0.0023544498],"category_scores_gemma":[0.00014072073,0.00040649791,0.00013429754,0.0004363153,0.00009592107,0.00023917563,0.00014494195,0.00054676435,0.00043415715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019088995,0.009416797,0.5434835,0.00030048218,0.00066148466,0.0020025347,0.0017353949,0.00008746706,0.39547196,0.0000027747424,0.0008598333,0.026888773],"study_design_scores_gemma":[0.09877407,0.0021879869,0.8569275,0.00039880752,0.00033348097,0.000038197664,0.0014107751,0.009262945,0.02789759,0.000018476172,0.0022232938,0.00052687293],"about_ca_topic_score_codex":0.0015316457,"about_ca_topic_score_gemma":0.00037052223,"teacher_disagreement_score":0.36757436,"about_ca_system_score_codex":0.0001510029,"about_ca_system_score_gemma":0.00017656105,"threshold_uncertainty_score":0.9998387},"labels":[],"label_agreement":null},{"id":"W2952510707","doi":"10.1097/01.hs9.0000568164.69011.0e","title":"PB2425 THE IMPACT OF SPECIMEN VOLUME AND HAEMOLYSIS ON ROUTINE COAGULATION TEST RESULTS: REDUCING THE RECOLLECTION BURDEN IN A HIGH‐THROUGHPUT LABORATORY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hatch (Canada)","funders":"","keywords":"Prothrombin time; Coagulation testing; Medicine; Haemolysis; Fibrinogen; Coagulation; Partial thromboplastin time; Surgery; Pathology; Internal medicine; Immunology","score_opus":0.009792584339988671,"score_gpt":0.2631019778187466,"score_spread":0.2533093934787579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952510707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877446,0.00031561425,0.0000063183675,0.004258726,0.00010246998,0.0009719454,0.000029234237,0.000023581426,0.0065474873],"genre_scores_gemma":[0.9962778,0.00020493858,0.00009941486,0.000121798585,0.00019778355,0.000029204986,0.000022482101,0.00002069978,0.0030258854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988769,0.0000844414,0.00034849692,0.0002749377,0.00022558254,0.00018961164],"domain_scores_gemma":[0.9989532,0.00023094061,0.00019513145,0.0004936762,0.00008899713,0.000038054422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055199204,0.00014622165,0.0003750832,0.000057916266,0.00008810852,0.00002723616,0.00007840945,0.00007148374,0.0003577779],"category_scores_gemma":[0.00023592132,0.00008252619,0.00007394978,0.00052702584,0.000052586274,0.00007514542,0.000050120758,0.00017565128,0.0000383915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031815663,0.003954296,0.46405134,0.00091277686,0.0017942003,0.00009237693,0.02895042,0.04849029,0.028898386,0.0017367046,0.37406275,0.043874897],"study_design_scores_gemma":[0.0026831755,0.0012492251,0.98544353,0.0004795501,0.0001482503,0.0000083953755,0.0018401089,0.004121463,0.0012034455,0.00011125021,0.002571057,0.00014056344],"about_ca_topic_score_codex":0.0039930334,"about_ca_topic_score_gemma":0.00018805575,"teacher_disagreement_score":0.52139217,"about_ca_system_score_codex":0.00021616062,"about_ca_system_score_gemma":0.00007708698,"threshold_uncertainty_score":0.6036298},"labels":[],"label_agreement":null},{"id":"W2952592194","doi":"10.1097/01.hs9.0000564128.13888.1d","title":"PS1466 CYTOREDUCTION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA: A SYSTEMATIC REVIEW","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Randomized controlled trial; Essential thrombocythemia; Anagrelide; Internal medicine; Observational study; Aspirin; Relative risk; Placebo; Hydroxycarbamide; Surgery; Polycythemia vera; Chemotherapy; Confidence interval; Pathology","score_opus":0.08401434338757563,"score_gpt":0.39626701586450297,"score_spread":0.31225267247692734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952592194","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003852863,0.97830623,0.000049208862,0.00016911008,0.00038867551,0.020631773,0.00011464482,0.000029185005,0.00030733543],"genre_scores_gemma":[0.000008187304,0.98714346,0.0002424246,0.00005686599,0.0003638698,0.008845379,0.00027546976,0.00008425841,0.002980117],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99764603,0.00013368574,0.0011418927,0.00048331695,0.00033259694,0.00026245438],"domain_scores_gemma":[0.9969809,0.00080512156,0.00090433884,0.0010372938,0.00018904227,0.00008332766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018345828,0.00060712075,0.0055583487,0.000039810395,0.00008586748,0.000016732474,0.0001329696,0.00025203303,0.00038147246],"category_scores_gemma":[0.00010190546,0.00027542748,0.0019189081,0.00020863149,0.00006141784,0.000030196139,0.000017696868,0.000121341,0.00015467979],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015664573,0.0006722928,0.0000018156326,0.93718815,0.0030575686,0.000007486804,0.000070558104,1.6030668e-7,3.936474e-7,0.00022901062,0.0025109588,0.056245934],"study_design_scores_gemma":[0.00071767345,0.0009185498,4.389762e-7,0.5414057,0.047058128,0.00020172393,0.000041789663,0.00000344712,0.000046320325,0.0000047234244,0.40943706,0.00016447985],"about_ca_topic_score_codex":0.000010773808,"about_ca_topic_score_gemma":0.000006692263,"teacher_disagreement_score":0.4069261,"about_ca_system_score_codex":0.00042777043,"about_ca_system_score_gemma":0.0004499265,"threshold_uncertainty_score":0.9999698},"labels":[],"label_agreement":null},{"id":"W2952644065","doi":"10.1097/01.hs9.0000559996.44290.19","title":"PF446 EVALUATING EX VIVO EXPANSION OF FUNCTIONALLY COMPETENT MULTI-SPECIFIC T LYMPHOCYTES TO MINOR HISTOCOMPATIBILITY ANTIGEN FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Minor histocompatibility antigen; Immunology; CD8; T cell; Cytotoxic T cell; Stem cell; Priming (agriculture); Antigen; Haematopoiesis; Major histocompatibility complex; Biology; Cancer research; Immune system; Medicine; In vitro; Cell biology","score_opus":0.12491271604417466,"score_gpt":0.36601823181520166,"score_spread":0.241105515771027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952644065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909687,0.0031757134,0.0009802328,0.00020274556,0.00020538362,0.004052801,0.000029860368,0.000025485484,0.00035908204],"genre_scores_gemma":[0.97750247,0.00018441188,0.0131707955,0.000051936175,0.000074436306,0.00028284817,0.000020200967,0.000028243889,0.008684652],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981492,0.000082785176,0.00051567674,0.00039094634,0.00058347173,0.00027791524],"domain_scores_gemma":[0.9978284,0.0008021671,0.00015510371,0.00065430754,0.0004614314,0.00009854352],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041973466,0.00019500841,0.0006236655,0.000042247804,0.000068586756,0.0000076271763,0.00013601883,0.000083793006,0.006107644],"category_scores_gemma":[0.000079195044,0.00011745007,0.00030260615,0.00016587433,0.00012214534,0.000026777645,0.000042945394,0.00005053822,0.000040077422],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028054907,0.0011443441,0.0676157,0.0004019141,0.00015578429,0.0000035600744,0.0014833988,0.00027678272,0.91112244,0.00014509766,0.00061647664,0.01422901],"study_design_scores_gemma":[0.0117613,0.009480156,0.18055765,0.00046762126,0.00013131347,0.000049422837,0.0042244387,0.009862926,0.7487285,0.000060349186,0.03436312,0.0003131792],"about_ca_topic_score_codex":0.00011583643,"about_ca_topic_score_gemma":0.000052146974,"teacher_disagreement_score":0.16239393,"about_ca_system_score_codex":0.0003594439,"about_ca_system_score_gemma":0.00021516722,"threshold_uncertainty_score":0.9948009},"labels":[],"label_agreement":null},{"id":"W2952690147","doi":"10.1097/01.hs9.0000558800.37954.72","title":"S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Multiple myeloma; Autologous stem-cell transplantation; Hazard ratio; Lenalidomide; Clinical endpoint; Thalidomide; Bortezomib; Surgery; Oncology; Gastroenterology; Randomized controlled trial; Confidence interval","score_opus":0.044020976145244646,"score_gpt":0.3431851252762097,"score_spread":0.29916414913096506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952690147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840941,0.0011488383,0.000019967609,0.00017890487,0.00047418242,0.007053339,0.00026858816,0.00010666982,0.0066554397],"genre_scores_gemma":[0.99569225,0.00037051484,0.0006855091,0.000028824057,0.0001265759,0.0005678342,0.00038675382,0.000088190114,0.0020535463],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99463123,0.00073117664,0.0015086534,0.0010268096,0.0011329749,0.00096914044],"domain_scores_gemma":[0.99461436,0.002954329,0.00038246086,0.001280876,0.0002261847,0.0005417767],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012499186,0.000595206,0.0023687717,0.00027520832,0.00010888966,0.00004288245,0.00030628487,0.00026713102,0.0009659888],"category_scores_gemma":[0.0015532577,0.0004625986,0.00040005537,0.00075286144,0.00017298531,0.00023835036,0.00008669929,0.0005835936,0.0002864766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9103877,0.01298712,0.05248932,0.0004458523,0.0014720411,0.004032203,0.004358251,0.000118854856,0.004648239,0.000022577147,0.0016883778,0.007349438],"study_design_scores_gemma":[0.9655581,0.0044440543,0.009126316,0.00067296624,0.00045624087,0.000040276598,0.0034330902,0.002306933,0.012326712,0.000010233957,0.0011839215,0.00044113863],"about_ca_topic_score_codex":0.0036267012,"about_ca_topic_score_gemma":0.004092028,"teacher_disagreement_score":0.055170394,"about_ca_system_score_codex":0.00022108553,"about_ca_system_score_gemma":0.0003292903,"threshold_uncertainty_score":0.99994725},"labels":[],"label_agreement":null},{"id":"W2952759225","doi":"10.1097/01.hs9.0000565740.21637.cb","title":"PB1809 REAL‐WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) AND COSTS OF PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMBCL) PATIENTS INITIATED ON ANTI‐CANCER THERAPIES IN THE UNITED STATES (US)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Medical diagnosis; Lymphoma; Cancer; Health care; Internal medicine; Oncology; Pathology","score_opus":0.032379214920534936,"score_gpt":0.2922569784763064,"score_spread":0.25987776355577147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952759225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99299735,0.0017257452,8.947106e-7,0.00075759646,0.000048900463,0.00088988285,0.00013366874,0.000030068048,0.003415923],"genre_scores_gemma":[0.9928836,0.0029560782,0.000031886335,0.002679458,0.000027796908,0.00006425197,0.00117026,0.00002910284,0.00015756494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984921,0.0001987694,0.00033789963,0.0002883379,0.0004048341,0.00027803765],"domain_scores_gemma":[0.99899787,0.00029053638,0.00018816395,0.00029334312,0.00014850183,0.0000815587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018023406,0.0002105195,0.00037830102,0.00012891686,0.00006161441,0.000015854308,0.00008042534,0.00008257506,0.00013518048],"category_scores_gemma":[0.00002036464,0.00013653682,0.000045861045,0.0005238615,0.00005266158,0.00005516805,0.00003587336,0.00008434723,0.000011310884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051151414,0.0022154113,0.9816865,0.00035721363,0.000051135732,0.000022351012,0.0024846059,0.000017077524,0.000045791287,0.00030984005,0.0010929729,0.01120563],"study_design_scores_gemma":[0.010583628,0.0007580007,0.97775215,0.0009216044,0.000048250997,0.0000025650215,0.0016657163,0.00021811506,0.0013670038,0.000015273868,0.006536057,0.00013161357],"about_ca_topic_score_codex":0.0019914864,"about_ca_topic_score_gemma":0.0008273358,"teacher_disagreement_score":0.011074017,"about_ca_system_score_codex":0.00026073927,"about_ca_system_score_gemma":0.00010646121,"threshold_uncertainty_score":0.556781},"labels":[],"label_agreement":null},{"id":"W2952813810","doi":"10.1097/01.hs9.0000560808.16752.64","title":"PF631 HEALTH‐RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW‐DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; McGill University Health Centre; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Medicine; Lenalidomide; Daratumumab; Multiple myeloma; Regimen; Internal medicine; Cohort; Clinical endpoint; Dexamethasone; Progressive disease; Oncology; Clinical trial; Chemotherapy","score_opus":0.020931311982442687,"score_gpt":0.28274938292954693,"score_spread":0.26181807094710424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952813810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398774,0.0012848827,0.000013117824,0.00024158238,0.000059567963,0.0033156818,0.00010006753,0.00007317993,0.0009241575],"genre_scores_gemma":[0.99473643,0.000056268105,0.0027714453,0.00014342504,0.000024050734,0.00024814674,0.00029979832,0.000101317004,0.0016191152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575806,0.00047952327,0.0010982429,0.0008081243,0.0010069248,0.00084914354],"domain_scores_gemma":[0.99698764,0.0004252781,0.00054582185,0.0010856794,0.00028214042,0.00067340955],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004067344,0.0005403597,0.001530164,0.00018715482,0.00007261836,0.000020072273,0.00013425031,0.00022051386,0.0009150933],"category_scores_gemma":[0.00025919668,0.00035232678,0.00017836844,0.0005530532,0.00017812647,0.0002334286,0.000058485923,0.0004074036,0.0001724319],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06604247,0.0040689996,0.9221093,0.0005645542,0.0006789165,0.0001790021,0.0006804645,0.000050322025,0.00029632202,0.000012510885,0.000052669315,0.005264459],"study_design_scores_gemma":[0.09038335,0.007235938,0.8995047,0.00092151924,0.000058564234,0.0000097882075,0.00033693845,0.00010496049,0.0009499964,0.000006439216,0.00016308129,0.00032468536],"about_ca_topic_score_codex":0.0032719253,"about_ca_topic_score_gemma":0.002468798,"teacher_disagreement_score":0.024340887,"about_ca_system_score_codex":0.0008484815,"about_ca_system_score_gemma":0.0008367308,"threshold_uncertainty_score":0.9999982},"labels":[],"label_agreement":null},{"id":"W2952817796","doi":"10.1097/01.hs9.0000560592.99613.ac","title":"PF576 NONSENSE‐MEDIATED MRNA DECAY IS A THERAPEUTIC TARGET IN MULTIPLE MYELOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Nonsense-mediated decay; Gene knockdown; RNA splicing; Cell culture; Biology; Molecular biology; Cancer cell; Translation (biology); Cancer research; Cancer; Messenger RNA; Cell biology; Chemistry; Gene; RNA; Biochemistry; Genetics","score_opus":0.01317766469733666,"score_gpt":0.2553419357255027,"score_spread":0.242164271028166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952817796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940528,0.0015637324,0.00012262618,0.00027639416,0.00007127681,0.00029788804,0.0000141151895,0.000015189045,0.0035859721],"genre_scores_gemma":[0.9897977,0.00011518867,0.00047213907,0.00068730506,0.00007024432,0.00002186535,0.00006220328,0.000031545413,0.008741816],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987791,0.00006439794,0.00018298606,0.00036221836,0.00017701965,0.00043426506],"domain_scores_gemma":[0.99934864,0.00004108448,0.00004228194,0.00040107098,0.000052850948,0.000114076145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001565841,0.00015597852,0.00017143086,0.00003304713,0.000040911338,0.000022550515,0.00018392557,0.00017084109,0.0006399996],"category_scores_gemma":[0.0000529437,0.00013935055,0.00008308716,0.00015013953,0.000040042563,0.0000044679477,0.00008404356,0.00015498177,0.0004377639],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014373544,0.000055156408,0.092029124,0.000027644644,0.000032248714,0.000017158367,0.00006518552,0.000027319284,0.9041967,0.000016882974,0.0018587989,0.0015300424],"study_design_scores_gemma":[0.0031705906,0.00046485473,0.03593666,0.00006832285,0.000006580154,0.00003095282,0.0004802334,0.0044535263,0.8765646,0.000079387406,0.07823006,0.00051421364],"about_ca_topic_score_codex":0.00010015426,"about_ca_topic_score_gemma":0.00024045876,"teacher_disagreement_score":0.07637126,"about_ca_system_score_codex":0.000020191588,"about_ca_system_score_gemma":0.00010338383,"threshold_uncertainty_score":0.70075464},"labels":[],"label_agreement":null},{"id":"W2952821043","doi":"10.1097/01.hs9.0000562176.15402.a3","title":"PS968 GENETIC LANDSCAPE OF FLT3‐MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Midostaurin; CEBPA; NPM1; Oncology; Neuroblastoma RAS viral oncogene homolog; Medicine; Internal medicine; Alectinib; Sanger sequencing; Myeloid leukemia; Cancer research; KRAS; Mutation; Biology; Genetics; Gene; Cancer; Crizotinib; Karyotype","score_opus":0.013724678406278864,"score_gpt":0.27149035263312354,"score_spread":0.25776567422684465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952821043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989244,0.0005566755,0.000024196952,0.0004180695,0.00036597578,0.0032159633,0.00005476133,0.00013425753,0.0059860987],"genre_scores_gemma":[0.9814614,0.00022722885,0.0010963499,0.00038755112,0.00020725178,0.00013390413,0.00025635445,0.00012624441,0.016103692],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965272,0.00024624262,0.0009081036,0.0006509137,0.0009998995,0.0006676597],"domain_scores_gemma":[0.9973377,0.00023435308,0.00040200583,0.0012498058,0.00048691704,0.00028923727],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00038583766,0.0004451603,0.00092522113,0.00007964115,0.000118361284,0.00004318073,0.0004974029,0.0003580555,0.0023901232],"category_scores_gemma":[0.00021597554,0.00028529373,0.00026513633,0.00086590956,0.00020287714,0.00012365491,0.00016498604,0.0007652854,0.00092021126],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.118458,0.001832969,0.5956222,0.0018672737,0.004617241,0.0008079633,0.0052022166,0.0012859452,0.12409274,0.0004234181,0.12642626,0.01936376],"study_design_scores_gemma":[0.4085298,0.013368293,0.32878822,0.0016776484,0.0024538736,0.00031492312,0.002652292,0.022580989,0.20212081,0.00028767684,0.014862687,0.0023628033],"about_ca_topic_score_codex":0.00034720494,"about_ca_topic_score_gemma":0.000062413856,"teacher_disagreement_score":0.2900718,"about_ca_system_score_codex":0.00053536583,"about_ca_system_score_gemma":0.0010324878,"threshold_uncertainty_score":0.99995995},"labels":[],"label_agreement":null},{"id":"W2952833516","doi":"10.1097/01.hs9.0000563300.27415.88","title":"PS1255 EFFICACY OF R-BAC IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA POST BTK INHIBITOR THERAPY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Mantle cell lymphoma; Follicular lymphoma; Internal medicine; Surgery; Chemotherapy; Radiation therapy; Refractory (planetary science); Lymphoma; Gastroenterology; Aggressive lymphoma","score_opus":0.004571677957232424,"score_gpt":0.20793314056298617,"score_spread":0.20336146260575375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952833516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911333,0.0018663306,4.7499412e-7,0.00012681325,0.00013581273,0.0010822831,0.00001544222,0.000035652803,0.0056039123],"genre_scores_gemma":[0.9976762,0.0003011105,0.00035331957,0.00035004897,0.00004401731,0.000032098378,0.000084037085,0.00006357944,0.0010956188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985308,0.000039420484,0.0003670249,0.0003768524,0.0003863909,0.0002995333],"domain_scores_gemma":[0.9988454,0.000096707336,0.00018900335,0.0006313213,0.00014091012,0.00009666416],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000696583,0.0002779681,0.0005107847,0.000068833295,0.000027353239,0.000011179987,0.00010284529,0.00014919162,0.0011463669],"category_scores_gemma":[0.000008939844,0.00019222448,0.00013239287,0.00021488294,0.000051605784,0.000104719926,0.000023748722,0.000085609856,0.00022302574],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005383474,0.011558363,0.946813,0.0001367298,0.00016262624,0.00003669086,0.000603445,0.0000028347972,0.0064187334,0.000027085653,0.0007230002,0.028134024],"study_design_scores_gemma":[0.059385035,0.0035614872,0.8758658,0.00037874794,0.000031303756,0.000004413738,0.0001783976,0.0000025288905,0.05602608,0.000004204707,0.004353319,0.00020867557],"about_ca_topic_score_codex":0.00019325089,"about_ca_topic_score_gemma":0.000011576846,"teacher_disagreement_score":0.070947185,"about_ca_system_score_codex":0.00023169494,"about_ca_system_score_gemma":0.00017690218,"threshold_uncertainty_score":0.9997667},"labels":[],"label_agreement":null},{"id":"W2952913340","doi":"10.1097/01.hs9.0000562668.33884.40","title":"PS1094 MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐FRACTIONATED DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Cytokine release syndrome; Adverse effect; Dosing; Gastroenterology; Internal medicine; Chills; Refractory (planetary science); Immunotherapy; Cancer; Chimeric antigen receptor","score_opus":0.0064557568911769725,"score_gpt":0.21729705728347315,"score_spread":0.21084130039229618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952913340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928072,0.000972228,0.000025434421,0.00019372473,0.00008421682,0.0010954435,0.000015496833,0.00006181909,0.0047444543],"genre_scores_gemma":[0.99768746,0.000229921,0.0008972697,0.00018891739,0.000021994212,0.00006240211,0.000031084895,0.000071391914,0.0008095762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981294,0.000058932674,0.0004627667,0.0005790276,0.00039882548,0.00037104465],"domain_scores_gemma":[0.9987735,0.00016445549,0.0002540622,0.00053729495,0.00008097369,0.00018967106],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012391829,0.00033951626,0.0006698713,0.00016149775,0.000058403373,0.000023032519,0.0000818177,0.00014964773,0.00041379503],"category_scores_gemma":[0.000021366177,0.00028349567,0.00009378027,0.0004225979,0.000076838056,0.0001572363,0.00006959545,0.00018383638,0.00005606824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004716283,0.0059574684,0.8791013,0.0023503713,0.00040899267,0.006156399,0.0005631032,0.00067165244,0.038845815,0.0001257472,0.0008135019,0.060289394],"study_design_scores_gemma":[0.022630269,0.0031102689,0.94139457,0.0018407403,0.0002685013,0.001520712,0.0006624179,0.0056084213,0.020946225,0.000033748773,0.0014896226,0.00049450796],"about_ca_topic_score_codex":0.0009992333,"about_ca_topic_score_gemma":0.00013355505,"teacher_disagreement_score":0.062293295,"about_ca_system_score_codex":0.00035116437,"about_ca_system_score_gemma":0.00017101344,"threshold_uncertainty_score":0.99996173},"labels":[],"label_agreement":null},{"id":"W2952930577","doi":"10.1097/01.hs9.0000559236.73191.39","title":"PF256 RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Midostaurin; Medicine; NPM1; Internal medicine; Oncology; Myeloid leukemia; Tyrosine kinase; Survival analysis; Cancer research; Biology; Genetics; Receptor; Gene","score_opus":0.005263333271571992,"score_gpt":0.25244300062050856,"score_spread":0.24717966734893657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952930577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956376,0.00027720418,0.00011784836,0.00010793794,0.000016505797,0.0032005422,0.00021163015,0.00007322575,0.00035750424],"genre_scores_gemma":[0.99412286,0.00013392983,0.0046281195,0.00007389998,0.000030468058,0.000090160254,0.00055122026,0.00013001569,0.00023929679],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971023,0.0001269323,0.00049936096,0.0006438491,0.0008510055,0.0007765391],"domain_scores_gemma":[0.99806803,0.00026274484,0.00026387002,0.00058063964,0.00044298472,0.00038174808],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000213798,0.00049360417,0.00091273006,0.00022150937,0.000056518464,0.00005056989,0.00012329247,0.0002016661,0.0005002428],"category_scores_gemma":[0.00010083187,0.00033076692,0.00008662787,0.0009162305,0.00022744376,0.000296447,0.00004822998,0.0004478804,0.000017997841],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029433781,0.0003803933,0.95430154,0.00032512206,0.00043789647,0.00043838593,0.0015963484,0.00019453,0.005076658,0.000014293683,0.00028880913,0.0075122397],"study_design_scores_gemma":[0.05753274,0.010697576,0.92120355,0.000837864,0.00015266996,0.000041807314,0.00077521044,0.0003360624,0.007909298,0.00002359106,0.00007839254,0.00041122577],"about_ca_topic_score_codex":0.0012587128,"about_ca_topic_score_gemma":0.00039219807,"teacher_disagreement_score":0.03309798,"about_ca_system_score_codex":0.001745392,"about_ca_system_score_gemma":0.0015194917,"threshold_uncertainty_score":0.9999144},"labels":[],"label_agreement":null},{"id":"W2952994283","doi":"10.1097/01.hs9.0000561608.73874.6a","title":"S832 A PHASE 2A STUDY OF THE LSD1 INHIBITOR IMG‐7289 FOR THE TREATMENT OF MYELOFIBROSIS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Bone marrow; Myeloid; Internal medicine; Progenitor cell; Chronic myelomonocytic leukemia; Gastroenterology; Pharmacology; Oncology; Myelodysplastic syndromes; Immunology; Stem cell; Biology","score_opus":0.02639573131401898,"score_gpt":0.3162784913377868,"score_spread":0.28988276002376784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952994283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919953,0.0013274123,0.0000099436975,0.0007519287,0.00022816019,0.004911227,0.00008356926,0.000013760616,0.0006787299],"genre_scores_gemma":[0.9964292,0.0001476894,0.00019947092,0.00007684145,0.00012330814,0.0007610276,0.000009876145,0.000027192937,0.0022254155],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99881285,0.00005041149,0.00036948605,0.00026922335,0.0003030852,0.00019492526],"domain_scores_gemma":[0.9985237,0.00039269085,0.00019993036,0.0006754937,0.00014734651,0.000060826664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008389754,0.00021618126,0.00052445754,0.00001999158,0.00009347015,0.000008686641,0.0001000144,0.00005887466,0.00051422557],"category_scores_gemma":[0.000030154895,0.00009649836,0.00028627727,0.00016946245,0.000057178055,0.000029551393,0.00002856346,0.000050837894,0.000019043884],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041736737,0.06401797,0.8080921,0.0006804181,0.003737029,0.00001702246,0.01916207,0.00008412325,0.023131007,0.0010305081,0.007246021,0.06862805],"study_design_scores_gemma":[0.07972416,0.066348344,0.17430915,0.0006875824,0.0033376783,0.000027492864,0.017343499,0.00056626945,0.59189236,0.00010788755,0.06521796,0.00043758628],"about_ca_topic_score_codex":0.00015054313,"about_ca_topic_score_gemma":0.00015346658,"teacher_disagreement_score":0.633783,"about_ca_system_score_codex":0.00009425411,"about_ca_system_score_gemma":0.000096912656,"threshold_uncertainty_score":0.563041},"labels":[],"label_agreement":null},{"id":"W2953069975","doi":"10.1097/01.hs9.0000561564.12955.95","title":"S821 NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED‐STAGE CLASSICAL HODGKIN LYMPHOMA: 2‐YEAR EXTENDED FOLLOW‐UP FROM COHORT D OF THE PHASE 2 CHECKMATE 205 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Dacarbazine; Nivolumab; Medicine; Vinblastine; Internal medicine; Oncology; Stage (stratigraphy); Cohort; Chemotherapy; Cancer; Immunotherapy","score_opus":0.012768751058135743,"score_gpt":0.27930889893961003,"score_spread":0.2665401478814743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953069975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920097,0.001366478,0.00007194974,0.00037345206,0.00048817115,0.0043609487,0.00030340382,0.0000722453,0.00095366326],"genre_scores_gemma":[0.9928528,0.00011175827,0.0009941064,0.0001862811,0.00013418331,0.00047936215,0.00012409243,0.000076152035,0.005041253],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974855,0.00007773109,0.00061306165,0.0007779926,0.0005433978,0.0005022765],"domain_scores_gemma":[0.9978533,0.00048124918,0.00030300563,0.00095564645,0.00016812082,0.00023871275],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001923392,0.00044249342,0.0010808443,0.000040755964,0.00012790441,0.000032333526,0.00019921194,0.00016227522,0.0008269372],"category_scores_gemma":[0.00021582094,0.0002951676,0.0002953729,0.00023395442,0.00012550269,0.00011904263,0.00019453386,0.000111224734,0.00003502307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012334701,0.018491192,0.8731711,0.00061515614,0.0028543766,0.0004185199,0.0022241652,0.00006768192,0.023069851,0.0013666381,0.012264127,0.053122472],"study_design_scores_gemma":[0.24719265,0.006343121,0.7048305,0.00067331234,0.0018281748,0.000031595413,0.0032105923,0.002204434,0.023402834,0.00025298115,0.009398654,0.0006311023],"about_ca_topic_score_codex":0.00046027402,"about_ca_topic_score_gemma":0.00036477236,"teacher_disagreement_score":0.23485796,"about_ca_system_score_codex":0.00029416694,"about_ca_system_score_gemma":0.0002543098,"threshold_uncertainty_score":0.99995005},"labels":[],"label_agreement":null},{"id":"W2953077540","doi":"10.1097/01.hs9.0000562152.07779.48","title":"PS962 PHASE 1 RESULTS OF ZUMA‐4: KTE‐X19, AN ANTI‐CD19 CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN PEDIATRIC AND ADOLESCENT PATIENTS WITH RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKEMIA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Refractory (planetary science); Gastroenterology; Bone marrow; Acute lymphocytic leukemia; Internal medicine; Hematopoietic stem cell transplantation; Transplantation; Immunology; Leukemia; Lymphoblastic Leukemia; Biology","score_opus":0.00894242772849638,"score_gpt":0.2504569139496639,"score_spread":0.24151448622116753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953077540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947306,0.0011620583,0.000013767204,0.000050777224,0.00016357277,0.0017965344,0.0001296725,0.000071313705,0.0018817352],"genre_scores_gemma":[0.9924441,0.003920072,0.00096149615,0.00016729612,0.00016317057,0.000024192375,0.0003045037,0.00013850543,0.0018766775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996381,0.00019681305,0.00078762183,0.00096149754,0.00088846183,0.0007846155],"domain_scores_gemma":[0.99764633,0.00015801698,0.00044946928,0.0009938759,0.00029314478,0.0004591814],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034312796,0.00051361887,0.000885083,0.000302274,0.000072913565,0.000029674582,0.00032242524,0.00032472258,0.00037196997],"category_scores_gemma":[0.00005074847,0.00040058262,0.00010401062,0.00088706217,0.0001540606,0.00032988063,0.00013527878,0.0007195733,0.00017999532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020263799,0.0061303684,0.8514506,0.0016067288,0.00014833499,0.0001839025,0.001765201,0.00007069776,0.09751571,0.000002561124,0.012098225,0.00876385],"study_design_scores_gemma":[0.16140088,0.0200653,0.74687475,0.0007589007,0.00030518943,0.000035132107,0.0009091032,0.0011662447,0.061429735,0.0000070655074,0.0056925216,0.0013551669],"about_ca_topic_score_codex":0.00016056426,"about_ca_topic_score_gemma":0.000012261177,"teacher_disagreement_score":0.1411371,"about_ca_system_score_codex":0.000691837,"about_ca_system_score_gemma":0.0012309379,"threshold_uncertainty_score":0.9998446},"labels":[],"label_agreement":null},{"id":"W2953212652","doi":"10.1097/01.hs9.0000559476.99472.fd","title":"PF316 THE CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH AGGRESSIVE LARGE CELL LYMPHOMA AND DIABETES MELLITUS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphoma; Internal medicine; Single Center; Retrospective cohort study; Diabetes mellitus; Aggressive lymphoma; Epidemiology; Medical record; Gastroenterology; Rituximab","score_opus":0.00951737541155937,"score_gpt":0.2762648557919237,"score_spread":0.26674748038036433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953212652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971124,0.0013676926,0.000002809853,0.00011373422,0.000075036995,0.0005734067,0.00004079659,0.000013162796,0.00070094963],"genre_scores_gemma":[0.9981808,0.00032827936,0.00014688422,0.0002364185,0.00004030338,0.000009826021,0.000022109043,0.000025675476,0.0010097206],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99867666,0.000063928244,0.00031899413,0.0002688114,0.00036632625,0.00030526027],"domain_scores_gemma":[0.99848527,0.00057424355,0.0002281671,0.00042400864,0.0001444851,0.00014384706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025051428,0.00015237859,0.00049096276,0.000017633418,0.000044079396,0.000016543516,0.000088973866,0.00010628347,0.00016652203],"category_scores_gemma":[0.00019266832,0.00008047445,0.000051448464,0.00007795953,0.0002386431,0.000047408026,0.00014984087,0.00012620667,0.000030473444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020982634,0.00037064202,0.9906569,0.00039134972,0.0001017225,0.000016907603,0.00016815448,4.6833147e-8,0.000013176532,0.000056798333,0.00020545977,0.0078090006],"study_design_scores_gemma":[0.027183134,0.0005419916,0.968717,0.00018981389,0.00010268105,0.000005781154,0.0001963181,0.0004599612,0.0003503652,0.000018336781,0.0021230108,0.00011161234],"about_ca_topic_score_codex":0.000019106026,"about_ca_topic_score_gemma":0.000007968383,"teacher_disagreement_score":0.026973307,"about_ca_system_score_codex":0.00024622792,"about_ca_system_score_gemma":0.0006473168,"threshold_uncertainty_score":0.32816526},"labels":[],"label_agreement":null},{"id":"W2953312502","doi":"10.1097/01.hs9.0000564320.41781.43","title":"PS1515 PREMEDICATION WITH MONTELUKAST AND RUPATADINE DECREASES INFUSION TIME, RATE AND SEVERITY OF REACTIONS AND OVERALL COST OF RITUXIMAB ADMINISTRATION","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine; Rituximab; Diphenhydramine; Montelukast; Premedication; Anesthesia; Placebo; Internal medicine; Gastroenterology; Asthma; Lymphoma","score_opus":0.009343387075642133,"score_gpt":0.24884803119882437,"score_spread":0.23950464412318223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953312502","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99329984,0.00019266835,0.000072716415,0.00024939066,0.000017559843,0.0005905886,0.000027989001,0.000024002162,0.0055252565],"genre_scores_gemma":[0.99714285,0.00031359814,0.0013025963,0.000026369691,0.00002039097,0.000012841865,0.00006227753,0.000013059214,0.0011060182],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99928397,0.000028811019,0.00023141396,0.00020544199,0.00015634402,0.00009399155],"domain_scores_gemma":[0.9992692,0.0000990168,0.00019021283,0.00018118163,0.00013125181,0.00012914151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011383181,0.00011379726,0.00026922493,0.000047457568,0.000040048995,0.000007673819,0.000018919012,0.000079435216,0.000058883772],"category_scores_gemma":[0.00010140118,0.000096014744,0.000017879085,0.000088120185,0.00011127439,0.00021951868,0.00002496566,0.00011055631,0.000004761314],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001420259,0.002157378,0.1597182,0.002813859,0.00038062132,0.00003400791,0.0009571355,0.00001594831,0.7653449,0.0014741761,0.00042041438,0.06526307],"study_design_scores_gemma":[0.005836006,0.00055356533,0.95408505,0.0010800726,0.00033761674,0.0006856201,0.00074105844,0.0017880276,0.030025467,0.00010722023,0.0045562875,0.00020399946],"about_ca_topic_score_codex":0.00023863174,"about_ca_topic_score_gemma":0.00014232124,"teacher_disagreement_score":0.79436684,"about_ca_system_score_codex":0.00002657683,"about_ca_system_score_gemma":0.00016040905,"threshold_uncertainty_score":0.39153677},"labels":[],"label_agreement":null},{"id":"W2953376933","doi":"10.1097/01.hs9.0000559544.58960.b9","title":"PF333 RISK OF BLEEDING COMPLICATIONS AND ATRIAL FIBRILLATION ASSOCIATED WITH IBRUTINIB TREATMENT: A SYSTEMATIC REVIEW AND META‐ANALYSIS","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atrial fibrillation; Medicine; Ibrutinib; Adverse effect; Internal medicine; Meta-analysis; Confidence interval; Randomized controlled trial; Cardiology; Chronic lymphocytic leukemia; Leukemia","score_opus":0.11408786172607231,"score_gpt":0.38178448752326927,"score_spread":0.26769662579719694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953376933","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018505873,0.9930016,0.000018406992,0.00004223191,0.0000071718505,0.006016507,0.0001922478,0.000028247827,0.0006750827],"genre_scores_gemma":[0.00016220001,0.99784803,0.00018715543,0.000010895302,0.000038917977,0.0001490635,0.00040390898,0.000049215916,0.0011506131],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9972686,0.00048218915,0.0010258986,0.00053791015,0.00043236115,0.00025300705],"domain_scores_gemma":[0.9957332,0.0017770255,0.0013459794,0.0007769911,0.00021384167,0.00015293733],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006693659,0.000445796,0.008277727,0.00016619322,0.00007801255,0.000028871911,0.000089160116,0.00024569163,0.00016938763],"category_scores_gemma":[0.00055329956,0.00025348537,0.0015094737,0.001082249,0.0001051116,0.000042911543,0.000063586245,0.00017603576,0.00001185973],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008153001,0.000012061572,0.000019024617,0.75663215,0.24112569,0.0000043957198,0.0000342382,0.000003704759,2.966206e-8,0.000028959288,0.0000126483465,0.0021189577],"study_design_scores_gemma":[0.0020351498,0.00020080766,0.0000049118366,0.122816734,0.869103,0.00014176875,0.000014016546,0.0005112896,1.2902792e-7,0.0000032176583,0.0049786535,0.00019033576],"about_ca_topic_score_codex":0.00024120789,"about_ca_topic_score_gemma":0.00006440306,"teacher_disagreement_score":0.6338154,"about_ca_system_score_codex":0.0023720274,"about_ca_system_score_gemma":0.0019786323,"threshold_uncertainty_score":0.9999917},"labels":[],"label_agreement":null},{"id":"W2974616558","doi":"10.1097/hs9.0000000000000286","title":"Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"National Heart, Lung, and Blood Institute","keywords":"Medicine; Intensive care medicine; Normality; Pathological; Disease; Systematic review; MEDLINE; Pathology; Psychiatry","score_opus":0.11921303329455317,"score_gpt":0.3737422878019674,"score_spread":0.2545292545074142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2974616558","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011428167,0.9813313,0.00027203816,0.000040410298,0.0001244036,0.013857559,0.00011453449,0.00009924636,0.003017699],"genre_scores_gemma":[0.0010122467,0.9788968,0.009018668,0.00015396932,0.00010294756,0.0032058868,0.001310766,0.00026235025,0.0060363766],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9973076,0.00008761289,0.0009782211,0.0008977341,0.00026904268,0.00045977987],"domain_scores_gemma":[0.9982951,0.00016187046,0.00047419974,0.0006717019,0.00007840767,0.00031871794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025267398,0.0006569284,0.003792031,0.00011721017,0.00012066353,0.0000988349,0.00010318318,0.00037344237,0.000020381518],"category_scores_gemma":[0.00010368097,0.0004798411,0.00038746017,0.00023373605,0.00003981264,0.000060019833,0.000065063214,0.00020441125,0.000035942507],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012972413,0.0008418682,0.000030465237,0.95201313,0.002005992,0.00038186123,0.00028666272,0.0000042538654,0.0000020236787,0.00012737543,0.0015460501,0.0426306],"study_design_scores_gemma":[0.00799671,0.0019895711,0.000011337647,0.4771262,0.018514404,0.014899804,0.002409475,0.0025976594,0.0000026905757,0.00028613588,0.47178376,0.0023822342],"about_ca_topic_score_codex":0.00003582737,"about_ca_topic_score_gemma":0.00001453039,"teacher_disagreement_score":0.4748869,"about_ca_system_score_codex":0.00014367924,"about_ca_system_score_gemma":0.00021018935,"threshold_uncertainty_score":0.99976534},"labels":[],"label_agreement":null},{"id":"W2977758416","doi":"10.1097/01.hs9.0000564720.36943.22","title":"S1618 TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH‐RISK CYTOGENETIC ABNORMALITIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Oncology; Internal medicine; Clinical endpoint; Gastroenterology; Clinical trial","score_opus":0.0034592202711760155,"score_gpt":0.20954569199890194,"score_spread":0.20608647172772593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977758416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949107,0.0009738241,0.000018912748,0.00001396952,0.00007340679,0.0015965598,0.000027826663,0.00004483771,0.0023399428],"genre_scores_gemma":[0.9937946,0.0013507863,0.0003585458,0.00006561178,0.000085118976,0.00009113956,0.000023337361,0.00009198021,0.0041388483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785596,0.00015608047,0.00026653617,0.0005924939,0.0005994121,0.00052951707],"domain_scores_gemma":[0.9987273,0.00030677416,0.00013291524,0.00040185134,0.00018502394,0.00024611602],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000182734,0.0003467328,0.0005160564,0.00015463398,0.00008169088,0.00004519217,0.00008827245,0.0001687402,0.0005524653],"category_scores_gemma":[0.000054013723,0.00025947826,0.000037420476,0.00038201825,0.00017436252,0.00017130736,0.000092952774,0.00044875476,0.00006281184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030294822,0.00012978181,0.98859423,0.00050386257,0.00018783122,0.00011009368,0.0012207617,0.000030484685,0.00081686693,0.000014785717,0.00007782556,0.0052839858],"study_design_scores_gemma":[0.01196087,0.0035817975,0.98213494,0.00037858755,0.00029235595,0.000109845794,0.000491792,0.00012468168,0.0004877952,0.00002011352,0.000073601856,0.00034362436],"about_ca_topic_score_codex":0.0008857195,"about_ca_topic_score_gemma":0.00057886756,"teacher_disagreement_score":0.008931387,"about_ca_system_score_codex":0.00039438173,"about_ca_system_score_gemma":0.00024288477,"threshold_uncertainty_score":0.99998575},"labels":[],"label_agreement":null},{"id":"W2977980618","doi":"10.1097/01.hs9.0000563228.79887.e0","title":"PS1237 DOSE DENSE ABVD (DD‐ABVD) AS FIRST LINE THERAPY IN EARLY‐STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI‐CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"ABVD; Dacarbazine; Medicine; Interim analysis; Vinblastine; Radiation therapy; Prospective cohort study; Surgery; Internal medicine; Nuclear medicine; Clinical trial; Chemotherapy; Vincristine","score_opus":0.01901969089911033,"score_gpt":0.3009490587376345,"score_spread":0.2819293678385242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977980618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99019325,0.0020111115,0.0000059235786,0.00049800915,0.00017648278,0.004446073,0.00031405687,0.00009330927,0.002261801],"genre_scores_gemma":[0.97478247,0.00060689397,0.00029428813,0.0002412698,0.00006727602,0.0003436868,0.00015386738,0.000088524175,0.023421746],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99666244,0.00009936087,0.0009942441,0.00093741616,0.0006322832,0.00067425024],"domain_scores_gemma":[0.99787724,0.00016909548,0.00038639302,0.0010611439,0.00023391291,0.00027222856],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003433998,0.0005659911,0.0010525227,0.00014132287,0.00013474746,0.00007156749,0.00021616308,0.00023163264,0.00041491742],"category_scores_gemma":[0.00013733974,0.0004462807,0.00026478447,0.0005433388,0.00008702748,0.00039197478,0.00012616298,0.00017663148,0.00022652831],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017427964,0.107432574,0.84108734,0.00021052781,0.0010313571,0.0012142523,0.008396124,0.000020952757,0.0037618268,0.000067771056,0.005767873,0.013581437],"study_design_scores_gemma":[0.45252874,0.03095714,0.44031605,0.0011443762,0.00023293673,0.00009558766,0.002980529,0.00038381148,0.054429293,0.00003628304,0.015964752,0.0009304941],"about_ca_topic_score_codex":0.004230987,"about_ca_topic_score_gemma":0.0013675569,"teacher_disagreement_score":0.4351008,"about_ca_system_score_codex":0.00051449565,"about_ca_system_score_gemma":0.00023950708,"threshold_uncertainty_score":0.9997989},"labels":[],"label_agreement":null},{"id":"W3005061455","doi":"10.1097/hs9.0000000000000327","title":"Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms","year":2020,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Cancer Council Western Australia; National Health and Medical Research Council; Queen's University; Queen's University Belfast; Medical Research Council; National Institute for Health and Care Research","keywords":"Medicine; Odds ratio; Confidence interval; Internal medicine; Population; Cohort study; Cohort; Essential thrombocythemia; Demography; Pediatrics; Polycythemia vera; Environmental health","score_opus":0.025835282769332987,"score_gpt":0.24792468086158065,"score_spread":0.22208939809224765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005061455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903975,0.0006282151,0.00016127127,0.004288035,0.000040635307,0.00066776806,0.00006309194,0.00016871098,0.0035847821],"genre_scores_gemma":[0.9967194,0.00034431618,0.00053363596,0.0015345139,0.00013874109,0.000095153286,0.00010256098,0.000052470456,0.00047920414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791944,0.00011593951,0.0003055304,0.0005621406,0.00070360786,0.00039336036],"domain_scores_gemma":[0.99819726,0.00039870842,0.00014864224,0.00018941771,0.00015198327,0.00091397733],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013115775,0.00036848127,0.0006686024,0.000025744273,0.00021689682,0.000048081518,0.00007361449,0.00022556314,0.0017158652],"category_scores_gemma":[0.0009929698,0.00023850298,0.000081838,0.00028651292,0.0001489096,0.000113625094,0.0000622478,0.00045292504,0.000056417033],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029498228,0.0004900783,0.98952,0.000067430476,0.0008518469,0.0003209792,0.002428131,0.00007051335,0.00005120729,0.0007856766,0.004202378,0.000916734],"study_design_scores_gemma":[0.0340329,0.013365898,0.8469813,0.001947358,0.0024262497,0.0002612629,0.005737524,0.04269196,0.035201352,0.0004038906,0.014753048,0.0021972517],"about_ca_topic_score_codex":0.000119345816,"about_ca_topic_score_gemma":0.00013837487,"teacher_disagreement_score":0.14253874,"about_ca_system_score_codex":0.00007784728,"about_ca_system_score_gemma":0.0002991214,"threshold_uncertainty_score":0.9991967},"labels":[],"label_agreement":null},{"id":"W3005070954","doi":"10.1097/hs9.0000000000000319","title":"The Pediatric Acute Leukemia Fusion Oncogene ETO2‐GLIS2 Increases Self‐Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cells‐Derived Model","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut National Du Cancer; Fondation pour la Recherche Médicale; Cancéropôle Ile de France; Agence Nationale de la Recherche; CNIB","keywords":"Induced pluripotent stem cell; Stem cell; Cell biology; Oncogene; Cancer research; Leukemia; Biology; Embryonic stem cell; Neuroscience; Immunology; Apoptosis; Cell cycle; Genetics; Gene","score_opus":0.007684411805674912,"score_gpt":0.21624016842295227,"score_spread":0.20855575661727735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005070954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984669,0.0006372836,0.00010992979,0.000043267046,0.00010902067,0.00041908477,0.00000922588,0.000022380236,0.00018291069],"genre_scores_gemma":[0.99817246,0.00086089084,0.00015493672,0.000079640515,0.00012687335,0.000035585348,0.00006403009,0.000023328503,0.00048222698],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989249,0.00008044169,0.00025331636,0.00035142887,0.00016635489,0.00022355639],"domain_scores_gemma":[0.9994345,0.000012178565,0.00013075826,0.00029337467,0.00004704267,0.00008217461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009999681,0.0001818852,0.00014677252,0.00003222163,0.00013863649,0.000037792233,0.0001421436,0.0001726526,0.000013242178],"category_scores_gemma":[0.000006351069,0.00014229635,0.00006154301,0.00008777291,0.000019403054,0.000010757824,0.00015993527,0.00011372984,0.0000064353767],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006018651,0.000052587286,0.0036693208,0.00002420293,0.000025690666,0.0000013649562,0.00006874329,0.00017913553,0.9950734,0.000041128253,0.00020852209,0.0005957666],"study_design_scores_gemma":[0.0015111067,0.00025266118,0.0012253459,0.000019745356,0.000043705448,0.000005361489,0.00022443963,0.004923293,0.99122167,0.00007390263,0.0002258658,0.000272883],"about_ca_topic_score_codex":0.00008901367,"about_ca_topic_score_gemma":0.00014493304,"teacher_disagreement_score":0.004744157,"about_ca_system_score_codex":0.000065233355,"about_ca_system_score_gemma":0.00010945112,"threshold_uncertainty_score":0.5802677},"labels":[],"label_agreement":null},{"id":"W3005555374","doi":"10.1097/01.hs9.0000563932.34778.38","title":"PS1414 A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Vancouver General Hospital; CancerCare Manitoba; Royal Victoria Hospital; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Carfilzomib; Internal medicine; Refractory (planetary science); Dexamethasone; Oncology; Phases of clinical research; Gastroenterology; Multiple myeloma; Lenalidomide; Adverse effect; Pharmacology; Chemotherapy","score_opus":0.029405700020044563,"score_gpt":0.32857225329266204,"score_spread":0.2991665532726175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005555374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99412096,0.0017935343,0.000007965105,0.00006961879,0.00007725014,0.002121269,0.000027356185,0.000048370515,0.0017337041],"genre_scores_gemma":[0.9965364,0.00008902177,0.0012012161,0.00004741146,0.00005438057,0.00009369149,0.000031931595,0.000050670053,0.0018952782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777246,0.00016127453,0.0005053141,0.0005530216,0.00053589465,0.00047205682],"domain_scores_gemma":[0.9984003,0.00037024912,0.00014217556,0.00063290645,0.0001389726,0.00031544588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003133193,0.00028580864,0.0007348915,0.00015803045,0.00004347991,0.000013716917,0.00011373928,0.00015037518,0.0006747404],"category_scores_gemma":[0.0003878608,0.00023328545,0.00008535286,0.00037362167,0.00007225003,0.00009969294,0.00011353065,0.00038607983,0.000113742084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038461227,0.0132921375,0.91625726,0.00041307046,0.00035691317,0.0006340999,0.0020935163,0.000008882732,0.019507796,0.0000111574345,0.00027160943,0.04330744],"study_design_scores_gemma":[0.2562304,0.01582117,0.6924486,0.0007349451,0.000300903,0.00015148162,0.012652497,0.006854496,0.0112333605,0.000045370805,0.0028639329,0.0006628316],"about_ca_topic_score_codex":0.0010803503,"about_ca_topic_score_gemma":0.0011723618,"teacher_disagreement_score":0.25238428,"about_ca_system_score_codex":0.000114593524,"about_ca_system_score_gemma":0.00014899454,"threshold_uncertainty_score":0.95131046},"labels":[],"label_agreement":null},{"id":"W3005643883","doi":"10.1097/01.hs9.0000561572.20578.17","title":"S823 RANDOMIZED, OPEN‐LABEL, NON‐INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Adverse effect; Internal medicine; Clinical endpoint; Neutropenia; Refractory (planetary science); Multiple myeloma; Population; Daratumumab; Phases of clinical research; Gastroenterology; Randomized controlled trial; Surgery; Lenalidomide; Clinical trial; Toxicity","score_opus":0.0321007392232158,"score_gpt":0.3338785845535127,"score_spread":0.3017778453302969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005643883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854378,0.000075244156,0.000009928961,0.000029152181,0.0002411254,0.011082599,0.00006729085,0.00004367646,0.0030131906],"genre_scores_gemma":[0.9969803,0.000023223562,0.00075003156,0.000017212504,0.000038421116,0.00034151407,0.00030795115,0.000071565984,0.0014697707],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99657923,0.0003145501,0.00083777716,0.00070362556,0.0009900912,0.0005747319],"domain_scores_gemma":[0.9974426,0.00059664424,0.0003798118,0.00087422767,0.00038500415,0.00032172282],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039922257,0.00041304293,0.0014977158,0.00013332824,0.00012436444,0.000079143494,0.00032058885,0.00019876278,0.00078522996],"category_scores_gemma":[0.0004924319,0.0003048829,0.000078640645,0.00049063005,0.00014285192,0.00029863056,0.00016915934,0.00048417095,0.00010457495],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8285289,0.02744186,0.1311497,0.00022988999,0.00065341964,0.0019020393,0.0009234131,0.000005627941,0.00037269737,0.000007549454,0.000094792915,0.008690124],"study_design_scores_gemma":[0.87757677,0.06829334,0.05058559,0.0003231239,0.0002673282,0.00004402029,0.0012127551,0.0007639211,0.0004681584,0.000003817342,0.00011728934,0.0003439021],"about_ca_topic_score_codex":0.0013688115,"about_ca_topic_score_gemma":0.0069179507,"teacher_disagreement_score":0.0805641,"about_ca_system_score_codex":0.00035019993,"about_ca_system_score_gemma":0.00080805004,"threshold_uncertainty_score":0.99994034},"labels":[],"label_agreement":null},{"id":"W3005831402","doi":"10.1097/01.hs9.0000562224.72710.77","title":"PS981 LONG TERM AML SURVIVORS HAVE INCREASED MORTALITY AND HIGH PREVALENCE OF CLONAL HEMATOPOIESIS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Bone marrow; Haematopoiesis; Oncology; Leukemia; Internal medicine; clone (Java method); Immunology; Stem cell; Biology; Gene","score_opus":0.02328574315126008,"score_gpt":0.30219314306076733,"score_spread":0.27890739990950725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005831402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949901,0.000780324,0.00005334144,0.0001842845,0.000060792583,0.00068474544,0.000049775397,0.000050214785,0.0031464086],"genre_scores_gemma":[0.99505883,0.00017693028,0.0006207758,0.00011384965,0.00008199285,0.000022043709,0.000030369987,0.000036524303,0.0038586827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980604,0.00010009467,0.00037704015,0.00044744476,0.000639392,0.00037561086],"domain_scores_gemma":[0.9984895,0.0002385852,0.00013383549,0.00070501823,0.00017960746,0.0002534501],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044420114,0.0002149522,0.00053321174,0.000055996294,0.00004313964,0.000015505759,0.00017526504,0.0001684356,0.003579117],"category_scores_gemma":[0.0001736164,0.0001825545,0.000101646445,0.00017051933,0.00023431669,0.00012694242,0.00018286049,0.0003064516,0.0000905797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019934443,0.00012085318,0.984549,0.0038766898,0.00013523099,0.00009060035,0.00016298465,9.886935e-7,0.009298123,0.00028077746,0.0005105483,0.0007748555],"study_design_scores_gemma":[0.0017926303,0.00018792412,0.97414947,0.00039722427,0.000120812,0.00010629521,0.00017287664,0.00018683293,0.022540355,0.00010881159,0.00006371702,0.00017304232],"about_ca_topic_score_codex":0.0024854068,"about_ca_topic_score_gemma":0.0003171034,"teacher_disagreement_score":0.013242232,"about_ca_system_score_codex":0.00013370419,"about_ca_system_score_gemma":0.0002807768,"threshold_uncertainty_score":0.99733174},"labels":[],"label_agreement":null},{"id":"W3005887319","doi":"10.1097/01.hs9.0000560956.60646.c2","title":"PF668 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL‐401) IN PATIENTS WITH INTERMEDIATE, OR HIGH RISK, RELAPSED/REFRACTORY MYELOFIBROSIS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Monocytosis; Refractory (planetary science); Internal medicine; Interleukin-3 receptor; Oncology; Phases of clinical research; Ruxolitinib; Myeloid; Clinical trial; Gastroenterology; Bone marrow","score_opus":0.024210525989180925,"score_gpt":0.3103908181273837,"score_spread":0.2861802921382028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005887319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954799,0.000075278556,0.000007670422,0.00011685973,0.0006292518,0.0021821982,0.0005427192,0.00004574174,0.00092041714],"genre_scores_gemma":[0.99614924,0.00023599528,0.0016951495,0.00015738874,0.0002710489,0.00009987439,0.000601596,0.00005843273,0.00073130114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99656624,0.00029156197,0.0013862589,0.0007895162,0.0005908783,0.00037552128],"domain_scores_gemma":[0.9964856,0.0015370122,0.00074875396,0.0007789685,0.000194194,0.00025549662],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042292156,0.00038244133,0.0012068716,0.00009231034,0.000046544617,0.000020726719,0.00013933632,0.00029323268,0.0012603853],"category_scores_gemma":[0.0007718987,0.00024357847,0.00020509712,0.00028764884,0.00011705286,0.00016513708,0.00007802845,0.0005546053,0.00017823387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2562397,0.008233009,0.713201,0.00006131294,0.00035431157,0.00006174321,0.00039867614,0.000005495787,0.000026001595,0.000012837037,0.0018093794,0.019596528],"study_design_scores_gemma":[0.39301857,0.023355758,0.5790825,0.0009851656,0.00026990726,8.7965344e-7,0.00018547816,0.00003822006,0.0012945933,0.000020265346,0.0014891871,0.00025950017],"about_ca_topic_score_codex":0.0007881827,"about_ca_topic_score_gemma":0.0006946308,"teacher_disagreement_score":0.13677886,"about_ca_system_score_codex":0.00015281118,"about_ca_system_score_gemma":0.0002868932,"threshold_uncertainty_score":0.9996526},"labels":[],"label_agreement":null},{"id":"W3005951838","doi":"10.1097/01.hs9.0000560716.15860.50","title":"PF607 MAINTENANCE WITH WEEKLY CARFILZOMIB IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (IFM 2012–03)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Carfilzomib; Medicine; Lenalidomide; Multiple myeloma; Adverse effect; Melphalan; Maintenance therapy; Internal medicine; Oncology; Chemotherapy","score_opus":0.014678304737559142,"score_gpt":0.2619128628335819,"score_spread":0.24723455809602274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005951838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97628,0.00089937745,0.000055712855,0.001050438,0.00011544503,0.0017282281,0.000031264255,0.00010983973,0.019729745],"genre_scores_gemma":[0.9624432,0.0001030151,0.0031388162,0.0002521627,0.00010176573,0.00019297238,0.00007871988,0.000075415715,0.03361396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974231,0.0000737342,0.0003439945,0.0006394144,0.0005931726,0.0009265898],"domain_scores_gemma":[0.99831504,0.000250262,0.00009635146,0.0007528196,0.000154165,0.00043135099],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015672087,0.00035913358,0.00060556433,0.00010670542,0.000062840125,0.000038489183,0.00018866002,0.00016801173,0.002291883],"category_scores_gemma":[0.00016396883,0.0002577487,0.0001224796,0.00042682947,0.00009438701,0.00025114286,0.000069179325,0.0004263762,0.0022022761],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003217754,0.0007330727,0.9488749,0.00031148733,0.00020083235,0.0030303611,0.00036503424,0.00003458104,0.00303368,0.00012356917,0.00975544,0.030319316],"study_design_scores_gemma":[0.039640196,0.002802322,0.91898,0.0011036653,0.000061639126,0.00022593068,0.0014135403,0.0015036223,0.005165891,0.00005481111,0.028480701,0.0005676636],"about_ca_topic_score_codex":0.0013365198,"about_ca_topic_score_gemma":0.003904162,"teacher_disagreement_score":0.036422443,"about_ca_system_score_codex":0.00023925446,"about_ca_system_score_gemma":0.0002726686,"threshold_uncertainty_score":0.9999875},"labels":[],"label_agreement":null},{"id":"W3006069344","doi":"10.1097/01.hs9.0000562576.71109.e9","title":"PS1071 PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST-IN-CLASS ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO-001, IN PATIENTS WITH ADVANCED B-CELL MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Brentuximab vedotin; Vincristine; Prednisone; Internal medicine; CHOP; Cyclophosphamide; Lymphoma; Oncology; Clinical endpoint; CD30; Gastroenterology; Randomized controlled trial; Chemotherapy","score_opus":0.0056829639859802645,"score_gpt":0.24285167385767537,"score_spread":0.2371687098716951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006069344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962547,0.00019544782,2.6002468e-7,0.0001240952,0.000075185984,0.0025779165,0.000056408546,0.000012096685,0.0007039294],"genre_scores_gemma":[0.99942213,0.000026555017,0.00005429857,0.000031068827,0.000008541601,0.00005058451,0.00007349961,0.000021930911,0.00031136602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983916,0.000061829596,0.0005677034,0.00035271607,0.0003996639,0.000226431],"domain_scores_gemma":[0.9987867,0.000103465536,0.0003600895,0.0005658663,0.0001359769,0.000047912497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010858373,0.00021030697,0.0005287979,0.000057980753,0.000028359756,0.0000056845442,0.00010494289,0.000057055488,0.000031978252],"category_scores_gemma":[0.000026520693,0.00012997744,0.00006169781,0.00031708155,0.000050296883,0.00011818179,0.00006414807,0.000089514,0.000007921026],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060456167,0.02354089,0.9658571,0.00027884205,0.0000563704,0.000046904584,0.0020003389,0.00050631515,0.0006316705,0.000008312545,0.00014429381,0.00088337733],"study_design_scores_gemma":[0.08994706,0.006522081,0.8925536,0.0009753071,0.00009942038,0.0000017222353,0.0015466152,0.00023719607,0.007904255,0.0000030542517,0.00008927611,0.00012036552],"about_ca_topic_score_codex":0.00046202302,"about_ca_topic_score_gemma":0.00035441847,"teacher_disagreement_score":0.08390144,"about_ca_system_score_codex":0.000103611965,"about_ca_system_score_gemma":0.00007425038,"threshold_uncertainty_score":0.53003263},"labels":[],"label_agreement":null},{"id":"W3006115592","doi":"10.1097/01.hs9.0000560972.91141.2d","title":"PF672 RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL‐401) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chronic myelomonocytic leukemia; Internal medicine; Refractory (planetary science); Oncology; Clinical trial; Interleukin-3 receptor; Gastroenterology; Leukemia; Myelodysplastic syndromes; Bone marrow","score_opus":0.030930928187522036,"score_gpt":0.3385047405346094,"score_spread":0.30757381234708736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006115592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892615,0.00044446244,0.000017779947,0.00006153676,0.0005424153,0.0025554649,0.00008458445,0.000075540906,0.0069566946],"genre_scores_gemma":[0.995699,0.00013750282,0.00059327745,0.000083129955,0.000551031,0.000044696215,0.0003475766,0.00010505468,0.0024387306],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946379,0.0002905271,0.0018202442,0.0010908217,0.0013348456,0.0008256297],"domain_scores_gemma":[0.99562925,0.0013755057,0.0006077569,0.0017361663,0.00024915097,0.00040218895],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010811256,0.00042813347,0.001316892,0.00015545092,0.000047242313,0.000027835858,0.00039971512,0.0005196132,0.0010275865],"category_scores_gemma":[0.0011459125,0.00034325736,0.00028059207,0.0005858688,0.0002881154,0.00024094306,0.00020549621,0.0011231129,0.0004945446],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8038009,0.008538579,0.049043205,0.0011926932,0.00094873883,0.0007605178,0.001328681,0.0004114113,0.0010538376,0.000114503964,0.005983019,0.12682392],"study_design_scores_gemma":[0.95654446,0.015342157,0.01245309,0.0017243427,0.00017869471,0.000008989168,0.00022591159,0.005544762,0.0011587463,0.000038726685,0.006299883,0.0004802434],"about_ca_topic_score_codex":0.0019637162,"about_ca_topic_score_gemma":0.00049205916,"teacher_disagreement_score":0.15274355,"about_ca_system_score_codex":0.016979886,"about_ca_system_score_gemma":0.01629385,"threshold_uncertainty_score":0.99990195},"labels":[],"label_agreement":null},{"id":"W3006397179","doi":"10.1097/01.hs9.0000559920.12010.ca","title":"PF427 FOSTAMATINIB, A SPLEEN TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA: INITIAL RESULTS OF THE OPEN‐LABEL EXTENSION PERIOD OF THE SOAR PHASE 2 STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Blood groups and transfusion","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Autoimmune hemolytic anemia; Syk; Clinical endpoint; Anemia; Internal medicine; Gastroenterology; Antibody; Immunology; Tyrosine kinase; Clinical trial","score_opus":0.03961826487134432,"score_gpt":0.3492578135471121,"score_spread":0.30963954867576776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006397179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98958457,0.0016263617,0.000019826986,0.0014129679,0.0003838184,0.006365482,0.00019383192,0.000013329173,0.00039979437],"genre_scores_gemma":[0.9986045,0.0000825234,0.00022625082,0.00006968078,0.000080036014,0.00006430959,0.0000328845,0.000037286376,0.00080255006],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99808,0.00010202808,0.00078969845,0.00034605656,0.00044623966,0.00023598257],"domain_scores_gemma":[0.9977053,0.00022731084,0.00042292487,0.0013274209,0.00026903892,0.00004802101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038975853,0.00025841774,0.000713902,0.000024110992,0.00017563568,0.000015030993,0.0003677435,0.00011613493,0.000092274735],"category_scores_gemma":[0.00009160686,0.000114333794,0.00024478513,0.00033071713,0.00017888079,0.000068397305,0.00016102991,0.0001609463,0.0000020044301],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016659237,0.037501626,0.008838592,0.0011367949,0.00061811,0.00003568662,0.015044918,0.000031858883,0.8852962,0.00021526215,0.0007796653,0.033842035],"study_design_scores_gemma":[0.17719723,0.030701572,0.04176675,0.0023858012,0.0028126854,0.00008931569,0.010706251,0.0019195016,0.7286649,0.00008302307,0.0033011737,0.00037183054],"about_ca_topic_score_codex":0.00056608056,"about_ca_topic_score_gemma":0.00008465638,"teacher_disagreement_score":0.16053799,"about_ca_system_score_codex":0.00004233231,"about_ca_system_score_gemma":0.0002056445,"threshold_uncertainty_score":0.4662397},"labels":[],"label_agreement":null},{"id":"W3129688332","doi":"10.1097/hs9.0000000000000540","title":"Hemophilia Gene Therapy: Approaching the First Licensed Product","year":2021,"lang":"en","type":"review","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Genetic enhancement; Clinical trial; Medicine; Intensive care medicine; Gene; Biology; Internal medicine; Genetics","score_opus":0.10629999907020828,"score_gpt":0.35996604074005584,"score_spread":0.2536660416698476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129688332","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003363579,0.97966456,0.0000109920775,0.0011339608,0.0003335927,0.003761744,0.000015902155,0.00014074848,0.014904863],"genre_scores_gemma":[0.000005033183,0.9420991,0.0004634087,0.0004331356,0.002365611,0.0005421371,0.0002310747,0.00028029596,0.05358023],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99603647,0.00039877603,0.00073860487,0.0011228212,0.00094522146,0.00075810874],"domain_scores_gemma":[0.99643445,0.00036620256,0.00027262926,0.00250444,0.00019929779,0.00022296683],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009472823,0.00076435576,0.0025713067,0.00008671641,0.00033047036,0.00012112125,0.0005749675,0.00039900182,0.010358447],"category_scores_gemma":[0.00019428607,0.0004443974,0.001315646,0.0010136836,0.00017914515,0.00005059218,0.0002571624,0.0018722111,0.00035048273],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039521434,0.00021157284,0.0000073565825,0.0115737,0.0008436888,0.00023582933,0.00024033278,5.1857245e-7,0.000047683166,0.00006742776,0.010017993,0.9767144],"study_design_scores_gemma":[0.00062282087,0.00009974595,0.000004135245,0.007547821,0.00046997552,0.0011241598,0.00006388997,0.0000066191915,0.00013706752,0.000005698907,0.9895067,0.0004113487],"about_ca_topic_score_codex":0.000047524674,"about_ca_topic_score_gemma":0.00001993599,"teacher_disagreement_score":0.97948873,"about_ca_system_score_codex":0.0003055897,"about_ca_system_score_gemma":0.0010995639,"threshold_uncertainty_score":0.9998008},"labels":[],"label_agreement":null},{"id":"W3157098966","doi":"10.1097/hs9.0000000000000562","title":"Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial","year":2021,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Incyte; Gilead Sciences; CTI Biopharma; Celgene; Sanofi; Bristol-Myers Squibb","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Quality of life (healthcare); Internal medicine; Clinical trial; Population; Physical therapy; Bone marrow","score_opus":0.027292318968595786,"score_gpt":0.2889486548959623,"score_spread":0.2616563359273665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157098966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918093,0.0016389708,0.000002777063,0.0018605731,0.00008724246,0.003950311,0.00022358906,0.00009952437,0.0003276883],"genre_scores_gemma":[0.9969534,0.00008638597,0.0005362889,0.0005680089,0.000026562358,0.00040314492,0.0011187962,0.00007964791,0.00022772205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949413,0.00051230204,0.002187576,0.00094840757,0.0008076667,0.0006027814],"domain_scores_gemma":[0.99629617,0.0005898773,0.0013369689,0.000848365,0.00048689733,0.00044170168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035908056,0.000638513,0.0019932233,0.00006525981,0.00030365077,0.000057291876,0.00010064188,0.00025556405,0.0004583766],"category_scores_gemma":[0.00040930064,0.00036303094,0.00020397152,0.0007001377,0.00025259968,0.0001816634,0.00009988011,0.00038050787,0.0000047530184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025965609,0.0061881486,0.9517774,0.00014541393,0.001781077,0.000045804467,0.002882026,0.000004674799,0.00016120532,0.000121346646,0.00018371797,0.010743592],"study_design_scores_gemma":[0.16700606,0.013119464,0.81549877,0.0009466852,0.00042733806,0.00000851997,0.00081389875,0.000023015475,0.0017210706,0.00002820985,0.00005522185,0.00035172192],"about_ca_topic_score_codex":0.0029139975,"about_ca_topic_score_gemma":0.0010834069,"teacher_disagreement_score":0.14104044,"about_ca_system_score_codex":0.00016717173,"about_ca_system_score_gemma":0.00075931934,"threshold_uncertainty_score":0.99988216},"labels":[],"label_agreement":null},{"id":"W3193211635","doi":"10.1097/hs9.0000000000000617","title":"Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial","year":2021,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Internal medicine; Cytarabine; Hazard ratio; Clinical endpoint; Myeloid leukemia; Randomized controlled trial; Surgery; Confidence interval","score_opus":0.021040620247418988,"score_gpt":0.31190299356853796,"score_spread":0.29086237332111897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193211635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905725,0.0003791067,0.0013016607,0.00071547367,0.0002911563,0.005735622,0.00013612914,0.000074931115,0.0007934178],"genre_scores_gemma":[0.9873887,0.00035195332,0.0041867117,0.0007193239,0.0004605745,0.0015818139,0.00096479425,0.0001391929,0.0042069927],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972998,0.00022892178,0.00055633724,0.000643779,0.0006963203,0.0005748681],"domain_scores_gemma":[0.9979571,0.00033334963,0.00017050105,0.0005000932,0.0008518362,0.00018711116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006598194,0.00033539056,0.0011573412,0.00013125916,0.00011270379,0.00005226259,0.00011514989,0.00024514523,0.0005627338],"category_scores_gemma":[0.0005817205,0.00024149765,0.0002627902,0.00064576825,0.00015330147,0.00024778722,0.000055644457,0.0005549182,0.000024604582],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96945876,0.00066111836,0.00049323787,0.000069212656,0.00071553607,0.00011464709,0.0004121431,0.000011495665,0.002886469,0.000058155467,0.0045740423,0.02054521],"study_design_scores_gemma":[0.9175329,0.0038271123,0.00033762868,0.00016175769,0.00024100316,0.000020268519,0.00030651814,0.00019164935,0.07067008,0.00011067274,0.006333383,0.00026699548],"about_ca_topic_score_codex":0.000107549444,"about_ca_topic_score_gemma":0.000056549892,"teacher_disagreement_score":0.06778361,"about_ca_system_score_codex":0.0013903461,"about_ca_system_score_gemma":0.0027989384,"threshold_uncertainty_score":0.98479885},"labels":[],"label_agreement":null},{"id":"W4210423203","doi":"10.1097/01.hs9.0000821540.81071.fa","title":"P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Thalassemia; Medicine; Internal medicine; Placebo; Ineffective erythropoiesis; Blood transfusion; Gastroenterology; Anemia; Erythropoiesis; Pathology","score_opus":0.01872629741786702,"score_gpt":0.2970107363367706,"score_spread":0.2782844389189036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210423203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781227,0.010327721,0.00016435381,0.001480606,0.00038001593,0.0065504527,0.000053021122,0.000093644296,0.0028274893],"genre_scores_gemma":[0.9738699,0.016918704,0.00045383433,0.00027942716,0.000098355784,0.0022265785,0.000056243487,0.00012010495,0.0059768525],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9948342,0.00044811587,0.0016285394,0.0010195574,0.001303964,0.000765633],"domain_scores_gemma":[0.9973113,0.0010284857,0.00042603048,0.00061080017,0.00025878142,0.00036459233],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014368288,0.0007614738,0.003186052,0.00031958567,0.0004014926,0.000028898314,0.0002665056,0.00026580627,0.0026616913],"category_scores_gemma":[0.00014290848,0.00044773606,0.00045591465,0.0007810865,0.0003947003,0.00016705286,0.00017384584,0.00092797034,0.0000060016246],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9756203,0.0022713752,0.00066958455,0.0009295816,0.002024617,0.0018512236,0.007231824,0.0017505515,0.0029398086,0.000121213954,0.00036274284,0.0042271535],"study_design_scores_gemma":[0.9549401,0.0027401878,0.000012678896,0.0011799046,0.0017223093,0.00058798876,0.031694565,0.0013025067,0.0048203883,0.000037256123,0.0003739392,0.00058821344],"about_ca_topic_score_codex":0.0013020517,"about_ca_topic_score_gemma":0.0034734635,"teacher_disagreement_score":0.024462743,"about_ca_system_score_codex":0.00021994456,"about_ca_system_score_gemma":0.0006076231,"threshold_uncertainty_score":0.99979746},"labels":[],"label_agreement":null},{"id":"W4210650909","doi":"10.1097/01.hs9.0000821448.70992.5a","title":"S120: RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY AND SAFETY OF DEFERIPRONE: SUBGROUP ANALYSIS OF PEDIATRIC PATIENTS IN IRON-OVERLOADED PATIENTS WITH SICKLE CELL DISEASE AND OTHER ANEMIAS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Deferiprone; Medicine; Deferoxamine; Clinical endpoint; Population; Anemia; Deferasirox; Sickle cell anemia; Thalassemia; Adverse effect; Randomized controlled trial; Subgroup analysis; Pediatrics; Internal medicine; Clinical trial; Disease; Meta-analysis","score_opus":0.0033041924031480007,"score_gpt":0.19530226310522733,"score_spread":0.19199807070207933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210650909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424565,0.0012820328,0.0000029065106,0.00003374401,0.000050127062,0.0038232263,0.000079145364,0.000005118078,0.0004780406],"genre_scores_gemma":[0.9995445,0.0001559868,0.000022944461,0.000048248003,0.000008842729,0.00007657366,0.000029939263,0.000016964927,0.000096008],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981388,0.00032111775,0.0007131443,0.00021957388,0.0004570408,0.00015035152],"domain_scores_gemma":[0.9987195,0.0003317885,0.0005269005,0.0002574766,0.000075812044,0.000088491295],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033061797,0.00016198619,0.0013660144,0.00011839617,0.00005456619,0.000002615263,0.00007003906,0.000062553445,0.00026027972],"category_scores_gemma":[0.00021630767,0.00009217134,0.00025564132,0.00074874575,0.00016424198,0.000022675511,0.00007753104,0.0001607237,1.4470949e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63161945,0.0015290037,0.365176,0.00017342366,0.00039511253,0.0000010257822,0.00056433317,0.00039336237,0.000016510556,0.000011668632,0.000024195924,0.000095941934],"study_design_scores_gemma":[0.8325365,0.0005536107,0.16119473,0.00002883496,0.0049283216,8.097245e-8,0.00030433523,0.0003308602,0.000015498461,0.0000055776623,0.000011582807,0.00009004473],"about_ca_topic_score_codex":0.00013421889,"about_ca_topic_score_gemma":0.000016106273,"teacher_disagreement_score":0.20398127,"about_ca_system_score_codex":0.000028179145,"about_ca_system_score_gemma":0.000090719215,"threshold_uncertainty_score":0.37586385},"labels":[],"label_agreement":null},{"id":"W4220715528","doi":"10.1097/hs9.0000000000000694","title":"Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; McMaster University; Impact","funders":"","keywords":"Interquartile range; Medicine; Logistic regression; Population; Internal medicine; Pediatrics","score_opus":0.01900083156459565,"score_gpt":0.27007809956408885,"score_spread":0.2510772679994932,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220715528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939229,0.00036738827,0.0000017154052,0.00322746,0.00010477805,0.0014647061,0.000042603988,0.0000619846,0.0008064759],"genre_scores_gemma":[0.9970205,0.0000084975445,0.0003521555,0.0010935046,0.00014433863,0.0005050229,0.00011483038,0.000058637852,0.00070250186],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969441,0.00015457447,0.00039300416,0.00061148976,0.0010858993,0.00081091357],"domain_scores_gemma":[0.9989149,0.000099579294,0.00008659112,0.00034004624,0.00007334774,0.00048554313],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036607086,0.00032269952,0.0005144579,0.00022512219,0.00017431696,0.00004633262,0.00019981456,0.000102184975,0.0016973023],"category_scores_gemma":[0.0001363996,0.00026033042,0.000058156278,0.00069444726,0.000047204325,0.00013717463,0.0003041666,0.00071361026,0.000028189137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022640144,0.0008259346,0.98761606,0.0001808603,0.00008275428,0.0009286359,0.0034807282,0.000075689844,0.000072898634,0.000012226084,0.00023237093,0.004227848],"study_design_scores_gemma":[0.008812093,0.0017821729,0.98287296,0.0005387755,0.00006278363,0.000055849705,0.0042147147,0.00030467566,0.00025811614,0.00002351053,0.0007051132,0.0003692024],"about_ca_topic_score_codex":0.00028378042,"about_ca_topic_score_gemma":0.0009663893,"teacher_disagreement_score":0.0065480783,"about_ca_system_score_codex":0.00033936347,"about_ca_system_score_gemma":0.0003961676,"threshold_uncertainty_score":0.9999849},"labels":[],"label_agreement":null},{"id":"W4225775959","doi":"10.1097/hs9.0000000000000705","title":"Concurrent Composite Lymphomas Collectively Bearing Three Diagnostic Entities of Shared Clonal Origin","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Lymphoma; Diffuse large B-cell lymphoma; Germinal center; Medicine; Internal medicine; Oncology; Cancer research; Pathology; B cell; Immunology; Antibody","score_opus":0.027527033035187592,"score_gpt":0.2662789280037343,"score_spread":0.23875189496854674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225775959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98486185,0.0043445723,0.000035818313,0.00027518318,0.0003777076,0.0006506483,0.00022584992,0.00006642252,0.009161932],"genre_scores_gemma":[0.9976857,0.0000737956,0.00037423943,0.00013244516,0.00007398078,0.0003865571,0.0001300848,0.000026576132,0.0011166299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857074,0.000044396787,0.00031493584,0.0002995144,0.00050489564,0.00026550228],"domain_scores_gemma":[0.9990432,0.00038036794,0.00013541336,0.00022970788,0.000090070636,0.000121215155],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007470597,0.00019229132,0.0004338854,0.00005920826,0.00024225285,0.000020243757,0.00010908887,0.000037178586,0.0050558527],"category_scores_gemma":[0.00005873667,0.00017820488,0.000184774,0.0002662855,0.000078006604,0.000053818632,0.00018777515,0.000103749255,0.000032448104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016985471,0.0019529819,0.9723302,0.00023506128,0.00051885954,0.00042608,0.00074298284,0.0001327245,0.0009366957,0.0052513145,0.011055435,0.0062477826],"study_design_scores_gemma":[0.011249347,0.0015117457,0.9337176,0.00038332955,0.00055787823,0.0003815371,0.0008858311,0.0005405526,0.011484896,0.0004899709,0.03840484,0.00039243983],"about_ca_topic_score_codex":0.00045436245,"about_ca_topic_score_gemma":0.000076998615,"teacher_disagreement_score":0.038612597,"about_ca_system_score_codex":0.00058630056,"about_ca_system_score_gemma":0.00030621584,"threshold_uncertainty_score":0.99585366},"labels":[],"label_agreement":null},{"id":"W4226046585","doi":"10.1097/01.hs9.0000829592.26407.09","title":"P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 POLLUX TRIAL","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Bible College","funders":"","keywords":"Daratumumab; Medicine; Lenalidomide; Internal medicine; Multiple myeloma; Hematology; Oncology; Family medicine","score_opus":0.03345863001137283,"score_gpt":0.2901135033741483,"score_spread":0.2566548733627755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226046585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99274135,0.001948069,0.000018733357,0.00065317244,0.00022938536,0.0032470943,0.0005394015,0.000084421175,0.0005383686],"genre_scores_gemma":[0.99704075,0.00010598608,0.00064486725,0.00015825134,0.00027184654,0.0002662772,0.0006730137,0.00010694663,0.0007320878],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9947926,0.00090423407,0.0008539679,0.0011322732,0.001413302,0.0009036239],"domain_scores_gemma":[0.99496007,0.0032968943,0.0003251206,0.0009058618,0.00015277002,0.00035930803],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013120687,0.0005341213,0.001154074,0.000116657735,0.00049137406,0.000100754005,0.00031129847,0.00018288188,0.00034393856],"category_scores_gemma":[0.0016715393,0.00038359486,0.000119989534,0.0006761613,0.00041332262,0.00020127036,0.0005289297,0.00092460506,0.000009080536],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97793305,0.0013744476,0.0061557093,0.000102373226,0.00064847054,0.00067914947,0.0032591827,0.00013202212,0.0003922547,0.000026534643,0.0021867196,0.007110089],"study_design_scores_gemma":[0.97313714,0.0046360837,0.012109929,0.00017646088,0.00037647923,0.00005859091,0.0014643602,0.004464462,0.0006023224,0.000020295587,0.0024601002,0.0004937558],"about_ca_topic_score_codex":0.014195607,"about_ca_topic_score_gemma":0.0034049712,"teacher_disagreement_score":0.010790636,"about_ca_system_score_codex":0.0053980025,"about_ca_system_score_gemma":0.0020779704,"threshold_uncertainty_score":0.9998616},"labels":[],"label_agreement":null},{"id":"W4244549863","doi":"10.1097/hs9.0000000000000081","title":"Relapsed/Refractory Hodgkin Lymphoma","year":2018,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Download; Medicine; Glioblastoma; Refractory (planetary science); Internal medicine; Oncology; Library science; Cancer research; Computer science; World Wide Web; Biology","score_opus":0.017253013479712986,"score_gpt":0.2710261903154046,"score_spread":0.2537731768356916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244549863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83278906,0.0012658841,0.000019446152,0.0007767714,0.00032249448,0.00023078741,0.000004748051,0.00014413035,0.16444667],"genre_scores_gemma":[0.98739415,0.00008910244,0.0014933995,0.0012272617,0.0006060594,0.000040231324,0.00001527267,0.00002956596,0.00910494],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990309,0.000019707804,0.00017798772,0.00028176693,0.00022220188,0.00026746697],"domain_scores_gemma":[0.99919015,0.000045986435,0.000053292133,0.00043485276,0.00009050691,0.00018523952],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000059926475,0.00016203217,0.00023861924,0.000026501992,0.00009350975,0.000016570499,0.000060542778,0.000109309854,0.0036755665],"category_scores_gemma":[0.000042877662,0.00012287118,0.000113917675,0.00013407125,0.000105221065,0.000062028725,0.000036300375,0.000038469865,0.0030555846],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062370836,0.0038906296,0.22399852,0.00014000761,0.0004955263,0.00092295423,0.00087370735,2.603313e-7,0.0043380037,0.0052988837,0.31619337,0.44322443],"study_design_scores_gemma":[0.00678353,0.0016072756,0.3148683,0.00018523748,0.00016789632,0.0002786121,0.00018767167,0.000030672978,0.025539909,0.0002597548,0.6498573,0.00023384411],"about_ca_topic_score_codex":0.0000825005,"about_ca_topic_score_gemma":0.00003519951,"teacher_disagreement_score":0.4429906,"about_ca_system_score_codex":0.0001926768,"about_ca_system_score_gemma":0.00013376623,"threshold_uncertainty_score":0.99772066},"labels":[],"label_agreement":null},{"id":"W4283217918","doi":"10.1097/hs9.0000000000000745","title":"A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Follicular lymphoma; Internal medicine; Refractory (planetary science); Retrospective cohort study; Rituximab; Confidence interval; Cohort; Oncology; Lymphoma; Surgery; Biology","score_opus":0.009417120956188822,"score_gpt":0.24231788140318222,"score_spread":0.2329007604469934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283217918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99589425,0.00009467978,8.6617274e-7,0.000038939175,0.00010292536,0.002520008,0.000089106754,0.000038530077,0.0012207071],"genre_scores_gemma":[0.9973127,0.00003500453,0.0002608695,0.00006093648,0.000013226884,0.0009051147,0.00006449624,0.000042606192,0.0013050099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980478,0.000091747985,0.00046726636,0.00044266117,0.0007311104,0.0002193936],"domain_scores_gemma":[0.99851733,0.00007516349,0.00037170903,0.00065374235,0.00027420322,0.00010783968],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00006130889,0.00028522202,0.0009850217,0.000063620464,0.000112376445,0.000004041151,0.000086292224,0.000047358444,0.00095561583],"category_scores_gemma":[0.0000490241,0.00017040843,0.00017789811,0.0003074039,0.00004251523,0.00004740678,0.00006993016,0.000053388605,0.00000552991],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021391883,0.0259385,0.9642947,0.000036733752,0.0022989921,0.00019155242,0.0012557934,0.000008883231,0.000009725144,0.000038504077,0.0002835366,0.0035038963],"study_design_scores_gemma":[0.030080175,0.032146856,0.93291175,0.00004974055,0.0010041991,0.000009203765,0.002839899,0.000007876529,0.00028551198,0.0000056363483,0.00050600356,0.0001531531],"about_ca_topic_score_codex":0.0024839747,"about_ca_topic_score_gemma":0.0005286744,"teacher_disagreement_score":0.03138295,"about_ca_system_score_codex":0.0017241047,"about_ca_system_score_gemma":0.000251923,"threshold_uncertainty_score":0.9999576},"labels":[],"label_agreement":null},{"id":"W4283311013","doi":"10.1097/01.hs9.0000848268.24972.7c","title":"P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cumulative incidence; Internal medicine; Transplantation; Incidence (geometry); Oncology; Lymphoma; Gastroenterology; Cancer; Immunotherapy","score_opus":0.010859275549186656,"score_gpt":0.22239159879390863,"score_spread":0.211532323244722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283311013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967908,0.0010171517,0.000029324125,0.00014748774,0.000060338625,0.0009644228,0.000040508166,0.00005679888,0.0008931671],"genre_scores_gemma":[0.99764407,0.000254281,0.00011693367,0.00055391894,0.000024598101,0.00035919237,0.00014492322,0.00004903234,0.00085303624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997968,0.00013603836,0.0003379303,0.00040774158,0.0006796038,0.00047066223],"domain_scores_gemma":[0.99933326,0.000061826206,0.000093495415,0.00034603188,0.00006486111,0.00010052722],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017816234,0.00021806243,0.00036980433,0.00008260813,0.000116842675,0.00001659059,0.00014067862,0.00007331395,0.0015292467],"category_scores_gemma":[0.0000024413794,0.0001711459,0.00007308086,0.0002922597,0.000054756198,0.00010116104,0.00005684622,0.00029197897,0.000032392174],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.078866296,0.0031908057,0.8644131,0.0033098732,0.00027023314,0.006441925,0.0124876695,0.0005361102,0.0144022675,0.00020299002,0.00039045583,0.015488302],"study_design_scores_gemma":[0.10856068,0.0028751337,0.8570638,0.0004334132,0.00009034282,0.0007283684,0.0014212902,0.00048274972,0.021161541,0.000023982004,0.0063663214,0.0007924181],"about_ca_topic_score_codex":0.00006909719,"about_ca_topic_score_gemma":0.000030732896,"teacher_disagreement_score":0.029694384,"about_ca_system_score_codex":0.0037301609,"about_ca_system_score_gemma":0.0012100874,"threshold_uncertainty_score":0.9993835},"labels":[],"label_agreement":null},{"id":"W4283312353","doi":"10.1097/01.hs9.0000843628.63947.e4","title":"S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Cytokine release syndrome; Chimeric antigen receptor; Cohort; Oncology; Antigen; Gastroenterology; Immunology; Cancer; Immunotherapy","score_opus":0.025269656908133178,"score_gpt":0.2987480830311138,"score_spread":0.2734784261229806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283312353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99369824,0.00031104885,0.000033943223,0.00014628314,0.00021172622,0.0020404204,0.0000262343,0.00009514454,0.0034369833],"genre_scores_gemma":[0.98737437,0.0000031204554,0.0022692238,0.00048483364,0.00008141463,0.00024801565,0.00017648314,0.00012714893,0.009235382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657154,0.00031229612,0.00045195472,0.0005880362,0.0015215613,0.0005545841],"domain_scores_gemma":[0.99878716,0.00011611533,0.00014055023,0.00061756244,0.0001434979,0.00019511957],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006909692,0.0002677094,0.00039614105,0.0001802722,0.00025965067,0.000038939448,0.00020476939,0.000101958154,0.008390976],"category_scores_gemma":[0.0001890559,0.00024650546,0.00012746012,0.00078763056,0.000023018532,0.00015346058,0.00016733813,0.0006379975,0.00007816631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064423904,0.0012554033,0.81108576,0.00013412816,0.00013316648,0.00016654187,0.0038760141,0.00084567256,0.15543461,0.0000025265535,0.0023450896,0.018278716],"study_design_scores_gemma":[0.028788904,0.006485465,0.9138435,0.00037182585,0.000080639,0.000009949596,0.0041620065,0.0017516519,0.011652397,0.000016604965,0.032065213,0.00077184336],"about_ca_topic_score_codex":0.00019784014,"about_ca_topic_score_gemma":0.00013018584,"teacher_disagreement_score":0.14378221,"about_ca_system_score_codex":0.0006328552,"about_ca_system_score_gemma":0.00020132898,"threshold_uncertainty_score":0.99999875},"labels":[],"label_agreement":null},{"id":"W4283314633","doi":"10.1097/01.hs9.0000844964.23639.25","title":"P519: TRANSFUSION INDEPENDENCE AMONG NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING VENETOCLAX-BASED COMBINATIONS VS OTHER THERAPIES: RESULTS FROM THE AML REAL WORLD EVIDENCE (ARC) INITIATIVE","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Venetoclax; Internal medicine; Ven; Cytarabine; Decitabine; Cohort; Oncology; Myeloid leukemia; Leukemia; Chronic lymphocytic leukemia","score_opus":0.03312147384718491,"score_gpt":0.2934403156632037,"score_spread":0.26031884181601883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283314633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98553157,0.0003429496,0.00027706084,0.0050701667,0.0003028142,0.0025460573,0.00060823024,0.00022593355,0.005095238],"genre_scores_gemma":[0.99223584,0.00045380538,0.00087825186,0.0026523343,0.0001984933,0.00076184416,0.00047080024,0.00012717862,0.002221445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943129,0.0011086927,0.0008016312,0.0009866769,0.0020423748,0.00074773695],"domain_scores_gemma":[0.9932807,0.0043371897,0.00040534692,0.0012312181,0.0004525172,0.00029303465],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011962616,0.00046011197,0.0005979561,0.00017434501,0.0011232988,0.00010638591,0.00091235706,0.00018695668,0.0024505942],"category_scores_gemma":[0.0010429786,0.00036710192,0.0002446585,0.0015765443,0.00039140505,0.0004494361,0.00032270746,0.0020626418,0.00007396494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024707846,0.0016834945,0.7708138,0.00021812,0.0016401419,0.0013844353,0.06504209,0.0055372315,0.0069682933,0.0004180525,0.08937382,0.03221264],"study_design_scores_gemma":[0.024726696,0.00210748,0.9403274,0.0017407815,0.0003915313,0.00001063119,0.0063065267,0.010191021,0.003795633,0.0004871638,0.009040423,0.0008746899],"about_ca_topic_score_codex":0.014727235,"about_ca_topic_score_gemma":0.0071341107,"teacher_disagreement_score":0.1695136,"about_ca_system_score_codex":0.004091649,"about_ca_system_score_gemma":0.0026202726,"threshold_uncertainty_score":0.9998781},"labels":[],"label_agreement":null},{"id":"W4283315560","doi":"10.1097/01.hs9.0000848220.74181.5a","title":"P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Calgary","funders":"","keywords":"Rituximab; Medicine; Transplantation; Internal medicine; Immunosuppression; Hematopoietic stem cell transplantation; Post-transplant lymphoproliferative disorder; Oncology; Salvage therapy; Immunology; Lymphoma; Chemotherapy","score_opus":0.016660536445774227,"score_gpt":0.29727953607706564,"score_spread":0.28061899963129144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283315560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932128,0.0027554862,0.000033150336,0.00037375191,0.0001467703,0.001818617,0.00009539333,0.000050004546,0.001513986],"genre_scores_gemma":[0.99751604,0.00042665037,0.00008450189,0.00069498434,0.000014621221,0.00019923548,0.00011707588,0.00003722517,0.00090969604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997641,0.0001799819,0.0006469383,0.00038819254,0.0009277023,0.00021616319],"domain_scores_gemma":[0.9990241,0.00009116813,0.0003623206,0.00026551785,0.0001701219,0.00008675312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004531063,0.00020196107,0.00087540696,0.000038123035,0.00016610128,0.0000077367,0.00010704229,0.000052153988,0.00056445925],"category_scores_gemma":[0.000035643498,0.00016635506,0.0002990929,0.00033981528,0.00003351955,0.00009212946,0.000034019056,0.00031812565,0.00001001116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029437686,0.0024728694,0.9921494,0.00080105604,0.00027672236,0.00003376332,0.001876333,0.0000070125607,0.0000026289788,0.00002807768,0.0015721569,0.00048560483],"study_design_scores_gemma":[0.022930974,0.0024716535,0.9630313,0.00072690233,0.0011051765,0.0000022948102,0.008830462,0.000023238823,0.00001807718,0.000026740512,0.00055936875,0.0002738072],"about_ca_topic_score_codex":0.000054157783,"about_ca_topic_score_gemma":0.000048863705,"teacher_disagreement_score":0.029118093,"about_ca_system_score_codex":0.00018859595,"about_ca_system_score_gemma":0.00013513214,"threshold_uncertainty_score":0.6783763},"labels":[],"label_agreement":null},{"id":"W4283315989","doi":"10.1097/01.hs9.0000843712.33707.fe","title":"S205: ZANUBRUTINIB + OBINUTUZUMAB (ZO) VS OBINUTUZUMAB (O) MONOTHERAPY IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PRIMARY ANALYSIS OF THE PHASE 2 RANDOMIZED ROSEWOOD TRIAL","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Clinical endpoint; Obinutuzumab; Internal medicine; Gastroenterology; Phases of clinical research; Follicular lymphoma; Progression-free survival; Refractory (planetary science); Randomized controlled trial; Surrogate endpoint; Surgery; Oncology; Clinical trial; Lymphoma; Chemotherapy; CD20","score_opus":0.013264919863490817,"score_gpt":0.27890062428605017,"score_spread":0.26563570442255935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283315989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908827,0.0007654286,0.00004270852,0.00012252474,0.00029627842,0.0057085427,0.00010065312,0.00008055955,0.002000613],"genre_scores_gemma":[0.99378735,0.00012614489,0.0002924975,0.0005482446,0.00010462635,0.0010989247,0.00032372327,0.00012698292,0.003591517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928858,0.0013499169,0.0015111314,0.0009386852,0.0025030691,0.00081136776],"domain_scores_gemma":[0.9959366,0.0008617371,0.00080740626,0.0018889643,0.0002600897,0.0002452557],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016663724,0.0005438222,0.0026623204,0.0004495527,0.0002891668,0.000035145298,0.0007170135,0.00023729139,0.0034659705],"category_scores_gemma":[0.0005912743,0.00033381354,0.001097413,0.003737339,0.00041829265,0.00015325217,0.00036203244,0.00062133244,0.000010650001],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9821133,0.0031739138,0.0003938275,0.00019206903,0.0037889436,0.00028536847,0.001565035,0.0013513162,0.00024977824,0.00007837463,0.0011719009,0.005636168],"study_design_scores_gemma":[0.9731329,0.0048652673,0.00084202876,0.00014716202,0.0023225995,0.00003865577,0.00050365174,0.012813588,0.000633326,0.00002697226,0.0042735925,0.0004002666],"about_ca_topic_score_codex":0.0017255567,"about_ca_topic_score_gemma":0.00024920233,"teacher_disagreement_score":0.018681215,"about_ca_system_score_codex":0.04146889,"about_ca_system_score_gemma":0.022787673,"threshold_uncertainty_score":0.99991137},"labels":[],"label_agreement":null},{"id":"W4283318495","doi":"10.1097/01.hs9.0000844896.35718.c4","title":"P502: CLINICAL IMPLEMENTATION OF GERMLINE GENETIC TESTING FOR HEMATOLOGIC DISORDERS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hematology; Genetic testing; Internal medicine; Germline; Cancer; Oncology; Germline mutation; Lynch syndrome; Population; Referral; Family medicine; Mutation; Genetics; Biology","score_opus":0.0748785243221959,"score_gpt":0.4288595605038129,"score_spread":0.353981036181617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283318495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954761,0.00081138854,0.0010538624,0.00045792855,0.00012617896,0.0011258938,0.000029143504,0.000050673545,0.00086879416],"genre_scores_gemma":[0.9778057,0.00002200525,0.021113006,0.00017560442,0.00010283866,0.0002822257,0.00005326137,0.000030116675,0.0004152613],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983696,0.000080088095,0.0005857381,0.00028695664,0.0003733565,0.00030431338],"domain_scores_gemma":[0.9986757,0.00062567566,0.00017102057,0.00030287114,0.00013182213,0.000092935414],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050163985,0.00010354299,0.0003322019,0.00003613767,0.00011822722,0.0000046154796,0.00012656783,0.00004648121,0.001723178],"category_scores_gemma":[0.00048080398,0.00009593348,0.00013108717,0.00033701214,0.000082742576,0.000021472399,0.00016316402,0.000169248,0.000008285507],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015090642,0.0017708219,0.51838225,0.0037992154,0.00053753064,0.00021751638,0.0010748063,0.00079112843,0.005509862,0.0018575982,0.029265322,0.4352849],"study_design_scores_gemma":[0.29477465,0.032472998,0.2486222,0.00053796096,0.0017120418,0.0040826267,0.042817224,0.24866942,0.020760767,0.013566389,0.08969488,0.002288862],"about_ca_topic_score_codex":0.00029492658,"about_ca_topic_score_gemma":0.000084634106,"teacher_disagreement_score":0.43299603,"about_ca_system_score_codex":0.0012684563,"about_ca_system_score_gemma":0.0028045923,"threshold_uncertainty_score":0.9991894},"labels":[],"label_agreement":null},{"id":"W4283320497","doi":"10.1097/01.hs9.0000845140.40137.c7","title":"P563: A RANDOMIZED, DOUBLE-BLIND, 2-ARM, MULTICENTER, PH3 STUDY OF VENETOCLAX & ORAL AZACITIDINE VS. ORAL AZACITIDINE AS MAINTENANCE THERAPY FOR PTS WITH AML IN FIRST REMISSION AFTER INTENSIVE CHEMOTHERAPHY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Medicine; Azacitidine; Venetoclax; Internal medicine; Induction chemotherapy; Maintenance therapy; Chemotherapy; Ven; Gastroenterology; Oncology; Leukemia; Surgery; Chronic lymphocytic leukemia","score_opus":0.03767137095473121,"score_gpt":0.3261266026400179,"score_spread":0.2884552316852867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283320497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98482585,0.00089619984,0.0002522147,0.0020200182,0.00013314027,0.011314008,0.000052728174,0.000081109036,0.00042471493],"genre_scores_gemma":[0.98735297,0.00034779968,0.002330473,0.0014798273,0.00012245183,0.004908492,0.00014494437,0.0001741128,0.0031389487],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958363,0.00034581558,0.0009483726,0.00094417174,0.001043128,0.0008822225],"domain_scores_gemma":[0.99708533,0.00043571455,0.0003873581,0.0009005445,0.00089928106,0.0002917799],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012934168,0.00057685806,0.0017964831,0.00031180005,0.0001957316,0.000034389774,0.0004070093,0.0001566522,0.0022847957],"category_scores_gemma":[0.0002894441,0.0004226254,0.00037148836,0.0009909143,0.00030699515,0.00016259788,0.00025982063,0.00088983314,0.000016740803],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96949476,0.0023806503,0.010748219,0.0003099192,0.00070960994,0.00040664824,0.0074340063,0.00025088535,0.0022520716,0.000023792747,0.00442972,0.0015597113],"study_design_scores_gemma":[0.95215696,0.0069743292,0.001031906,0.0007061515,0.0001836501,0.00022231633,0.009829578,0.0018061821,0.0063384078,0.000083335006,0.020069435,0.0005977349],"about_ca_topic_score_codex":0.0018886798,"about_ca_topic_score_gemma":0.0011883251,"teacher_disagreement_score":0.017337793,"about_ca_system_score_codex":0.0010091546,"about_ca_system_score_gemma":0.0005556067,"threshold_uncertainty_score":0.99982256},"labels":[],"label_agreement":null},{"id":"W4283325455","doi":"10.1097/01.hs9.0000843736.56298.a7","title":"S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Chemoimmunotherapy; Hazard ratio; Internal medicine; Oncology; Refractory (planetary science); Phases of clinical research; Surgery; Clinical trial; Lymphoma; Confidence interval; Rituximab","score_opus":0.02406320880621695,"score_gpt":0.3345384065848873,"score_spread":0.3104751977786704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283325455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99540466,0.0009576049,0.0000025653915,0.00004033896,0.000115257666,0.0023727186,0.00014806743,0.000027722357,0.0009310806],"genre_scores_gemma":[0.9989232,0.00005449442,0.0001191208,0.000075349315,0.000012688912,0.00015220964,0.00006162871,0.000071405404,0.0005299488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99556977,0.0004901409,0.0014106806,0.0006510558,0.0014043814,0.00047395864],"domain_scores_gemma":[0.99792856,0.00030057543,0.00047150935,0.00078685686,0.0003049988,0.00020751503],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006756591,0.00030524837,0.0012803646,0.000250436,0.0000824502,0.000010349552,0.00018045299,0.00013163855,0.0016203503],"category_scores_gemma":[0.00020458111,0.00026025408,0.00014196684,0.0006503707,0.000137275,0.00009024134,0.00027342935,0.0005820518,0.0000016728641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026285527,0.034464825,0.87913305,0.0002541829,0.00018118619,0.0005636227,0.0066617364,0.0000063654475,0.00034813397,0.0000025852582,0.000115015704,0.051983792],"study_design_scores_gemma":[0.2828547,0.12554732,0.5311832,0.00031523747,0.00020611243,0.00001713175,0.049557503,0.0000542705,0.0013634651,0.000012249126,0.008335871,0.00055294635],"about_ca_topic_score_codex":0.00025736753,"about_ca_topic_score_gemma":0.0007365393,"teacher_disagreement_score":0.34794986,"about_ca_system_score_codex":0.00029188173,"about_ca_system_score_gemma":0.00050137093,"threshold_uncertainty_score":0.999985},"labels":[],"label_agreement":null},{"id":"W4283326517","doi":"10.1097/01.hs9.0000843644.02496.66","title":"S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Oncology; Multiple myeloma; Adverse effect; Phases of clinical research; Refractory (planetary science); Clinical trial; Bortezomib","score_opus":0.035882064541854906,"score_gpt":0.30806208928966367,"score_spread":0.2721800247478088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283326517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9594774,0.004302337,0.01629328,0.00137496,0.00014632907,0.01257668,0.0021231838,0.00015876241,0.0035470573],"genre_scores_gemma":[0.9863131,0.000051200375,0.007209936,0.00006382853,0.000019517756,0.0022187172,0.002371971,0.000041227322,0.0017105003],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981762,0.00010280743,0.000437453,0.00042693855,0.0004878434,0.0003687232],"domain_scores_gemma":[0.99844694,0.0004522394,0.00020691054,0.0006553283,0.0001571002,0.00008149917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026883246,0.00025787207,0.00044065338,0.00014150668,0.00031258966,0.000016577535,0.00015752073,0.000070295784,0.0000999096],"category_scores_gemma":[0.000070374204,0.00016385355,0.00014171009,0.00056772586,0.00011606377,0.000058413356,0.00002350733,0.00020259732,0.0000012511608],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41441232,0.27269512,0.02081575,0.0008676185,0.0033938268,0.00039174707,0.0052648555,0.007186006,0.039482847,0.00073570677,0.0050135534,0.22974063],"study_design_scores_gemma":[0.6621848,0.03387045,0.011810321,0.00015065918,0.0003189195,0.000041047166,0.0035969731,0.1698995,0.02093859,0.000021359232,0.096690394,0.00047703995],"about_ca_topic_score_codex":0.00046499597,"about_ca_topic_score_gemma":0.00014239346,"teacher_disagreement_score":0.24777243,"about_ca_system_score_codex":0.0005956608,"about_ca_system_score_gemma":0.0003923757,"threshold_uncertainty_score":0.66817534},"labels":[],"label_agreement":null},{"id":"W4283326697","doi":"10.1097/01.hs9.0000843684.97625.7e","title":"S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Myeloproliferative neoplasm; Oncology; Bone marrow","score_opus":0.02699854354408923,"score_gpt":0.26657649225316404,"score_spread":0.2395779487090748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283326697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98752,0.00011078471,0.000005093715,0.0027386944,0.00011482267,0.006965617,0.0019793937,0.00012546184,0.00044016395],"genre_scores_gemma":[0.99109644,0.0000051599577,0.0023340075,0.0010078531,0.00022036218,0.0022394436,0.0018130752,0.0001828154,0.0011008229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99417955,0.00081450475,0.0007667155,0.0016132231,0.0017482511,0.0008777338],"domain_scores_gemma":[0.99543154,0.0012228308,0.00032095492,0.0022619562,0.00029390608,0.0004687997],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065035885,0.0008062852,0.001041142,0.00013744773,0.00063385186,0.00013145221,0.000660127,0.00009377904,0.0016918296],"category_scores_gemma":[0.00018774562,0.0004491476,0.00006787417,0.0010141908,0.00017857764,0.0003120188,0.00096469064,0.0007424924,0.000077378056],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2107571,0.008112353,0.7674115,0.00005605328,0.00047840737,0.0015802385,0.004011159,0.00008258043,0.000028945791,0.000023798055,0.0070805685,0.00037730098],"study_design_scores_gemma":[0.030587645,0.06890293,0.87971586,0.00068278133,0.0005612932,0.00009069586,0.015555069,0.0000559539,0.0003623497,0.0000042050915,0.0028492848,0.0006319398],"about_ca_topic_score_codex":0.00091009523,"about_ca_topic_score_gemma":0.0027712246,"teacher_disagreement_score":0.18016945,"about_ca_system_score_codex":0.00045555652,"about_ca_system_score_gemma":0.00076880405,"threshold_uncertainty_score":0.99979603},"labels":[],"label_agreement":null},{"id":"W4283326710","doi":"10.1097/01.hs9.0000846056.58461.6d","title":"P793: SCREENING OF NATURALLY OCCURRING CXCR4 VARIANTS FOR IDENTIFICATION OF NOVEL PATHOGENIC MUTATIONS FOR WHIM SYNDROME","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chemokine receptors and signaling","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Biology; CXCR4; Genetics; Primary immunodeficiency; Population; Chemokine receptor; Phenotype; Chemokine; Immunology; Gene; Immune system; Medicine","score_opus":0.033617274508355416,"score_gpt":0.2977253516566775,"score_spread":0.2641080771483221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283326710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8589914,0.0004488254,0.13884297,0.00011060213,0.00018211268,0.0009332921,0.00038898643,0.000026324657,0.00007549486],"genre_scores_gemma":[0.9730927,0.0000020340717,0.025906509,0.000037228954,0.000048694827,0.00018049039,0.00023409931,0.000027678032,0.00047060355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99890715,0.000011763091,0.00048287405,0.0002082118,0.00023165671,0.00015832033],"domain_scores_gemma":[0.9990794,0.00016227544,0.00030449612,0.00018697549,0.00022222452,0.00004461974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035367583,0.00009647817,0.0002907863,0.000059859096,0.00013797673,0.0000064995656,0.000095191375,0.000045590972,0.00021320599],"category_scores_gemma":[0.0001960997,0.00010027348,0.0002028192,0.00022867082,0.00002124164,0.00006108894,0.000044065946,0.00010188266,3.708919e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023285406,0.0003444293,0.0018412024,0.001075891,0.0001854735,0.000003090432,0.0007162823,0.0025627469,0.98767895,0.0011602981,0.00039800064,0.0038007617],"study_design_scores_gemma":[0.031265818,0.0031229313,0.033430807,0.0019404107,0.0025797838,0.001253213,0.018901305,0.32728267,0.56772006,0.0018883732,0.009161431,0.0014531949],"about_ca_topic_score_codex":0.000013441863,"about_ca_topic_score_gemma":0.000002935946,"teacher_disagreement_score":0.4199589,"about_ca_system_score_codex":0.000045166456,"about_ca_system_score_gemma":0.00009088355,"threshold_uncertainty_score":0.4089034},"labels":[],"label_agreement":null},{"id":"W4283328755","doi":"10.1097/01.hs9.0000847280.69256.81","title":"P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Rituximab; Lenalidomide; Medicine; Follicular lymphoma; Internal medicine; Lymphoma; Phases of clinical research; Oncology; CD20; Gastroenterology; Clinical trial; Multiple myeloma","score_opus":0.031827012363458154,"score_gpt":0.3023487328686932,"score_spread":0.27052172050523504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283328755","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845473,0.009047923,0.00010411663,0.00043265978,0.00042982885,0.0045174183,0.00034518866,0.00012160571,0.00045393128],"genre_scores_gemma":[0.9934293,0.00034050073,0.0015040438,0.0002559332,0.00021755876,0.0024711674,0.00016710737,0.00015198419,0.0014624313],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953779,0.00030191138,0.001082716,0.0012981391,0.0010648852,0.0008744643],"domain_scores_gemma":[0.9967301,0.0010146593,0.0005629463,0.0009437788,0.00021214012,0.0005363575],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006383764,0.00082201464,0.0019906661,0.0002486434,0.00070708035,0.00008919885,0.00027708587,0.00022875615,0.0005844633],"category_scores_gemma":[0.00024460338,0.0007005427,0.0003502058,0.00046455016,0.00023815173,0.00027392307,0.0004752844,0.00019916074,0.000017277534],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65580904,0.11938917,0.007490213,0.0025979741,0.0077181505,0.011913036,0.012536647,0.00012754381,0.0019319962,0.0010214549,0.012976242,0.16648851],"study_design_scores_gemma":[0.9180947,0.020705907,0.003651556,0.00032696457,0.0031941067,0.0016750281,0.019717716,0.0016505701,0.0029621266,0.00005561401,0.027006418,0.0009592703],"about_ca_topic_score_codex":0.0012442764,"about_ca_topic_score_gemma":0.00048999675,"teacher_disagreement_score":0.26228565,"about_ca_system_score_codex":0.0018316875,"about_ca_system_score_gemma":0.0011153854,"threshold_uncertainty_score":0.99954456},"labels":[],"label_agreement":null},{"id":"W4283328977","doi":"10.1097/01.hs9.0000845556.79615.3f","title":"P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Medicine; Idelalisib; Internal medicine; Chronic lymphocytic leukemia; Gastroenterology; Tolerability; Rituximab; Progression-free survival; Oncology; Ibrutinib; Chemotherapy; Leukemia; Adverse effect; Lymphoma","score_opus":0.030805073093128868,"score_gpt":0.3009799521374058,"score_spread":0.27017487904427695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283328977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98532516,0.0042283596,0.0000067158767,0.00027942454,0.00069318403,0.0013660556,0.00025121623,0.00017699596,0.007672919],"genre_scores_gemma":[0.95089215,0.00038912066,0.0003239485,0.00027746943,0.00031896302,0.00020361767,0.00025805572,0.00016428108,0.047172412],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936116,0.00032828678,0.0015361856,0.0011584612,0.0020435147,0.0013219522],"domain_scores_gemma":[0.99634415,0.0009281088,0.00046753875,0.0016280168,0.00018242167,0.00044977164],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013298456,0.0004983818,0.0014103357,0.00032587725,0.00023404336,0.000022402915,0.00068744685,0.00039186087,0.006689806],"category_scores_gemma":[0.0014275032,0.0004881329,0.0003547455,0.0015707255,0.00036109312,0.00013537165,0.0012860612,0.0012874511,0.00034194614],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.28222325,0.003871256,0.0021362123,0.013718944,0.0024501758,0.06079539,0.021733303,0.06436542,0.033319186,0.0019785475,0.46610618,0.047302127],"study_design_scores_gemma":[0.57741016,0.0072028083,0.0026392057,0.0017745445,0.000510719,0.0045271395,0.0034003092,0.09020625,0.008379738,0.00010698066,0.30229214,0.0015500011],"about_ca_topic_score_codex":0.004159596,"about_ca_topic_score_gemma":0.0019663963,"teacher_disagreement_score":0.29518694,"about_ca_system_score_codex":0.24866745,"about_ca_system_score_gemma":0.06376139,"threshold_uncertainty_score":0.99975705},"labels":[],"label_agreement":null},{"id":"W4283328999","doi":"10.1097/01.hs9.0000843512.62237.dc","title":"S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Bosutinib; Discontinuation; Tolerability; Internal medicine; Adverse effect; Imatinib; Myeloid leukemia; Nilotinib; Gastroenterology","score_opus":0.010204334073727377,"score_gpt":0.2673810174070419,"score_spread":0.2571766833333145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283328999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917406,0.0024528063,0.0000035276323,0.00014655992,0.00016709376,0.0044891555,0.00079935224,0.000076535376,0.00012439305],"genre_scores_gemma":[0.9974115,0.000106343374,0.00023404078,0.00010128231,0.00020850885,0.0005080762,0.0010954988,0.00012661159,0.00020815743],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99481815,0.00032313753,0.0015497335,0.0013866551,0.0010651797,0.0008571567],"domain_scores_gemma":[0.9975198,0.00023299675,0.0005574384,0.001256175,0.00010552464,0.0003280454],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047196727,0.0006852962,0.0012810112,0.00029008198,0.00015983936,0.000029603012,0.00026356458,0.00017150183,0.0014029779],"category_scores_gemma":[0.00014980361,0.0006139732,0.00010341642,0.0010415104,0.00017692248,0.00024741556,0.00046654016,0.0009309865,0.00002436377],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45501977,0.07333038,0.27867305,0.0014049885,0.0017191237,0.007328571,0.02295156,0.0037840013,0.004954127,0.000013807291,0.0031338169,0.14768678],"study_design_scores_gemma":[0.6287124,0.03445343,0.3225434,0.0016134065,0.00050628756,0.000028104549,0.0012870212,0.001621094,0.0029668543,0.0000065186637,0.0053729275,0.0008885365],"about_ca_topic_score_codex":0.002193982,"about_ca_topic_score_gemma":0.0028495628,"teacher_disagreement_score":0.17369263,"about_ca_system_score_codex":0.012501303,"about_ca_system_score_gemma":0.002972149,"threshold_uncertainty_score":0.99963117},"labels":[],"label_agreement":null},{"id":"W4283329542","doi":"10.1097/01.hs9.0000845096.01949.78","title":"P552: TREATMENT OUTCOMES IN NEWLY DIAGNOSED, UNTREATED PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Myeloid leukemia; Ven; Venetoclax; Oncology; Randomized controlled trial; Leukemia; Gastroenterology","score_opus":0.01886784192203424,"score_gpt":0.2840499807896953,"score_spread":0.26518213886766107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283329542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.718968,0.25936073,0.00002191363,0.0059430166,0.000039902076,0.013437997,0.0010927814,0.00026383193,0.0008718355],"genre_scores_gemma":[0.9164514,0.022967085,0.0018222074,0.0065255747,0.000030092811,0.00960826,0.003282395,0.0002662034,0.0390468],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9962509,0.00061704294,0.00082760083,0.0008066432,0.000921152,0.0005766204],"domain_scores_gemma":[0.9978008,0.00032832503,0.00030725452,0.0009958977,0.00026177327,0.00030593947],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038748066,0.0005970838,0.0039384635,0.00037393495,0.0001853539,0.00006883746,0.00021745195,0.00012424968,0.0019265823],"category_scores_gemma":[0.00013620108,0.0003429261,0.0007023917,0.0033436061,0.00006876948,0.0001577069,0.00018509827,0.0006102941,0.00002903659],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013306229,0.0026069123,0.24644145,0.07849441,0.6466139,0.014251178,0.003855808,0.00047677572,0.00003883821,0.000070342016,0.0054679634,0.00035178108],"study_design_scores_gemma":[0.01605508,0.0026304629,0.028234206,0.00221,0.94782317,0.00037816731,0.0007624885,0.00042911308,0.000055946915,0.000011599489,0.00058599864,0.00082378316],"about_ca_topic_score_codex":0.0004240796,"about_ca_topic_score_gemma":0.00034425186,"teacher_disagreement_score":0.30120924,"about_ca_system_score_codex":0.0021567347,"about_ca_system_score_gemma":0.0003705908,"threshold_uncertainty_score":0.99990225},"labels":[],"label_agreement":null},{"id":"W4283331887","doi":"10.1097/01.hs9.0000843912.35755.7f","title":"S255: EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL): THE PHASE II BIANCA STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Fludarabine; Internal medicine; Phases of clinical research; Lymphoma; Clinical endpoint; Refractory (planetary science); Oncology; Cyclophosphamide; Gastroenterology; Surgery; Chemotherapy; Clinical trial","score_opus":0.01166383156354024,"score_gpt":0.2766023768999559,"score_spread":0.2649385453364157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283331887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941341,0.0011369681,0.0000025959368,0.00014297433,0.00009286665,0.0024752994,0.00004329871,0.000028272476,0.0019435994],"genre_scores_gemma":[0.9916879,0.0005613066,0.00011273346,0.00012346802,0.00008340883,0.00013552277,0.000030934036,0.00007257815,0.0071921656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753255,0.00026603567,0.00044864585,0.0005237913,0.0008417244,0.00038727935],"domain_scores_gemma":[0.99866694,0.00023838649,0.00019383691,0.0005946165,0.00014268431,0.00016353535],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048799452,0.00027289536,0.0004917737,0.00013195506,0.00031507498,0.000019661842,0.00019466918,0.000096413845,0.0015676711],"category_scores_gemma":[0.000091721246,0.00017822719,0.00004821904,0.00087488315,0.000112209746,0.00007880796,0.0003200424,0.0005631141,0.0000034226318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0934571,0.03743836,0.6536688,0.0012893043,0.00036362442,0.0012047271,0.037563395,0.000026378322,0.010590959,0.000009483484,0.008769423,0.15561844],"study_design_scores_gemma":[0.21657382,0.048419956,0.70430994,0.00021615234,0.00051858363,0.00020979824,0.018884404,0.00041164807,0.0010949805,0.000008889905,0.008622909,0.00072894397],"about_ca_topic_score_codex":0.00025467988,"about_ca_topic_score_gemma":0.00038918044,"teacher_disagreement_score":0.15488951,"about_ca_system_score_codex":0.00018209632,"about_ca_system_score_gemma":0.00025624238,"threshold_uncertainty_score":0.999345},"labels":[],"label_agreement":null},{"id":"W4283333295","doi":"10.1097/01.hs9.0000845116.46694.aa","title":"P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Placebo; Myeloid leukemia; Internal medicine; Gastroenterology; Azacitidine; Population; Surgery; Pathology; Biology","score_opus":0.011609486325459929,"score_gpt":0.2448589086781847,"score_spread":0.23324942235272475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283333295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914663,0.00015498564,0.00020975975,0.0007257791,0.00006673376,0.0040088464,0.00015648126,0.00028062894,0.0029305248],"genre_scores_gemma":[0.9875982,0.000027697564,0.005898543,0.0010723561,0.00007832842,0.0014402008,0.0008821858,0.00022194891,0.0027805334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99411744,0.00022757615,0.0007525627,0.0012945388,0.002137453,0.0014704061],"domain_scores_gemma":[0.9972289,0.00023191006,0.00038758316,0.0011840228,0.00039953864,0.0005680536],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003883963,0.00082157296,0.0013759612,0.00034234728,0.0004371031,0.0000743429,0.0005853202,0.00016890292,0.00248826],"category_scores_gemma":[0.000059258215,0.00058366643,0.00010928158,0.0018126632,0.0003489723,0.00035280606,0.00046827339,0.0015904907,0.000079958416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050268266,0.0020460864,0.9150624,0.0006344706,0.0014052049,0.008717207,0.0010476698,0.002392926,0.0021673127,0.00018509361,0.014454955,0.0016184051],"study_design_scores_gemma":[0.43265557,0.045212813,0.45461008,0.002577555,0.0019233716,0.0027981896,0.013814969,0.0054088933,0.02210734,0.00016524349,0.01346133,0.0052646617],"about_ca_topic_score_codex":0.00070631766,"about_ca_topic_score_gemma":0.0009296462,"teacher_disagreement_score":0.46045232,"about_ca_system_score_codex":0.0030986657,"about_ca_system_score_gemma":0.0016498619,"threshold_uncertainty_score":0.9996615},"labels":[],"label_agreement":null},{"id":"W4283366934","doi":"10.1097/01.hs9.0000846464.96684.8e","title":"P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Population; Oncology; Surgery; Gastroenterology","score_opus":0.04771458878182294,"score_gpt":0.29972435333488623,"score_spread":0.2520097645530633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283366934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553263,0.0005092161,0.00006569038,0.00004506653,0.000083322346,0.0025987981,0.00020464198,0.00010272927,0.00085787824],"genre_scores_gemma":[0.99496496,0.0000066812654,0.0033854048,0.000024373498,0.000028609324,0.00024120597,0.0007729717,0.00011589891,0.00045986997],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995891,0.00036750332,0.0008709146,0.0007240781,0.0013610226,0.00078551145],"domain_scores_gemma":[0.99795604,0.0002768709,0.0005695308,0.00070562295,0.00016711008,0.00032479977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019786728,0.0005493379,0.0014442985,0.0003327665,0.00032863682,0.000027262044,0.00021256169,0.00013250714,0.0006103208],"category_scores_gemma":[0.000054980675,0.0004085505,0.00014582401,0.0008622001,0.0001423161,0.00014810117,0.00014064925,0.00065122853,0.000012511197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02000734,0.00935955,0.9539988,0.00020828731,0.00057647005,0.0002970979,0.0025052642,0.0012067464,0.0011762124,0.000005512453,0.00011236045,0.010546348],"study_design_scores_gemma":[0.06342581,0.012013094,0.9031653,0.0004189739,0.00031548485,0.00003904624,0.0056681386,0.006202848,0.007653547,0.0000036291797,0.00062123,0.00047294344],"about_ca_topic_score_codex":0.0016167994,"about_ca_topic_score_gemma":0.0022826449,"teacher_disagreement_score":0.050833553,"about_ca_system_score_codex":0.0015620872,"about_ca_system_score_gemma":0.00045398026,"threshold_uncertainty_score":0.9998366},"labels":[],"label_agreement":null},{"id":"W4283370847","doi":"10.1097/01.hs9.0000848944.56958.95","title":"P1522: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Hemolysis; Ineffective erythropoiesis; Thalassemia; Adverse effect; Pyruvate kinase; Internal medicine; Erythropoiesis; Anemia; Pharmacology; Glycolysis; Metabolism","score_opus":0.0076543691600737904,"score_gpt":0.2325502291694925,"score_spread":0.22489586000941872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283370847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955242,0.0006886104,0.000014248614,0.0012962852,0.00013340169,0.0012292339,0.000028589897,0.000031771768,0.0010536017],"genre_scores_gemma":[0.99784005,0.00047249385,0.00008924359,0.00023602185,0.000023058465,0.000052681797,0.000019972125,0.000046520596,0.0012199635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99826527,0.000094072006,0.00039200613,0.00040073582,0.00049875135,0.0003491966],"domain_scores_gemma":[0.99913275,0.00009115274,0.0001325394,0.00044511104,0.00005009881,0.00014835793],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017909959,0.00025318895,0.0004554727,0.000050504404,0.00021141354,0.000009539442,0.00017202903,0.00012685283,0.0012581439],"category_scores_gemma":[0.000034531662,0.0001452734,0.000093095136,0.0005047064,0.00014621504,0.00006911273,0.00017219178,0.0006401167,0.0000037888892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026440654,0.0025217347,0.90088916,0.0017652201,0.00046196207,0.0016828374,0.00621174,0.0004092758,0.024495237,0.000092245435,0.0011038844,0.03392604],"study_design_scores_gemma":[0.033414748,0.0021804862,0.9337189,0.002553761,0.0003777946,0.00045138464,0.00666147,0.00018517092,0.018305602,0.00001266344,0.001583164,0.00055483705],"about_ca_topic_score_codex":0.00025132866,"about_ca_topic_score_gemma":0.0005812866,"teacher_disagreement_score":0.033371203,"about_ca_system_score_codex":0.000115640636,"about_ca_system_score_gemma":0.00023645411,"threshold_uncertainty_score":0.9996548},"labels":[],"label_agreement":null},{"id":"W4283372513","doi":"10.1097/01.hs9.0000846600.20422.ca","title":"P933: DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Lenalidomide; Daratumumab; Clinical endpoint; Oncology; Dexamethasone; Subgroup analysis; Clinical trial; Confidence interval","score_opus":0.03893365579631453,"score_gpt":0.3151773999234155,"score_spread":0.27624374412710095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283372513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99780923,0.0006210727,0.0000013395743,0.00007351314,0.00003284597,0.0013127199,0.00008331791,0.000018060216,0.000047880327],"genre_scores_gemma":[0.9979948,0.00012074468,0.00039269228,0.000044727087,0.000008749406,0.0004662855,0.00010917953,0.000041452608,0.0008214161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976995,0.00028670233,0.00048170754,0.00046946743,0.000676742,0.00038587878],"domain_scores_gemma":[0.9989246,0.00030190678,0.00017886343,0.0003322744,0.00014590163,0.000116430034],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025373013,0.00027163592,0.00080271106,0.0006186325,0.00008451623,0.000012742934,0.00008436303,0.000081366576,0.00055258797],"category_scores_gemma":[0.00017661699,0.00015890587,0.0000492956,0.002033508,0.00016057931,0.00017746168,0.00009143478,0.0004169952,0.0000017994273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11461328,0.0023701887,0.870625,0.00011090418,0.00087751716,0.0023701326,0.0043442366,0.000039439732,0.000042871354,0.0000016709531,0.000022950406,0.004581781],"study_design_scores_gemma":[0.047901273,0.010258331,0.93845105,0.00024269149,0.00015273898,0.000009108149,0.0022354682,0.00042740983,0.000069182606,0.0000026958405,0.000061738305,0.0001883166],"about_ca_topic_score_codex":0.0013368166,"about_ca_topic_score_gemma":0.034317892,"teacher_disagreement_score":0.067826025,"about_ca_system_score_codex":0.00046458395,"about_ca_system_score_gemma":0.00022064544,"threshold_uncertainty_score":0.9833033},"labels":[],"label_agreement":null},{"id":"W4283376400","doi":"10.1097/01.hs9.0000846460.44039.3d","title":"P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre; University of Calgary; Institute of Cancer Research","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Cytokine release syndrome; Adverse effect; Common Terminology Criteria for Adverse Events; Minimal residual disease; Oncology; Transplantation; Immunology; Gastroenterology; Immunotherapy; Cancer; Chimeric antigen receptor; Bone marrow","score_opus":0.024270762174428962,"score_gpt":0.29195613847621205,"score_spread":0.2676853763017831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283376400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99310726,0.00035631197,0.000029234341,0.00011501529,0.00012828792,0.0044516833,0.0013913565,0.000105371815,0.00031550042],"genre_scores_gemma":[0.9939693,0.000013268601,0.0019014465,0.000083573,0.00007355678,0.0005652192,0.0021009187,0.000097749034,0.0011949707],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99693966,0.0003270453,0.00067252765,0.00062845345,0.000932083,0.0005002048],"domain_scores_gemma":[0.9968104,0.0013466165,0.0004536983,0.0009177988,0.00031424733,0.00015724865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043358526,0.00031474337,0.0005516502,0.00007482824,0.00065605174,0.00002565924,0.0002927734,0.00006777125,0.0008522149],"category_scores_gemma":[0.00067621924,0.00019196792,0.00012468481,0.00053882273,0.000061485,0.00010939658,0.00014055464,0.00045845006,0.0000061067817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45754027,0.053554524,0.31159493,0.00021044088,0.0042707184,0.00070140464,0.023575034,0.00016301444,0.026404629,0.0000020518858,0.016390815,0.10559218],"study_design_scores_gemma":[0.6372588,0.06074689,0.20051762,0.0004088886,0.0007511685,0.000019828407,0.05046181,0.005997847,0.015656695,0.000013738936,0.027202904,0.00096378836],"about_ca_topic_score_codex":0.0020164181,"about_ca_topic_score_gemma":0.00056602363,"teacher_disagreement_score":0.17971855,"about_ca_system_score_codex":0.00023417806,"about_ca_system_score_gemma":0.0002624526,"threshold_uncertainty_score":0.9331155},"labels":[],"label_agreement":null},{"id":"W4283379313","doi":"10.1097/01.hs9.0000850132.55221.5c","title":"PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Venetoclax; Azacitidine; CD47; Medicine; Myeloid leukemia; Myeloid; Hypomethylating agent; Leukemia; Cancer research; Oncology; Minimal residual disease; Internal medicine; Immunology; Chronic lymphocytic leukemia; Biology; Receptor","score_opus":0.005121433250560848,"score_gpt":0.19006292908842065,"score_spread":0.1849414958378598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283379313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972515,0.00040969788,0.000029241815,0.000090840724,0.000105442574,0.0016211102,0.00015679952,0.0000967523,0.00023859624],"genre_scores_gemma":[0.9956418,0.00002539563,0.00027295662,0.00015203284,0.000011251317,0.00028228405,0.0020031892,0.00011589391,0.0014951463],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99709016,0.0002928961,0.0006104392,0.0008730319,0.0002868355,0.0008466305],"domain_scores_gemma":[0.9986221,0.000089023924,0.0004132356,0.0005527612,0.00023777601,0.00008506718],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017769194,0.0006475296,0.00089009805,0.00023683868,0.00038158233,0.000045783894,0.00029337834,0.00023666043,0.00088597636],"category_scores_gemma":[0.000014997899,0.0004372386,0.00004496928,0.0010859051,0.00032734184,0.00040606834,0.00018474911,0.00076620106,0.000023935749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051683716,0.0012929712,0.9330027,0.00012858708,0.000999176,0.0001546683,0.0014897562,0.0014688666,0.004418764,0.000120584555,0.0009194731,0.0043206997],"study_design_scores_gemma":[0.05558571,0.022911705,0.90771395,0.0006129762,0.00030753444,0.00012577901,0.00076001853,0.00010616922,0.007241178,0.000037353122,0.0033140243,0.0012836201],"about_ca_topic_score_codex":0.0005361985,"about_ca_topic_score_gemma":0.0016667602,"teacher_disagreement_score":0.025288802,"about_ca_system_score_codex":0.0007295364,"about_ca_system_score_gemma":0.0005078133,"threshold_uncertainty_score":0.99980795},"labels":[],"label_agreement":null},{"id":"W4283379818","doi":"10.1097/01.hs9.0000846628.17113.b2","title":"P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Adverse effect; Multiple myeloma; Oncology; Clinical endpoint; Expanded access; Clinical trial; Surgery; Gastroenterology; Immunotherapy; Cancer","score_opus":0.016813890652781462,"score_gpt":0.28782187908842116,"score_spread":0.2710079884356397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283379818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964956,0.0000976825,0.000010575568,0.00006443842,0.000038436363,0.002197683,0.000099607205,0.000039346083,0.0009566416],"genre_scores_gemma":[0.9987395,0.000023669985,0.0003736412,0.00002638934,0.000024173782,0.000102431826,0.00008338465,0.000054863525,0.00057196984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970652,0.0004254332,0.00048246526,0.0006189609,0.0009556427,0.00045233234],"domain_scores_gemma":[0.99840117,0.00038310874,0.00023221258,0.0005749241,0.00011861813,0.00028997287],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004019303,0.00028747896,0.0007580748,0.0001082681,0.00018430203,0.000010564129,0.00013038916,0.00007838065,0.00044824422],"category_scores_gemma":[0.00013646738,0.00020682634,0.00007487523,0.0003676546,0.00016986903,0.00012523726,0.00024489453,0.0007286842,0.0000073531055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052591935,0.010114823,0.91262335,0.00008854349,0.00041369925,0.0004795118,0.00037091377,0.000013230294,0.000021813154,0.0000037637587,0.000051096176,0.023227343],"study_design_scores_gemma":[0.06026847,0.014181216,0.9236943,0.000085604384,0.00012844517,0.00003337016,0.0009114629,0.00016357772,0.00006623075,0.0000018641696,0.0002771905,0.00018824272],"about_ca_topic_score_codex":0.00077054196,"about_ca_topic_score_gemma":0.0016477793,"teacher_disagreement_score":0.0230391,"about_ca_system_score_codex":0.00024893146,"about_ca_system_score_gemma":0.00028534757,"threshold_uncertainty_score":0.84341335},"labels":[],"label_agreement":null},{"id":"W4283381234","doi":"10.1097/01.hs9.0000846956.81764.f3","title":"P1022: OUTCOMES IN MYELOPROLIFERATIVE NEOPLASM PATIENTS WITH OR WITHOUT PRIOR HISTORY OF CANCER: A POPULATION-BASED STUDY FROM ONTARIO","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloproliferative neoplasm; Polycythemia vera; Internal medicine; Cancer; Essential thrombocythemia; Oncology; Myelofibrosis; Population; Radiation therapy; Cohort; Retrospective cohort study; Hormonal therapy; Bone marrow; Breast cancer","score_opus":0.01836061546473317,"score_gpt":0.2678379448957078,"score_spread":0.24947732943097461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283381234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961114,0.00022760156,0.0000031052264,0.0001519874,0.00020545133,0.002759572,0.00011317614,0.00003436211,0.00039336568],"genre_scores_gemma":[0.9920178,0.0000014273045,0.00094691233,0.0005075209,0.000020742164,0.0019046634,0.00020563747,0.00004458033,0.004350693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978123,0.00014225965,0.00051836984,0.0005167621,0.00075662014,0.00025370435],"domain_scores_gemma":[0.998878,0.00018650491,0.00029220994,0.0003788586,0.00014646446,0.000117980715],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008806646,0.00032482058,0.00092850457,0.00010388418,0.00010823321,0.0000075916037,0.00009985512,0.00004971954,0.00612372],"category_scores_gemma":[0.000036599053,0.00022243398,0.00008504826,0.00019753336,0.000030179115,0.000071986055,0.00005688596,0.0003152511,0.0000040894797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028872497,0.0056987097,0.98072773,0.000033713397,0.00039761522,0.00007901537,0.0086042695,0.00039142897,0.0000032477012,0.000008174776,0.00021851384,0.0009503171],"study_design_scores_gemma":[0.015322177,0.0027183755,0.9784696,0.00011040229,0.0002555509,8.401099e-7,0.0011184437,0.000108917986,0.000048576716,0.0000056762274,0.0016095011,0.00023193502],"about_ca_topic_score_codex":0.13021606,"about_ca_topic_score_gemma":0.58880913,"teacher_disagreement_score":0.45859307,"about_ca_system_score_codex":0.004086388,"about_ca_system_score_gemma":0.0018862733,"threshold_uncertainty_score":0.9997367},"labels":[],"label_agreement":null},{"id":"W4283384745","doi":"10.1097/01.hs9.0000851224.51567.a8","title":"PB2098: ‘REAL-WORLD’ TREATMENT PATTERNS AND PATHWAYS OF SECOND LINE DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS IN UK, CANADA, FRANCE, GERMANY, ITALY AND SPAIN USING A PROSPECTIVE SURVEY OF PHYSICIANS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Lymphoma; Internal medicine; Refractory (planetary science); Pediatrics; Oncology","score_opus":0.012443807399632972,"score_gpt":0.23042647623620943,"score_spread":0.21798266883657647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283384745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995876,0.0004768658,0.0000018533505,0.0000160634,0.000050040566,0.00075268047,0.0023974015,0.0000072253088,0.00042184882],"genre_scores_gemma":[0.9991067,0.000109501234,0.000046530346,0.00009068867,0.000014760753,0.00009037726,0.00018918198,0.000028802462,0.00032346486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986172,0.000103331404,0.00037331,0.00034917644,0.0002834168,0.00027360287],"domain_scores_gemma":[0.9992565,0.0001242026,0.00023085604,0.0002381142,0.00006668002,0.00008367009],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010496953,0.00023569043,0.00061765494,0.00006718913,0.0000798888,0.000006079938,0.000044015535,0.00003448101,0.000103828614],"category_scores_gemma":[0.000007947041,0.00020728761,0.000054540105,0.00025345376,0.000037735743,0.00003731048,0.000091456255,0.000050647624,2.1979342e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017475747,0.008370383,0.9872462,0.0001712394,0.00014305176,0.00012826687,0.0010385884,0.0000045689294,0.00015812769,0.000019811809,0.000061320374,0.0024836625],"study_design_scores_gemma":[0.02092522,0.00090539845,0.9728941,0.000118397315,0.000105500716,0.0000055222044,0.00043161164,0.00038197372,0.0039746203,0.000006553085,0.000095856456,0.00015526006],"about_ca_topic_score_codex":0.5796244,"about_ca_topic_score_gemma":0.846426,"teacher_disagreement_score":0.2668016,"about_ca_system_score_codex":0.0006965383,"about_ca_system_score_gemma":0.00033750437,"threshold_uncertainty_score":0.84529436},"labels":[],"label_agreement":null},{"id":"W4283389183","doi":"10.1097/01.hs9.0000850912.43010.d3","title":"PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research","funders":"","keywords":"Lenalidomide; Daratumumab; Medicine; Internal medicine; Pomalidomide; Oncology; Multiple myeloma; Bortezomib; Dexamethasone","score_opus":0.02841387785979811,"score_gpt":0.30961096755874207,"score_spread":0.28119708969894397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283389183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922508,0.00031335565,0.000012709469,0.000048539652,0.00019588691,0.0052192267,0.00012260664,0.00006786044,0.0017690175],"genre_scores_gemma":[0.9965668,0.000013577358,0.0003943522,0.000026561636,0.00003627165,0.0010024356,0.00026046878,0.00007451996,0.0016250187],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99622476,0.00049725734,0.00070373697,0.0006175664,0.0013877695,0.0005689154],"domain_scores_gemma":[0.9977758,0.0006861808,0.00028792096,0.00078360067,0.00018252834,0.00028395426],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041274284,0.00037291524,0.0012153994,0.00021086111,0.00023822379,0.000019160074,0.00023933887,0.00008073249,0.0025031844],"category_scores_gemma":[0.0006118084,0.00025991508,0.000151971,0.0007252203,0.00015331937,0.00013977922,0.00024876496,0.00063191063,0.000030417867],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8765176,0.016928723,0.09455125,0.00015941441,0.00078115077,0.0016269602,0.0017683933,0.00010016957,0.000040235085,0.000010459752,0.00043099406,0.0070846668],"study_design_scores_gemma":[0.9414495,0.018409014,0.03135681,0.00010317585,0.00026497286,0.000014393411,0.006240982,0.0006990132,0.00012624187,0.0000034404738,0.0010571704,0.00027524252],"about_ca_topic_score_codex":0.0007190753,"about_ca_topic_score_gemma":0.001064816,"teacher_disagreement_score":0.06493196,"about_ca_system_score_codex":0.00064038654,"about_ca_system_score_gemma":0.00043348892,"threshold_uncertainty_score":0.9999853},"labels":[],"label_agreement":null},{"id":"W4283392950","doi":"10.1097/01.hs9.0000847476.69621.cd","title":"P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacokinetics; Antibody-drug conjugate; Internal medicine; Cmax; Refractory (planetary science); Phases of clinical research; Gastroenterology; Lymphoma; Oncology; Antibody; Pharmacology; Toxicity; Adverse effect; Monoclonal antibody; Immunology","score_opus":0.012692541623903398,"score_gpt":0.29003734080215277,"score_spread":0.2773447991782494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283392950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926269,0.0006287458,0.000016678285,0.00008173749,0.0001455757,0.0027223558,0.00056025,0.000053800537,0.0031639803],"genre_scores_gemma":[0.997069,0.000073618656,0.00039820958,0.00013290816,0.00008927034,0.00010398449,0.0005388419,0.00011737271,0.0014767859],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958989,0.00032149494,0.0010032682,0.000932212,0.0012467479,0.0005973951],"domain_scores_gemma":[0.9979665,0.00045026536,0.0004091435,0.00068963756,0.00020730165,0.00027711954],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008402198,0.00041793313,0.0008731701,0.00020057551,0.00020078986,0.000024610628,0.00027509965,0.00008394457,0.0023702653],"category_scores_gemma":[0.00010120622,0.00037740442,0.000092270566,0.0007754774,0.0001327314,0.00013984526,0.0003439179,0.0006788909,0.000007767393],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13880919,0.066234134,0.28211394,0.0005365031,0.00073024275,0.0009035453,0.024662627,0.0003568779,0.44950482,0.0000026062673,0.0031719268,0.03297361],"study_design_scores_gemma":[0.680592,0.019429602,0.22966509,0.0007027533,0.0005127135,0.00003401615,0.023218561,0.004491675,0.020490004,0.0000124293365,0.019537218,0.0013139436],"about_ca_topic_score_codex":0.0019271246,"about_ca_topic_score_gemma":0.00013529345,"teacher_disagreement_score":0.5417828,"about_ca_system_score_codex":0.00032305508,"about_ca_system_score_gemma":0.0002803144,"threshold_uncertainty_score":0.9998678},"labels":[],"label_agreement":null},{"id":"W4283395768","doi":"10.1097/01.hs9.0000849792.13840.5e","title":"P1734: LESSONS FROM HIV- HAEMOPHILIA CRISIS AND CURRICULAR LEARNING IN POST COVID TIMES","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Interpreting and Communication in Healthcare","field":"Health Professions","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Haemophilia; Context (archaeology); Medical education; Curriculum; Psychology; Medicine; Pandemic; Family medicine; Coronavirus disease 2019 (COVID-19); Pediatrics; Pedagogy; History","score_opus":0.04389367298885071,"score_gpt":0.40279913000719353,"score_spread":0.3589054570183428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283395768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9296788,0.005403843,0.00007364954,0.04309477,0.0004507923,0.00059391477,0.00016739113,0.00028014372,0.020256706],"genre_scores_gemma":[0.99106723,0.00014688852,0.00048017225,0.0040589673,0.000078014484,0.0003713114,0.00016613961,0.000032481003,0.0035987657],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.99680746,0.0018268803,0.00044233783,0.00032682027,0.00022003536,0.00037647557],"domain_scores_gemma":[0.9983402,0.00077879365,0.00018621386,0.00047407803,0.00009442333,0.00012628397],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00062886305,0.00013850593,0.00025388144,0.000058540754,0.0017840037,0.000011609091,0.0002928807,0.000119552424,0.009586735],"category_scores_gemma":[0.00031018612,0.0001440509,0.000047725465,0.00022154438,0.000035296256,0.00005816883,0.00061807974,0.001767649,0.00020250144],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019716081,0.00017536845,0.8110965,0.00040777447,0.000053034364,0.000061675455,0.07660774,0.000749941,0.00013763279,0.0121543845,0.092443764,0.0059150215],"study_design_scores_gemma":[0.0017523742,0.000234386,0.050925966,0.000762725,0.00004314176,0.000015739479,0.50347847,0.005186498,0.000025143729,0.006802563,0.43012905,0.00064392976],"about_ca_topic_score_codex":0.0068268273,"about_ca_topic_score_gemma":0.0008157705,"teacher_disagreement_score":0.7601705,"about_ca_system_score_codex":0.0002456307,"about_ca_system_score_gemma":0.00028118148,"threshold_uncertainty_score":0.9997868},"labels":[],"label_agreement":null},{"id":"W4283396501","doi":"10.1097/01.hs9.0000848948.50002.24","title":"P1523: DEMOGRAPHICS, CLINICAL CHARACTERISTICS, AND REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH BETA-THALASSEMIA: A RETROSPECTIVE MEDICAL RECORD ABSTRACTION STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Medical record; Demographics; Anemia; Retrospective cohort study; Thalassemia; Pediatrics; Beta thalassemia; Blood transfusion; Internal medicine; Demography","score_opus":0.01256129364801823,"score_gpt":0.2802278295499557,"score_spread":0.26766653590193745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283396501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960817,0.000052597232,0.000007790576,0.00040276576,0.000438994,0.0012779624,0.00005927361,0.00010365065,0.0015752753],"genre_scores_gemma":[0.997673,0.0006478911,0.00004668295,0.00012710085,0.00014647847,0.0001450571,0.000169566,0.000054197688,0.0009900708],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973872,0.00015707493,0.0006649285,0.0006408611,0.00080460345,0.0003453829],"domain_scores_gemma":[0.9986786,0.0001136817,0.0003005519,0.0003776203,0.00012604172,0.00040348596],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039004255,0.0002961873,0.00068154547,0.000095837466,0.0003289233,0.000024542034,0.00008314539,0.0001788523,0.0016992337],"category_scores_gemma":[0.00006920667,0.00021855402,0.00014208021,0.00032182457,0.00016158419,0.00007536436,0.000100175064,0.00092751853,0.0000072602074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055657927,0.0037041402,0.97539407,0.00003273969,0.00049960386,0.0004020609,0.0003218601,3.9091532e-7,4.0889975e-7,0.0000135577575,0.00045100276,0.018623563],"study_design_scores_gemma":[0.005959501,0.0057243956,0.9835013,0.000094980765,0.00049262505,0.000022405316,0.002528272,0.000046078723,0.0000013851035,0.000007719368,0.001398414,0.00022287936],"about_ca_topic_score_codex":0.002263008,"about_ca_topic_score_gemma":0.0050611063,"teacher_disagreement_score":0.018400682,"about_ca_system_score_codex":0.00028653053,"about_ca_system_score_gemma":0.00014752537,"threshold_uncertainty_score":0.99921334},"labels":[],"label_agreement":null},{"id":"W4283397661","doi":"10.1097/01.hs9.0000846624.61314.38","title":"P939: SYNERGISTIC EFFECTS OF LOW DOSE BELANTAMAB MAFODOTIN IN COMBINATION WITH A GAMMA-SECRETASE INHIBITOR (NIROGACESTAT) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-5 STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Cohort; Adverse effect; Internal medicine; Pharmacology; Combination therapy; Oncology; Gastroenterology","score_opus":0.006609456375418366,"score_gpt":0.23269093646809835,"score_spread":0.22608148009267998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283397661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950479,0.00018492607,0.000012144838,0.000029715367,0.00006727211,0.0043685073,0.0000600582,0.00004861875,0.00018081686],"genre_scores_gemma":[0.9980695,0.0000071274585,0.00030215955,0.000024803287,0.00001754376,0.00080470403,0.00041006194,0.000077453515,0.00028659188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99659127,0.00043581234,0.00052055507,0.00061652734,0.001260766,0.00057509844],"domain_scores_gemma":[0.99830824,0.00048149395,0.0002549675,0.0005516753,0.00014608518,0.0002575299],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028753994,0.00037173938,0.00068998284,0.00032954232,0.00012630419,0.00001720314,0.00016330185,0.00007713188,0.00020761442],"category_scores_gemma":[0.00028809006,0.00029125382,0.000061369254,0.0008590673,0.000107980835,0.00016243824,0.0001562217,0.00060721056,0.000014358116],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013993072,0.018698249,0.95598984,0.0007602749,0.00019119155,0.0034376243,0.0014512936,0.00015699181,0.00049239816,0.000009965351,0.00006601573,0.0047531105],"study_design_scores_gemma":[0.08179709,0.014659424,0.89886445,0.00063910795,0.00009614293,0.00001238061,0.0016335764,0.00053360756,0.0014538585,0.0000066937855,0.000035715075,0.00026793394],"about_ca_topic_score_codex":0.0010046192,"about_ca_topic_score_gemma":0.0021459935,"teacher_disagreement_score":0.06780402,"about_ca_system_score_codex":0.00063489605,"about_ca_system_score_gemma":0.0003117771,"threshold_uncertainty_score":0.999954},"labels":[],"label_agreement":null},{"id":"W4283397932","doi":"10.1097/01.hs9.0000844608.72364.51","title":"P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"IDH1; Isocitrate dehydrogenase; Myeloid leukemia; Medicine; Peripheral blood mononuclear cell; Internal medicine; Bone marrow; Azacitidine; Placebo; Oncology; Gastroenterology; Mutation; Biology; Pathology; Genetics","score_opus":0.02239487869927134,"score_gpt":0.3108922617448699,"score_spread":0.2884973830455986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283397932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951012,0.00002964315,0.00022259942,0.0011034245,0.00008934719,0.002595092,0.0003024978,0.000115394825,0.00044079794],"genre_scores_gemma":[0.9943705,0.00003351274,0.0012770712,0.0009434952,0.00007569912,0.0005223607,0.0012913622,0.00012642931,0.0013595254],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9949204,0.00097552553,0.0013265758,0.00084161817,0.0012354357,0.00070044614],"domain_scores_gemma":[0.9973058,0.00049625506,0.00038234296,0.0008660291,0.00043695827,0.00051261595],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011758656,0.00042158877,0.0012356463,0.0003917235,0.00013626981,0.000024815057,0.00038012292,0.00018659605,0.001284571],"category_scores_gemma":[0.0006631379,0.00039206096,0.00018730904,0.0018270455,0.00015399678,0.00015715192,0.00036656004,0.0009037023,0.00005926199],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16311876,0.001614872,0.40878558,0.00020697618,0.0005318896,0.0041725575,0.00097260624,0.00085001695,0.41338632,0.000037735044,0.0033843354,0.0029383318],"study_design_scores_gemma":[0.05735031,0.009082534,0.82509893,0.0005033987,0.00032050625,0.00014149153,0.00081317493,0.0034056066,0.09620758,0.000008163193,0.006246935,0.00082138425],"about_ca_topic_score_codex":0.0002881401,"about_ca_topic_score_gemma":0.000067737936,"teacher_disagreement_score":0.41631332,"about_ca_system_score_codex":0.0013854932,"about_ca_system_score_gemma":0.0013185946,"threshold_uncertainty_score":0.99985313},"labels":[],"label_agreement":null},{"id":"W4283714328","doi":"10.1097/01.hs9.0000846716.90763.d0","title":"P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Oncology; Internal medicine; Cytokine release syndrome; Biomarker; Refractory (planetary science); Surrogate endpoint; Gastroenterology; Immunology; Immunotherapy; Cancer; Biology","score_opus":0.0712361846644057,"score_gpt":0.32797489408794434,"score_spread":0.2567387094235386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283714328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948288,0.00032085655,5.0297575e-7,0.00074343255,0.00007853693,0.0026553737,0.0012212953,0.000016377624,0.00013478057],"genre_scores_gemma":[0.9966614,0.000023279965,0.00027052153,0.00017147858,0.000030635278,0.00034137352,0.00019637756,0.000050842107,0.002254046],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964825,0.00067626074,0.0007172276,0.00055067684,0.0011158178,0.00045750788],"domain_scores_gemma":[0.9981015,0.0007249612,0.00022187507,0.0005805346,0.00018665649,0.00018452026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084597204,0.00026623797,0.0006439071,0.0002893759,0.00008064776,0.0000071208665,0.00025647666,0.00008178947,0.0006735317],"category_scores_gemma":[0.00021948235,0.00021782181,0.00008069232,0.0007598936,0.00007700624,0.00012016121,0.00031514937,0.000515335,0.000006164778],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4363626,0.009476086,0.5233063,0.000048640308,0.00009672887,0.00034304766,0.01976613,0.000015749605,0.0020942667,8.2744316e-7,0.00042376397,0.0080658635],"study_design_scores_gemma":[0.050768334,0.042799294,0.8988377,0.00023995104,0.000017002027,0.0000027725455,0.0037404818,0.000109239656,0.000796583,0.0000029778193,0.00248407,0.000201621],"about_ca_topic_score_codex":0.015340397,"about_ca_topic_score_gemma":0.0023850463,"teacher_disagreement_score":0.38559425,"about_ca_system_score_codex":0.00015741141,"about_ca_system_score_gemma":0.00022290842,"threshold_uncertainty_score":0.99121654},"labels":[],"label_agreement":null},{"id":"W4283733969","doi":"10.1097/01.hs9.0000846900.48214.5b","title":"P1008: ASSOCIATION BETWEEN FRAILTY AND CLINICAL OUTCOMES IN MYELOPROLIFERATIVE NEOPLAMS: A POPULATION-BASED STUDY FROM ONTARIO, CANADA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto General Hospital; Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Hazard ratio; Confidence interval; Proportional hazards model; Population; Cumulative incidence; Internal medicine; Cohort; Environmental health","score_opus":0.029322913248741055,"score_gpt":0.3064895132019538,"score_spread":0.27716659995321274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283733969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960236,0.000060952512,0.0000040818495,0.0017995076,0.00018837268,0.0013635978,0.00019819544,0.000028320334,0.00033338732],"genre_scores_gemma":[0.9964623,0.0000022324232,0.00033022882,0.0010312835,0.00009159101,0.0003744776,0.00046595652,0.000023784718,0.0012181379],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974418,0.0003619302,0.00067324046,0.00052286644,0.00072687137,0.00027326142],"domain_scores_gemma":[0.9979771,0.0012731554,0.00024191322,0.00025720955,0.0000752139,0.00017545126],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036388045,0.00025123972,0.0008201144,0.00004547907,0.00024547632,0.000027899356,0.00006963816,0.00008894766,0.002232241],"category_scores_gemma":[0.00026398007,0.00022059339,0.00009426607,0.00017352571,0.000009728103,0.000055533455,0.00007942258,0.0005507201,0.000004597939],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000120127,0.001006981,0.9954661,0.000006243724,0.00058641133,0.00013358038,0.00091871165,0.000051429968,4.6575659e-7,0.000011069099,0.00086875533,0.0008300905],"study_design_scores_gemma":[0.0056871474,0.00073384796,0.99054545,0.000022721622,0.0002750191,9.038055e-7,0.0013548834,0.00007799405,0.000013327142,0.000058505233,0.0010384324,0.00019175213],"about_ca_topic_score_codex":0.9507717,"about_ca_topic_score_gemma":0.99540955,"teacher_disagreement_score":0.044637833,"about_ca_system_score_codex":0.0031892501,"about_ca_system_score_gemma":0.0014767324,"threshold_uncertainty_score":0.9986799},"labels":[],"label_agreement":null},{"id":"W4283734564","doi":"10.1097/01.hs9.0000849024.60193.ea","title":"P1542: COMORBIDITIES AND COMPLICATIONS ACROSS GENOTYPES IN ADULT PATIENTS WITH PYRUVATE KINASE DEFICIENCY: ANALYSIS FROM THE PEAK REGISTRY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Missense mutation; Medicine; Pyruvate kinase deficiency; Genotype; Internal medicine; Pediatrics; Compound heterozygosity; Frameshift mutation; Gastroenterology; Pyruvate kinase; Allele; Genetics; Mutation; Gene; Biology; Glycolysis","score_opus":0.013395521145066114,"score_gpt":0.24664726234078235,"score_spread":0.23325174119571623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283734564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969134,0.00048375098,0.000070492846,0.0009502358,0.000049912596,0.00020064016,0.00026540112,0.000030442821,0.0010357419],"genre_scores_gemma":[0.997163,0.00003398252,0.00020486537,0.0015435427,0.00002742459,0.00006960277,0.0005509226,0.00001091898,0.00039573282],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99916905,0.00007322781,0.00016011775,0.00025573233,0.00017745949,0.00016442449],"domain_scores_gemma":[0.99928814,0.00010967916,0.00008713954,0.0003812825,0.00008529056,0.000048472633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060775907,0.00010379967,0.00021393178,0.000024383187,0.00035024213,0.000013959868,0.00008896142,0.000032292064,0.00058594096],"category_scores_gemma":[0.000031978852,0.00007100275,0.0000481621,0.0004858651,0.00015239452,0.000029213066,0.00009018627,0.00022196857,0.000009935184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023786967,0.00024188696,0.9936234,0.000022164299,0.000112902584,0.000013490223,0.002298734,0.00038171266,0.000331877,0.000404181,0.0016636929,0.00066811946],"study_design_scores_gemma":[0.0011327037,0.00016219856,0.98866236,0.000014050211,0.0001542879,0.000003190918,0.005905672,0.0002666811,0.000030234803,0.0000910921,0.0034847297,0.00009277259],"about_ca_topic_score_codex":0.0012175563,"about_ca_topic_score_gemma":0.0025941203,"teacher_disagreement_score":0.004960983,"about_ca_system_score_codex":0.00004453615,"about_ca_system_score_gemma":0.000042628682,"threshold_uncertainty_score":0.64156425},"labels":[],"label_agreement":null},{"id":"W4291493138","doi":"10.1097/01.hs9.0000872968.02648.ef","title":"P-017: POINT-OF-CARE DIAGNOSTIC FOR QUANTIFICATION OF FOETAL HAEMOGLOBIN (HB F) LEVELS IN MONITORING HYDROXYUREA THERAPY FOR CHILDREN WITH SICKLE CELL DISEASE (SCD) IN GHANA","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Disease; Pediatrics; Anemia; Fetal hemoglobin; Sickle cell anemia; Hemoglobin; Transfusion therapy; Newborn screening; Internal medicine; Blood transfusion; Pregnancy; Biology","score_opus":0.017200286557764077,"score_gpt":0.2639512468813468,"score_spread":0.24675096032358274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4291493138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883931,0.0074513443,0.0004606744,0.00030903702,0.000107654574,0.0029086582,0.00020685067,0.00002307163,0.00013959655],"genre_scores_gemma":[0.99785113,0.00012696507,0.0009902109,0.000032558644,0.000040388524,0.0005824187,0.0002017612,0.000049392285,0.00012514259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986728,0.000045421624,0.0004240022,0.00032608278,0.00024449662,0.0002872129],"domain_scores_gemma":[0.9990986,0.00022378626,0.00018699896,0.00030987122,0.00008871652,0.00009203339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015551489,0.00018379935,0.00040188906,0.000101796395,0.000078661644,0.000005751421,0.00012506895,0.00007754029,0.000060790015],"category_scores_gemma":[0.000118381446,0.00015889677,0.00014035408,0.00034885376,0.000058096834,0.000066159904,0.00003213475,0.00018465002,8.9488043e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005129677,0.0029019373,0.9330511,0.002441612,0.00020326907,0.000045740224,0.007519416,0.010328415,0.009116072,0.00046005126,0.0005149569,0.028287727],"study_design_scores_gemma":[0.038418476,0.005592842,0.8144491,0.0017735233,0.0004361455,0.000022677343,0.040957946,0.0029698268,0.09309966,0.00060701923,0.000704923,0.0009678901],"about_ca_topic_score_codex":0.00018751803,"about_ca_topic_score_gemma":0.000046620484,"teacher_disagreement_score":0.11860205,"about_ca_system_score_codex":0.00010276869,"about_ca_system_score_gemma":0.00021780534,"threshold_uncertainty_score":0.6479622},"labels":[],"label_agreement":null},{"id":"W4296686347","doi":"10.1097/hs9.0000000000000779","title":"U2AF1 S34/Q157 Variants Detected in cis Arise Sequentially in an MDS Patient With Serial Sequencing Spanning 18 Years","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kingston Health Sciences Centre; Ontario Institute for Cancer Research; Queen's University","funders":"","keywords":"DNA sequencing; Computational biology; Genetics; Computer science; Biology; Psychology; Gene","score_opus":0.029689907945200766,"score_gpt":0.28319871875837477,"score_spread":0.253508810813174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296686347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964528,0.00013371457,0.000085533895,0.00015256603,0.00013659429,0.00079532486,0.000024090008,0.00009954696,0.002119832],"genre_scores_gemma":[0.9955349,0.000012094322,0.0033075057,0.0003295726,0.00012469878,0.00017381922,0.00007905591,0.000088940345,0.00034940292],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9967654,0.00035647495,0.0004855356,0.00059039483,0.0010968456,0.0007053885],"domain_scores_gemma":[0.9988864,0.000065486,0.000118819305,0.00054449844,0.00010172912,0.00028306013],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006210506,0.00024249537,0.00044197368,0.00025952974,0.0001184494,0.00004618281,0.0002793375,0.0001497708,0.0055893],"category_scores_gemma":[0.00017736616,0.00024246272,0.000050682847,0.0012621575,0.0000639776,0.00021140219,0.00033067702,0.0012163323,0.000034164135],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025524836,0.0025786918,0.24576315,0.00095405657,0.00057112076,0.17263469,0.04269158,0.034634408,0.34390277,0.0003089758,0.0056431717,0.12479257],"study_design_scores_gemma":[0.12243323,0.030855488,0.40851265,0.0050411327,0.0005980203,0.0166193,0.10812837,0.20906189,0.06902426,0.00082028436,0.021914486,0.0069908993],"about_ca_topic_score_codex":0.002760427,"about_ca_topic_score_gemma":0.0028951399,"teacher_disagreement_score":0.2748785,"about_ca_system_score_codex":0.0021606956,"about_ca_system_score_gemma":0.0023726828,"threshold_uncertainty_score":0.9953197},"labels":[],"label_agreement":null},{"id":"W4296908362","doi":"10.1097/hs9.0000000000000774","title":"Heterozygous Variants in the DNA-binding Domain of c-Myb May Affect Normal B/T Cell Development","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; Newborn Screening Ontario; University of Ottawa; Children's Hospital of Eastern Ontario","funders":"","keywords":"Biology; Transcription factor; MYB; Thymocyte; CD8; Cell biology; T cell; Genetics; Immune system; Gene","score_opus":0.009115415642182254,"score_gpt":0.2121903345966441,"score_spread":0.20307491895446184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296908362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98178226,0.0058737723,0.000037179743,0.00007835556,0.00045251817,0.0002927889,0.000011962754,0.000023631581,0.011447523],"genre_scores_gemma":[0.9972604,0.0000087533435,0.000062871026,0.00013204833,0.0000016797736,0.00009106033,0.000071472125,0.000014280543,0.0023574154],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844825,0.00044916477,0.0003650204,0.00022780181,0.00008331664,0.0004264492],"domain_scores_gemma":[0.99942136,0.00012246157,0.000144686,0.00029617595,0.000012081165,0.0000032329528],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00076520926,0.0001665786,0.0002426707,0.00007024132,0.0004912687,0.0000089783425,0.000514497,0.00008742829,0.0023077913],"category_scores_gemma":[0.00001229005,0.00013433861,0.00008859606,0.00031998206,0.00009806044,0.000056184213,0.00021272493,0.0004186706,0.00017507594],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037469453,0.0016742769,0.0047011375,0.00015403787,0.00013090926,0.00009574049,0.036864635,0.00031249723,0.9408563,0.0015857137,0.0014392321,0.01181086],"study_design_scores_gemma":[0.009759881,0.001010753,0.054637402,0.00014144543,0.000067704204,0.00057074253,0.099345945,0.000011680341,0.5118555,0.00036308012,0.32094228,0.0012935783],"about_ca_topic_score_codex":0.0000666832,"about_ca_topic_score_gemma":0.000011050939,"teacher_disagreement_score":0.42900077,"about_ca_system_score_codex":0.00005542924,"about_ca_system_score_gemma":0.00010254761,"threshold_uncertainty_score":0.99860424},"labels":[],"label_agreement":null},{"id":"W4303983498","doi":"10.1097/01.hs9.0000890608.32200.eb","title":"P010: Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Young adult; Stage (stratigraphy); Internal medicine; Hazard ratio; Pediatrics; Confidence interval","score_opus":0.17519443905383938,"score_gpt":0.4587363563995281,"score_spread":0.2835419173456887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303983498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98171574,0.0007001622,0.00026332863,0.008984882,0.0022858721,0.003024032,0.0012005169,0.0002575553,0.0015678874],"genre_scores_gemma":[0.9814949,0.00004733617,0.0008447789,0.006578562,0.0008812023,0.0008276156,0.00068399275,0.000092712246,0.008548904],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99467736,0.0011575727,0.0021808238,0.000783262,0.0007980432,0.0004029491],"domain_scores_gemma":[0.989095,0.008133031,0.0010572484,0.001333827,0.00013559291,0.00024530798],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004800908,0.00034166698,0.0015855175,0.000030219066,0.0003407214,0.000035459158,0.0002720281,0.00013422023,0.0023869073],"category_scores_gemma":[0.016747983,0.00024036196,0.00075212185,0.00020091537,0.00013627624,0.00006150129,0.00013962599,0.00068129133,0.000034340144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014120911,0.0015001349,0.90505236,0.00023035295,0.0011985601,0.0007456759,0.0024726568,0.00008090129,0.00010457109,0.0006824251,0.05798696,0.015824484],"study_design_scores_gemma":[0.028243223,0.0023806165,0.72317374,0.00042537952,0.0010137956,0.000120238554,0.012084171,0.00028889565,0.00037897905,0.00042749802,0.23074105,0.00072240346],"about_ca_topic_score_codex":0.0017407453,"about_ca_topic_score_gemma":0.0011548202,"teacher_disagreement_score":0.18187861,"about_ca_system_score_codex":0.00017687069,"about_ca_system_score_gemma":0.00041253926,"threshold_uncertainty_score":0.998525},"labels":[],"label_agreement":null},{"id":"W4303983518","doi":"10.1097/01.hs9.0000890604.66330.a0","title":"P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Brentuximab vedotin; Dacarbazine; ABVD; Medicine; Hazard ratio; Internal medicine; Vinblastine; Oncology; Population; Progression-free survival; Vincristine; Lymphoma; Confidence interval; Surgery; Chemotherapy; Hodgkin lymphoma; Cyclophosphamide","score_opus":0.008250420486286589,"score_gpt":0.23995847702341683,"score_spread":0.23170805653713022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303983518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778885,0.00012431637,0.000087362365,0.0003382935,0.000052468702,0.001004549,0.00021496548,0.000071916125,0.00031726962],"genre_scores_gemma":[0.9958649,0.000030587325,0.0011987969,0.0002554833,0.000022722887,0.00020030573,0.0018085394,0.00006979409,0.0005488271],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974366,0.00010621283,0.0005367771,0.0007105872,0.00074314175,0.00046670475],"domain_scores_gemma":[0.9984877,0.00007874364,0.00033821556,0.00071984774,0.0001574866,0.00021798925],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014976106,0.0004100843,0.0011635267,0.00019222815,0.000121056866,0.000019649377,0.0001771553,0.000091874535,0.0016086912],"category_scores_gemma":[0.000011247517,0.0003025925,0.00017869056,0.0012680809,0.00008623344,0.0001412972,0.00008681092,0.00015505776,0.0000021844646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025556095,0.017531153,0.9301711,0.00010377254,0.0034464602,0.00023587172,0.001113016,0.0059759268,0.0002628025,0.00013112025,0.00022575363,0.015246944],"study_design_scores_gemma":[0.09646687,0.0068714777,0.88101953,0.00007072486,0.0011608488,0.0000047552885,0.0005707352,0.01054123,0.0012500267,0.00000680096,0.001589361,0.0004476233],"about_ca_topic_score_codex":0.0009143157,"about_ca_topic_score_gemma":0.0030941127,"teacher_disagreement_score":0.070910774,"about_ca_system_score_codex":0.00095728104,"about_ca_system_score_gemma":0.0004033351,"threshold_uncertainty_score":0.9999426},"labels":[],"label_agreement":null},{"id":"W4304701174","doi":"10.1097/hs9.0000000000000787","title":"Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dyskeratosis congenita; CEBPA; Myeloid leukemia; Medicine; Germline; Bone marrow failure; Myeloid; Telomerase; Oncology; Internal medicine; Telomere; Germline mutation; Immunology; Mutation; Biology; Gene; Genetics; Haematopoiesis; Stem cell","score_opus":0.013380467579370657,"score_gpt":0.2523804352887737,"score_spread":0.23899996770940302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304701174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620813,0.0005102366,0.00016038348,0.0002745349,0.0001513385,0.0018315054,0.00015819562,0.000058080008,0.0006476155],"genre_scores_gemma":[0.99446756,0.000110980145,0.0028218424,0.00015728963,0.0000865506,0.00048734513,0.00022155537,0.00009200246,0.0015548855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973615,0.00013451223,0.0004407171,0.00062590843,0.0006686303,0.00076873845],"domain_scores_gemma":[0.99903446,0.00015002183,0.00014350902,0.00037063126,0.00012315332,0.00017820402],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005115402,0.000309217,0.0005822975,0.00018988359,0.00020478891,0.00004457565,0.0001972663,0.00011484209,0.00017531027],"category_scores_gemma":[0.000102329665,0.00027652262,0.000067517765,0.0005072499,0.00009671315,0.00023891452,0.00031818263,0.0004886856,0.00000295463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004482898,0.0003011433,0.9780259,0.0003577493,0.0001686481,0.00045565597,0.0018225865,0.00034082914,0.008629229,0.00021242486,0.0007662196,0.004436705],"study_design_scores_gemma":[0.01683516,0.0012258334,0.9733991,0.00022906401,0.00008903042,0.00016100034,0.0014535133,0.0043356144,0.0008682184,0.00012962426,0.00086617685,0.00040766955],"about_ca_topic_score_codex":0.00089400687,"about_ca_topic_score_gemma":0.0009829007,"teacher_disagreement_score":0.012352263,"about_ca_system_score_codex":0.0016734594,"about_ca_system_score_gemma":0.0008480475,"threshold_uncertainty_score":0.9999687},"labels":[],"label_agreement":null},{"id":"W4308963956","doi":"10.1097/hs9.0000000000000801","title":"Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"Janssen Biotech; Novo Nordisk; Ascentage Pharma; Servier; Moderna; Celltrion; Incyte; Pharmacyclics; MEI Pharma; Karyopharm Therapeutics; Gilead Sciences; BeiGene; Sanofi; Cilag; TG Therapeutics; Pfizer; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Bendamustine; Chronic lymphocytic leukemia; Tolerability; Ofatumumab; Gastroenterology; Adverse effect; Oncology; Leukemia","score_opus":0.07152014511977556,"score_gpt":0.33529776259184485,"score_spread":0.2637776174720693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308963956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971468,0.003054276,0.0000020611383,0.0006219083,0.0016551169,0.0017409291,0.000053449272,0.00023277856,0.021171492],"genre_scores_gemma":[0.9826602,0.000117849566,0.00020333868,0.0005881799,0.0015122417,0.0005201862,0.00018996501,0.00013275818,0.014075315],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941876,0.00045778253,0.0011013276,0.0011359784,0.0018187666,0.0012985314],"domain_scores_gemma":[0.9961385,0.0013447456,0.00028687125,0.0013461354,0.00010443522,0.00077927625],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013040561,0.00047504072,0.00082106923,0.00024623142,0.00034191203,0.000045689452,0.00059991935,0.000355101,0.0034730113],"category_scores_gemma":[0.004126677,0.0004869902,0.00027245737,0.0013089804,0.000347533,0.00014732846,0.000677428,0.002007885,0.00046337664],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6186721,0.0013203624,0.00043124953,0.0016839523,0.00065554125,0.009717964,0.0023106216,0.015763003,0.0035278047,0.0010441549,0.32730487,0.017568413],"study_design_scores_gemma":[0.7278039,0.0052903574,0.00033129842,0.0002407996,0.00012442928,0.00028827996,0.00048346122,0.02065491,0.00096997066,0.000058478843,0.2432011,0.0005530145],"about_ca_topic_score_codex":0.0046892213,"about_ca_topic_score_gemma":0.00088778866,"teacher_disagreement_score":0.13744491,"about_ca_system_score_codex":0.265405,"about_ca_system_score_gemma":0.1279601,"threshold_uncertainty_score":0.9997582},"labels":[],"label_agreement":null},{"id":"W4362668845","doi":"10.1097/hs9.0000000000000863","title":"Genetic and Microenvironment Features Do Not Distinguish Follicular Lymphoma Patients Requiring Immediate or Deferred Treatment","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"Takeda Oncology; Blood Cancer UK; Genentech; Celgene; KWF Kankerbestrijding; Teva Pharmaceutical Industries; National Cancer Institute; Cancer Research UK; GlaxoSmithKline; Pfizer","keywords":"Medicine; Follicular lymphoma; Asymptomatic; Rituximab; Lymphoma; Stage (stratigraphy); Biopsy; International Prognostic Index; Internal medicine; Surgery; Oncology","score_opus":0.018462729907170905,"score_gpt":0.25210918094393764,"score_spread":0.23364645103676673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362668845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957122,0.0021785,0.0000014848769,0.0003318324,0.00015992715,0.00074608077,0.00004561359,0.000118908596,0.00070545456],"genre_scores_gemma":[0.99415296,0.0019191672,0.00071703095,0.00021931365,0.00014960715,0.0002568202,0.00012371562,0.00005344671,0.0024079112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998417,0.000030324169,0.00028045854,0.0005253278,0.0003059862,0.0004408626],"domain_scores_gemma":[0.99914366,0.00008679807,0.00008820226,0.0003890435,0.000026017406,0.0002662794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042647116,0.00032351547,0.00040868024,0.00004768739,0.00015204238,0.00005120846,0.000055828532,0.00010059289,0.00014164219],"category_scores_gemma":[0.000056309713,0.00021720718,0.0001383444,0.00016019466,0.0000632338,0.00003471619,0.00009552005,0.000031659543,0.0001835777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051778567,0.0013738842,0.8041718,0.00017104916,0.00049702585,0.001939945,0.0008426822,0.0000142262825,0.0008897038,0.000027886557,0.0044024456,0.18515158],"study_design_scores_gemma":[0.009326715,0.00087216543,0.97247696,0.0001952437,0.00034453877,0.000087887456,0.00019091097,0.000030371017,0.0063146497,0.000026377451,0.009902475,0.00023169644],"about_ca_topic_score_codex":0.00012687838,"about_ca_topic_score_gemma":0.000055443998,"teacher_disagreement_score":0.18491988,"about_ca_system_score_codex":0.00043939508,"about_ca_system_score_gemma":0.000054041953,"threshold_uncertainty_score":0.88574517},"labels":[],"label_agreement":null},{"id":"W4364378600","doi":"10.1097/01.hs9.0000928476.36016.9a","title":"5607225 ADDITION OF THERAPEUTIC PLASMA EXCHANGE TO RED CELL EXCHANGE IMPROVES OUTCOMES OF FAT EMBOLISM SYNDROME IN SICKLE CELL DISEASE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Blood groups and transfusion","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Disease; Fat embolism; Neurocognitive; Complication; Internal medicine; Surgery; Intensive care medicine; Psychiatry","score_opus":0.016169864464464976,"score_gpt":0.24687736096864446,"score_spread":0.2307074965041795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364378600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994432,0.0010486938,0.000018716182,0.00080392376,0.0001724858,0.0008845768,0.00014855312,0.00007847823,0.0024125762],"genre_scores_gemma":[0.9952955,0.00032026917,0.00013731519,0.00020201893,0.000049130398,0.00010862273,0.00009611718,0.000048719274,0.003742288],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99859524,0.000041452367,0.00038288097,0.00031850985,0.0003413857,0.00032053996],"domain_scores_gemma":[0.99914265,0.000083789564,0.00010331058,0.00039897132,0.000063524756,0.00020778611],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001243398,0.00021174671,0.00054802705,0.00017249156,0.00002985639,0.0000052777714,0.00010745536,0.000119022916,0.0008809128],"category_scores_gemma":[0.000016234531,0.000178719,0.00016586257,0.00057005126,0.000040456875,0.000078071615,0.000056882174,0.00013798877,0.00007786111],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033982573,0.007090267,0.17513469,0.028708348,0.00041315393,0.001711483,0.015059859,0.00009724365,0.6524157,0.00046262008,0.012364381,0.10314401],"study_design_scores_gemma":[0.007861723,0.0012196935,0.92399514,0.0009036428,0.0004030992,0.0000124161,0.0015331923,0.0004910174,0.060200304,0.00049917685,0.0024324346,0.00044813714],"about_ca_topic_score_codex":0.00015524703,"about_ca_topic_score_gemma":0.0001249524,"teacher_disagreement_score":0.7488605,"about_ca_system_score_codex":0.000027738837,"about_ca_system_score_gemma":0.00003749849,"threshold_uncertainty_score":0.96453774},"labels":[],"label_agreement":null},{"id":"W4365144810","doi":"10.1097/01.hs9.0000928200.69096.c5","title":"5612992 SICKLE CELL HEALTH AWARENESS, PERSPECTIVES, AND EXPERIENCES (SHAPE) SURVEY: FINDINGS ON THE BURDEN OF SICKLE CELL DISEASE AND IMPACT ON THE QUALITY OF LIFE OF PATIENTS AND CAREGIVERS IN THE UK","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Context (archaeology); Quality of life (healthcare); Disease; Computer-assisted web interviewing; Family medicine; Descriptive statistics; Burden of disease; Descriptive research; Gerontology; Nursing","score_opus":0.02599522399579153,"score_gpt":0.2985872115201608,"score_spread":0.2725919875243693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365144810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457383,0.002456055,3.0049216e-7,0.0019008038,0.00002229216,0.0005694576,0.00011808918,0.000006902571,0.00035226633],"genre_scores_gemma":[0.9987821,0.00096863596,0.0000016389155,0.00013315096,0.000009997526,0.000012780571,0.000016147067,0.000010583175,0.000064975546],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985848,0.0003614036,0.00028960424,0.00022694276,0.00034346659,0.00019379795],"domain_scores_gemma":[0.9985544,0.0008149113,0.00019247399,0.0002560425,0.00007076947,0.00011137496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007920054,0.000152154,0.00034566826,0.000036433852,0.00012371974,0.000010318116,0.000108155255,0.00005939269,0.00009786397],"category_scores_gemma":[0.00029980278,0.00006953019,0.00006125487,0.00031481375,0.00040176965,0.000028043638,0.00005380632,0.00017130651,8.469529e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016991656,0.00052935956,0.6827234,0.0010395431,0.00007022022,0.0000046034256,0.30661604,0.00009594765,0.00019688868,0.0002992183,0.0062858486,0.00043978522],"study_design_scores_gemma":[0.0011468325,0.0005896787,0.58432007,0.00015572258,0.000018737299,1.9154032e-7,0.41321728,0.00021387254,0.00019165278,0.00003574411,0.00003130342,0.00007893747],"about_ca_topic_score_codex":0.006311235,"about_ca_topic_score_gemma":0.00012281165,"teacher_disagreement_score":0.10660124,"about_ca_system_score_codex":0.000026791475,"about_ca_system_score_gemma":0.00019274882,"threshold_uncertainty_score":0.95407414},"labels":[],"label_agreement":null},{"id":"W4376106087","doi":"10.1097/01.hs9.0000936160.56974.35","title":"P08 TEMPORAL TRENDS IN PROGNOSIS OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA (SMM) WHO MEET CRITERIA FOR BIOMARKER-DEFINED EARLY MULTIPLE MYELOMA (SLIM CRAB POSITIVE MM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; Centre Hospitalier Universitaire de Toulouse; Syddansk Universitet; Université de Toulouse; Memorial Sloan-Kettering Cancer Center; Karolinska Institutet; University of Alberta; University of Wolverhampton; National Institute for Health and Care Research; Massachusetts General Hospital; St Vincent's Hospital Melbourne; Université de Lille","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Biomarker; Progression-free survival; Overall survival","score_opus":0.04316716519591803,"score_gpt":0.31308169024064814,"score_spread":0.2699145250447301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376106087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951099,0.00011350133,0.00007791439,0.0004056326,0.0000985913,0.0024584476,0.0008654835,0.00020147732,0.0006690389],"genre_scores_gemma":[0.9910961,0.0000120505065,0.0050633876,0.0000440384,0.00006483552,0.0008844487,0.0016340527,0.00014677797,0.0010543164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963982,0.00012848662,0.0007400971,0.0008491234,0.0007917781,0.0010923106],"domain_scores_gemma":[0.99786866,0.00046365932,0.0002509131,0.00055550085,0.00044314034,0.0004181114],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027418602,0.00054118683,0.00097163545,0.0005765201,0.00017606809,0.000057792542,0.00022219312,0.00023753499,0.00023776738],"category_scores_gemma":[0.0004057451,0.0004417939,0.0002803633,0.0015764199,0.00017842434,0.00029590988,0.00016078616,0.0001961081,0.000029555513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006979205,0.0011634592,0.9480844,0.00049807946,0.00051480613,0.0002507892,0.0008717967,0.0000050964154,0.0031920185,0.0000148390745,0.0015849512,0.036840536],"study_design_scores_gemma":[0.022133669,0.0023145003,0.9580553,0.0008119846,0.00010988804,0.0000068731615,0.00038846946,0.0040963655,0.011294956,0.000022524226,0.00035849516,0.00040693392],"about_ca_topic_score_codex":0.0010241485,"about_ca_topic_score_gemma":0.0016550518,"teacher_disagreement_score":0.0364336,"about_ca_system_score_codex":0.00020431414,"about_ca_system_score_gemma":0.00013137414,"threshold_uncertainty_score":0.99980336},"labels":[],"label_agreement":null},{"id":"W4378078281","doi":"10.1097/hs9.0000000000000886","title":"Bleeding and Thrombosis in Patients With Cirrhosis: What’s New?","year":2023,"lang":"en","type":"editorial","venue":"HemaSphere","topic":"Liver Disease and Transplantation","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cirrhosis; Thrombosis; Medicine; Internal medicine; Cardiology","score_opus":0.009926677538678964,"score_gpt":0.24616217742995147,"score_spread":0.23623549989127252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378078281","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12625107,0.0020053387,0.000010407183,0.00024526208,0.86945826,0.0009454314,0.00013157331,0.00020426493,0.00074836676],"genre_scores_gemma":[0.081283815,0.0109041,0.00029887637,0.00015758634,0.8988292,0.000113389746,0.005062826,0.00032920897,0.0030210016],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9986645,0.000014443035,0.00018949973,0.00036273713,0.000546104,0.00022272814],"domain_scores_gemma":[0.999326,0.00017905381,0.0000733143,0.0001623935,0.0000943743,0.0001648584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005472219,0.00022013756,0.00037043728,0.00007433267,0.000033308814,0.000069140035,0.000049811177,0.0003406929,0.000103124126],"category_scores_gemma":[0.0000237488,0.00018114779,0.000041784868,0.00019496014,0.000024738714,0.00028536888,0.00001864223,0.00034228904,0.00004881997],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005188553,0.00010951313,0.077557996,0.001400205,0.00048692132,0.000057505906,0.0010405272,0.0000013994653,0.0000026644527,0.000006376859,0.9177515,0.0010665174],"study_design_scores_gemma":[0.032838646,0.0021399884,0.7850998,0.02787444,0.009222418,0.0000018003169,0.0035855507,0.000027297303,0.00007964193,0.00021307459,0.13729528,0.0016220685],"about_ca_topic_score_codex":0.00027832988,"about_ca_topic_score_gemma":0.00019666155,"teacher_disagreement_score":0.78045624,"about_ca_system_score_codex":0.00006598867,"about_ca_system_score_gemma":0.000242754,"threshold_uncertainty_score":0.73869926},"labels":[],"label_agreement":null},{"id":"W4379467996","doi":"10.1097/hs9.0000000000000900","title":"Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Antithrombotic; Hemostasis; Thrombosis; Atrial fibrillation; Clotting factor; Stroke (engine); Venous thrombosis; Intensive care medicine; Internal medicine; Physical therapy","score_opus":0.053939705051948755,"score_gpt":0.3947387255850169,"score_spread":0.3407990205330681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379467996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98860765,0.00024913083,0.000004614409,0.0024380207,0.00014161768,0.0011845996,0.000011142178,0.00018309968,0.0071801436],"genre_scores_gemma":[0.9856065,0.0003270403,0.0034723112,0.00026822244,0.00024478478,0.00008822687,0.00019479045,0.00007283816,0.009725288],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973648,0.00019739164,0.000510504,0.00064621057,0.0006769215,0.0006041396],"domain_scores_gemma":[0.99826974,0.00030351203,0.000104401166,0.0007278404,0.00022582598,0.00036868957],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004679924,0.0002885292,0.00059315545,0.00010998237,0.00010714133,0.000032368305,0.00012346626,0.00018765102,0.000323067],"category_scores_gemma":[0.0003540431,0.00019047172,0.000112324095,0.00085265905,0.00016011907,0.0002733598,0.00005382717,0.00030067787,0.00090783765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010413282,0.0042077866,0.97684515,0.000091707014,0.00017779079,0.001347213,0.0002376004,0.000017394375,0.00002353042,0.000081814,0.0020225963,0.013906092],"study_design_scores_gemma":[0.009575013,0.006587997,0.9705141,0.00024593258,0.00015483273,0.000025112144,0.0004158825,0.00027628578,0.0001382553,0.000035836427,0.011791393,0.00023933296],"about_ca_topic_score_codex":0.00013221412,"about_ca_topic_score_gemma":0.00012285377,"teacher_disagreement_score":0.013666759,"about_ca_system_score_codex":0.00025477642,"about_ca_system_score_gemma":0.0003253563,"threshold_uncertainty_score":0.99987006},"labels":[],"label_agreement":null},{"id":"W4379792669","doi":"10.1097/hs9.0000000000000905","title":"Prevalence and Clinical Outcome of Omicron Breakthrough Infection in Patients With Hematologic Disease: A Prospective Observational Cohort Study","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Observational study; Medicine; Cohort study; Disease; Prospective cohort study; Cohort; Hematologic disease; Internal medicine; Outcome (game theory); Pediatrics; Intensive care medicine","score_opus":0.06786149260716626,"score_gpt":0.3959144969358488,"score_spread":0.32805300432868256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379792669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976641,0.00005572305,0.000007533955,0.00005473464,0.000036696994,0.0019587993,0.000008584024,0.000053599215,0.000160252],"genre_scores_gemma":[0.9992594,0.0000073517817,0.00004706338,0.00044293154,0.000020895655,0.00014179845,0.000007045861,0.000013945799,0.00005953851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99856764,0.00007860719,0.00038549327,0.00036436744,0.0004267596,0.0001771358],"domain_scores_gemma":[0.9992976,0.0001616288,0.000092409005,0.00023005773,0.00018072547,0.000037580827],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039268812,0.00011599291,0.00034280884,0.000054026714,0.00003493527,0.000008571651,0.00005018434,0.00006165525,0.000017472434],"category_scores_gemma":[0.00039178957,0.00008617173,0.000044529184,0.0004652813,0.000119244374,0.00009837831,0.000077370896,0.00019230333,0.000018211711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009300339,0.0013012317,0.9969023,0.0004384725,0.00007047416,0.000034168443,0.00009494459,6.914298e-7,0.000009267439,0.00003954875,0.00004436274,0.00013448876],"study_design_scores_gemma":[0.0035308443,0.00087287795,0.9950042,0.00013689915,0.00007171296,0.0000019117708,0.00005237896,0.00006947608,0.000052265877,0.00008758165,0.000034191344,0.00008567651],"about_ca_topic_score_codex":0.00017257928,"about_ca_topic_score_gemma":0.00015095089,"teacher_disagreement_score":0.0026008105,"about_ca_system_score_codex":0.00008223858,"about_ca_system_score_gemma":0.000118650816,"threshold_uncertainty_score":0.3513981},"labels":[],"label_agreement":null},{"id":"W4382313481","doi":"10.1097/01.hs9.0000936256.84340.a7","title":"P32 MAJESTEC-1: CORRELATIVE ANALYSES OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Bone marrow; Internal medicine; CD8; Antibody; Oncology; Immunology; Immune system; Gastroenterology","score_opus":0.037613535713238215,"score_gpt":0.32640413410390967,"score_spread":0.28879059839067145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382313481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450886,0.00038103678,0.00008022794,0.000058996022,0.000086495136,0.0012887986,0.000101393394,0.00012319387,0.003371009],"genre_scores_gemma":[0.9951442,0.00015832657,0.0010861786,0.000017891487,0.000040969033,0.00005146698,0.0011669596,0.0000648959,0.0022691202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974112,0.0001247457,0.00053464115,0.0005384249,0.0008381842,0.0005528073],"domain_scores_gemma":[0.9983654,0.0002621375,0.0002678969,0.00056326104,0.00031794762,0.00022333146],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016275443,0.00032989503,0.0006175046,0.00038419612,0.00010422438,0.00002581015,0.00013806857,0.00018815153,0.00036286234],"category_scores_gemma":[0.00020361406,0.0002478919,0.0001364133,0.0014263205,0.00015518427,0.00024538412,0.00008031372,0.0003666532,0.00029063819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034602857,0.0013740049,0.9763292,0.00028134394,0.00020469353,0.00033468477,0.00048102593,0.00006701166,0.013397673,0.000011645847,0.0008663634,0.0031920744],"study_design_scores_gemma":[0.013063308,0.0011029361,0.9717628,0.00043814635,0.00006711905,0.0000044107483,0.0007448841,0.0012487852,0.010778749,0.000016580103,0.00054091116,0.0002313772],"about_ca_topic_score_codex":0.00036615532,"about_ca_topic_score_gemma":0.00025302073,"teacher_disagreement_score":0.009603022,"about_ca_system_score_codex":0.00018052585,"about_ca_system_score_gemma":0.0001918269,"threshold_uncertainty_score":0.9999973},"labels":[],"label_agreement":null},{"id":"W4382513940","doi":"10.1097/01.hs9.0000936124.56965.24","title":"B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Pomalidomide; Medicine; Lenalidomide; Regimen; Internal medicine; Dexamethasone; Ixazomib; Oncology; Multiple myeloma; Carfilzomib; Clinical endpoint; Randomized controlled trial","score_opus":0.02313725160101678,"score_gpt":0.3011518509707363,"score_spread":0.27801459936971956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382513940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848542,0.00045757418,0.000018946665,0.0002990963,0.00035293674,0.012166675,0.00008244991,0.00021792806,0.0015501868],"genre_scores_gemma":[0.994318,0.00019875797,0.0005777427,0.00005275162,0.000120947574,0.0014338956,0.00035817263,0.00009065207,0.0028490855],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99583715,0.00055803964,0.0009262025,0.00072436867,0.0011395742,0.00081467914],"domain_scores_gemma":[0.9962434,0.0020319389,0.00031891002,0.00058868196,0.0002701795,0.00054684887],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010950343,0.00048577174,0.002399844,0.0003100264,0.00017010687,0.000055262157,0.00011725679,0.00023017683,0.00038159374],"category_scores_gemma":[0.003268078,0.00032741748,0.00032851804,0.0006686717,0.00024011222,0.00017943137,0.000080693055,0.0004259892,0.00009036094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98494405,0.0016169092,0.0053737145,0.00008310036,0.0011257187,0.0006809466,0.00033861244,0.000003499,0.0005490213,0.000015312811,0.0012035741,0.004065562],"study_design_scores_gemma":[0.98419577,0.008152865,0.003724379,0.00022158539,0.00039159504,0.0000030389997,0.00024479875,0.0012657518,0.00060844334,0.000016725015,0.00086785166,0.00030719137],"about_ca_topic_score_codex":0.00006657931,"about_ca_topic_score_gemma":0.00017952768,"teacher_disagreement_score":0.01073278,"about_ca_system_score_codex":0.00032670196,"about_ca_system_score_gemma":0.00038801413,"threshold_uncertainty_score":0.9999178},"labels":[],"label_agreement":null},{"id":"W4385644673","doi":"10.1097/01.hs9.0000967692.36989.7b","title":"S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Regimen; Oncology; Refractory (planetary science); Lenalidomide; Population; Multiple myeloma","score_opus":0.012653030857564059,"score_gpt":0.2517735670351252,"score_spread":0.23912053617756115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385644673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99667275,0.00033738592,0.000031560317,0.0003601463,0.00008912034,0.0015947944,0.00013345898,0.00019551563,0.0005852845],"genre_scores_gemma":[0.99219865,0.0004018853,0.00064463203,0.00012853189,0.00006774072,0.0001246519,0.0003651806,0.00013942589,0.0059293304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952936,0.00041739724,0.0008641935,0.0010746615,0.0013596877,0.000990457],"domain_scores_gemma":[0.9973448,0.000576716,0.00028075723,0.0010938407,0.00026280398,0.00044111183],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011548179,0.000489327,0.0012909999,0.0009609066,0.00013629586,0.00006307651,0.00022875647,0.00033814757,0.0016417602],"category_scores_gemma":[0.0004892182,0.00042380654,0.00021027304,0.0045905104,0.00019739731,0.00022316801,0.00016916012,0.0009342292,0.00007390177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013921869,0.0005299776,0.9605591,0.00015870697,0.0006861307,0.0005541751,0.0016257456,0.00012534503,0.009297656,0.000010253372,0.0012089039,0.011322129],"study_design_scores_gemma":[0.03335174,0.0021022875,0.9538229,0.00023242188,0.0003670098,0.000004340199,0.0011614227,0.00131833,0.0040966487,0.0000466182,0.0030006368,0.0004956046],"about_ca_topic_score_codex":0.0013530658,"about_ca_topic_score_gemma":0.011666938,"teacher_disagreement_score":0.019429874,"about_ca_system_score_codex":0.0007132029,"about_ca_system_score_gemma":0.0002700971,"threshold_uncertainty_score":0.99982136},"labels":[],"label_agreement":null},{"id":"W4385644723","doi":"10.1097/01.hs9.0000967696.13096.54","title":"S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Discontinuation; Internal medicine; Refractory (planetary science); Adverse effect; Gastroenterology; Multiple myeloma; Surgery","score_opus":0.018638708852403377,"score_gpt":0.2789849677210768,"score_spread":0.2603462588686734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385644723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467987,0.0006296995,0.00038736945,0.00031085368,0.00024055826,0.0024017175,0.000516365,0.00022480689,0.0006087891],"genre_scores_gemma":[0.98351,0.00036466127,0.0046679643,0.000044528108,0.00015813728,0.00020993003,0.0072226045,0.000087952554,0.0037342007],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99762464,0.00006556839,0.00038997762,0.0007259314,0.00062644796,0.000567454],"domain_scores_gemma":[0.9984278,0.00029140883,0.00016979844,0.0004949869,0.00026627397,0.0003497025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012293969,0.00036146396,0.00044391953,0.0001480263,0.0002727044,0.000100399135,0.000105904175,0.00021389539,0.00029880396],"category_scores_gemma":[0.00015740184,0.0002887423,0.00011599673,0.0004003114,0.00009719472,0.00032105183,0.000052912863,0.00021444591,0.00016980885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03383932,0.0036841864,0.79389757,0.0011319113,0.0007827071,0.0008333362,0.0012096833,0.0000046574587,0.05526668,0.00009625209,0.022972297,0.086281374],"study_design_scores_gemma":[0.028596416,0.0036686605,0.94943756,0.00022890342,0.00014123443,0.000010630433,0.0005482322,0.0018384872,0.006166654,0.000115166615,0.0088619795,0.0003860859],"about_ca_topic_score_codex":0.00018015389,"about_ca_topic_score_gemma":0.0003896834,"teacher_disagreement_score":0.15553996,"about_ca_system_score_codex":0.00009150258,"about_ca_system_score_gemma":0.0001943432,"threshold_uncertainty_score":0.9999565},"labels":[],"label_agreement":null},{"id":"W4385644849","doi":"10.1097/01.hs9.0000967680.90062.ca","title":"S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Oncology; Refractory (planetary science); CD38; Gastroenterology; Lenalidomide; Multiple myeloma; CD34","score_opus":0.020957787947047585,"score_gpt":0.2764088675186831,"score_spread":0.2554510795716355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385644849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692737,0.00016808041,0.000006053307,0.0004644179,0.00026284336,0.0015093635,0.00010288774,0.0004292791,0.027783409],"genre_scores_gemma":[0.9491892,0.00007668828,0.00027136962,0.0001727777,0.00020937163,0.000099057295,0.001294833,0.00016153954,0.048525196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995917,0.0001966848,0.0007236379,0.0009427381,0.0012264928,0.0009934069],"domain_scores_gemma":[0.9976684,0.00024236541,0.00018303144,0.0011765207,0.00036684828,0.00036285206],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005894813,0.00044184813,0.0006920364,0.0003424537,0.00016387721,0.000051588577,0.00030613036,0.00034561675,0.0029051793],"category_scores_gemma":[0.00043523867,0.00036938553,0.00015333475,0.0021920467,0.000240462,0.00023409438,0.00017218341,0.0009146763,0.0016829837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10525242,0.005628404,0.35156307,0.00079401163,0.0010259917,0.0047731865,0.00525307,0.000154778,0.06635723,0.00009054659,0.300951,0.15815628],"study_design_scores_gemma":[0.092767216,0.0068533253,0.540109,0.0009814963,0.000111920875,0.000078184596,0.0015431412,0.0020930998,0.025714695,0.00006267607,0.32848838,0.0011968712],"about_ca_topic_score_codex":0.00026408755,"about_ca_topic_score_gemma":0.00077619165,"teacher_disagreement_score":0.18854593,"about_ca_system_score_codex":0.00048564453,"about_ca_system_score_gemma":0.00037301562,"threshold_uncertainty_score":0.9998758},"labels":[],"label_agreement":null},{"id":"W4385655000","doi":"10.1097/01.hs9.0000975056.36410.cc","title":"PB2064: THE COMPLETE STUDY: A SINGLE ARM, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF PEGCETACOPLAN UNDER REAL WORLD CONDITIONS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Paroxysmal nocturnal hemoglobinuria; Eculizumab; Medicine; Anemia; Observational study; Internal medicine; Hemolysis; Hemoglobinuria; Pediatrics; Intensive care medicine; Complement system; Immunology; Antibody","score_opus":0.07548879676121699,"score_gpt":0.3284828945546748,"score_spread":0.2529940977934578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952416,0.000025322752,0.000010865476,0.00007356723,0.00032876004,0.0037585567,0.00030822045,0.000062679464,0.00019041984],"genre_scores_gemma":[0.9987636,1.9278819e-7,0.000014176023,0.000052390802,0.000018728295,0.00038161498,0.00046493558,0.000026168862,0.00027816015],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971832,0.0013404154,0.0004972897,0.00040128297,0.00020851295,0.0003692961],"domain_scores_gemma":[0.9983372,0.0007953585,0.00018159045,0.0004310644,0.00021707297,0.00003770529],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006374415,0.00024257433,0.0004297264,0.00012529142,0.00021466964,0.000023082275,0.00030701602,0.000035169774,0.0010375961],"category_scores_gemma":[0.000057147376,0.00017037685,0.00006825922,0.0006519529,0.000102054495,0.00008136991,0.00019497152,0.0001738772,0.00022974196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016089305,0.0055701328,0.9865759,0.00006713701,0.00046606135,0.000008540156,0.0012695788,0.0015706605,0.0018603035,0.00010486669,0.00087144563,0.000026430776],"study_design_scores_gemma":[0.008961699,0.0017417261,0.9834053,0.00019867036,0.00013752557,0.0000012388131,0.0050268625,0.000018061257,0.00016456738,0.00006358349,0.00009510092,0.00018566646],"about_ca_topic_score_codex":0.0004363607,"about_ca_topic_score_gemma":0.004867287,"teacher_disagreement_score":0.007352768,"about_ca_system_score_codex":0.00014762806,"about_ca_system_score_gemma":0.000081697704,"threshold_uncertainty_score":0.9998756},"labels":[],"label_agreement":null},{"id":"W4385655001","doi":"10.1097/01.hs9.0000974372.45108.8e","title":"PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME: A FIRST-IN-CLINIC PHASE 1 STUDY OF GSK3745417","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Sting; Myelodysplastic syndromes; Leukemia; Azacitidine; Tolerability; Stimulator of interferon genes; Internal medicine; Cancer research; Immunology; Bone marrow; Oncology; Immune system; Innate immune system; Biology; Adverse effect","score_opus":0.021151025363478813,"score_gpt":0.28826571158633224,"score_spread":0.26711468622285345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655001","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941541,0.0039714687,0.000029329052,0.000053876352,0.0005165628,0.0010192543,0.00015443492,0.00004638039,0.000054594933],"genre_scores_gemma":[0.9910774,0.0022568712,0.00002734209,0.000007904473,0.000013759853,0.00019550776,0.00004500281,0.00003125202,0.006344965],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984243,0.00021309985,0.000622751,0.00033332483,0.000048912974,0.00035761378],"domain_scores_gemma":[0.9965917,0.0025786813,0.00033414536,0.0004163273,0.000059292153,0.00001985338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003060493,0.00025509542,0.000627583,0.000103750695,0.00026058388,0.000010131952,0.00019247028,0.00017957181,0.0003631751],"category_scores_gemma":[0.0002029739,0.00017084612,0.0001349559,0.0002335799,0.00023535803,0.000052931275,0.00006960413,0.00019808281,0.00009043978],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081837386,0.032036748,0.06426758,0.0019874738,0.02526831,0.0010022802,0.09151612,0.00076063524,0.4450576,0.0005067939,0.01933814,0.23642094],"study_design_scores_gemma":[0.16851927,0.17368199,0.33093593,0.0014685502,0.0057163783,0.0006560772,0.08884459,0.0010134882,0.16338296,0.0002678915,0.06351353,0.0019993498],"about_ca_topic_score_codex":0.00067990395,"about_ca_topic_score_gemma":0.0004987648,"teacher_disagreement_score":0.28167462,"about_ca_system_score_codex":0.0001035798,"about_ca_system_score_gemma":0.000114389564,"threshold_uncertainty_score":0.69669026},"labels":[],"label_agreement":null},{"id":"W4385655058","doi":"10.1097/01.hs9.0000975232.20009.f4","title":"PB2114: BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL-WORLD OBSERVATIONAL STUDY UPDATE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Observational study; Adverse effect; Retrospective cohort study; Refractory (planetary science); Incidence (geometry); Oncology; Surgery","score_opus":0.12397344370946108,"score_gpt":0.3756518300853904,"score_spread":0.2516783863759293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908705,0.00018992968,0.00006950706,0.0011971593,0.00024820978,0.003315756,0.00025655143,0.00048174453,0.003370666],"genre_scores_gemma":[0.9512653,0.00008931775,0.0030730679,0.00019164068,0.0003752256,0.0009871578,0.0015468155,0.00009626967,0.042375255],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99742746,0.00008634538,0.0004586713,0.00061041897,0.00069654244,0.0007205471],"domain_scores_gemma":[0.99812835,0.0005766341,0.000116359246,0.00059197226,0.00023067127,0.00035601837],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00039364284,0.00030296345,0.0004877826,0.00018342897,0.00027661372,0.00003996839,0.00017486917,0.00010410622,0.0010303289],"category_scores_gemma":[0.00044445388,0.00025626872,0.00019987948,0.00074698887,0.000055986053,0.00015437437,0.00012951667,0.00027182745,0.0013061624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019584734,0.0017204203,0.9184111,0.00022498066,0.00053539715,0.0007002222,0.00028116713,0.000011032202,0.0013871968,0.0003000755,0.060398426,0.014071512],"study_design_scores_gemma":[0.014910008,0.0009734753,0.9407736,0.0000997488,0.00012705624,0.000015350213,0.00069546944,0.0023297616,0.0006845318,0.00017818612,0.038955055,0.0002577683],"about_ca_topic_score_codex":0.0005110424,"about_ca_topic_score_gemma":0.002445891,"teacher_disagreement_score":0.039605226,"about_ca_system_score_codex":0.00020938856,"about_ca_system_score_gemma":0.0002594031,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W4385655197","doi":"10.1097/01.hs9.0000976148.07947.e7","title":"PB2358: PHASE 1-2 STUDY OF THE SAFETY, PK, PD, AND PRELIMINARY ACTIVITY OF TOLINAPANT IN COMBINATION WITH ORAL DECITABINE/CEDAZURIDINE AND ORAL DECITABINE/CEDAZURIDINE ALONE IN SUBJECTS WITH R/R PTCL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Medicine; Hypomethylating agent; Azacitidine; Pharmacology; Leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndromes; Internal medicine; Lymphoma; Oncology; Bone marrow; DNA methylation","score_opus":0.01645214141555534,"score_gpt":0.26647213130217584,"score_spread":0.2500199898866205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99808675,0.00042051644,0.00004040238,0.00017692591,0.000026511483,0.0010521293,0.000033732747,0.000012520193,0.00015052191],"genre_scores_gemma":[0.9994007,0.0001247333,0.00020799079,0.000016723123,0.000016915286,0.00006904464,0.00003767053,0.000031359014,0.000094863586],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985652,0.00018690558,0.00031084337,0.0004201826,0.00023786919,0.00027901743],"domain_scores_gemma":[0.99922484,0.00006346398,0.00018395345,0.00036256318,0.000097363896,0.00006783201],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042211998,0.0002412289,0.00041528288,0.00007961435,0.000059091508,0.000011197413,0.0001466303,0.00011555779,0.0000100015295],"category_scores_gemma":[0.00009140168,0.000168972,0.00003010577,0.00054952834,0.00015882961,0.00001930504,0.00023050922,0.00016246914,4.5822807e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02310948,0.0059549822,0.4139658,0.0007599311,0.00023385527,0.00017165778,0.0028052044,0.0006445194,0.5349121,0.00019200909,0.00020835802,0.017042069],"study_design_scores_gemma":[0.026705606,0.013003483,0.3880666,0.00037198776,0.000083054285,0.00008996905,0.0022551978,0.0010465571,0.5676628,0.00011520479,0.000145041,0.00045453137],"about_ca_topic_score_codex":0.00029640328,"about_ca_topic_score_gemma":0.003072457,"teacher_disagreement_score":0.032750636,"about_ca_system_score_codex":0.000018285706,"about_ca_system_score_gemma":0.000099724624,"threshold_uncertainty_score":0.68904775},"labels":[],"label_agreement":null},{"id":"W4385655501","doi":"10.1097/01.hs9.0000975184.86472.15","title":"PB2100: REAL-WORLD TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A RETROSPECTIVE CHART STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Retrospective cohort study; Salvage therapy; Pediatrics; Chemotherapy","score_opus":0.03435706065089352,"score_gpt":0.3202322981013255,"score_spread":0.285875237450432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958447,0.000074848045,0.0000016232984,0.0005552102,0.00009349898,0.001873168,0.0006018725,0.00011076294,0.00084432156],"genre_scores_gemma":[0.94732267,0.0005015464,0.0000103795,0.000101634105,0.0000799342,0.00019129501,0.00040093533,0.00007222146,0.0513194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733925,0.0002196236,0.00045377534,0.0005629572,0.0007420452,0.00068233063],"domain_scores_gemma":[0.9980423,0.00038262343,0.0001861732,0.0007505851,0.0002861119,0.0003522429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026235447,0.00037890198,0.00063326716,0.00011388382,0.00027247652,0.000041662064,0.00016347304,0.000059493348,0.0001463923],"category_scores_gemma":[0.00015572686,0.0002409757,0.00008760373,0.00083263573,0.00012939132,0.00007095705,0.00017213373,0.00025715833,0.00003429684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074183615,0.0007223742,0.9890602,0.00009310657,0.000718026,0.0012465473,0.003246824,0.000007503467,0.00017637752,0.000008914387,0.0013183551,0.0026598999],"study_design_scores_gemma":[0.007626676,0.0019080245,0.97094905,0.000114620845,0.000116645686,0.000019007499,0.0043359455,0.0005317193,0.0008713182,0.0000048694787,0.013335291,0.00018681842],"about_ca_topic_score_codex":0.66332346,"about_ca_topic_score_gemma":0.92150384,"teacher_disagreement_score":0.25818038,"about_ca_system_score_codex":0.0006786986,"about_ca_system_score_gemma":0.00039930837,"threshold_uncertainty_score":0.98267037},"labels":[],"label_agreement":null},{"id":"W4385655633","doi":"10.1097/01.hs9.0000975804.42824.bf","title":"PB2268: PAX5 ABERRANT EXPRESSION INCORPORATED IN MIPI-SP RISK SCORING SYSTEM EXHIBITS ADDITIVE VALUE IN MANTLE CELL LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mental Health Research Canada","funders":"","keywords":"Mantle cell lymphoma; Medicine; Internal medicine; Proportional hazards model; Receiver operating characteristic; Lymphoma; Oncology; PAX5; International Prognostic Index; Immunohistochemistry; Cancer research; Diffuse large B-cell lymphoma; B cell; Immunology; Antibody","score_opus":0.014580188775644943,"score_gpt":0.23519362272452113,"score_spread":0.2206134339488762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98826814,0.0010604406,0.000008996168,0.00007600081,0.0002588852,0.00085073966,0.00007121523,0.00023272008,0.0091728745],"genre_scores_gemma":[0.99779844,0.00042512777,0.0003459228,0.000041748364,0.000106441206,0.00034156887,0.00014970265,0.000060209917,0.00073081226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977672,0.00017031698,0.0005398739,0.000599248,0.00039440347,0.000528967],"domain_scores_gemma":[0.9988985,0.00020826157,0.00020913991,0.00043060642,0.00006175968,0.00019172138],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002884466,0.0003245701,0.000588584,0.00019969342,0.000089050875,0.000026423291,0.00010207229,0.00020403342,0.00012414796],"category_scores_gemma":[0.00005706827,0.00026490967,0.00011835062,0.00096616097,0.000035098215,0.00012108201,0.000114252536,0.00014333072,0.0006947614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006553381,0.002296501,0.93987644,0.0012872695,0.00010239865,0.011703549,0.002406971,0.0010640277,0.011645656,0.00026935732,0.00840463,0.020287866],"study_design_scores_gemma":[0.018134924,0.00033300705,0.7833373,0.007343671,0.00011032511,0.00009191788,0.0053413366,0.006240764,0.17752706,0.00007362318,0.0009887202,0.00047739007],"about_ca_topic_score_codex":0.0016500944,"about_ca_topic_score_gemma":0.00032200615,"teacher_disagreement_score":0.1658814,"about_ca_system_score_codex":0.00082760374,"about_ca_system_score_gemma":0.00018804398,"threshold_uncertainty_score":0.99998033},"labels":[],"label_agreement":null},{"id":"W4385655716","doi":"10.1097/01.hs9.0000974860.48116.9c","title":"PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; International Prognostic Scoring System; Myelodysplastic syndromes; Demographics; Internal medicine; Pediatrics; Demography","score_opus":0.02821752694280383,"score_gpt":0.26571849908287903,"score_spread":0.2375009721400752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385655716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973921,0.00002824414,0.00029881657,0.00022727076,0.00009867236,0.0011309272,0.00004112062,0.00019774919,0.00058509386],"genre_scores_gemma":[0.9973698,0.000038447073,0.00056117936,0.00009133915,0.0000609165,0.00018697049,0.00011055367,0.00009354241,0.001487212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977565,0.00007487777,0.00030382272,0.0005419209,0.00052240334,0.0008005231],"domain_scores_gemma":[0.9987816,0.0001899429,0.00006822158,0.0004999016,0.000092955954,0.00036738077],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019613424,0.00029710087,0.00047012692,0.00029318727,0.000112534646,0.000036110094,0.0001456128,0.00011223544,0.00028754643],"category_scores_gemma":[0.00015743067,0.00022262191,0.0000685384,0.0010037594,0.000032798544,0.00013220588,0.00013607822,0.00034114422,0.0012628412],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046072758,0.00018291853,0.98514485,0.00009653782,0.00010713111,0.0010686663,0.0006354594,0.00040775788,0.000079107784,0.000008623396,0.000476549,0.011331644],"study_design_scores_gemma":[0.005537555,0.0017793456,0.98872495,0.0005352939,0.00008881089,0.000051280258,0.0018302089,0.00059712975,0.00027151647,0.00001172056,0.00029237536,0.00027979832],"about_ca_topic_score_codex":0.0013330817,"about_ca_topic_score_gemma":0.0004995824,"teacher_disagreement_score":0.011051846,"about_ca_system_score_codex":0.0012692122,"about_ca_system_score_gemma":0.00024727642,"threshold_uncertainty_score":0.9995148},"labels":[],"label_agreement":null},{"id":"W4385658467","doi":"10.1097/01.hs9.0000967408.39207.65","title":"S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Midostaurin; Medicine; Myeloid leukemia; Internal medicine; Oncology; Phosphoproteomics; Fms-Like Tyrosine Kinase 3; Refractory (planetary science); Biology; Kinase","score_opus":0.030261329363964085,"score_gpt":0.3435764329594033,"score_spread":0.31331510359543924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385658467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911741,0.00021545765,0.00014334677,0.0025699546,0.00017199006,0.0031114377,0.0002132012,0.00024277133,0.0021577298],"genre_scores_gemma":[0.98841554,0.00080751156,0.001775514,0.0008268785,0.00017516309,0.00032304972,0.00013673863,0.00015685376,0.007382728],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958399,0.00018164833,0.0008506681,0.00087998126,0.0011785778,0.0010692335],"domain_scores_gemma":[0.99760544,0.00039097428,0.00020803239,0.0009184008,0.00035710444,0.0005200485],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00094013574,0.0004830136,0.0010623608,0.00044890342,0.00009514209,0.000043412223,0.00046114402,0.0003022798,0.0006443492],"category_scores_gemma":[0.00047484465,0.00045326055,0.00019512708,0.0021158597,0.0001909516,0.00019115343,0.00038474007,0.000888289,0.00041310838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051530294,0.0006864401,0.13870472,0.00087121397,0.0015121192,0.012271528,0.0119993035,0.0010499054,0.73567164,0.000409324,0.022793708,0.022499813],"study_design_scores_gemma":[0.014354556,0.0010788667,0.20847844,0.0009904251,0.00011581847,0.00042941063,0.0021518802,0.0022379837,0.767931,0.00018791053,0.0014486002,0.0005951149],"about_ca_topic_score_codex":0.0010024305,"about_ca_topic_score_gemma":0.00050843495,"teacher_disagreement_score":0.069773726,"about_ca_system_score_codex":0.0016457059,"about_ca_system_score_gemma":0.0019223222,"threshold_uncertainty_score":0.9997919},"labels":[],"label_agreement":null},{"id":"W4385666327","doi":"10.1097/01.hs9.0000967372.19440.62","title":"S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Blinatumomab; Internal medicine; Minimal residual disease; Oncology; Rituximab; Induction chemotherapy; Chemotherapy; Acute lymphocytic leukemia; Chemotherapy regimen; Lymphoblastic Leukemia; Leukemia; Lymphoma","score_opus":0.017448307798226627,"score_gpt":0.27229854191145964,"score_spread":0.254850234113233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385666327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978395,0.00011902989,0.000010862231,0.00006182109,0.000031947588,0.0009534482,0.00007411314,0.000039206512,0.00087005424],"genre_scores_gemma":[0.99734104,0.00021083542,0.00032228578,0.000025987436,0.000022878417,0.000040756804,0.000105785046,0.00006555446,0.0018648994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816394,0.00008663442,0.00034647156,0.00044231626,0.00049140526,0.000469218],"domain_scores_gemma":[0.9988152,0.00033692838,0.00012344924,0.00042350596,0.00011652009,0.00018444107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025521882,0.000277788,0.0005722096,0.00023457139,0.00003380759,0.000035065303,0.00011392838,0.00015133596,0.00015154478],"category_scores_gemma":[0.00013875596,0.00020817401,0.000045612847,0.0006249098,0.00018951498,0.00018403887,0.00013327146,0.00033896187,0.000005313974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009475654,0.0005806146,0.9436383,0.00060792983,0.00022545099,0.0013957145,0.0013339017,0.00016390525,0.03555335,0.000030795072,0.0007037716,0.006290597],"study_design_scores_gemma":[0.03756919,0.0030686064,0.95552826,0.000373489,0.00005847605,0.00002071598,0.00029838367,0.0007851392,0.001960393,0.0000784381,0.000022622258,0.00023630496],"about_ca_topic_score_codex":0.001606701,"about_ca_topic_score_gemma":0.002443408,"teacher_disagreement_score":0.033592958,"about_ca_system_score_codex":0.00037380133,"about_ca_system_score_gemma":0.0004465444,"threshold_uncertainty_score":0.84890896},"labels":[],"label_agreement":null},{"id":"W4385666344","doi":"10.1097/01.hs9.0000967592.61626.0d","title":"S170: MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022): AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Myelodysplastic syndromes; Cohort; Medicine; Internal medicine; Oncology; Overall survival; Library science; Bone marrow","score_opus":0.040441073439601675,"score_gpt":0.32979848741790174,"score_spread":0.28935741397830006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385666344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99580353,0.000046170404,0.00024359737,0.0009820652,0.00025609828,0.0008529118,0.0010415597,0.000028737832,0.0007453495],"genre_scores_gemma":[0.99437284,0.00011258063,0.00031955267,0.00021830664,0.00011641977,0.00015729273,0.0010597999,0.000034346787,0.003608845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99784607,0.00008791486,0.0004955773,0.00044143264,0.00082634727,0.00030265117],"domain_scores_gemma":[0.99786586,0.0005663946,0.00027978866,0.0006780942,0.0004016152,0.00020826461],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003568264,0.00018676584,0.0005213304,0.00029898458,0.00011203171,0.00002437055,0.00035153335,0.0001455831,0.00041777725],"category_scores_gemma":[0.00081119966,0.0001450123,0.0001720103,0.0009320493,0.00013444161,0.0001171053,0.00018902704,0.00021319627,0.000020159723],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003002168,0.0007212211,0.83934176,0.0002703988,0.0024759392,0.000008895542,0.0029597548,0.0005392688,0.03844032,0.0009552299,0.100956775,0.010328264],"study_design_scores_gemma":[0.0027509371,0.00053471606,0.9454222,0.00019520984,0.00073966105,0.0000013315683,0.0012255957,0.035929803,0.010980827,0.00006567393,0.001987467,0.00016663522],"about_ca_topic_score_codex":0.00034905798,"about_ca_topic_score_gemma":0.00043479117,"teacher_disagreement_score":0.10608038,"about_ca_system_score_codex":0.00020834828,"about_ca_system_score_gemma":0.00018003165,"threshold_uncertainty_score":0.591343},"labels":[],"label_agreement":null},{"id":"W4385666962","doi":"10.1097/01.hs9.0000970384.26808.c7","title":"P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Cytokine release syndrome; Adverse effect; Gastroenterology; Bortezomib; Oncology; Refractory (planetary science); Surgery; Cancer; Immunotherapy; Chimeric antigen receptor","score_opus":0.014217060108590156,"score_gpt":0.2678927841424802,"score_spread":0.25367572403389005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385666962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99378407,0.0047374694,0.000011257593,0.00011311024,0.000020066243,0.0010294728,0.00012046308,0.00009069875,0.000093409355],"genre_scores_gemma":[0.9957077,0.001858642,0.0015252023,0.000018866363,0.000016450127,0.000037665242,0.0004837737,0.000029415838,0.0003222737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836224,0.00012091219,0.00036449308,0.00044354433,0.00041529175,0.00029352188],"domain_scores_gemma":[0.99875927,0.00046143893,0.00014145758,0.00031889117,0.00017918626,0.00013977158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000126863,0.00023554917,0.00065364473,0.00024967708,0.000093775016,0.00001815511,0.000056606306,0.000103587765,0.00012422321],"category_scores_gemma":[0.00020221468,0.00016867157,0.000058773057,0.0009757742,0.0001272523,0.00012247577,0.00006990873,0.0001612607,0.00001063284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069458587,0.00061344105,0.9488086,0.00019893995,0.0025787149,0.000083476516,0.0025815768,0.000008553862,0.001481342,0.0000016042587,0.000106182015,0.03659172],"study_design_scores_gemma":[0.021634163,0.00067787746,0.9737742,0.00021706334,0.00052668195,6.617315e-7,0.0012066237,0.001126974,0.00059523684,0.000010340236,0.00008054343,0.00014966933],"about_ca_topic_score_codex":0.0004615384,"about_ca_topic_score_gemma":0.00093179767,"teacher_disagreement_score":0.036442053,"about_ca_system_score_codex":0.0000641222,"about_ca_system_score_gemma":0.000049578306,"threshold_uncertainty_score":0.6878227},"labels":[],"label_agreement":null},{"id":"W4385666975","doi":"10.1097/01.hs9.0000970432.75766.0c","title":"P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Thames Valley Children's Centre; Princess Margaret Cancer Centre; McGill University Health Centre; University of Calgary","funders":"","keywords":"Lenalidomide; Pomalidomide; Daratumumab; Medicine; Internal medicine; Multiple myeloma; Cohort; Dexamethasone; Regimen; Clinical endpoint; Oncology; Gastroenterology; Surgery; Clinical trial","score_opus":0.04037242643722707,"score_gpt":0.3232737664310684,"score_spread":0.28290133999384137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385666975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99704844,0.00016817395,0.000005036905,0.000101123886,0.00005661228,0.0022303155,0.0001877083,0.000047872196,0.00015469184],"genre_scores_gemma":[0.9967673,0.00004658035,0.00025091946,0.000036666304,0.000029441897,0.0003238341,0.0001750162,0.000049322425,0.0023209425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969926,0.0003897519,0.00055348704,0.00063997996,0.0008716537,0.0005525325],"domain_scores_gemma":[0.9979831,0.0005787938,0.00019503816,0.00082356343,0.00015959168,0.000259903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031839794,0.00039666728,0.0010191427,0.0003403176,0.00012256374,0.00002990771,0.00013594862,0.00011108198,0.00045516307],"category_scores_gemma":[0.0003219693,0.00021410915,0.00021875554,0.0016885428,0.00015244457,0.00013193641,0.00012665414,0.00023468497,0.000016857235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036388088,0.005544786,0.94656456,0.00006617572,0.002968498,0.00071941444,0.00096703845,0.00004303933,0.00018299493,0.0000019532238,0.000075360156,0.0064780707],"study_design_scores_gemma":[0.07309336,0.004729921,0.91839284,0.00012503995,0.0012990482,0.000003332415,0.0006686478,0.00092950574,0.00034202883,0.000003085717,0.00021661747,0.00019656777],"about_ca_topic_score_codex":0.0013668411,"about_ca_topic_score_gemma":0.009905138,"teacher_disagreement_score":0.036705274,"about_ca_system_score_codex":0.0002983145,"about_ca_system_score_gemma":0.0002050506,"threshold_uncertainty_score":0.8731118},"labels":[],"label_agreement":null},{"id":"W4385667024","doi":"10.1097/01.hs9.0000969844.13426.20","title":"P735: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta Hospital; Queen Elizabeth II Health Sciences Centre; University of Ottawa; Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"","keywords":"Decitabine; Medicine; Internal medicine; Chronic myelomonocytic leukemia; International Prognostic Scoring System; Monocytosis; Oncology; Leukemia; Gastroenterology; Bone marrow; Myelodysplastic syndromes","score_opus":0.0784401128588723,"score_gpt":0.41816012080025994,"score_spread":0.3397200079413876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99270415,0.0028077858,0.000035781635,0.0033322962,0.00004035163,0.00071903475,0.000072033414,0.000045717457,0.00024284594],"genre_scores_gemma":[0.9974929,0.0012158012,0.00047123377,0.00013306757,0.00009997961,0.00003365856,0.00022973293,0.0000259713,0.00029766114],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984889,0.00014704735,0.0003825332,0.00031909326,0.00037066464,0.00029173362],"domain_scores_gemma":[0.99862427,0.00075330294,0.000079940975,0.00032301445,0.000121555306,0.00009791478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000695992,0.00017812446,0.0004619515,0.00010286777,0.00008652362,0.000015551366,0.00009585269,0.00008651282,0.00015150815],"category_scores_gemma":[0.00096567057,0.000120742436,0.0000374199,0.00076933164,0.00019134075,0.00009577228,0.000117527736,0.0002657802,0.000015040456],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026081575,0.0041593374,0.14415231,0.0020937754,0.0016769497,0.0025227347,0.035438,0.0001812843,0.11781245,0.0020661154,0.095118105,0.56869733],"study_design_scores_gemma":[0.24240309,0.0059706517,0.58996516,0.0021636947,0.0009836081,0.00028396666,0.053357743,0.03521619,0.01641673,0.0033278994,0.048640117,0.0012711402],"about_ca_topic_score_codex":0.00048385694,"about_ca_topic_score_gemma":0.00034969766,"teacher_disagreement_score":0.5674262,"about_ca_system_score_codex":0.000084441715,"about_ca_system_score_gemma":0.00009287721,"threshold_uncertainty_score":0.49237338},"labels":[],"label_agreement":null},{"id":"W4385667045","doi":"10.1097/01.hs9.0000970976.05785.80","title":"P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Discontinuation; Oncology; Gastroenterology; Bone marrow","score_opus":0.024068135180549254,"score_gpt":0.296001022558554,"score_spread":0.27193288737800475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724218,0.00015036263,0.0000014643683,0.0032842844,0.00009476075,0.0010479348,0.00057087734,0.00011254389,0.022315932],"genre_scores_gemma":[0.9948582,0.00028820985,0.00067981804,0.0006055505,0.00012479362,0.000085762666,0.00076252286,0.000048127116,0.0025469884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780613,0.000085575026,0.00064097234,0.0006638195,0.00039877734,0.0004047286],"domain_scores_gemma":[0.9982961,0.000666688,0.00012664402,0.0005055504,0.00009637475,0.00030867665],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002076688,0.00031066986,0.0006380856,0.00014079038,0.00007307336,0.000021810327,0.000093148,0.0001594986,0.0013417017],"category_scores_gemma":[0.00039873857,0.00025909086,0.0000819847,0.0006220039,0.000055864635,0.00005050781,0.000100120706,0.00019561176,0.00087742857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09214003,0.0129832765,0.43626285,0.0011224687,0.0024588602,0.0058515673,0.024027178,0.00087540946,0.029855115,0.018970396,0.2567039,0.11874894],"study_design_scores_gemma":[0.016695295,0.002447636,0.9211441,0.001530769,0.00013289896,0.000024331055,0.0010534871,0.00009833608,0.034436498,0.0002493192,0.021834502,0.00035278333],"about_ca_topic_score_codex":0.0008806901,"about_ca_topic_score_gemma":0.0005457924,"teacher_disagreement_score":0.4848813,"about_ca_system_score_codex":0.000103922626,"about_ca_system_score_gemma":0.00010029695,"threshold_uncertainty_score":0.9999861},"labels":[],"label_agreement":null},{"id":"W4385667055","doi":"10.1097/01.hs9.0000968868.83152.da","title":"P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Servier; Agios Pharmaceuticals","keywords":"Medicine; Internal medicine; IDH1; Isocitrate dehydrogenase; Myeloid leukemia; Placebo; Azacitidine; Gastroenterology; Clinical endpoint; Randomized controlled trial; Pathology; Biology","score_opus":0.017165133778774964,"score_gpt":0.25780168387298313,"score_spread":0.24063655009420817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076974,0.00006624313,0.00001232453,0.0012453315,0.000065875414,0.0046661436,0.0015619999,0.00032182518,0.0012904893],"genre_scores_gemma":[0.9921444,0.00015622769,0.00041065709,0.00034372706,0.00013244881,0.00024083976,0.003713416,0.0001563494,0.0027019018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99521935,0.00037573194,0.00085222814,0.0012352462,0.0013491521,0.00096831046],"domain_scores_gemma":[0.9966769,0.0008837578,0.0002166754,0.0012677453,0.0004853354,0.00046955977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008546926,0.0006412327,0.001119663,0.00021367412,0.00029243255,0.00012089979,0.0003958328,0.00019318589,0.0002835217],"category_scores_gemma":[0.0002604214,0.0004011673,0.00006435071,0.0024615205,0.00020428601,0.00024502096,0.00033642128,0.00081669143,0.00017128797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10688553,0.0010772211,0.84730756,0.00006294516,0.0023802184,0.0025832958,0.0025169163,0.0006993571,0.0014189832,0.00000703305,0.033921435,0.0011394877],"study_design_scores_gemma":[0.07351253,0.0043175765,0.91101277,0.0006316628,0.0007138058,0.000034862736,0.0048394767,0.00050415617,0.0015407423,0.000008491688,0.0022215687,0.00066234893],"about_ca_topic_score_codex":0.0054797884,"about_ca_topic_score_gemma":0.01133732,"teacher_disagreement_score":0.0637052,"about_ca_system_score_codex":0.00088916573,"about_ca_system_score_gemma":0.00068322703,"threshold_uncertainty_score":0.999844},"labels":[],"label_agreement":null},{"id":"W4385667081","doi":"10.1097/01.hs9.0000972868.69615.42","title":"P1497: MITAPIVAT IMPROVES IRON OVERLOAD IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Pyruvate kinase deficiency; Iron deficiency; Anemia; Pyruvate kinase; Internal medicine; Pediatrics; Glycolysis; Metabolism","score_opus":0.00943849145740466,"score_gpt":0.21526379523876396,"score_spread":0.2058253037813593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677277,0.00022211939,0.000026817219,0.00041784788,0.00020584826,0.0005267801,0.00001701472,0.0001953059,0.0016154875],"genre_scores_gemma":[0.99478245,0.000067068075,0.00017396607,0.0005839735,0.000073179195,0.000042992095,0.00010229874,0.00004766583,0.004126413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985389,0.00004475184,0.0002647475,0.0004429164,0.0002935041,0.00041515572],"domain_scores_gemma":[0.9992536,0.000038882965,0.00008541199,0.00039487254,0.00009459695,0.00013269128],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008404944,0.00022549454,0.0004094517,0.00010575159,0.000077492594,0.000013475352,0.000077219964,0.00016307151,0.00030545192],"category_scores_gemma":[0.000047194768,0.00017582977,0.000085027066,0.00069153454,0.00008462998,0.000122024576,0.000022812197,0.0002551639,0.00021580046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032435283,0.0011231891,0.9040414,0.0011524911,0.000055657852,0.0003644617,0.0021495104,0.00008352218,0.06573689,0.00030411984,0.0089623965,0.012782833],"study_design_scores_gemma":[0.0064169928,0.0013210219,0.986924,0.000376185,0.000041707903,0.0000029210069,0.00091233983,0.0000621405,0.0016483197,0.00006974719,0.0019731869,0.00025146184],"about_ca_topic_score_codex":0.000068006164,"about_ca_topic_score_gemma":0.0001724138,"teacher_disagreement_score":0.082882576,"about_ca_system_score_codex":0.000069625,"about_ca_system_score_gemma":0.00006703979,"threshold_uncertainty_score":0.717013},"labels":[],"label_agreement":null},{"id":"W4385667083","doi":"10.1097/01.hs9.0000967892.54405.ff","title":"S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Ruxolitinib; Clinical endpoint; Refractory (planetary science); Graft-versus-host disease; Internal medicine; Transplantation; Calcineurin; Hematopoietic stem cell transplantation; Phases of clinical research; Gastroenterology; Clinical trial; Surgery; Bone marrow; Myelofibrosis","score_opus":0.028344298142356752,"score_gpt":0.29474154981119316,"score_spread":0.26639725166883643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957215,0.00046993725,0.000004739505,0.00019208019,0.0002307281,0.002427433,0.00030414047,0.00016155593,0.00048789298],"genre_scores_gemma":[0.9965245,0.00024068046,0.00004310371,0.00006862359,0.0002624766,0.0003010475,0.0012182355,0.00007271163,0.001268621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978312,0.0001236149,0.00041355088,0.0005547535,0.0006137653,0.00046308368],"domain_scores_gemma":[0.99836576,0.0006460627,0.000120557575,0.0005665961,0.00006434644,0.00023668511],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013007091,0.00034533226,0.00044091247,0.000091042544,0.00017415115,0.000025469883,0.0001485476,0.00008771496,0.0005680741],"category_scores_gemma":[0.000060577746,0.00020697211,0.00008282853,0.0006528995,0.000057117235,0.00013908718,0.00004555371,0.00021660131,0.00018910161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010624468,0.0049805827,0.9715865,0.00034295133,0.00025384728,0.0009974051,0.007836703,0.0000049980094,0.00012240463,0.0000047373132,0.0010152456,0.0022301448],"study_design_scores_gemma":[0.05028934,0.0074989195,0.9376156,0.00026168188,0.00094615936,0.0000020395223,0.002176148,0.000023445973,0.00007564034,0.0000033465167,0.0008461488,0.0002615429],"about_ca_topic_score_codex":0.00018150025,"about_ca_topic_score_gemma":0.00050858676,"teacher_disagreement_score":0.039664872,"about_ca_system_score_codex":0.00054442,"about_ca_system_score_gemma":0.0005017683,"threshold_uncertainty_score":0.84400773},"labels":[],"label_agreement":null},{"id":"W4385667085","doi":"10.1097/01.hs9.0000971256.60488.02","title":"P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Venetoclax; Ibrutinib; Medicine; Mantle cell lymphoma; Obinutuzumab; Internal medicine; Bendamustine; Regimen; Oncology; Adverse effect; Gastroenterology; Lymphoma; Rituximab; Leukemia; Chronic lymphocytic leukemia","score_opus":0.014988999691284768,"score_gpt":0.26361219385610113,"score_spread":0.24862319416481637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667085","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556535,0.0004136512,0.000018728402,0.00022040178,0.00009933045,0.00069856894,0.000010039185,0.000086952445,0.002886969],"genre_scores_gemma":[0.9937017,0.000057590518,0.000053897445,0.00006590662,0.00004104504,0.00003004117,0.000090720736,0.00004472094,0.005914356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998443,0.000052629995,0.00023397229,0.0002877407,0.00060524733,0.00037737965],"domain_scores_gemma":[0.9988769,0.00024344394,0.000099509096,0.00044645046,0.0002079521,0.00012569505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019648283,0.00017151806,0.00029506016,0.00006380622,0.00014345918,0.000028956303,0.00013159646,0.00010116616,0.0002339383],"category_scores_gemma":[0.00010776974,0.000108042135,0.00005791779,0.00058656826,0.00024801592,0.00008151122,0.00012979924,0.00018820759,0.00006942342],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047509028,0.0005136262,0.84900343,0.0040314076,0.0015585719,0.00079103565,0.008988517,0.0003982199,0.0019751322,0.0025429109,0.04599991,0.07944635],"study_design_scores_gemma":[0.14871456,0.00262448,0.8127386,0.003151012,0.000633331,0.00022853298,0.0020630683,0.015767843,0.009248661,0.0003078373,0.0037662466,0.0007558515],"about_ca_topic_score_codex":0.00029034197,"about_ca_topic_score_gemma":0.00010026355,"teacher_disagreement_score":0.14396365,"about_ca_system_score_codex":0.0034430772,"about_ca_system_score_gemma":0.0023426134,"threshold_uncertainty_score":0.9003527},"labels":[],"label_agreement":null},{"id":"W4385667119","doi":"10.1097/01.hs9.0000968768.84940.f7","title":"P465: N-MYRISTOYLATION INHIBITION ABROGATES OXIDATIVE PHOSPHORYLATION TO TARGET ACUTE MYELOID LEUKEMIA STEM CELLS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Alberta","funders":"","keywords":"Myristoylation; Myeloid leukemia; Signal transduction; Biology; Cancer research; Stem cell; Phosphorylation; Oxidative phosphorylation; Kinase; Leukemia; Cell biology; Immunology; Biochemistry","score_opus":0.009386436860841752,"score_gpt":0.2357359665776633,"score_spread":0.22634952971682154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98969907,0.00023440995,0.0055951094,0.00033715577,0.0003386386,0.00055777945,0.00008771682,0.00014985807,0.0030002594],"genre_scores_gemma":[0.9818441,0.00014266075,0.0023765366,0.00039854608,0.00030046128,0.000117311785,0.0012709463,0.000048508686,0.01350088],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99874794,0.00005831889,0.00026806744,0.00043032994,0.00022388014,0.0002714387],"domain_scores_gemma":[0.9993283,0.00001222323,0.000116630006,0.00028371075,0.00013460091,0.00012451826],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017660983,0.00019610807,0.000143159,0.000061376195,0.00014822434,0.000044717555,0.000099653684,0.00019424263,0.00019428646],"category_scores_gemma":[0.000025185016,0.00020269783,0.000085023225,0.00040572684,0.000033814613,0.000020385125,0.00009926794,0.000095324736,0.0010016483],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007254391,0.000015833193,0.00018254534,0.000016311751,0.00003401986,0.0000067579167,0.00013249609,0.00077621185,0.93896663,0.00011331998,0.056272477,0.003410834],"study_design_scores_gemma":[0.00035406876,0.00015960506,0.0005173041,0.000026806078,0.000011931204,0.000004178221,0.00024095425,0.00043027176,0.91075134,0.00015668182,0.08711695,0.00022989648],"about_ca_topic_score_codex":0.000016922002,"about_ca_topic_score_gemma":0.000017323422,"teacher_disagreement_score":0.030844474,"about_ca_system_score_codex":0.00009766803,"about_ca_system_score_gemma":0.00008903316,"threshold_uncertainty_score":0.9997762},"labels":[],"label_agreement":null},{"id":"W4385667237","doi":"10.1097/01.hs9.0000970732.34300.9d","title":"P957: AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"","keywords":"Cohort; Multiple myeloma; Medicine; Internal medicine; Oncology; Refractory (planetary science); Biology","score_opus":0.05037156805333891,"score_gpt":0.351355052474519,"score_spread":0.30098348442118006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913613,0.00064334756,0.000037148176,0.00027042924,0.00038047362,0.0016843155,0.0004465435,0.00025822865,0.0049181986],"genre_scores_gemma":[0.9909835,0.00012674175,0.0007864056,0.000055246142,0.00019285276,0.00022237893,0.00038120447,0.000113599075,0.00713811],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946198,0.0014515572,0.0009844718,0.0009620593,0.0009893597,0.0009927414],"domain_scores_gemma":[0.9938906,0.0038547695,0.00038821273,0.0010070761,0.0002248387,0.0006344974],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013088123,0.0005426613,0.0014264038,0.0005936663,0.00014108396,0.000047251877,0.00035487543,0.00029568275,0.0012231605],"category_scores_gemma":[0.001660206,0.00049609656,0.00027050744,0.0010839131,0.00026123013,0.00029744982,0.00012477295,0.00081717456,0.00035315714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23096272,0.0020810487,0.62882483,0.0001823008,0.00086822495,0.0035871,0.0033564244,0.00014439692,0.091972224,0.000048204118,0.0019691605,0.03600337],"study_design_scores_gemma":[0.04492596,0.0026896123,0.91425335,0.00041097417,0.00016315788,0.00000700385,0.0018423892,0.012110053,0.02169172,0.0000972769,0.0014044079,0.00040409353],"about_ca_topic_score_codex":0.0048554097,"about_ca_topic_score_gemma":0.012869494,"teacher_disagreement_score":0.28542852,"about_ca_system_score_codex":0.0007402142,"about_ca_system_score_gemma":0.00059622875,"threshold_uncertainty_score":0.99974906},"labels":[],"label_agreement":null},{"id":"W4385667241","doi":"10.1097/01.hs9.0000970972.77960.03","title":"P1017: REDUCTIONS IN INDOLENT SYSTEMIC MASTOCYTOSIS BIOMARKER BURDEN WITH AVAPRITINIB IN THE REGISTRATIONAL, DOUBLE-BLIND PLACEBO-CONTROLLED PIONEER TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Systemic mastocytosis; Tryptase; Placebo; Internal medicine; Gastroenterology; Biomarker; Placebo-controlled study; Randomized controlled trial; Mast cell; Bone marrow; Immunology; Double blind; Pathology","score_opus":0.04868060214724758,"score_gpt":0.2799370876052603,"score_spread":0.23125648545801275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98030275,0.0014703353,0.00001960749,0.002344751,0.0005436932,0.002803328,0.000022217673,0.000075931406,0.012417362],"genre_scores_gemma":[0.9804732,0.00007568968,0.00002268123,0.00003872146,0.00012342303,0.001194185,0.00020585467,0.00002055161,0.017845651],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99834853,0.00028414503,0.0005381896,0.0003605053,0.0001022944,0.000366351],"domain_scores_gemma":[0.9991532,0.0002453188,0.0001611229,0.00036827347,0.000052764895,0.000019350846],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00075588166,0.00020673689,0.00042255895,0.0001801822,0.00016769877,0.000039829512,0.00023686426,0.00024350396,0.0011594446],"category_scores_gemma":[0.00003962043,0.00013892271,0.000096109026,0.00060794293,0.00014567487,0.00007212738,0.00003657168,0.0003619273,0.00043869624],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8760981,0.000979932,0.00074556464,0.0002612882,0.0006034032,0.00021937491,0.0065542976,0.0014397962,0.05399968,0.008610368,0.048888605,0.0015995894],"study_design_scores_gemma":[0.9286179,0.00068934914,0.0013114552,0.0005315238,0.00015810292,0.0004962235,0.013080562,0.000098293065,0.001042716,0.0001322024,0.053242624,0.0005990585],"about_ca_topic_score_codex":0.00030799292,"about_ca_topic_score_gemma":0.0010564859,"teacher_disagreement_score":0.052956965,"about_ca_system_score_codex":0.0000691488,"about_ca_system_score_gemma":0.00015082996,"threshold_uncertainty_score":0.99975365},"labels":[],"label_agreement":null},{"id":"W4385667275","doi":"10.1097/01.hs9.0000972412.18474.98","title":"P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Chimeric antigen receptor; Medicine; Immunotherapy; Cytokine; Lymphoma; Oncology; Internal medicine; Immunology; Immune system","score_opus":0.03743959570515347,"score_gpt":0.32109295928812887,"score_spread":0.2836533635829754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854155,0.0014299841,0.0001707952,0.001582028,0.0001844631,0.0012001067,0.00022637034,0.00033350234,0.009457247],"genre_scores_gemma":[0.9665949,0.00033417772,0.0013242575,0.0005089589,0.00035322184,0.00010719134,0.00018448634,0.00013237727,0.030460458],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965848,0.0001159896,0.0006726936,0.00079382374,0.000984106,0.00084863004],"domain_scores_gemma":[0.9976172,0.0002975372,0.00014094362,0.0009477702,0.00028840164,0.0007081338],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005926757,0.00044132525,0.00097127364,0.00031124032,0.00015472108,0.000047896923,0.00033096084,0.00024719027,0.006603171],"category_scores_gemma":[0.0002618247,0.00040209203,0.00023561301,0.0016167662,0.00022895695,0.000090178786,0.00041101567,0.00043416783,0.0002739035],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011915937,0.0002552616,0.011351358,0.0005917449,0.00023554558,0.00036446538,0.00060338643,0.00013625536,0.9356954,0.00012012693,0.030435275,0.019019559],"study_design_scores_gemma":[0.0077945637,0.0014940448,0.36202928,0.0006169765,0.00025587578,0.00015369407,0.0013548358,0.003110599,0.51187485,0.000363583,0.109874845,0.0010768666],"about_ca_topic_score_codex":0.00017853668,"about_ca_topic_score_gemma":0.00013823605,"teacher_disagreement_score":0.42382059,"about_ca_system_score_codex":0.00012226717,"about_ca_system_score_gemma":0.00016844834,"threshold_uncertainty_score":0.9998431},"labels":[],"label_agreement":null},{"id":"W4385667297","doi":"10.1097/01.hs9.0000968132.86513.06","title":"S305: PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF RECOMBINANT ADAMTS13 IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital; Western University","funders":"","keywords":"Medicine; ADAMTS13; Thrombotic thrombocytopenic purpura; Placebo; Internal medicine; Gastroenterology; Clinical endpoint; Adverse effect; Thrombotic microangiopathy; Randomized controlled trial; Platelet; Disease; Pathology","score_opus":0.024403662248074116,"score_gpt":0.29099441286025657,"score_spread":0.26659075061218246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98597383,0.0007456191,0.0000056689883,0.00005095654,0.0009708833,0.011762512,0.00003890692,0.00015268526,0.000298908],"genre_scores_gemma":[0.9969299,0.000025879719,0.000010694121,0.000016742746,0.000011705219,0.0014523073,0.000525785,0.000057637117,0.000969362],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960581,0.000969978,0.0014926356,0.0006048239,0.00020099155,0.0006734399],"domain_scores_gemma":[0.99738353,0.00095511694,0.0006468707,0.00076442887,0.00019955423,0.000050497674],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008852269,0.00045627457,0.0021963257,0.00025297192,0.00014617143,0.000026486681,0.0004755413,0.00017127964,0.0027580787],"category_scores_gemma":[0.00017720011,0.00032448518,0.00026078295,0.00063527666,0.00020525044,0.00018985783,0.00024416187,0.00030893917,0.0008091716],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91090655,0.009628217,0.07249175,0.00015160491,0.0020857349,0.000033798246,0.002116231,0.00009953657,0.00090607745,0.000054749642,0.0013029961,0.00022272595],"study_design_scores_gemma":[0.9676386,0.0014071402,0.02461364,0.00029451188,0.00044771744,0.0000018053016,0.0046838075,0.0000704804,0.00038088628,0.000016689748,0.0000818635,0.0003628713],"about_ca_topic_score_codex":0.00045795125,"about_ca_topic_score_gemma":0.0005707,"teacher_disagreement_score":0.056732006,"about_ca_system_score_codex":0.000097319746,"about_ca_system_score_gemma":0.000101040525,"threshold_uncertainty_score":0.9999688},"labels":[],"label_agreement":null},{"id":"W4385667424","doi":"10.1097/01.hs9.0000969628.70235.a8","title":"P681: MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS OTHER TYROSINE KINASE INHIBITORS IN THIRD-OR-LATER LINE CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Bosutinib; Medicine; Dasatinib; Nilotinib; Ponatinib; Internal medicine; Oncology; Population; Myeloid leukemia; Imatinib","score_opus":0.05732872494174309,"score_gpt":0.3475958001907948,"score_spread":0.2902670752490517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98915523,0.0047163065,0.000019118419,0.00038162703,0.0008415937,0.0013338208,0.00007901888,0.00047185118,0.0030014378],"genre_scores_gemma":[0.9918282,0.00031283524,0.000448094,0.000090407506,0.00075012574,0.00013973878,0.0003563192,0.00019447124,0.005879806],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958542,0.00013632474,0.0012796243,0.00087305065,0.0008073415,0.0010494594],"domain_scores_gemma":[0.99773127,0.00035351512,0.00044021866,0.0010410444,0.00011256032,0.0003214081],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00041485653,0.0006712619,0.0014767796,0.00038415013,0.000112871356,0.000031018164,0.0003030099,0.0005064355,0.0026697894],"category_scores_gemma":[0.00017950228,0.00055663165,0.00028550337,0.0017047328,0.00021903723,0.00019294283,0.00023006367,0.00081078196,0.0007883055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04454716,0.009844407,0.073318765,0.014020315,0.0045117964,0.0072453367,0.022452328,0.02026852,0.3501832,0.00043865308,0.11887057,0.33429897],"study_design_scores_gemma":[0.20017536,0.015099511,0.020914774,0.008349274,0.0014050764,0.00016289402,0.0039425227,0.034711637,0.65737647,0.00010215312,0.05540026,0.0023600464],"about_ca_topic_score_codex":0.0009713293,"about_ca_topic_score_gemma":0.0049118786,"teacher_disagreement_score":0.33193892,"about_ca_system_score_codex":0.0065567493,"about_ca_system_score_gemma":0.0025459223,"threshold_uncertainty_score":0.9999897},"labels":[],"label_agreement":null},{"id":"W4385667566","doi":"10.1097/01.hs9.0000970804.07945.f9","title":"P975: THREE-DIMENSIONAL TELOMERE PROFILING PREDICTS RISK OF RELAPSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Genomics; University of Manitoba","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology; Disease; Regimen; Cancer","score_opus":0.022002173980866648,"score_gpt":0.27496340337460623,"score_spread":0.2529612293937396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996731,0.00030452802,0.0000075234993,0.00008980492,0.00013493876,0.0014809372,0.00018159447,0.00014867933,0.00092101935],"genre_scores_gemma":[0.99605125,0.000081002625,0.00249752,0.000028617618,0.000068080815,0.00017984388,0.0004280084,0.000056476336,0.0006091976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974404,0.00009859903,0.0005226408,0.00047971783,0.0008360634,0.0006225974],"domain_scores_gemma":[0.9982896,0.0005395237,0.0001657254,0.00047283663,0.00021214002,0.0003201939],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002747478,0.0002599546,0.0004949899,0.00020512313,0.00009482294,0.000009872074,0.00012772703,0.00017585055,0.0002891244],"category_scores_gemma":[0.0016697623,0.00021148742,0.0001557618,0.00085025653,0.000097593795,0.00011930579,0.00015441314,0.00037678052,0.00035970012],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010592127,0.00076938514,0.9775614,0.00024688724,0.00015798584,0.00052983535,0.0001500584,0.00020343615,0.0006220151,0.00001732035,0.0014766519,0.017205793],"study_design_scores_gemma":[0.014359891,0.0005510616,0.966392,0.0004540241,0.00005480767,0.000005922777,0.00013176903,0.011396321,0.006188388,0.00013677035,0.00016391414,0.00016517886],"about_ca_topic_score_codex":0.00071500096,"about_ca_topic_score_gemma":0.0009964942,"teacher_disagreement_score":0.017040614,"about_ca_system_score_codex":0.00012258209,"about_ca_system_score_gemma":0.00020306943,"threshold_uncertainty_score":0.8624207},"labels":[],"label_agreement":null},{"id":"W4385667600","doi":"10.1097/01.hs9.0000973232.36093.e7","title":"P1589: PATIENT (PT) AND PHYSICIAN (MD) PERCEPTIONS OF THE BURDEN OF IMMUNE THROMBOCYTOPENIA (ITP) AND ITS MANAGEMENT: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH) 2.0","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Disease Management Strategies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Immune thrombocytopenia; Quality of life (healthcare); Wish; Pediatrics; Family medicine; Internal medicine; Platelet","score_opus":0.034350664308736074,"score_gpt":0.30341095817431124,"score_spread":0.2690602938655752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97649616,0.0014902707,0.0000014303072,0.0012299073,0.00009044817,0.00095135084,0.0005384713,0.00004679086,0.019155188],"genre_scores_gemma":[0.9966357,0.0006282688,0.000020897241,0.0000850738,0.000075738244,0.000019951556,0.0002075868,0.000027970718,0.0022988303],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9984529,0.000142569,0.00044079198,0.00032519692,0.000385451,0.00025309398],"domain_scores_gemma":[0.9986423,0.0002635676,0.00023190188,0.00071472034,0.000077539684,0.00006995081],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031224705,0.00021035338,0.00041522807,0.000046972164,0.00013758129,0.000038227485,0.00021659896,0.000038996797,0.0003461394],"category_scores_gemma":[0.00008173106,0.00012528645,0.0001380421,0.00066814513,0.00020636157,0.000105781524,0.00045499238,0.000146101,0.000027610036],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059956005,0.0022645914,0.13512233,0.006231221,0.0109708505,0.00025921926,0.058053713,0.004304664,0.040137876,0.011238856,0.63785815,0.08756293],"study_design_scores_gemma":[0.0021965543,0.00011749972,0.98397285,0.0006906654,0.00036858735,0.0000010769734,0.009896666,0.0006850947,0.00038491763,0.00037511933,0.001165136,0.0001458484],"about_ca_topic_score_codex":0.0022430536,"about_ca_topic_score_gemma":0.0006874595,"teacher_disagreement_score":0.8488505,"about_ca_system_score_codex":0.000052202224,"about_ca_system_score_gemma":0.000053141077,"threshold_uncertainty_score":0.5109033},"labels":[],"label_agreement":null},{"id":"W4385667605","doi":"10.1097/01.hs9.0000970892.97539.5e","title":"P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Myeloproliferative neoplasm; Medicine; Kinome; Cancer research; Dasatinib; Internal medicine; Janus kinase 2; Immunology; Oncology; Pharmacology; Bone marrow; Kinase; Biology; Tyrosine kinase; Receptor","score_opus":0.050313681724031015,"score_gpt":0.3819137140479928,"score_spread":0.3316000323239618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98502207,0.00047480446,0.000015306101,0.0028438147,0.00026877093,0.0013251612,0.000058252695,0.00011816027,0.009873668],"genre_scores_gemma":[0.99430937,0.00053553836,0.0008003032,0.0007946595,0.00021100846,0.0003664155,0.000050592294,0.000032901884,0.002899203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980003,0.00020546542,0.00066816044,0.0005549612,0.00024297058,0.00032811824],"domain_scores_gemma":[0.99731123,0.0019463195,0.000100638405,0.00030089647,0.000083224666,0.00025768348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005209483,0.00022014133,0.00059551996,0.000064431726,0.00010599547,0.000028216466,0.000047718266,0.0002270173,0.0007904048],"category_scores_gemma":[0.00047261908,0.00017599811,0.00015967523,0.0003205487,0.00016472713,0.00005994138,0.00007038045,0.00039208116,0.0007539097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004885822,0.0008700236,0.96108574,0.00013489866,0.00017438238,0.0003362235,0.0008193752,0.000006166289,0.00017428758,0.0020167322,0.021221215,0.012672378],"study_design_scores_gemma":[0.005209832,0.0011483296,0.9759866,0.0003518993,0.00013566457,0.000017814806,0.00046808674,0.0009559827,0.0013991775,0.0006821728,0.013441211,0.00020325747],"about_ca_topic_score_codex":0.000049587532,"about_ca_topic_score_gemma":0.00019830068,"teacher_disagreement_score":0.014900836,"about_ca_system_score_codex":0.000047764748,"about_ca_system_score_gemma":0.00013077873,"threshold_uncertainty_score":0.9690235},"labels":[],"label_agreement":null},{"id":"W4385667614","doi":"10.1097/01.hs9.0000971072.43107.6c","title":"P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Anemia; Blood transfusion; Internal medicine; Bone marrow","score_opus":0.00935522102421016,"score_gpt":0.21967169838021455,"score_spread":0.2103164773560044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959582,0.00008230863,0.00009225664,0.0005307796,0.00003523604,0.002044872,0.00007080995,0.00016261834,0.0010229263],"genre_scores_gemma":[0.9960863,0.00030505273,0.000581565,0.000017964001,0.000052277366,0.00043660327,0.0005593578,0.00008569349,0.001875177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99647486,0.00010329173,0.0006760375,0.0011034596,0.0010207592,0.0006215774],"domain_scores_gemma":[0.99879175,0.00007678484,0.00016043244,0.0005093477,0.00020916159,0.00025254214],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023730715,0.0005502713,0.0010405831,0.0007083278,0.00013458064,0.000044108303,0.00011123443,0.00022726151,0.0010491692],"category_scores_gemma":[0.000012731252,0.0003977414,0.00019874527,0.0033669062,0.000062994724,0.00017587311,0.000028091663,0.00035009987,0.00007569513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041672587,0.0044851634,0.97557604,0.00014941323,0.00096512487,0.000370677,0.0013526987,0.0048447475,0.0068536093,0.000003827158,0.000048613725,0.0011828438],"study_design_scores_gemma":[0.02789403,0.0032884846,0.93790126,0.0005784603,0.002435642,0.000036169684,0.00075374555,0.0009810099,0.025601927,0.0000031938866,0.000020453132,0.00050564186],"about_ca_topic_score_codex":0.0017568849,"about_ca_topic_score_gemma":0.0031560776,"teacher_disagreement_score":0.03767478,"about_ca_system_score_codex":0.000297332,"about_ca_system_score_gemma":0.00013500443,"threshold_uncertainty_score":0.999864},"labels":[],"label_agreement":null},{"id":"W4385667651","doi":"10.1097/01.hs9.0000971208.36694.eb","title":"P1078: MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Refractory (planetary science); Clinical endpoint; Phases of clinical research; Surrogate endpoint; Lymphoma; Clinical trial; Oncology; Surgery; Gastroenterology","score_opus":0.021690606153916586,"score_gpt":0.3096533414890721,"score_spread":0.2879627353351555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711835,0.00034232216,0.0000034091645,0.00012492371,0.000019143063,0.0018577406,0.00005783144,0.00010430349,0.00037196174],"genre_scores_gemma":[0.9850062,0.00017422931,0.00013759002,0.0000380801,0.000015268002,0.00012166351,0.0001800716,0.00007004258,0.014256831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969408,0.0003981643,0.000635825,0.0006484773,0.000859876,0.00051684043],"domain_scores_gemma":[0.998161,0.0003561858,0.0002159828,0.00075074076,0.0003162814,0.0001997987],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006630454,0.0003369322,0.001075051,0.0006581812,0.0001659041,0.000035170917,0.0001682052,0.00016632889,0.0022365104],"category_scores_gemma":[0.00023444142,0.00024248491,0.00015182182,0.003274766,0.00019884815,0.00015995574,0.00009885259,0.00024158944,0.000007640129],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.080064066,0.008628425,0.8345962,0.00014290381,0.0066662384,0.0008177492,0.011585189,0.00006771899,0.021806011,0.000003241059,0.00063385157,0.034988366],"study_design_scores_gemma":[0.05463182,0.019620892,0.89818454,0.00032562145,0.0013077129,0.000009530123,0.017311921,0.0035800356,0.0036026565,0.000008475543,0.0009788119,0.00043797825],"about_ca_topic_score_codex":0.0005454008,"about_ca_topic_score_gemma":0.0012211355,"teacher_disagreement_score":0.06358831,"about_ca_system_score_codex":0.00020732572,"about_ca_system_score_gemma":0.00037119508,"threshold_uncertainty_score":0.9986756},"labels":[],"label_agreement":null},{"id":"W4385667659","doi":"10.1097/01.hs9.0000972428.19857.ae","title":"P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Medicine; Oncology; Chimeric antigen receptor; Internal medicine; Immunotherapy; Immunology; Cytokine; Immune system","score_opus":0.04156970555081718,"score_gpt":0.32604922160139255,"score_spread":0.28447951605057537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98632574,0.0050208527,0.000095416966,0.0012964002,0.00010421813,0.0009147277,0.0003237053,0.0002512426,0.005667684],"genre_scores_gemma":[0.9655217,0.0017213211,0.0006285492,0.0002241179,0.00061250804,0.000068228575,0.00024402716,0.00015449249,0.030825088],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99672335,0.00018945057,0.00062397507,0.00074943394,0.00088383135,0.0008299563],"domain_scores_gemma":[0.997607,0.0006709027,0.00018448617,0.00087079155,0.00023770891,0.00042912303],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063742325,0.000495612,0.0010130125,0.0002064024,0.00017491098,0.00004954295,0.00034270066,0.00028822714,0.0049899626],"category_scores_gemma":[0.00012778277,0.0004203563,0.00028554097,0.00095665816,0.00042233907,0.00010197161,0.00025333496,0.000632237,0.00011058323],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004924454,0.00019825621,0.06786856,0.00078729703,0.0004004277,0.00023403771,0.0008432514,0.00003473311,0.9112409,0.00004502271,0.006858112,0.010996971],"study_design_scores_gemma":[0.0077323117,0.0014388228,0.17378113,0.00038043523,0.00038786646,0.000028475437,0.0025857766,0.0006901717,0.76726043,0.00054531527,0.044311166,0.00085810135],"about_ca_topic_score_codex":0.0002679382,"about_ca_topic_score_gemma":0.000085448635,"teacher_disagreement_score":0.14398046,"about_ca_system_score_codex":0.00009310389,"about_ca_system_score_gemma":0.00019921869,"threshold_uncertainty_score":0.9998248},"labels":[],"label_agreement":null},{"id":"W4385667677","doi":"10.1097/01.hs9.0000970376.71405.63","title":"P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE-EXPANSION PHASE OF THE CC-92480-MM-001 TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Pomalidomide; Lenalidomide; Internal medicine; Tolerability; Multiple myeloma; Daratumumab; Dexamethasone; Oncology; Gastroenterology; Adverse effect","score_opus":0.019468430145642306,"score_gpt":0.2564835981051531,"score_spread":0.23701516795951078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970349,0.00024932047,0.00003717099,0.00031015647,0.00043756532,0.0010921479,0.00023478772,0.000031137428,0.00057281036],"genre_scores_gemma":[0.9967105,0.00006906422,0.0002650415,0.00020134167,0.00026791118,0.00007761089,0.00081322895,0.000042647203,0.0015526611],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99788654,0.00030925949,0.0005564922,0.00051469693,0.0004195702,0.00031347037],"domain_scores_gemma":[0.9983398,0.00019592814,0.00035176988,0.00091721513,0.00011577067,0.00007954082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000426081,0.00025250987,0.00028186012,0.000031186857,0.00014044398,0.000023138593,0.0004194197,0.00025662966,0.000046076562],"category_scores_gemma":[0.0009591094,0.0001490583,0.00013389085,0.0004036704,0.00016275054,0.000015823045,0.0002142477,0.00027016504,0.000029382092],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2927387,0.011179143,0.015599899,0.00012144371,0.00059872644,0.000044993518,0.003330018,0.0009753309,0.4426603,0.00007939981,0.14550626,0.08716579],"study_design_scores_gemma":[0.49193645,0.002724742,0.013377295,0.00029901494,0.0000754597,0.0000020384907,0.00093542796,0.0007209449,0.40130287,0.000067573215,0.08791961,0.00063856423],"about_ca_topic_score_codex":0.00048227148,"about_ca_topic_score_gemma":0.0009795403,"teacher_disagreement_score":0.19919775,"about_ca_system_score_codex":0.00006177396,"about_ca_system_score_gemma":0.00024438126,"threshold_uncertainty_score":0.6078421},"labels":[],"label_agreement":null},{"id":"W4385667722","doi":"10.1097/01.hs9.0000968360.32403.e2","title":"P362: OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING HEMATOPOIETIC CELL TRANSPLANTATION USING REAL-WORLD DATA FROM HARMONY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Hematopoietic cell; Transplantation; Internal medicine; Lymphoblastic Leukemia; Pediatrics; Leukemia; Stem cell; Haematopoiesis","score_opus":0.0433941005268015,"score_gpt":0.3125400517115001,"score_spread":0.26914595118469864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99656314,0.000026935119,0.0005285688,0.0001688505,0.00016352133,0.0008766297,0.0004863589,0.000278378,0.00090759824],"genre_scores_gemma":[0.9873485,0.00024264326,0.005502816,0.0002077732,0.00009921516,0.00003890324,0.0027869556,0.00018118566,0.0035920306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961528,0.00014734024,0.00072110567,0.0009969672,0.0011661873,0.00081559626],"domain_scores_gemma":[0.9967737,0.0010883547,0.0002603248,0.0014292536,0.00014038428,0.00030795712],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032717272,0.00044878194,0.0008534389,0.00034422928,0.00013840396,0.000062179184,0.0005190787,0.00018457833,0.0005196619],"category_scores_gemma":[0.00021077563,0.00033299686,0.00007238897,0.0016274031,0.00015313306,0.00047075006,0.0002326543,0.0004785915,0.00030297966],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008383909,0.0005867945,0.96900743,0.0010307084,0.00049374334,0.0035788945,0.0016722744,0.00045008413,0.0036067895,0.000008323552,0.009721731,0.001459314],"study_design_scores_gemma":[0.022021344,0.0006016519,0.9496668,0.001814036,0.00078162266,0.000036561003,0.0005936375,0.022012921,0.0014860673,0.00003551724,0.00028064524,0.0006691846],"about_ca_topic_score_codex":0.0036488343,"about_ca_topic_score_gemma":0.003355383,"teacher_disagreement_score":0.021562837,"about_ca_system_score_codex":0.0023133957,"about_ca_system_score_gemma":0.0016795279,"threshold_uncertainty_score":0.9999122},"labels":[],"label_agreement":null},{"id":"W4385667785","doi":"10.1097/01.hs9.0000969412.43267.61","title":"P627: LONG-TERM OUTCOMES WITH CONTINUOUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: ANALYSIS OF TIME TO PROGRESSION","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Medicine; Internal medicine; Oncology; Progression-free survival; Chronic lymphocytic leukemia; Population; Bruton's tyrosine kinase; Chemotherapy; Leukemia; Tyrosine kinase","score_opus":0.011910645621016498,"score_gpt":0.2973486943511449,"score_spread":0.2854380487301284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969104,0.00013036854,0.00002447782,0.00007803714,0.000022538246,0.0015061729,0.00001950593,0.00015851953,0.0011499698],"genre_scores_gemma":[0.9928141,0.000012454977,0.0002500723,0.00007589927,0.00003120785,0.00012601832,0.00023213077,0.00007461706,0.0063834595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967386,0.00007822309,0.0005359947,0.00063105643,0.0012335283,0.0007825781],"domain_scores_gemma":[0.9981354,0.00023397934,0.00018084895,0.00087517075,0.00026129975,0.0003133147],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032248578,0.00033756113,0.0011719433,0.0005768821,0.00006057632,0.000025414265,0.0002451136,0.00016896972,0.0012413019],"category_scores_gemma":[0.00014749744,0.00021987753,0.00015605577,0.0041098176,0.00016767293,0.00009969249,0.0001799335,0.00024701556,0.0005755619],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0021915566,0.0001771234,0.9836484,0.000578662,0.0013850647,0.00061158254,0.00035843038,0.0038122453,0.00013435617,0.0000046696473,0.00066877087,0.006429142],"study_design_scores_gemma":[0.03545636,0.0021581522,0.9473085,0.0012943766,0.00095135893,0.000017052545,0.000066970664,0.011255695,0.0010625741,0.0000011957052,0.000091497444,0.00033628521],"about_ca_topic_score_codex":0.00047763277,"about_ca_topic_score_gemma":0.00059497176,"teacher_disagreement_score":0.036339916,"about_ca_system_score_codex":0.030606331,"about_ca_system_score_gemma":0.0111646075,"threshold_uncertainty_score":0.9996717},"labels":[],"label_agreement":null},{"id":"W4385697375","doi":"10.1097/01.hs9.0000970688.75458.a8","title":"P946: TOCILIZUMAB PRE-TREATMENT SIGNIFICANTLY REDUCES THE INCIDENCE OF CYTOKINE RELEASE SYNDROME IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVE CEVOSTAMAB","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; McGill University; University of Toronto; Jewish General Hospital; Institute of Cancer Research","funders":"","keywords":"Medicine; Tocilizumab; Internal medicine; Multiple myeloma; Cytokine release syndrome; Incidence (geometry); Refractory (planetary science); Gastroenterology; Immunotherapy; Chimeric antigen receptor; Rheumatoid arthritis; Cancer","score_opus":0.0166835084563772,"score_gpt":0.2672355611624662,"score_spread":0.25055205270608905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955505,0.0003695276,0.0000031871791,0.00037788527,0.000064654465,0.0025855992,0.00018029021,0.000115911644,0.00075241097],"genre_scores_gemma":[0.99553573,0.00025220402,0.00029839875,0.000030892006,0.0000352496,0.00039362305,0.000264826,0.000068163674,0.0031209127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968769,0.0002009176,0.00056198833,0.00064848736,0.0010045232,0.0007071741],"domain_scores_gemma":[0.9977109,0.0005651791,0.00024714976,0.0008813705,0.00028139932,0.00031399867],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021705434,0.0004046474,0.00068364304,0.00017779,0.0001546689,0.000024009574,0.00024841353,0.00015605708,0.0002652045],"category_scores_gemma":[0.0005169633,0.0002414689,0.0001409625,0.0010344437,0.00024995164,0.00019975573,0.00010943449,0.00033091314,0.0001520325],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012263175,0.0028266995,0.9154882,0.00035231007,0.00065813476,0.002431333,0.0023370404,0.00017376317,0.0021568951,0.000020255828,0.0012738018,0.060018413],"study_design_scores_gemma":[0.014364492,0.005440374,0.9648847,0.0008661529,0.000105362116,0.000037793016,0.0008801854,0.00040831452,0.012184744,0.000030422287,0.000549207,0.00024826857],"about_ca_topic_score_codex":0.0011979813,"about_ca_topic_score_gemma":0.0008057551,"teacher_disagreement_score":0.059770145,"about_ca_system_score_codex":0.0005508354,"about_ca_system_score_gemma":0.0004025091,"threshold_uncertainty_score":0.98468155},"labels":[],"label_agreement":null},{"id":"W4385697599","doi":"10.1097/01.hs9.0000977076.25234.7f","title":"PB2596: OPTIMIZING PLATELET TRANSFUSION FOR CLINICAL PRACTICE. DO PLATELETS AGE MATTER FOR THERAPEUTIC PLATELETS TRANSFUSION?","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Blood transfusion and management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Platelet; Platelet transfusion; Epinephrine; Medicine; Transfusion medicine; Adenosine diphosphate; Blood transfusion; Platelet aggregation; Chemistry; Immunology; Internal medicine","score_opus":0.0662538977394633,"score_gpt":0.37862377868737435,"score_spread":0.31236988094791107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73345965,0.0043281307,0.12352324,0.07116666,0.0051476727,0.027368542,0.0002973256,0.002504123,0.032204676],"genre_scores_gemma":[0.7545948,0.054497298,0.117121,0.042099528,0.002885338,0.0047774306,0.0015554624,0.0011428739,0.021326292],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964145,0.000107032174,0.0011118322,0.0009981549,0.00048031862,0.00088817126],"domain_scores_gemma":[0.99753046,0.0011102601,0.00016378058,0.0006410501,0.00019624052,0.00035819144],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013245705,0.0005090355,0.0009612781,0.00017250626,0.00037117553,0.00009703871,0.00023916317,0.00048641616,0.001521483],"category_scores_gemma":[0.00009667187,0.00042133892,0.0007940303,0.0004775366,0.00010016431,0.00024444584,0.000042877356,0.00050554355,0.00040945382],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020576905,0.0041979873,0.0014156522,0.005383692,0.0028676572,0.0030037812,0.0067746653,0.00033165244,0.025781514,0.005396898,0.32075676,0.6035128],"study_design_scores_gemma":[0.021584949,0.0015862155,0.0016106453,0.0005104954,0.0011456108,0.00028442734,0.0027934911,0.0013426227,0.004694528,0.00078125705,0.96290505,0.0007606878],"about_ca_topic_score_codex":0.000024149651,"about_ca_topic_score_gemma":0.00003773901,"teacher_disagreement_score":0.6421483,"about_ca_system_score_codex":0.00004942032,"about_ca_system_score_gemma":0.0000983923,"threshold_uncertainty_score":0.99982387},"labels":[],"label_agreement":null},{"id":"W4385697656","doi":"10.1097/01.hs9.0000970368.33859.48","title":"P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Regimen; Oncology; Multiple myeloma; Lenalidomide; Hazard ratio; Confidence interval","score_opus":0.016896486216187306,"score_gpt":0.26855701842140345,"score_spread":0.2516605322052161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958765,0.0012292167,0.000036543963,0.0004159469,0.00007018007,0.0016349669,0.00014203743,0.00015319459,0.00044142836],"genre_scores_gemma":[0.9875108,0.00090287067,0.0006055094,0.00015857763,0.00006361768,0.00008553994,0.00037409688,0.00013278522,0.010166226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607325,0.00024634262,0.0008402903,0.00082118437,0.0013125329,0.0007063844],"domain_scores_gemma":[0.99742246,0.0004814112,0.00032869854,0.00097374426,0.00045669515,0.00033700845],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007892984,0.00044378664,0.0012456762,0.00052249443,0.00011482201,0.000040046463,0.00022872574,0.00028851358,0.0014729102],"category_scores_gemma":[0.0002582061,0.00035578286,0.00024398464,0.0029497417,0.00024110453,0.00017233749,0.000100600475,0.0004910164,0.00002028185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020783672,0.0007819139,0.73491275,0.00022814,0.0012983654,0.000106143256,0.0014076725,0.000025634057,0.21078338,0.000003804793,0.005611556,0.024056938],"study_design_scores_gemma":[0.050439633,0.005448932,0.79455054,0.0003433772,0.00042874124,0.0000049299133,0.0010813816,0.00097095186,0.12102409,0.00002266619,0.024957662,0.0007270874],"about_ca_topic_score_codex":0.00025106908,"about_ca_topic_score_gemma":0.0006712973,"teacher_disagreement_score":0.0897593,"about_ca_system_score_codex":0.0002587707,"about_ca_system_score_gemma":0.00023766466,"threshold_uncertainty_score":0.99988943},"labels":[],"label_agreement":null},{"id":"W4385697662","doi":"10.1097/01.hs9.0000977500.02308.e3","title":"PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Clinical trial; Medical physics; Internal medicine; Oncology; Intensive care medicine","score_opus":0.08775879929521231,"score_gpt":0.3152991802851121,"score_spread":0.22754038098989982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96421957,0.0011427532,0.000737001,0.0009296959,0.0011670899,0.00041685477,0.0004996928,0.0001257134,0.030761648],"genre_scores_gemma":[0.98810506,0.0008325036,0.0030224805,0.00038491242,0.00033802105,0.00007414511,0.000063771215,0.000048533926,0.0071305586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748796,0.000011421788,0.0013676904,0.00056268566,0.00005245991,0.00051779265],"domain_scores_gemma":[0.99839854,0.00028641103,0.00061945134,0.0004286508,0.000104802035,0.00016215],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00092251884,0.00022330417,0.0010792089,0.000104913495,0.00013308981,0.00003612435,0.00035108195,0.00036465906,0.0011521914],"category_scores_gemma":[0.00046378636,0.00023924478,0.00046863672,0.00027712333,0.00019377714,0.0002592064,0.00013454122,0.00017757909,0.001723089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034170158,0.00031034136,0.6413049,0.00038218076,0.00012919065,0.00001772522,0.0003327561,0.00029397532,0.0000444969,0.26047674,0.09049966,0.0058663297],"study_design_scores_gemma":[0.003536163,0.00067289575,0.46555978,0.00016580411,0.000042244177,0.00001095193,0.00049217243,0.0020367312,0.0013874855,0.13367784,0.39157298,0.00084493763],"about_ca_topic_score_codex":0.00014908747,"about_ca_topic_score_gemma":0.000097616554,"teacher_disagreement_score":0.30107334,"about_ca_system_score_codex":0.00005104751,"about_ca_system_score_gemma":0.00005443401,"threshold_uncertainty_score":0.99976087},"labels":[],"label_agreement":null},{"id":"W4385697716","doi":"10.1097/01.hs9.0000976796.54495.8a","title":"PB2524: TRIAL IN PROGRESS: THE HIBISCUS-KIDS STUDY, A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF ETAVOPIVAT IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Tolerability; Anemia; Sickle cell anemia; Hemolytic anemia; Hemolysis; Adverse effect; Pharmacokinetics; Vaso-occlusive crisis; Disease; Internal medicine; Pharmacology; Gastroenterology","score_opus":0.03078124962771077,"score_gpt":0.3320431455114856,"score_spread":0.30126189588377483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98450655,0.00081026513,0.000001049888,0.0013709186,0.00014018592,0.012814526,0.000019700208,0.000032564985,0.0003042518],"genre_scores_gemma":[0.99896127,0.00016687081,0.000024444458,0.00015287893,0.000063265885,0.00033648097,0.000017318262,0.000044422253,0.00023303452],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974756,0.0004010984,0.0006080614,0.000449692,0.00067145564,0.0003940469],"domain_scores_gemma":[0.9988649,0.00018684028,0.00012600384,0.0004947009,0.00012695428,0.00020058465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094668,0.0002702236,0.00046598882,0.000109554014,0.00012316248,0.00004801746,0.00031639385,0.00005002695,0.00006412152],"category_scores_gemma":[0.00016821292,0.00013481698,0.000033022636,0.0016803634,0.00010649131,0.00007710219,0.00038522613,0.00036089926,0.000013535531],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0983588,0.08721292,0.77813023,0.00030034376,0.00015559503,0.0002867234,0.01731551,0.0003122361,0.000032494863,0.000005415737,0.001990794,0.015898958],"study_design_scores_gemma":[0.68883836,0.03795209,0.23631124,0.0002976208,0.0016432543,0.000001594357,0.03221796,0.0010911325,0.00005052979,0.00003302243,0.0010246148,0.00053856656],"about_ca_topic_score_codex":0.00006709152,"about_ca_topic_score_gemma":0.00014133635,"teacher_disagreement_score":0.59047955,"about_ca_system_score_codex":0.00005508728,"about_ca_system_score_gemma":0.00020232161,"threshold_uncertainty_score":0.5497677},"labels":[],"label_agreement":null},{"id":"W4385697895","doi":"10.1097/01.hs9.0000973532.28562.11","title":"P1665: USE OF DOACS IN THE MANAGEMENT OF UPPER EXTREMITY DEEP VENOUS THROMBOSIS; A SYSTEMATIC REVIEW","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Rivaroxaban; Apixaban; Edoxaban; Internal medicine; Venous thrombosis; Randomized controlled trial; Clinical trial; Relative risk; Thrombosis; Retrospective cohort study; MEDLINE; Meta-analysis; Cohort study; Intensive care medicine; Surgery; Warfarin; Confidence interval; Atrial fibrillation","score_opus":0.1280275703078243,"score_gpt":0.37147829852940983,"score_spread":0.24345072822158553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697895","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018231838,0.98678267,0.000015704481,0.0000952013,0.00012517006,0.0107416175,0.000026283065,0.000045738554,0.0021493966],"genre_scores_gemma":[0.000031735388,0.9968051,0.0004295744,0.00032096496,0.00003775277,0.0016400168,0.000067928515,0.00010317224,0.0005638109],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.995539,0.00046607768,0.0021999842,0.0005196092,0.0008574734,0.00041787198],"domain_scores_gemma":[0.99635273,0.00042841746,0.0011871458,0.0018544059,0.00010133123,0.00007597755],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013504724,0.00056117476,0.0069908914,0.0001541457,0.000041638923,0.00002106743,0.00057520356,0.00021812839,0.00023589375],"category_scores_gemma":[0.0001365525,0.00033417594,0.0011260976,0.0012160088,0.0000829521,0.0000647328,0.00027860518,0.0003695909,0.00014919657],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000001984755,0.0008956564,0.000008328996,0.972067,0.0019133248,0.00013405293,0.00018628703,8.9987793e-7,3.5799292e-8,0.0015924639,0.0032998659,0.019900117],"study_design_scores_gemma":[0.00021600285,0.000109820496,0.00016806973,0.87285143,0.022652006,0.00003332229,0.0003518867,0.0000029425837,1.8339344e-7,0.000028966015,0.103343025,0.00024232917],"about_ca_topic_score_codex":0.00010051287,"about_ca_topic_score_gemma":0.000036848072,"teacher_disagreement_score":0.100043155,"about_ca_system_score_codex":0.00016113721,"about_ca_system_score_gemma":0.00009727119,"threshold_uncertainty_score":0.999911},"labels":[],"label_agreement":null},{"id":"W4385697974","doi":"10.1097/01.hs9.0000976792.25698.9f","title":"PB2523: DI-2-ETHYLHEXYL PHTHALATE (DEHP) INHIBITS HEMOGLOBIN S POLYMERIZATION","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Phthalate; Polymerization; Chemistry; Hemoglobin; Valine; Buffy coat; Plasticizer; Phlebotomy; Food science; Biochemistry; Medicine; Surgery; Polymer; Organic chemistry; Amino acid","score_opus":0.01348634383864467,"score_gpt":0.25899750011339767,"score_spread":0.245511156274753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9399062,0.0014998374,0.00014113067,0.0038183564,0.0004914188,0.00051830144,0.000013599116,0.0008352347,0.052775957],"genre_scores_gemma":[0.97562945,0.00063877687,0.00014742152,0.0006658538,0.00018842045,0.000028411945,0.00020066492,0.000082714585,0.022418309],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982094,0.00004135905,0.00037171214,0.0004248253,0.00039323,0.0005594394],"domain_scores_gemma":[0.99911004,0.000041619533,0.00009380153,0.00040758224,0.000081408536,0.0002655388],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00015238425,0.00026579006,0.00036496005,0.000114147755,0.00016820231,0.000030668994,0.00010038297,0.00031481293,0.0011449415],"category_scores_gemma":[0.00010450959,0.00022918807,0.0001684205,0.001291623,0.00009283584,0.000120649864,0.00008661511,0.0003254673,0.0020263046],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097148295,0.0014284467,0.1014371,0.0022769952,0.00091529434,0.0030536614,0.0053490684,0.0013284105,0.4718342,0.005644652,0.14471512,0.26104558],"study_design_scores_gemma":[0.02685647,0.0024023198,0.13307123,0.0038544636,0.0012146613,0.002414751,0.013032028,0.024685405,0.47460726,0.0029635362,0.31075177,0.0041461056],"about_ca_topic_score_codex":0.00005996005,"about_ca_topic_score_gemma":0.000007318341,"teacher_disagreement_score":0.25689948,"about_ca_system_score_codex":0.000059720023,"about_ca_system_score_gemma":0.00013164757,"threshold_uncertainty_score":0.99976814},"labels":[],"label_agreement":null},{"id":"W4385697985","doi":"10.1097/01.hs9.0000974984.02232.24","title":"PB2045: USE OF ANAKINRA IN THE TREATMENT OF ADULT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SYSTEMATIC REVIEW","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; McMaster University","funders":"","keywords":"Anakinra; Hemophagocytic lymphohistiocytosis; Medicine; Macrophage activation syndrome; Pediatrics; Retrospective cohort study; Internal medicine; Cytokine storm; Primary immunodeficiency; Immunology; Immune system","score_opus":0.12310567898537979,"score_gpt":0.38720029081714685,"score_spread":0.2640946118317671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697985","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000547065,0.9922697,0.0000011814476,0.000042631007,0.000035092286,0.0071885353,0.00004123262,0.000029767634,0.0003371586],"genre_scores_gemma":[0.000024512789,0.9957717,0.000032980897,0.00008160676,0.000024049094,0.0017250576,0.000096638534,0.000078170786,0.0021652998],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99568105,0.0005830439,0.0023442735,0.00035193202,0.00070284127,0.0003368721],"domain_scores_gemma":[0.99665153,0.0006189225,0.0009921537,0.0014564263,0.00021763779,0.000063354004],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045665982,0.0004699595,0.0059873713,0.00018854215,0.000033226297,0.000012783185,0.0003389248,0.0002488224,0.00014285887],"category_scores_gemma":[0.00082285993,0.0002508569,0.0011632394,0.0012891969,0.000120575736,0.000056467557,0.00004132337,0.00020458452,0.00018929376],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013252305,0.00038972095,0.000007868367,0.95511776,0.00052439154,0.00013735014,0.0002109159,2.1207217e-7,2.1573616e-7,0.00010477192,0.00069500424,0.042798508],"study_design_scores_gemma":[0.0006520996,0.00045208514,0.000005448927,0.86569417,0.0048136776,0.00011973777,0.0002789296,0.000015626394,0.0000026003195,0.0000037491604,0.12778799,0.00017388983],"about_ca_topic_score_codex":0.00019659096,"about_ca_topic_score_gemma":0.000038448066,"teacher_disagreement_score":0.12709299,"about_ca_system_score_codex":0.00039154149,"about_ca_system_score_gemma":0.00096995407,"threshold_uncertainty_score":0.99999434},"labels":[],"label_agreement":null},{"id":"W4385698049","doi":"10.1097/01.hs9.0000970532.16622.f0","title":"P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Discontinuation; Multiple myeloma; Refractory (planetary science); Lenalidomide; Oncology; Cohort; Surgery; Gastroenterology","score_opus":0.009288876697198186,"score_gpt":0.24197565072692845,"score_spread":0.23268677402973026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385698049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976119,0.00051428756,0.00003439896,0.00008240326,0.000029298393,0.00078666396,0.0005432122,0.00009059201,0.00030726494],"genre_scores_gemma":[0.99594516,0.0004938379,0.0015376621,0.000016985923,0.000028814438,0.000044039614,0.001435454,0.00004616555,0.00045189218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99790674,0.00013032563,0.00041919557,0.00053332077,0.00057797786,0.00043244803],"domain_scores_gemma":[0.9983556,0.0005709111,0.00015755503,0.0005479992,0.00009003988,0.00027788992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013717574,0.0002525139,0.00069104636,0.00032057497,0.0000761159,0.000015783267,0.00010600038,0.0001401551,0.0007836631],"category_scores_gemma":[0.00026486625,0.00019081337,0.00010401038,0.0016000683,0.0001226198,0.00012962813,0.000104540006,0.0002938635,0.00007299202],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004229281,0.0007544457,0.9677392,0.00008185288,0.0010473003,0.00023496946,0.0002920104,0.00005107536,0.00010466179,0.000009339447,0.00020237915,0.025253482],"study_design_scores_gemma":[0.028468985,0.0007725245,0.9680615,0.00014466081,0.0006140922,8.039967e-7,0.00018908837,0.0010216064,0.00022958212,0.000023688846,0.00030823544,0.0001652524],"about_ca_topic_score_codex":0.0042753066,"about_ca_topic_score_gemma":0.0029332773,"teacher_disagreement_score":0.02508823,"about_ca_system_score_codex":0.00007723496,"about_ca_system_score_gemma":0.00007208542,"threshold_uncertainty_score":0.8580562},"labels":[],"label_agreement":null},{"id":"W4385698344","doi":"10.1097/01.hs9.0000971164.88567.72","title":"P1067: ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Refractory (planetary science); Medicine; Internal medicine; Oncology; Lymphoma; Phases of clinical research; Clinical trial; Immunotherapy; Cancer","score_opus":0.014650674941796147,"score_gpt":0.2512173056998726,"score_spread":0.23656663075807646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385698344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693567,0.000054883974,0.000046787387,0.000606185,0.000037880458,0.00096547726,0.0000066290067,0.000051687453,0.0012947753],"genre_scores_gemma":[0.9981614,0.0000039479937,0.001366586,0.000052351617,0.000017728493,0.00012272636,0.0000859376,0.00003493659,0.00015438502],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844736,0.00010335668,0.00034736848,0.0003089536,0.0005114019,0.0002815696],"domain_scores_gemma":[0.9988084,0.0005247335,0.00018648258,0.00031783571,0.00009544919,0.00006709748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014702881,0.0002100876,0.00041321025,0.000104830935,0.00005486384,0.000014593965,0.000084843625,0.000096050026,0.000051336705],"category_scores_gemma":[0.00013317756,0.00012014368,0.000055596196,0.00056261016,0.00011352885,0.00013802356,0.000043142827,0.00013051253,0.00003122265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016833408,0.0031807537,0.9732407,0.00008476531,0.000110367895,0.00012079759,0.0030918352,0.00023434279,0.000011857465,0.0006399844,0.00022431846,0.017376952],"study_design_scores_gemma":[0.03698033,0.0015755619,0.957252,0.0007958818,0.00008066595,0.0000054245415,0.00035039545,0.0023988995,0.00018708337,0.00016536575,0.00007677887,0.00013156235],"about_ca_topic_score_codex":0.00019537013,"about_ca_topic_score_gemma":0.00022886915,"teacher_disagreement_score":0.035296988,"about_ca_system_score_codex":0.0004176003,"about_ca_system_score_gemma":0.00019110745,"threshold_uncertainty_score":0.48993173},"labels":[],"label_agreement":null},{"id":"W4385698349","doi":"10.1097/01.hs9.0000970456.81043.cc","title":"P888: MATCHED-ADJUSTED INDIRECT COMPARISON OF TALQUETAMAB VS SELINEXOR-DEXAMETHASONE AND VS BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Refractory (planetary science); Medicine; Internal medicine; Cohort; Dexamethasone; Oncology; Multiple myeloma; Lenalidomide; Gastroenterology","score_opus":0.031120390621193254,"score_gpt":0.29201849263677154,"score_spread":0.2608981020155783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385698349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972405,0.00060758466,0.000013489831,0.00014267625,0.000055763834,0.0012869227,0.00010602911,0.00015883823,0.000388207],"genre_scores_gemma":[0.9964465,0.00009438125,0.0018896238,0.000040867802,0.00003744915,0.00011976454,0.00045428288,0.0000825207,0.0008346394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972353,0.00016132827,0.0005999523,0.00056764565,0.0007847112,0.0006510679],"domain_scores_gemma":[0.998345,0.00041726974,0.00022170029,0.0004964657,0.00018477252,0.0003347488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002755146,0.00036863363,0.0010447894,0.00028404492,0.00007336807,0.000019744217,0.00012153071,0.00023473531,0.0003064231],"category_scores_gemma":[0.00033899513,0.00028776893,0.00008585954,0.00094233727,0.00016265568,0.00014074522,0.00013578091,0.00049264857,0.00012840156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0083406605,0.001339218,0.97318465,0.00054555584,0.00025207383,0.00026063976,0.00080422184,0.00001650717,0.00056376006,0.0000036534905,0.00060431974,0.014084747],"study_design_scores_gemma":[0.019996306,0.0018238071,0.96949047,0.000586449,0.00010434824,0.000011103011,0.00068309775,0.0015813713,0.0051100687,0.00000784304,0.0003484254,0.00025670923],"about_ca_topic_score_codex":0.00043687585,"about_ca_topic_score_gemma":0.0006631769,"teacher_disagreement_score":0.013828038,"about_ca_system_score_codex":0.00014401056,"about_ca_system_score_gemma":0.00013451163,"threshold_uncertainty_score":0.99995744},"labels":[],"label_agreement":null},{"id":"W4385698393","doi":"10.1097/01.hs9.0000977272.39179.7d","title":"PB2647: USE OF EMICIZUMAB FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A: A SYSTEMATIC REVIEW","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Bleed; Cochrane Library; Internal medicine; Pediatrics; Systematic review; Surgery; MEDLINE; Meta-analysis","score_opus":0.22911928166151782,"score_gpt":0.42180933272901006,"score_spread":0.19269005106749224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385698393","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010909946,0.98022956,0.0000061361416,0.0001941127,0.000117053256,0.019075122,0.00023530408,0.00005112464,0.00008067526],"genre_scores_gemma":[0.000004171332,0.97246116,0.0001661246,0.000023774284,0.00012803596,0.0034996541,0.00024637525,0.00013123469,0.023339463],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.996647,0.00020848756,0.0017234772,0.00043729178,0.0005765553,0.00040721073],"domain_scores_gemma":[0.9945286,0.002665014,0.00083964795,0.0015372612,0.00029258966,0.00013688614],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040121403,0.0005730285,0.0063183648,0.00010823166,0.00007196454,0.000012430915,0.00027242154,0.00030631226,0.00016089856],"category_scores_gemma":[0.0006741808,0.00025770566,0.0023509709,0.00070951827,0.00015183607,0.000035075187,0.000051389572,0.00008145177,0.00011068627],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035147146,0.0003797696,0.0000020711961,0.9347716,0.002889049,0.000044442717,0.000058850623,7.7575606e-8,0.0000011969505,0.00006217666,0.0025452324,0.059210416],"study_design_scores_gemma":[0.00072859525,0.0008792916,5.167681e-7,0.7203259,0.021808583,0.000082447645,0.00003650957,0.000012040821,0.000018574803,0.000010150221,0.25593704,0.00016036164],"about_ca_topic_score_codex":0.000029457598,"about_ca_topic_score_gemma":0.000008946316,"teacher_disagreement_score":0.2533918,"about_ca_system_score_codex":0.00031335634,"about_ca_system_score_gemma":0.0006090927,"threshold_uncertainty_score":0.99998754},"labels":[],"label_agreement":null},{"id":"W4385699036","doi":"10.1097/01.hs9.0000972748.88204.9a","title":"P1466: EFFECT OF LUSPATERCEPT ON BONE MINERAL DENSITY IN PATIENTS WITH BETA‑THALASSEMIA ENROLLED IN THE PHASE 3 BELIEVE TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Bone and Joint Diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Thalassemia; Osteopenia; Ineffective erythropoiesis; Bone mineral; Anemia; Osteoporosis; Placebo; Internal medicine; Beta thalassemia; Surgery; Erythropoiesis","score_opus":0.010005040724014438,"score_gpt":0.27798255912096614,"score_spread":0.2679775183969517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385699036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974425,0.000034559336,5.1142905e-7,0.00021933873,0.00007003613,0.0014107111,0.00001413121,0.00003178806,0.0007764486],"genre_scores_gemma":[0.9992078,0.0000052121122,0.0000140914235,0.00017808874,0.00007967615,0.00007325458,0.00011562102,0.000020061221,0.00030618018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986055,0.00018894943,0.00031426034,0.00023297998,0.00040509095,0.00025321383],"domain_scores_gemma":[0.9992612,0.00023415934,0.00008611301,0.00031203032,0.000036937152,0.000069585585],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033329282,0.00017890746,0.0005472686,0.000091531256,0.000024758392,0.000007079977,0.000061362465,0.00008489156,0.0001354428],"category_scores_gemma":[0.00013938223,0.00010127923,0.00011070597,0.00047824282,0.000044850378,0.00004397169,0.000025562857,0.00020392085,0.000049541195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21213675,0.0023808235,0.766903,0.00036806922,0.000081077706,0.0006812315,0.0010225108,0.000016295564,0.0012163902,0.000012023913,0.009927947,0.0052539157],"study_design_scores_gemma":[0.26385784,0.011046506,0.720737,0.000519,0.0001515761,0.0000046394543,0.00018904112,0.00006628599,0.0031308935,0.000015441108,0.00010606566,0.00017574192],"about_ca_topic_score_codex":0.00009314238,"about_ca_topic_score_gemma":0.00015127065,"teacher_disagreement_score":0.05172108,"about_ca_system_score_codex":0.00003974426,"about_ca_system_score_gemma":0.000050968007,"threshold_uncertainty_score":0.4130047},"labels":[],"label_agreement":null},{"id":"W4385699183","doi":"10.1097/01.hs9.0000972624.95131.86","title":"P1435: OUTCOMES OF COVID-19 INFECTION IN INDIVIDUALS WITH SICKLE CELL DISEASE OR SICKLE CELL TRAIT: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Centre Hospitalier de l’Université de Montréal; University of Toronto","funders":"","keywords":"Medicine; Sickle cell trait; Disease; Population; Meta-analysis; Acute chest syndrome; Cochrane Library; Sickle cell anemia; Pediatrics; Intensive care medicine; Inclusion and exclusion criteria; Confounding; Internal medicine; Pathology; Environmental health","score_opus":0.0739883264840827,"score_gpt":0.35140447403681047,"score_spread":0.27741614755272775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385699183","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003609077,0.9922304,0.000031004933,0.0003359235,0.000020590163,0.006500328,0.0003495899,0.00009525086,0.00040081574],"genre_scores_gemma":[0.000092750066,0.9882125,0.00010109112,0.00064974977,0.000008551152,0.0010114219,0.00026639778,0.00010954732,0.009547989],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99572337,0.0006111679,0.0019302639,0.00073057716,0.00061013375,0.0003945141],"domain_scores_gemma":[0.99647784,0.00063876045,0.0013050124,0.00091755105,0.000091358284,0.0005695037],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009768278,0.00078314816,0.011996772,0.000448763,0.00006901257,0.000028067889,0.00017508485,0.00039161448,0.0013721676],"category_scores_gemma":[0.0005756652,0.00039861238,0.0023548293,0.0029853329,0.00011321735,0.000072276285,0.000089708985,0.00053758867,0.00006694607],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009674424,0.00029205086,0.00035447764,0.9551311,0.04316489,0.00015412873,0.00014787841,0.0000177261,1.5011354e-8,0.000008528319,0.0005597063,0.00015982421],"study_design_scores_gemma":[0.0008122517,0.00014933349,0.000037391022,0.0516008,0.9225491,0.000031130814,0.0002001426,0.000005498331,1.7734554e-7,0.000009302234,0.02414873,0.0004561089],"about_ca_topic_score_codex":0.0003963634,"about_ca_topic_score_gemma":0.0003991963,"teacher_disagreement_score":0.9035303,"about_ca_system_score_codex":0.0001430265,"about_ca_system_score_gemma":0.0010230201,"threshold_uncertainty_score":0.9998466},"labels":[],"label_agreement":null},{"id":"W4385702448","doi":"10.1097/01.hs9.0000971168.59900.67","title":"P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Refractory (planetary science); Cohort; Salvage therapy; Chemotherapy; Gastroenterology; Cancer; Immunotherapy","score_opus":0.03137807776785468,"score_gpt":0.3217374355978094,"score_spread":0.2903593578299547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385702448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971301,0.000044069166,0.0000015214868,0.00018060347,0.00005633754,0.002177906,0.00016211245,0.000057430305,0.00018993439],"genre_scores_gemma":[0.99786377,0.0000308351,0.00014489547,0.00008509125,0.000015238773,0.00018817351,0.0010742523,0.000053377375,0.0005443718],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9978977,0.0001848425,0.0005924325,0.00057918654,0.00045284774,0.00029302994],"domain_scores_gemma":[0.99890333,0.000078044795,0.00022304813,0.000590257,0.00010993063,0.00009536066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017262938,0.00028352163,0.0006081075,0.00016627656,0.000040457224,0.00003193749,0.00015558391,0.00013138604,0.00016249971],"category_scores_gemma":[0.000022105316,0.00018061911,0.0000210575,0.0009959014,0.00007668209,0.00027089473,0.000048536916,0.000117143616,0.000008797276],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6482593,0.07478619,0.2086949,0.000039872917,0.0004337167,0.0010261447,0.0060579455,0.000007856434,0.0012393617,0.000002087062,0.00047671088,0.05897591],"study_design_scores_gemma":[0.3253472,0.039052904,0.6321606,0.00033612462,0.000079932805,0.0000025988586,0.0017603429,0.00024620863,0.00046217273,0.0000027127692,0.000360418,0.00018881739],"about_ca_topic_score_codex":0.0026265497,"about_ca_topic_score_gemma":0.0069669206,"teacher_disagreement_score":0.42346567,"about_ca_system_score_codex":0.00049495214,"about_ca_system_score_gemma":0.0003000231,"threshold_uncertainty_score":0.73654336},"labels":[],"label_agreement":null},{"id":"W4385702552","doi":"10.1097/01.hs9.0000973276.11676.38","title":"P1600: USE OF RITUXIMAB PLUS STANDARD OF CARE FOR TREATMENT OF PRIMARY IMMUNE THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Rituximab; Medicine; Regimen; Immune thrombocytopenia; Meta-analysis; Randomized controlled trial; Dosing; Internal medicine; Platelet; Systematic review; Immunology; MEDLINE; Pediatrics; Antibody; Intensive care medicine","score_opus":0.1647180651050469,"score_gpt":0.3795282762577729,"score_spread":0.214810211152726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385702552","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001984577,0.98619926,0.000018650822,0.000021082478,0.000013162969,0.010188047,0.0034383244,0.000018339351,0.000083315696],"genre_scores_gemma":[0.000046358728,0.99497604,0.0011850795,0.000012353031,0.000004102584,0.0012868606,0.0011120614,0.000075319025,0.0013018067],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99671537,0.00016106517,0.0020583023,0.0004533298,0.00039197333,0.00021993644],"domain_scores_gemma":[0.99636537,0.00048509194,0.0016981257,0.001010046,0.00035839243,0.000082970575],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.00016470464,0.0005950256,0.037854005,0.00016352857,0.000033490855,0.000008400651,0.00011486356,0.00022082658,0.00015339855],"category_scores_gemma":[0.000108085565,0.0003393275,0.0052801245,0.00069651636,0.00008097112,0.000050934636,0.000056374465,0.00006018002,0.0000042683714],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049437014,0.00023197834,7.902029e-7,0.75771236,0.23948269,0.000048941896,0.000098293676,3.0662932e-7,1.92161e-7,0.00001603658,0.00003909083,0.0023198656],"study_design_scores_gemma":[0.0018803751,0.0011327268,0.0000011143788,0.097313985,0.8909683,0.00004015297,0.000093099814,8.5980594e-7,0.000009085312,0.0000051857487,0.008376634,0.00017844373],"about_ca_topic_score_codex":0.00016422164,"about_ca_topic_score_gemma":0.000119520584,"teacher_disagreement_score":0.66039836,"about_ca_system_score_codex":0.0002965474,"about_ca_system_score_gemma":0.0004496598,"threshold_uncertainty_score":0.9999059},"labels":[],"label_agreement":null},{"id":"W4385702649","doi":"10.1097/01.hs9.0000975280.98608.35","title":"PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Daratumumab; CD38; Multiple myeloma; Medicine; Monoclonal antibody; Innate immune system; Acquired immune system; Immunology; Cancer research; Immune system; Antibody; Biology; Stem cell; Cell biology","score_opus":0.30247108323643784,"score_gpt":0.49072210878978006,"score_spread":0.18825102555334222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385702649","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99369925,0.0005514792,0.0016249141,0.0009821048,0.000080541424,0.002797036,0.000098775556,0.000039519633,0.00012640424],"genre_scores_gemma":[0.95929295,0.00046097673,0.035429902,0.00012714502,0.00022113202,0.00068608474,0.00040074243,0.000033321274,0.0033477577],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997698,0.0003615697,0.0010709842,0.00023279541,0.00036850994,0.00026813243],"domain_scores_gemma":[0.99700505,0.00196466,0.00028605622,0.0002574835,0.0003734769,0.00011327965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004244028,0.00014958662,0.0006508349,0.00005728468,0.00015116457,0.00001310702,0.0001454896,0.00010224852,0.00019531559],"category_scores_gemma":[0.0013636954,0.00009151662,0.00013358155,0.00036219513,0.0002671827,0.00006383646,0.00009911201,0.00018987464,0.000008492605],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011124125,0.0024101785,0.0028762438,0.0010565636,0.00072031067,0.000019526115,0.0014794928,0.000052495387,0.13108979,0.0006160949,0.0043223677,0.8442328],"study_design_scores_gemma":[0.027878003,0.007613459,0.04361844,0.0006739255,0.00027769626,0.000041598993,0.0019325494,0.04840027,0.7193879,0.0023947016,0.14719835,0.0005831259],"about_ca_topic_score_codex":0.000041666306,"about_ca_topic_score_gemma":0.000030304058,"teacher_disagreement_score":0.8436497,"about_ca_system_score_codex":0.000014090537,"about_ca_system_score_gemma":0.00037319152,"threshold_uncertainty_score":0.37319392},"labels":[],"label_agreement":null},{"id":"W4385702657","doi":"10.1097/01.hs9.0000972808.84024.73","title":"P1481: SYSTEMATICALLY REDUCED RED CELL PHOSPHATIDYLSERINE FLIPPASE ACTIVITY IS SUFFICIENT TO INDUCE HEREDITARY HEMOLYTIC ANEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Flippase; Phosphatidylserine; Biology; Red blood cell; Molecular biology; Biochemistry; Cell biology; Chemistry; Phospholipid; Membrane","score_opus":0.024815715547615153,"score_gpt":0.27410591985452976,"score_spread":0.2492902043069146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385702657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827419,0.00012989037,0.00016021199,0.0042285346,0.0010771888,0.0010624051,0.000026128715,0.0004938766,0.010079891],"genre_scores_gemma":[0.9753222,0.000024331337,0.0012426708,0.002912206,0.0004613358,0.00011141422,0.00006680032,0.00007101222,0.019788072],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99768794,0.00010142478,0.00047373897,0.00067132246,0.00047599536,0.00058960076],"domain_scores_gemma":[0.99813646,0.00016266386,0.00012938553,0.0008492722,0.00018319346,0.00053903967],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002813759,0.00033906262,0.0006955182,0.00011395204,0.00013596509,0.000020568774,0.00015274558,0.00025841856,0.0027670565],"category_scores_gemma":[0.0002244251,0.000297943,0.00018382771,0.001074557,0.000055636792,0.00007778789,0.00014560373,0.00038018727,0.003641511],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012697191,0.0009054109,0.0006561048,0.005140833,0.00009711754,0.001363721,0.0018905863,0.00017216502,0.675397,0.00008797206,0.31064013,0.0023792721],"study_design_scores_gemma":[0.011167189,0.006366099,0.07052317,0.0033292368,0.0006791512,0.0013289466,0.0062523256,0.007790432,0.86328286,0.00026248387,0.026698314,0.0023198058],"about_ca_topic_score_codex":0.000052850053,"about_ca_topic_score_gemma":0.000009849529,"teacher_disagreement_score":0.2839418,"about_ca_system_score_codex":0.000170726,"about_ca_system_score_gemma":0.00022253819,"threshold_uncertainty_score":0.99994725},"labels":[],"label_agreement":null},{"id":"W4385702799","doi":"10.1097/01.hs9.0000975724.65819.6e","title":"PB2248: BONE MARROW NECROSIS: RARE PRESENTATION OF CHRONIC MYELOID NEOPLASMS SYSTEMIC REVIEW AND CASE REPORT","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloproliferative neoplasm; Medicine; Myelofibrosis; Pathology; Bone marrow; Essential thrombocythemia; Myeloid; Internal medicine; Polycythemia vera","score_opus":0.020819081014949736,"score_gpt":0.2954762781996693,"score_spread":0.2746571971847196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385702799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.893169,0.09953657,0.000017364735,0.0025901708,0.00015906942,0.002204932,0.000052578504,0.00015896866,0.0021113856],"genre_scores_gemma":[0.9701319,0.023109386,0.00026941762,0.00022543097,0.00011491156,0.000523845,0.00021680843,0.00004412202,0.0053641805],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9983121,0.00006958161,0.00063646317,0.0004249646,0.00029232746,0.00026451916],"domain_scores_gemma":[0.9987805,0.00012500524,0.00028602424,0.0004562276,0.0001813183,0.00017095936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026943552,0.00023374884,0.00073383935,0.000057659872,0.00009237084,0.000016418522,0.000036122008,0.0000986959,0.00064293947],"category_scores_gemma":[0.00017362591,0.00018599025,0.000123118,0.0004150267,0.000060825187,0.000094216164,0.000057166606,0.00012383421,0.000092456576],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037957967,0.0013558852,0.2125372,0.118808985,0.0020734333,0.33891112,0.0023624355,0.000087133834,0.014541123,0.0008770142,0.25509587,0.052970245],"study_design_scores_gemma":[0.014078027,0.0035622157,0.05007172,0.052216206,0.0068063927,0.790252,0.0034951686,0.0013409441,0.054782823,0.00022331206,0.021652605,0.0015186307],"about_ca_topic_score_codex":0.00014800634,"about_ca_topic_score_gemma":0.00012650424,"teacher_disagreement_score":0.45134085,"about_ca_system_score_codex":0.00012031372,"about_ca_system_score_gemma":0.00018106245,"threshold_uncertainty_score":0.7584463},"labels":[],"label_agreement":null},{"id":"W4385703588","doi":"10.1097/01.hs9.0000969476.05517.0d","title":"P643: CUMULATIVE REVIEW OF HEART FAILURE WITH ACALABRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA USING DATA FROM CLINICAL TRIALS AND POST-MARKETING EXPERIENCE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"MedDRA; Medicine; Chronic lymphocytic leukemia; Clinical trial; Population; Internal medicine; Cumulative incidence; Oncology; Adverse effect; Leukemia; Pharmacovigilance; Environmental health","score_opus":0.2531484660242522,"score_gpt":0.4870230859130047,"score_spread":0.23387461988875252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385703588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96722287,0.030537978,0.0000102529075,0.00041469646,0.000040387633,0.0015545079,0.00009062677,0.000023765135,0.00010491901],"genre_scores_gemma":[0.975475,0.021660788,0.0018998522,0.00027860652,0.00025457243,0.00006552006,0.00021234593,0.000043656597,0.0001096351],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9954067,0.0015027558,0.0013708009,0.0006260038,0.00070747215,0.0003862803],"domain_scores_gemma":[0.99085295,0.007078925,0.0004122734,0.0013779014,0.0001545489,0.00012339711],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005467397,0.00023750792,0.0014737656,0.00005691725,0.00005275218,0.000013572613,0.00032655222,0.00012429128,0.00042080675],"category_scores_gemma":[0.0049660867,0.00013516912,0.00013935618,0.00075584266,0.0004209036,0.000095977375,0.00018961815,0.00018063858,0.0000147287265],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.053658508,0.006272699,0.20174097,0.16945428,0.010404906,0.008826102,0.07218793,0.004543867,0.067516774,0.00036519,0.075798094,0.3292307],"study_design_scores_gemma":[0.14018165,0.0075275335,0.037558366,0.12734504,0.00270716,0.001163813,0.026114404,0.61736774,0.007988677,0.00006110904,0.030785106,0.001199381],"about_ca_topic_score_codex":0.0035711832,"about_ca_topic_score_gemma":0.00037897876,"teacher_disagreement_score":0.6128239,"about_ca_system_score_codex":0.008754943,"about_ca_system_score_gemma":0.015445738,"threshold_uncertainty_score":0.99505025},"labels":[],"label_agreement":null},{"id":"W4385704562","doi":"10.1097/01.hs9.0000976692.37823.82","title":"PB2497: HEMATOLOGIC TOXICITIES WITH IMMUNOTHERAPY IN CANCER PATIENTS AT THE ALLAN BLAIR CANCER CENTRE: RETROSPECTIVE DATA COLLECTION STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Health Authority; Saskatchewan Health; University of Saskatchewan","funders":"","keywords":"Medicine; Cancer; Immunotherapy; Internal medicine; Oncology; Context (archaeology); Incidence (geometry); Neutropenia; Chemotherapy","score_opus":0.03287270210165945,"score_gpt":0.31162655776670695,"score_spread":0.2787538556650475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385704562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922052,0.0025752138,0.0000013219454,0.00212477,0.00032687304,0.0016635485,0.000112993395,0.00012839731,0.0008616835],"genre_scores_gemma":[0.9864344,0.002242419,0.000013671601,0.0005333362,0.00008271484,0.00030942485,0.00012508388,0.000047853955,0.0102110775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982294,0.000100499645,0.0003068179,0.0005225406,0.0004548838,0.0003858664],"domain_scores_gemma":[0.9989107,0.00006822831,0.00014670182,0.0007227978,0.000106328625,0.000045239543],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024666826,0.00024439953,0.00039327613,0.00006555941,0.00024753375,0.000030102416,0.00024830925,0.000087019274,0.0021001701],"category_scores_gemma":[0.000020399219,0.00014711113,0.00005438365,0.0011115348,0.00014034956,0.00009885609,0.00012416767,0.00020988155,0.000024485564],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003629161,0.0005439661,0.9556688,0.00004918786,0.00046812766,0.000038852868,0.0044161766,0.000015872387,0.0006380976,0.0000052260393,0.032282155,0.0022443586],"study_design_scores_gemma":[0.008211148,0.00087149383,0.97293365,0.00027074706,0.00007815398,0.000010609432,0.008005475,0.00014855995,0.0012832026,0.000018303279,0.00790809,0.00026057984],"about_ca_topic_score_codex":0.0085141435,"about_ca_topic_score_gemma":0.085974954,"teacher_disagreement_score":0.07746081,"about_ca_system_score_codex":0.00090422796,"about_ca_system_score_gemma":0.00020876917,"threshold_uncertainty_score":0.998812},"labels":[],"label_agreement":null},{"id":"W4385704654","doi":"10.1097/01.hs9.0000970536.69350.bb","title":"P908: IDENTIFICATION OF CYTOKINES ASSOCIATED WITH RESPONSE AND CYTOKINE RELEASE SYNDROME – ANALYSIS OF MAGNETISMM-3 COHORT A","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Cytokine; Cytokine release syndrome; Internal medicine; Cohort; Multiple myeloma; Immunology; Gastroenterology; Immunotherapy; Immune system","score_opus":0.016902216350578165,"score_gpt":0.2862964662391734,"score_spread":0.2693942498885952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385704654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99876654,0.00016539996,0.000024761926,0.00022003124,0.000008070205,0.00042828755,0.00019642575,0.00005331454,0.00013719023],"genre_scores_gemma":[0.99589616,0.0001036731,0.000104881365,0.0000079927395,0.000003942821,0.000046187273,0.00035970818,0.000018499359,0.003458955],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986024,0.00011886361,0.0003462898,0.0002567651,0.00047531,0.00020035688],"domain_scores_gemma":[0.99879634,0.00028651874,0.00018831452,0.00035494185,0.00023762058,0.00013624484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004825046,0.00011994781,0.00050655904,0.00033861096,0.00003818292,0.000007988434,0.00005280594,0.000069436755,0.00022589006],"category_scores_gemma":[0.00072834606,0.00009240864,0.00009094017,0.0021236588,0.00012095484,0.000052174033,0.000034725745,0.00007114431,0.000012989658],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032837733,0.00030493355,0.93362457,0.00017399288,0.0036506394,0.00070133235,0.00014740892,0.000052046507,0.0567447,0.000019766094,0.00019360002,0.0011032452],"study_design_scores_gemma":[0.0019650857,0.0005910146,0.9850429,0.00012998759,0.0016238401,0.000030375486,0.00013316784,0.0031028313,0.0072715036,0.000012252803,0.000024984676,0.00007202659],"about_ca_topic_score_codex":0.00017526488,"about_ca_topic_score_gemma":0.00011497187,"teacher_disagreement_score":0.051418368,"about_ca_system_score_codex":0.000046065496,"about_ca_system_score_gemma":0.000081851744,"threshold_uncertainty_score":0.37683153},"labels":[],"label_agreement":null},{"id":"W4385704694","doi":"10.1097/01.hs9.0000977504.69432.f9","title":"PB2708: SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE IN PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN’S DISEASE (IMCD): AN EXPLORATORY ANALYSIS OF THE SURVEY’S INTERNAL CONSTRUCT VALIDITY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Construct validity; Disease; Quality of life (healthcare); Likert scale; Scale (ratio); Construct (python library); Physical therapy; Family medicine; Clinical psychology; Internal medicine; Psychometrics; Psychology; Nursing","score_opus":0.023791958138850676,"score_gpt":0.28237069934428294,"score_spread":0.2585787412054323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385704694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99865735,0.00045446664,0.0000022680406,0.00008388967,0.0000795616,0.00039695424,0.00023879918,0.000032952477,0.000053769974],"genre_scores_gemma":[0.99962735,0.00006647695,0.0000017864844,0.00010595864,0.000030564668,0.000014469224,0.00008927177,0.000025541482,0.000038601935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982303,0.00032192393,0.0003223439,0.00033409605,0.00049734476,0.00029399578],"domain_scores_gemma":[0.998866,0.0000769285,0.00022051952,0.00034909483,0.00016554174,0.0003218981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040030878,0.00021093147,0.00053054746,0.0001864957,0.000064455955,0.000020488647,0.00012056891,0.00007981654,0.00010459206],"category_scores_gemma":[0.00040344612,0.00013291682,0.00014176093,0.0015137235,0.00007933871,0.00011933179,0.00005997979,0.00022060619,0.000007813197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014079699,0.00014985733,0.9949639,0.00008792099,0.00043688266,0.000023945797,0.0008325666,0.0015068181,0.000011765316,0.000005009563,0.00012797512,0.0004454317],"study_design_scores_gemma":[0.0042432453,0.00039405504,0.98732376,0.00027938557,0.0006570575,3.1058772e-7,0.001078787,0.0058495007,0.000017672068,0.000006471257,0.0000033756216,0.00014636079],"about_ca_topic_score_codex":0.00094916625,"about_ca_topic_score_gemma":0.001328417,"teacher_disagreement_score":0.007640078,"about_ca_system_score_codex":0.00017295199,"about_ca_system_score_gemma":0.00032192798,"threshold_uncertainty_score":0.54201907},"labels":[],"label_agreement":null},{"id":"W4385705588","doi":"10.1097/01.hs9.0000976912.69182.0b","title":"PB2554: DESIGN OF A PHASE 1B OPEN-LABEL STUDY TO ASSESS THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF POVETACICEPT (ALPN-303) IN SUBJECTS WITH AUTOIMMUNE CYTOPENIAS (RUBY-4)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Autoimmune hemolytic anemia; Medicine; B-cell activating factor; Rituximab; Pharmacodynamics; Pharmacokinetics; Immunology; Antibody; Pure red cell aplasia; Internal medicine; Autoantibody; Anemia; Pharmacology; B cell","score_opus":0.11378934319641971,"score_gpt":0.4204725488922121,"score_spread":0.3066832056957924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385705588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906422,0.0005455207,0.000893952,0.0005773294,0.000087200824,0.0060483734,0.00003853125,0.000064639564,0.0011022679],"genre_scores_gemma":[0.9961803,0.0003426823,0.0016001004,0.0001553775,0.000042522857,0.00015351844,0.000024313897,0.00009112742,0.0014100746],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966098,0.00042163947,0.00081378105,0.00059725,0.0009233972,0.00063411955],"domain_scores_gemma":[0.9974197,0.0009996556,0.00022507655,0.00082403154,0.00028946073,0.00024208195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001853412,0.00035400467,0.000982247,0.00019431445,0.000098159595,0.00005278901,0.00076135347,0.00008071281,0.00023098903],"category_scores_gemma":[0.00030160585,0.00024563642,0.000044448345,0.0019157786,0.0002515317,0.0001485812,0.000895367,0.00043272754,0.000032748187],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09959183,0.09532247,0.012840555,0.005657548,0.0050903894,0.009358667,0.04793344,0.014583051,0.5848849,0.0007333148,0.011132555,0.11287132],"study_design_scores_gemma":[0.6508647,0.014355363,0.012271479,0.0018941232,0.0011834077,0.0005115985,0.013169706,0.24381188,0.059308484,0.000046174573,0.0015518768,0.0010312],"about_ca_topic_score_codex":0.0011948638,"about_ca_topic_score_gemma":0.0002818199,"teacher_disagreement_score":0.55127287,"about_ca_system_score_codex":0.0012865856,"about_ca_system_score_gemma":0.003087766,"threshold_uncertainty_score":0.9999996},"labels":[],"label_agreement":null},{"id":"W4385705882","doi":"10.1097/01.hs9.0000973540.85675.29","title":"P1667: ATTRIBUTES OF RANDOMIZED CONTROLLED TRIALS AND THEIR ASSOCIATIONS WITH FUNDING SOURCE IN VENOUS THROMBOEMBOLISM PROPHYLAXIS FOR PATIENTS WITH CANCER: A BIBLIOGRAPHICAL ANALYSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Academic Publishing and Open Access","field":"Decision Sciences","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Randomized controlled trial; Sample size determination; MEDLINE; Exact test; Publication bias; Meta-analysis; Confounding; Internal medicine; Family medicine; Statistics; Mathematics","score_opus":0.07382410853550792,"score_gpt":0.37412042654940986,"score_spread":0.30029631801390194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385705882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901973,0.00086289033,0.0049970606,0.0007138453,0.00007705698,0.0026042948,0.0003620992,0.00004808607,0.000137373],"genre_scores_gemma":[0.9984737,0.00018490046,0.00026386708,0.000042458254,0.00005187801,0.00068285,0.00005301422,0.000017102671,0.00023021977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950776,0.0012503444,0.0016502448,0.0005178724,0.0011236932,0.00038022123],"domain_scores_gemma":[0.97114545,0.02594702,0.0016957655,0.00029207,0.000804997,0.00011469199],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.020595888,0.0002270934,0.0052826162,0.0025859317,0.00021105623,0.0005563435,0.00056720997,0.00019629147,0.00007855294],"category_scores_gemma":[0.026238495,0.00010442039,0.00064801227,0.017943004,0.0002033244,0.000574055,0.00010051675,0.00023605964,0.0000011968734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02616388,0.00021158227,0.956752,0.000022036016,0.0038949975,8.758996e-7,0.0019062564,0.0019994373,0.000011802231,0.00029984768,0.00208428,0.0066530136],"study_design_scores_gemma":[0.4456501,0.0006504588,0.51462287,0.00027675452,0.0032125413,6.1820555e-7,0.005163537,0.017206375,0.000087510794,0.012009453,0.00048313235,0.0006366708],"about_ca_topic_score_codex":0.0005725512,"about_ca_topic_score_gemma":0.0007467481,"teacher_disagreement_score":0.44212916,"about_ca_system_score_codex":0.000032657208,"about_ca_system_score_gemma":0.00015147353,"threshold_uncertainty_score":0.98196393},"labels":[],"label_agreement":null},{"id":"W4385705955","doi":"10.1097/01.hs9.0000971156.02746.02","title":"P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Refractory (planetary science); Oncology; Lymphoma; Cohort; Phases of clinical research; Cancer; Chemotherapy; Gastroenterology; Immunotherapy","score_opus":0.033128835339500215,"score_gpt":0.32422289692761935,"score_spread":0.2910940615881191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385705955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99702036,0.000031477986,0.0000033997826,0.00020947447,0.00007603896,0.002068717,0.00014556048,0.00007399082,0.00037097538],"genre_scores_gemma":[0.9978681,0.000022642054,0.00017622748,0.00011833892,0.000017490614,0.00007385454,0.0012567097,0.000059268044,0.00040734108],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9975358,0.00022907331,0.0006892326,0.0006267405,0.00059199095,0.0003271154],"domain_scores_gemma":[0.9986461,0.00012342946,0.00032239238,0.0006177736,0.00018542772,0.00010487936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003058072,0.00027882028,0.00065496156,0.00020083979,0.000058458052,0.000035581852,0.00025609738,0.00016048868,0.00013125394],"category_scores_gemma":[0.00006870618,0.00019359542,0.000019561954,0.0014909772,0.00010701169,0.00035685563,0.000080277016,0.00021731615,0.0000092853525],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.66584986,0.070449345,0.19181101,0.00008809666,0.00050251564,0.00096237974,0.008608941,0.000019104733,0.003896383,0.000011614611,0.0024367922,0.055363964],"study_design_scores_gemma":[0.33144104,0.026265567,0.63633597,0.0005040986,0.000065898654,0.00000330012,0.0037535764,0.000528492,0.0005554691,0.000007322978,0.00030077633,0.00023845039],"about_ca_topic_score_codex":0.0024963443,"about_ca_topic_score_gemma":0.0041085933,"teacher_disagreement_score":0.44452497,"about_ca_system_score_codex":0.00031432966,"about_ca_system_score_gemma":0.00036789654,"threshold_uncertainty_score":0.78945917},"labels":[],"label_agreement":null},{"id":"W4385706381","doi":"10.1097/01.hs9.0000971268.84093.15","title":"P1093: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Percentile; Internal medicine; Progression-free survival; Oncology; Overall survival; Statistics; Mathematics","score_opus":0.05043493318807855,"score_gpt":0.3075699623141653,"score_spread":0.2571350291260867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385706381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792633,0.0018504567,0.0000067125916,0.00047295485,0.00071956904,0.0007403372,0.000052510324,0.00032244972,0.016571684],"genre_scores_gemma":[0.99605304,0.00035033765,0.00075494754,0.00011275296,0.00016588262,0.00012290655,0.00027492497,0.00008668087,0.0020785355],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966735,0.00014584893,0.00095904904,0.0006824224,0.0007613405,0.0007778015],"domain_scores_gemma":[0.9978346,0.0006191708,0.0003793872,0.0007580596,0.000105584215,0.00030320388],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038784408,0.00048365345,0.0012434368,0.0003065918,0.00010972065,0.0000283192,0.00023002419,0.00034294344,0.0009578569],"category_scores_gemma":[0.00014723661,0.00043662766,0.00030568367,0.0012570105,0.00014575163,0.00011072446,0.00016463018,0.0002487268,0.0007722483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009480462,0.007911374,0.82398957,0.0011037367,0.0011594568,0.0030600324,0.0057989303,0.00022203318,0.00278416,0.0015482093,0.036575764,0.10636628],"study_design_scores_gemma":[0.03987514,0.0018584824,0.9172044,0.001131828,0.00034312886,0.000089211164,0.003969275,0.00046429297,0.012990349,0.00009932795,0.02138383,0.00059077353],"about_ca_topic_score_codex":0.0010318349,"about_ca_topic_score_gemma":0.00051958585,"teacher_disagreement_score":0.1057755,"about_ca_system_score_codex":0.00055224367,"about_ca_system_score_gemma":0.00039166943,"threshold_uncertainty_score":0.9999554},"labels":[],"label_agreement":null},{"id":"W4385706419","doi":"10.1097/01.hs9.0000967312.24545.68","title":"S101: OMISSION OF RADIOTHERAPY IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA PATIENTS FOLLOWING COMPLETE METABOLIC RESPONSE TO STANDARD IMMUNOCHEMOTHERAPY: RESULTS OF THE IELSG37 RANDOMISED TRIAL (NCT01599559)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Hazard ratio; Regimen; Interim analysis; Rituximab; Diffuse large B-cell lymphoma; Randomized controlled trial; Oncology; Lymphoma; Confidence interval","score_opus":0.014219195408720247,"score_gpt":0.2630733071617222,"score_spread":0.24885411175300198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385706419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99402225,0.0012319575,0.000014888925,0.0007671437,0.00041314852,0.0026996892,0.00011774586,0.000041038256,0.00069213455],"genre_scores_gemma":[0.99777776,0.00018403215,0.0009700894,0.00024592187,0.00007347188,0.00014906345,0.00004850818,0.000050713796,0.0005004378],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970222,0.0004270548,0.0009827778,0.0003817014,0.0008312722,0.00035501155],"domain_scores_gemma":[0.9978651,0.00086111034,0.0003470505,0.0006614943,0.000117303425,0.00014795183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011306785,0.00028497362,0.0010877622,0.00016493023,0.00007070497,0.000011142248,0.00022093442,0.00012395596,0.00006049854],"category_scores_gemma":[0.00050731696,0.0001854149,0.00051639875,0.0008891753,0.00006401903,0.000049564318,0.00007474735,0.00007862976,0.000009087284],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8807487,0.002032806,0.01598032,0.00011723761,0.00030661872,0.000050336403,0.0021766946,0.000032662898,0.075382076,0.000008470046,0.0024425024,0.02072158],"study_design_scores_gemma":[0.7029637,0.0018984501,0.22866397,0.00059486984,0.00013799187,0.0000027398796,0.00020052455,0.000032353037,0.058905233,0.000018859399,0.006407038,0.00017425776],"about_ca_topic_score_codex":0.00013511362,"about_ca_topic_score_gemma":0.000010128502,"teacher_disagreement_score":0.21268365,"about_ca_system_score_codex":0.00037404927,"about_ca_system_score_gemma":0.0005763746,"threshold_uncertainty_score":0.75610006},"labels":[],"label_agreement":null},{"id":"W4385707156","doi":"10.1097/01.hs9.0000971348.10013.c4","title":"P1113: COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Propensity score matching; Oncology; Internal medicine; Progression-free survival; Rituximab; Population; Overall survival; Lymphoma","score_opus":0.09647680593430397,"score_gpt":0.37119411444094036,"score_spread":0.2747173085066364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385707156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98003435,0.0010402947,0.000054149707,0.0002516384,0.0004310675,0.0012567103,0.000031759417,0.00033000976,0.016569996],"genre_scores_gemma":[0.99522555,0.00008381084,0.0009596959,0.000046948237,0.00017045117,0.00008230671,0.00022658844,0.00008804035,0.0031166035],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99531996,0.00030763535,0.0011141518,0.0008064516,0.0013395743,0.0011122309],"domain_scores_gemma":[0.9966101,0.0015400363,0.0003344998,0.0009345888,0.00021626048,0.0003644943],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00079041836,0.00048948004,0.0017344876,0.00045328774,0.00012883406,0.000034241926,0.00043487066,0.00036298428,0.0009926729],"category_scores_gemma":[0.0003600161,0.00046852004,0.00027188586,0.0026382979,0.00038539254,0.000107902335,0.00031593718,0.0006024887,0.0013724788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2728759,0.04142116,0.061854616,0.014670074,0.007836364,0.023413433,0.13441022,0.01659283,0.03285926,0.011024464,0.23149177,0.1515499],"study_design_scores_gemma":[0.64508045,0.003988561,0.17885652,0.0038164868,0.00053498487,0.00054418005,0.024717294,0.085676625,0.0405237,0.00022491119,0.014208004,0.0018282835],"about_ca_topic_score_codex":0.0019748139,"about_ca_topic_score_gemma":0.0008666079,"teacher_disagreement_score":0.37220454,"about_ca_system_score_codex":0.0057686563,"about_ca_system_score_gemma":0.003955799,"threshold_uncertainty_score":0.99992055},"labels":[],"label_agreement":null},{"id":"W4385707163","doi":"10.1097/01.hs9.0000970568.75232.84","title":"P916: LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE (ISA-KD) IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Internal medicine; Medicine; Carfilzomib; Multiple myeloma; Oncology; Subgroup analysis; Gastroenterology; Confidence interval; Bortezomib","score_opus":0.04083135418477333,"score_gpt":0.32573524028162926,"score_spread":0.2849038860968559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385707163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99280405,0.00013290127,0.00001253906,0.00058562483,0.00010215499,0.004564856,0.001025523,0.00032421935,0.00044815443],"genre_scores_gemma":[0.99283296,0.000029884292,0.0007610305,0.00017535244,0.000072010065,0.0003599621,0.0036519263,0.00014443918,0.0019724236],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99490994,0.00038714748,0.00077369524,0.0011447503,0.0015315393,0.0012528971],"domain_scores_gemma":[0.99614584,0.0011783297,0.000271821,0.0015467231,0.00031843473,0.00053882384],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042680925,0.00065039657,0.0010066798,0.00018297353,0.0002650494,0.000097766766,0.00035224017,0.00016816588,0.000451959],"category_scores_gemma":[0.0008458278,0.0003545077,0.00012731645,0.0015457348,0.00022452264,0.00021081803,0.00020964377,0.00069848984,0.0004420437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022899587,0.006116389,0.9520742,0.00004279644,0.0011037086,0.0022666282,0.0028642928,0.000019557372,0.00008263786,0.0000014060597,0.0014657482,0.011062994],"study_design_scores_gemma":[0.14138396,0.003375246,0.85046834,0.00029924806,0.00021599518,0.0000052514642,0.0030543269,0.000340656,0.00028980398,0.000005232458,0.00020937076,0.00035256892],"about_ca_topic_score_codex":0.0028078896,"about_ca_topic_score_gemma":0.00977791,"teacher_disagreement_score":0.11848438,"about_ca_system_score_codex":0.00030657655,"about_ca_system_score_gemma":0.00029062174,"threshold_uncertainty_score":0.9998907},"labels":[],"label_agreement":null},{"id":"W4385707295","doi":"10.1097/01.hs9.0000970420.62475.d0","title":"P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Multiple myeloma; Daratumumab; Cytokine release syndrome; Oncology; Bortezomib; Refractory (planetary science); Gastroenterology; Surgery; Cancer; Clinical trial; Immunotherapy; Chimeric antigen receptor","score_opus":0.019967407386132292,"score_gpt":0.2765928248278406,"score_spread":0.2566254174417083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385707295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960107,0.0004617136,0.000046721732,0.00006765494,0.00023942707,0.0015307115,0.00021929818,0.00015860304,0.0012651383],"genre_scores_gemma":[0.9934517,0.00020488464,0.000739126,0.000023324188,0.00008454984,0.00006704694,0.0029438867,0.00009451175,0.0023909486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970549,0.000105019215,0.000576996,0.0006640239,0.00094531185,0.00065376336],"domain_scores_gemma":[0.9982257,0.00021446504,0.00024728334,0.0007833213,0.0002445047,0.00028470944],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014492848,0.0003815315,0.00065158936,0.00027882514,0.000104139785,0.000040199473,0.00019929145,0.0002400882,0.00059788505],"category_scores_gemma":[0.00013770674,0.0003025954,0.00015584973,0.0008873714,0.00012392922,0.0002589116,0.00011186968,0.00037053248,0.00041326942],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046617035,0.0012298551,0.9696454,0.00031263076,0.00016889536,0.00057708635,0.00038061288,0.000004172569,0.01402189,0.000004032561,0.00079882785,0.008194899],"study_design_scores_gemma":[0.023399018,0.0008250996,0.9647265,0.000648917,0.000056585348,0.0000033746664,0.00023572422,0.0001690668,0.009324816,0.000013361632,0.00032779918,0.000269727],"about_ca_topic_score_codex":0.00052830204,"about_ca_topic_score_gemma":0.0009489454,"teacher_disagreement_score":0.018737314,"about_ca_system_score_codex":0.00019116339,"about_ca_system_score_gemma":0.000194049,"threshold_uncertainty_score":0.9999426},"labels":[],"label_agreement":null},{"id":"W4385707424","doi":"10.1097/01.hs9.0000970528.04188.9f","title":"P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; CD38; Medicine; Plasma cell; Internal medicine; Oncology; Bortezomib; Exome sequencing; Cohort; Immunology; Bone marrow; Biology; Gene; Phenotype; Genetics; Stem cell","score_opus":0.028456850265645473,"score_gpt":0.3646396066653157,"score_spread":0.3361827563996702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385707424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977299,0.00040679894,0.000017130038,0.00046955704,0.000020242966,0.00095893606,0.000060112514,0.000030621417,0.00030670807],"genre_scores_gemma":[0.9928094,0.00010045752,0.0010998828,0.00006735509,0.000012364066,0.00010569394,0.000019128842,0.000021398053,0.005764325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833906,0.00011664483,0.00035867083,0.00041758368,0.00038501574,0.00038300146],"domain_scores_gemma":[0.99891376,0.00015713109,0.00004788547,0.00045880608,0.00007114924,0.00035123972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005160889,0.00015261752,0.0005159822,0.0005055248,0.000037803646,0.000017345323,0.00010445347,0.00006308335,0.00029237004],"category_scores_gemma":[0.00038809847,0.00013408302,0.00008669719,0.0018361429,0.00003561353,0.00003860252,0.0001405611,0.0000900694,0.00017443708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004798303,0.00010472413,0.9749496,0.00015015135,0.00029212172,0.0011401672,0.00046556393,0.0000203656,0.012669365,0.0000044814788,0.0014374712,0.0039677024],"study_design_scores_gemma":[0.001668936,0.0002551222,0.99419826,0.00015046462,0.00016908595,0.0000064893825,0.00023885882,0.00020677896,0.0023498205,0.0000220964,0.0006269099,0.0001071517],"about_ca_topic_score_codex":0.00044878724,"about_ca_topic_score_gemma":0.0052104513,"teacher_disagreement_score":0.019248702,"about_ca_system_score_codex":0.00013411447,"about_ca_system_score_gemma":0.00008924604,"threshold_uncertainty_score":0.5467747},"labels":[],"label_agreement":null},{"id":"W4385723082","doi":"10.1097/01.hs9.0000968448.07133.3e","title":"P385: COMPARISON OF CLINICAL OUTCOMES AND ADVERSE EVENTS IN OLDER ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH NATIVE VS PEGYLATED ASPARAGINASE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Asparaginase; Adverse effect; Regimen; Internal medicine; Pediatrics; Leukemia; Gastroenterology; Lymphoblastic Leukemia","score_opus":0.023321284646198773,"score_gpt":0.34625746314514005,"score_spread":0.3229361784989413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385723082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975269,0.000051070114,0.000095146184,0.00020069428,0.000039905946,0.0012037732,0.000031783497,0.00014576034,0.0007049576],"genre_scores_gemma":[0.99674994,0.000062539206,0.0006687733,0.00008556863,0.000029045723,0.00008802839,0.00011699238,0.00007658577,0.0021225323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968072,0.000167705,0.0008650804,0.00069483154,0.0008545068,0.00061063946],"domain_scores_gemma":[0.9976321,0.0008978643,0.00030495942,0.00046922613,0.0003146947,0.000381182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033239552,0.000401836,0.0013590859,0.00023281935,0.00006041924,0.000005281001,0.00016288772,0.00026521328,0.00015271326],"category_scores_gemma":[0.00033355382,0.00026304004,0.000103201775,0.0013218819,0.00037976343,0.0001412182,0.00012957645,0.00046689645,0.00008035203],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013584455,0.0005073278,0.9793474,0.00036168916,0.0007390401,0.0018871513,0.0014252393,0.00025044478,0.000035559642,0.00001526488,0.00082979584,0.0010166301],"study_design_scores_gemma":[0.039496172,0.0023389794,0.923775,0.001733535,0.00035903975,0.00017421602,0.0025807212,0.02853667,0.00066820433,0.000006857349,0.000032303793,0.00029826158],"about_ca_topic_score_codex":0.00069387566,"about_ca_topic_score_gemma":0.0004855271,"teacher_disagreement_score":0.05557236,"about_ca_system_score_codex":0.00058249716,"about_ca_system_score_gemma":0.0013396181,"threshold_uncertainty_score":0.9999822},"labels":[],"label_agreement":null},{"id":"W4385727291","doi":"10.1097/01.hs9.0000970360.06967.6b","title":"P864: A PHASE 1 STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF DREAMM-9","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Lenalidomide; Multiple myeloma; Interim analysis; Bortezomib; Internal medicine; Adverse effect; Tolerability; Clinical endpoint; Dexamethasone; Gastroenterology; Oncology; Surgery; Clinical trial","score_opus":0.028782846873924205,"score_gpt":0.35307287331456155,"score_spread":0.32429002644063737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385727291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.998267,0.000113983806,0.000017591896,0.00002418101,0.000010310655,0.0012230992,0.00017364282,0.00002334013,0.00014682797],"genre_scores_gemma":[0.9990831,0.000019552534,0.00029188246,0.000002543463,0.000004379718,0.00009217301,0.00043424478,0.000021828226,0.000050319883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981942,0.00015431034,0.0005328862,0.0002967747,0.0005737672,0.0002480308],"domain_scores_gemma":[0.99885917,0.0001911506,0.00018673716,0.00039710547,0.00025964747,0.000106208645],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002316916,0.0001605059,0.0008804169,0.0007011952,0.000017787941,0.000004851443,0.000107647036,0.00006417835,0.00015628908],"category_scores_gemma":[0.00017726963,0.0001292798,0.00008402515,0.0024218692,0.00006293457,0.000084659965,0.00005427338,0.00013124805,0.0000021971769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0107706655,0.006240403,0.9505344,0.00034611777,0.0007415608,0.00060979964,0.01495239,0.0002949185,0.0015184424,0.0000066065772,0.0000146325265,0.013970083],"study_design_scores_gemma":[0.052216582,0.0153069,0.86137044,0.0003332386,0.0004091465,0.000001396012,0.055130128,0.0043657613,0.010756152,0.0000038402686,0.0000056640515,0.00010073617],"about_ca_topic_score_codex":0.0044854726,"about_ca_topic_score_gemma":0.059213456,"teacher_disagreement_score":0.08916392,"about_ca_system_score_codex":0.00017846022,"about_ca_system_score_gemma":0.00013573546,"threshold_uncertainty_score":0.95795345},"labels":[],"label_agreement":null},{"id":"W4385739932","doi":"10.1097/01.hs9.0000968596.43178.c6","title":"P422: TARGETING THE WT1MUT-MIR-193A TRANSCRIPTIONAL AXIS WITH INT-1B3, A NOVEL LIPID NANOPARTICLE-FORMULATED MIR-193A-3P MIMIC IN ACUTE MYELOID LEUKEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Cancer research; Myeloid leukemia; DNA methylation; Epigenetics; microRNA; Decitabine; Biology; Methylation; Gene silencing; Leukemia; Gene; Immunology; Gene expression; Genetics","score_opus":0.023723318740459826,"score_gpt":0.27592224410783833,"score_spread":0.25219892536737853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385739932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98771876,0.0006260556,0.00021139979,0.0073685003,0.00021497326,0.0015172657,0.00007690146,0.00049076416,0.0017753957],"genre_scores_gemma":[0.98847616,0.00036561227,0.0020888138,0.0013612893,0.0004197632,0.0003542203,0.00031706542,0.00019676096,0.0064203176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99505585,0.00015652334,0.00089820265,0.0009432796,0.0013451756,0.0016009901],"domain_scores_gemma":[0.9978276,0.00036876625,0.00017784732,0.0008683511,0.00030934016,0.00044811654],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011516833,0.0005953888,0.000775554,0.00027763713,0.00037855734,0.00010323643,0.0005885956,0.00038480578,0.0012564624],"category_scores_gemma":[0.0002852568,0.000412788,0.0002528434,0.0027952045,0.00037549992,0.00038503244,0.00021304791,0.0015782383,0.0009003024],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026323793,0.0003563806,0.010167688,0.00045301917,0.0006978023,0.00097441796,0.0049149054,0.00096223183,0.93842274,0.000685117,0.03653414,0.0031991585],"study_design_scores_gemma":[0.065416135,0.004064623,0.2298475,0.0032469877,0.0017093264,0.0028181067,0.019605676,0.17033267,0.26786846,0.0006413897,0.23010743,0.0043416945],"about_ca_topic_score_codex":0.00066344225,"about_ca_topic_score_gemma":0.0005848129,"teacher_disagreement_score":0.6705543,"about_ca_system_score_codex":0.0014538914,"about_ca_system_score_gemma":0.0014806682,"threshold_uncertainty_score":0.99987763},"labels":[],"label_agreement":null},{"id":"W4385856058","doi":"10.1097/01.hs9.0000971412.45898.1a","title":"P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Regimen; Post-hoc analysis; Internal medicine; Phases of clinical research; Clinical endpoint; Toxicity; Oncology; Nuclear medicine; Clinical trial; Surgery","score_opus":0.027672898584496907,"score_gpt":0.33315772246846176,"score_spread":0.30548482388396486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385856058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99557155,0.00088913046,0.000015098681,0.000080581376,0.00011748593,0.0015584069,0.00010069242,0.00017067968,0.0014963814],"genre_scores_gemma":[0.9865863,0.00015133643,0.00013545589,0.00013321597,0.00010403972,0.00012442254,0.0002477394,0.00011557642,0.012401916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701273,0.00019559769,0.00044297756,0.0007772852,0.0008901279,0.0006812696],"domain_scores_gemma":[0.9985029,0.00019657926,0.00012287241,0.00074108446,0.00013514703,0.0003014007],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003503783,0.0003974611,0.0007436257,0.00024348064,0.0001781101,0.000050047664,0.00017466667,0.00016909772,0.0024185064],"category_scores_gemma":[0.000056418772,0.0003125345,0.0001299452,0.0009900084,0.00007629924,0.00017058836,0.00014570166,0.0003128774,0.00007902076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035415124,0.03715246,0.8091195,0.00013612819,0.0011112103,0.001296508,0.008668346,0.0000035696978,0.020414338,0.000005795354,0.0044766054,0.082200415],"study_design_scores_gemma":[0.35747376,0.016907573,0.60605705,0.00023523888,0.00028001962,0.000007013417,0.0071726977,0.0005859952,0.0026662818,0.000065090426,0.007843069,0.00070619344],"about_ca_topic_score_codex":0.0006405698,"about_ca_topic_score_gemma":0.00088887673,"teacher_disagreement_score":0.32205865,"about_ca_system_score_codex":0.00019137945,"about_ca_system_score_gemma":0.00017571493,"threshold_uncertainty_score":0.99993265},"labels":[],"label_agreement":null},{"id":"W4385856750","doi":"10.1097/01.hs9.0000972776.91875.6f","title":"P1473: CLINICALLY RELEVANT HEMOGLOBIN RESPONSE IN ADULTS WITH PYRUVATE KINASE DEFICIENCY TREATED WITH MITAPIVAT – A SUB-ANALYSIS OF THE ACTIVATE TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Anemia; Hemoglobin; Hemolysis; Clinical endpoint; Pyruvate kinase; Placebo; Pyruvate kinase deficiency; Internal medicine; Randomized controlled trial; Gastroenterology; Clinical trial; Pharmacology; Glycolysis; Pathology; Metabolism","score_opus":0.012357796401671143,"score_gpt":0.2720941681591238,"score_spread":0.2597363717574527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385856750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984622,0.00014470232,0.000038373295,0.00038847458,0.00001685014,0.0006068788,0.00003588894,0.000020625544,0.00028601507],"genre_scores_gemma":[0.99879843,0.00009034362,0.000111199115,0.00008318964,0.000021790389,0.00008018268,0.00009210671,0.000031559146,0.00069118576],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99782443,0.00031505467,0.00041795176,0.00059435004,0.00041300803,0.0004352207],"domain_scores_gemma":[0.9986998,0.000099055105,0.00016326948,0.0007755779,0.00015012387,0.000112193724],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005774867,0.0002233267,0.00037365805,0.00010107248,0.000064252235,0.000016654374,0.00037455882,0.00021578874,0.000024328938],"category_scores_gemma":[0.00044488188,0.00012935464,0.0002446799,0.0022568728,0.000262027,0.0000041675326,0.00020000753,0.0002293596,0.000007636143],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16199587,0.00028549522,0.009434856,0.00004702431,0.0003245469,0.00006889337,0.00006094711,0.00019928608,0.8267913,0.000011735148,0.00023041325,0.0005496542],"study_design_scores_gemma":[0.018887097,0.0030848181,0.021624884,0.00017295711,0.00027011463,0.000005565217,0.00025719657,0.00025295434,0.954566,0.000015066063,0.00053395214,0.00032942064],"about_ca_topic_score_codex":0.00009315971,"about_ca_topic_score_gemma":0.00027153073,"teacher_disagreement_score":0.14310877,"about_ca_system_score_codex":0.000026048085,"about_ca_system_score_gemma":0.00022324438,"threshold_uncertainty_score":0.5274929},"labels":[],"label_agreement":null},{"id":"W4385955561","doi":"10.1097/01.hs9.0000972472.24418.bc","title":"P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; CD33; Plerixafor; Fludarabine; CD34; Myeloid; Hematopoietic stem cell transplantation; Stem cell; Melphalan; Busulfan; Haematopoiesis; Internal medicine; Immunology; Transplantation; Oncology; Chemotherapy; Immune system; CXCR4; Cyclophosphamide; Biology; Chemokine","score_opus":0.013684587279929656,"score_gpt":0.2551828161038957,"score_spread":0.24149822882396604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385955561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355906,0.001822019,0.00004185129,0.00058726367,0.00018788248,0.0026207124,0.00013973015,0.0002971518,0.00074430724],"genre_scores_gemma":[0.96930903,0.00071872585,0.000345411,0.00033582115,0.00017248992,0.00036937825,0.00009642667,0.00019172077,0.028461019],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99586874,0.00020233972,0.0007365683,0.0010460215,0.0009653082,0.0011810269],"domain_scores_gemma":[0.99791735,0.00024596447,0.00013708604,0.00078653387,0.00020450416,0.000708561],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044314982,0.0007001029,0.0010337507,0.00019533341,0.00022355936,0.00023046565,0.00020144413,0.00032101956,0.0018162291],"category_scores_gemma":[0.000011861291,0.00058312673,0.00022693657,0.0005408836,0.0002673021,0.0002624519,0.00019923726,0.00064286415,0.000438489],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064662946,0.0007534248,0.037862785,0.0058961487,0.00056264334,0.005125505,0.014552759,0.000027408876,0.92166567,0.000074869444,0.0016884095,0.005324102],"study_design_scores_gemma":[0.018253384,0.0036125067,0.025221169,0.0022162364,0.0010598728,0.0033995854,0.0058885417,0.0033329825,0.92001337,0.000051206367,0.014694411,0.002256735],"about_ca_topic_score_codex":0.00010619459,"about_ca_topic_score_gemma":0.000110234,"teacher_disagreement_score":0.027716711,"about_ca_system_score_codex":0.00017519243,"about_ca_system_score_gemma":0.00022749658,"threshold_uncertainty_score":0.99966204},"labels":[],"label_agreement":null},{"id":"W4385955625","doi":"10.1097/01.hs9.0000970028.58190.a6","title":"P781: EVALUATION OF PEGCETACOPLAN TREATMENT SUCCESS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WITH AND WITHOUT BONE MARROW FAILURE: A MOVE TOWARDS INDIVIDUALIZED PATIENT TREATMENT","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital","funders":"","keywords":"Paroxysmal nocturnal hemoglobinuria; Medicine; Eculizumab; Bone marrow failure; Internal medicine; Myelodysplastic syndromes; Hemoglobinuria; Bone marrow; Aplastic anemia; Gastroenterology; Anemia; Immunology; Complement system; Antibody; Haematopoiesis","score_opus":0.031413617580858234,"score_gpt":0.2932572643693684,"score_spread":0.26184364678851013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385955625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99439085,0.002952399,0.000003840596,0.00018201541,0.00014120917,0.0014827437,0.0002538008,0.0000680605,0.00052509457],"genre_scores_gemma":[0.9982929,0.00004842029,0.00013631977,0.000013658157,0.000017380917,0.0005358454,0.0004705687,0.000024872732,0.0004599975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980392,0.0004620494,0.0004872049,0.00042762302,0.00019888023,0.0003850829],"domain_scores_gemma":[0.99916923,0.00007079564,0.00026590656,0.00033240736,0.000110473426,0.00005119239],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029091918,0.00032333296,0.0005864541,0.00012819075,0.00008992096,0.000021974762,0.00009488663,0.00012806218,0.00130412],"category_scores_gemma":[0.000029447207,0.00022877392,0.00008327263,0.00028196018,0.00011385686,0.00008569906,0.00006132362,0.00007003887,0.000050552633],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021783374,0.0012336178,0.90204746,0.00018699595,0.0013884733,0.000060834547,0.008243325,0.00046447583,0.017026374,0.0001427398,0.0016239672,0.065403424],"study_design_scores_gemma":[0.06828103,0.0071587316,0.7917674,0.00094875897,0.0020632106,0.0004730557,0.013563586,0.000645149,0.10354352,0.00043118984,0.009847917,0.0012764552],"about_ca_topic_score_codex":0.00093299267,"about_ca_topic_score_gemma":0.0027322853,"teacher_disagreement_score":0.110280044,"about_ca_system_score_codex":0.00035131836,"about_ca_system_score_gemma":0.0002878072,"threshold_uncertainty_score":0.9996088},"labels":[],"label_agreement":null},{"id":"W4385955746","doi":"10.1097/01.hs9.0000969496.68553.26","title":"P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Venetoclax; Obinutuzumab; Medicine; Bendamustine; Rituximab; Ibrutinib; Internal medicine; IGHV@; Chlorambucil; Fludarabine; Oncology; Population; Chronic lymphocytic leukemia; Cyclophosphamide; Leukemia; Chemotherapy; Lymphoma","score_opus":0.04471865988519662,"score_gpt":0.3370424558678615,"score_spread":0.2923237959826649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385955746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99689573,0.000109428634,0.0000057897823,0.00019552132,0.0001005399,0.0017838958,0.000021303997,0.00006420669,0.000823579],"genre_scores_gemma":[0.99712425,0.00085788156,0.000095324496,0.00007727596,0.00009849847,0.00022363094,0.00009429222,0.000049409977,0.0013794219],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779767,0.000082121274,0.00044568704,0.00047455478,0.0007942836,0.00040570062],"domain_scores_gemma":[0.99857336,0.00036880618,0.0001298265,0.0006832084,0.00012794466,0.0001168489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004048246,0.00028193608,0.0004890718,0.00018058295,0.00009290487,0.000037066817,0.00026676504,0.00006469917,0.00020303126],"category_scores_gemma":[0.00007093926,0.00016107573,0.00006888006,0.0006622477,0.00011257303,0.00013895027,0.00009588581,0.0001610986,0.000014009426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011221116,0.0013511905,0.97386664,0.00011533346,0.00053929084,0.00016845856,0.0053433166,0.001781021,0.00005216899,0.00006201037,0.000107120504,0.015491319],"study_design_scores_gemma":[0.05100516,0.0032817128,0.92941314,0.0001631631,0.000064564745,0.000013188855,0.0010329387,0.01413102,0.00013629062,0.000012739031,0.0005814379,0.00016464191],"about_ca_topic_score_codex":0.014962798,"about_ca_topic_score_gemma":0.033845443,"teacher_disagreement_score":0.04988305,"about_ca_system_score_codex":0.03346279,"about_ca_system_score_gemma":0.0046719895,"threshold_uncertainty_score":0.99159664},"labels":[],"label_agreement":null},{"id":"W4386021597","doi":"10.1097/01.hs9.0000968124.64352.6e","title":"S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"","keywords":"Medicine; Tolerability; Haemophilia; Haemophilia B; Adverse effect; Clotting factor; Haemophilia A; Clinical endpoint; Internal medicine; Surgery; Clinical trial","score_opus":0.06836513171879907,"score_gpt":0.37283611116258636,"score_spread":0.3044709794437873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386021597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99398017,0.00018923664,0.000016688626,0.00073350256,0.000043777138,0.0047769174,0.00005240882,0.00008929595,0.000118008844],"genre_scores_gemma":[0.995653,0.00006554713,0.0005373822,0.00004336696,0.000092644295,0.00014984822,0.00004280156,0.00006640644,0.0033490432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970475,0.00018906043,0.0006140774,0.00071379653,0.00079220824,0.0006433856],"domain_scores_gemma":[0.99834514,0.00048460066,0.00013675471,0.0004708421,0.00015845646,0.00040422354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004085685,0.00036366636,0.0009309174,0.00015050752,0.00015711435,0.0000548668,0.000132199,0.00011957013,0.000732871],"category_scores_gemma":[0.0005136567,0.00021192535,0.00006588501,0.0010877697,0.000092941686,0.00009455494,0.00014811518,0.00031611195,0.000043843855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049845893,0.0052970448,0.67760646,0.0009930745,0.0010171526,0.00473117,0.08266785,0.00008945784,0.05518519,0.0000020286498,0.0003971734,0.12216752],"study_design_scores_gemma":[0.084745355,0.019099822,0.83263814,0.0034170088,0.00042224978,0.00004509544,0.025965136,0.004706423,0.027789557,0.000009879588,0.00043795398,0.00072335906],"about_ca_topic_score_codex":0.0006753209,"about_ca_topic_score_gemma":0.0025246744,"teacher_disagreement_score":0.15503173,"about_ca_system_score_codex":0.00020181891,"about_ca_system_score_gemma":0.0005935576,"threshold_uncertainty_score":0.8642065},"labels":[],"label_agreement":null},{"id":"W4386021623","doi":"10.1097/01.hs9.0000967992.84731.80","title":"S270: TRANSFUSION INDEPENDENCE AFTER EXAGAMGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Prenatal Screening and Diagnostics","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto; BC Children's Hospital; University of British Columbia","funders":"","keywords":"Medicine; Thalassemia; Clinical endpoint; Internal medicine; Blood transfusion; Pediatrics; Clinical trial","score_opus":0.008949082000055683,"score_gpt":0.2283407603991669,"score_spread":0.21939167839911122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386021623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946184,0.00022728824,0.00040233677,0.00028587735,0.00013594092,0.0007056473,0.00004466173,0.00024598764,0.0033338664],"genre_scores_gemma":[0.9979139,0.00017589069,0.00055575464,0.00019799205,0.000061481194,0.00010156118,0.000093691284,0.000053998116,0.0008457619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769884,0.000053154687,0.00035270955,0.0005252741,0.0008630173,0.00050702435],"domain_scores_gemma":[0.999036,0.00013228167,0.00005129998,0.00042123685,0.000101576414,0.00025758063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021820526,0.00027950606,0.00038749215,0.00012171364,0.000067389956,0.000021921685,0.00013382907,0.00027203592,0.00083921157],"category_scores_gemma":[0.00009602398,0.00021743079,0.00009088959,0.0006404004,0.00005671755,0.00013106439,0.000053393465,0.00046258513,0.00028126643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014053074,0.0004243194,0.98083663,0.00017014744,0.00004108378,0.00083787873,0.0005241172,0.00018812824,0.00070454535,0.0000245787,0.00040267722,0.014440608],"study_design_scores_gemma":[0.0048384257,0.00055925234,0.9903209,0.00068890513,0.000079578225,0.000023006201,0.00017366212,0.00020604944,0.0024748002,0.00005558566,0.00029285092,0.0002869923],"about_ca_topic_score_codex":0.00035616185,"about_ca_topic_score_gemma":0.0006648732,"teacher_disagreement_score":0.014153616,"about_ca_system_score_codex":0.00010283605,"about_ca_system_score_gemma":0.00013810076,"threshold_uncertainty_score":0.9188778},"labels":[],"label_agreement":null},{"id":"W4386021670","doi":"10.1097/01.hs9.0000967980.32472.94","title":"S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Dosing; Pharmacokinetics; Pharmacodynamics; Adverse effect; Clinical trial; Internal medicine; Pediatrics","score_opus":0.019485327373507614,"score_gpt":0.29444070520883964,"score_spread":0.274955377835332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386021670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99600524,0.00040981025,0.000029912795,0.00037331376,0.00012808952,0.0017642926,0.00068316766,0.00006916128,0.0005370428],"genre_scores_gemma":[0.99807864,0.00032591686,0.00011148128,0.00024049496,0.00005809671,0.000013021405,0.0007755778,0.000056671004,0.00034008847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99823266,0.000115362185,0.00038560596,0.0005143404,0.0004194129,0.00033263108],"domain_scores_gemma":[0.99855494,0.0001818883,0.00009138175,0.0008176115,0.00005378778,0.0003003875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022064544,0.00022705027,0.00036490214,0.000057906487,0.000071997834,0.00002055029,0.0003051653,0.00006065996,0.0005198496],"category_scores_gemma":[0.00012098217,0.00015900597,0.000040254006,0.0004950638,0.00009680502,0.00008109736,0.00035614832,0.000309292,0.000062522995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03503044,0.015690878,0.8410999,0.00044576454,0.00079504005,0.00079893257,0.011287519,0.0015235239,0.0016883768,0.000009339692,0.052015852,0.039614413],"study_design_scores_gemma":[0.071841486,0.0013544224,0.9068826,0.0003295827,0.00083404116,7.192704e-7,0.005235769,0.005512647,0.000081738566,0.000008794615,0.0075137382,0.0004044985],"about_ca_topic_score_codex":0.00017586183,"about_ca_topic_score_gemma":0.00009112073,"teacher_disagreement_score":0.065782644,"about_ca_system_score_codex":0.000036189827,"about_ca_system_score_gemma":0.00010741365,"threshold_uncertainty_score":0.6484075},"labels":[],"label_agreement":null},{"id":"W4386023903","doi":"10.1097/01.hs9.0000968792.87320.b0","title":"P471: POLO-LIKE KINASE 4 INHIBITION INDUCED ANTI-LEUKAEMIC EFFECTS THROUGH HISTONE MODIFICATION IN TP53 MUTATED ACUTE MYELOID LEUKAEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Health and Medical Research Fund; Innovation and Technology Commission; Li Shu Fan Medical Foundation","keywords":"Biology; Transcriptome; Cancer research; Myeloid leukemia; Gene; Epigenetics; Haematopoiesis; Myeloid; Genetics; Gene expression; Stem cell","score_opus":0.03625720728268949,"score_gpt":0.34509045741194355,"score_spread":0.30883325012925406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386023903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915198,0.00032141255,0.00017435082,0.0022564726,0.00032140032,0.0017660676,0.000023725488,0.00074060867,0.0028761332],"genre_scores_gemma":[0.993595,0.00041263856,0.00077544246,0.0007813074,0.00020746373,0.00034066648,0.0009706411,0.00014409701,0.002772732],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99631506,0.00023136193,0.00068902294,0.000926991,0.0008058375,0.001031747],"domain_scores_gemma":[0.99812424,0.00025486568,0.00019580948,0.0009121718,0.00022411437,0.0002887966],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00051476195,0.00046674296,0.00076958816,0.00040568828,0.0001795246,0.000044012795,0.00023151905,0.00055781275,0.00025446812],"category_scores_gemma":[0.00034465283,0.00045683893,0.00017655145,0.002822767,0.00018340923,0.0004339783,0.0001919463,0.0011464651,0.0019977489],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005360556,0.00026979682,0.0024730894,0.00072234153,0.0001459895,0.0032566055,0.0014774164,0.000079196405,0.9614264,0.00047980068,0.023778278,0.0053550424],"study_design_scores_gemma":[0.016213227,0.0009798062,0.0998792,0.0015710298,0.0003603676,0.0006378027,0.0013961794,0.008718316,0.86453325,0.0012655007,0.0032471062,0.0011982386],"about_ca_topic_score_codex":0.001097108,"about_ca_topic_score_gemma":0.00009887251,"teacher_disagreement_score":0.09740611,"about_ca_system_score_codex":0.0021412508,"about_ca_system_score_gemma":0.00070934044,"threshold_uncertainty_score":0.99978834},"labels":[],"label_agreement":null},{"id":"W4386023953","doi":"10.1097/01.hs9.0000969228.34230.b4","title":"P581: A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Azacitidine; Internal medicine; Adverse effect; Myeloid leukemia; Induction chemotherapy; Regimen; Venetoclax; Oncology; Ven; Leukemia; Chemotherapy","score_opus":0.025608959099345466,"score_gpt":0.31400439331626406,"score_spread":0.2883954342169186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386023953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99723804,0.0002755013,0.0005750646,0.00052589393,0.00006666897,0.0010922342,0.00007876858,0.000032083157,0.00011572309],"genre_scores_gemma":[0.9906357,0.003555713,0.0040700207,0.000056825524,0.000111807865,0.00022115116,0.00029918554,0.000054669672,0.0009949162],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984461,0.000027619411,0.0003384906,0.00031509035,0.0006017767,0.00027092305],"domain_scores_gemma":[0.9983788,0.0006025135,0.00015886237,0.00045556517,0.00027580847,0.00012845898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021523079,0.00018629717,0.0005728389,0.00020513534,0.000079166275,0.000008143566,0.00010855232,0.00013375422,0.00023627962],"category_scores_gemma":[0.0000974824,0.00010642472,0.00017770469,0.0014475664,0.00019762335,0.000049180882,0.00003087897,0.00009960761,0.0000032253586],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04690881,0.0005988052,0.046192706,0.00029899727,0.021815246,0.000047030368,0.0024783937,0.0006049428,0.005664324,0.0000745577,0.008551156,0.866765],"study_design_scores_gemma":[0.079928026,0.020567918,0.7784582,0.00042222228,0.013823306,0.000018363957,0.0022785896,0.050070956,0.023664977,0.00011168038,0.030085592,0.0005701902],"about_ca_topic_score_codex":0.0001581255,"about_ca_topic_score_gemma":0.00010497124,"teacher_disagreement_score":0.86619484,"about_ca_system_score_codex":0.0007029965,"about_ca_system_score_gemma":0.0004023534,"threshold_uncertainty_score":0.4339874},"labels":[],"label_agreement":null},{"id":"W4386024046","doi":"10.1097/01.hs9.0000968416.51811.f0","title":"P376: VENO-OCCLUSIVE DISEASE RISK AND OTHER OUTCOMES IN PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING INOTUZUMAB OZOGAMICIN AND PROCEEDING TO HEMATOPOIETIC STEM CELL TRANSPLANTATION","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); McGill University Health Centre","funders":"","keywords":"Medicine; Internal medicine; Hematopoietic stem cell transplantation; Hepatic veno-occlusive disease; Salvage therapy; Gastroenterology; Oncology; Transplantation; Surgery; Chemotherapy","score_opus":0.007626346877796342,"score_gpt":0.23954685595891162,"score_spread":0.23192050908111528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9971251,0.00008787074,0.00034325317,0.000117065465,0.000046642286,0.0015707271,0.00013537773,0.00011206841,0.00046188585],"genre_scores_gemma":[0.9977357,0.00008001574,0.0004716484,0.00015862117,0.000031965315,0.00011905281,0.000036983638,0.00009976392,0.0012662415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977221,0.00006140754,0.0003705348,0.0006610872,0.00060173316,0.0005831214],"domain_scores_gemma":[0.99869174,0.0003306709,0.00013169947,0.0002574981,0.000108708395,0.00047970566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018608414,0.0003553552,0.0005060349,0.00024595283,0.00013152932,0.00005696076,0.00011416376,0.00011434651,0.000036878904],"category_scores_gemma":[0.000056281206,0.00028387338,0.000043432025,0.00065130735,0.00009006892,0.0001681475,0.00010996933,0.00024716766,0.000071292736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021355604,0.00019208633,0.9855055,0.0018350624,0.00008727301,0.00024178324,0.00748128,0.00018887703,0.0005966546,0.000013424104,0.0002663393,0.0014561546],"study_design_scores_gemma":[0.02279212,0.001157779,0.9614124,0.0019109179,0.0007274586,0.00003928767,0.0029076326,0.0052953917,0.002918505,0.00008498348,0.00007715724,0.00067637616],"about_ca_topic_score_codex":0.000110319306,"about_ca_topic_score_gemma":0.000042666663,"teacher_disagreement_score":0.024093114,"about_ca_system_score_codex":0.00080493354,"about_ca_system_score_gemma":0.00049065036,"threshold_uncertainty_score":0.9999613},"labels":[],"label_agreement":null},{"id":"W4386024051","doi":"10.1097/01.hs9.0000967672.15362.d7","title":"S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McGill University","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Oncology; Lenalidomide; Regimen; Expanded access","score_opus":0.014696673516677618,"score_gpt":0.24480891604604155,"score_spread":0.23011224252936394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944704,0.00035525966,0.0000040324967,0.00052668614,0.00006877521,0.002956595,0.00026839596,0.0002853915,0.0010644476],"genre_scores_gemma":[0.9967368,0.00008898172,0.0006457355,0.000077570905,0.00012799418,0.00022727017,0.0006658407,0.00012268,0.0013071216],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960447,0.00022310927,0.00062870426,0.0010801993,0.001150272,0.00087304285],"domain_scores_gemma":[0.9963909,0.0018363069,0.000234145,0.00091282686,0.00025902165,0.0003668171],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046293778,0.00053069164,0.0006695639,0.00012650175,0.00044748583,0.00009587134,0.0002492635,0.0001730388,0.000107813175],"category_scores_gemma":[0.0016700076,0.00031260354,0.00007173914,0.000952916,0.00022738277,0.00020149363,0.00021510561,0.00070714054,0.00013798253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01782329,0.0021231573,0.95226103,0.000097942735,0.0004675698,0.0040194225,0.004471352,0.0001773256,0.00012515996,0.0000014746919,0.002158739,0.016273526],"study_design_scores_gemma":[0.053766362,0.005357316,0.9232613,0.0007437002,0.00015593416,0.000029246465,0.0075006126,0.0031098046,0.00026640686,0.000009145233,0.005312648,0.0004875083],"about_ca_topic_score_codex":0.003953477,"about_ca_topic_score_gemma":0.013843854,"teacher_disagreement_score":0.035943072,"about_ca_system_score_codex":0.00027202288,"about_ca_system_score_gemma":0.00015174321,"threshold_uncertainty_score":0.9999326},"labels":[],"label_agreement":null},{"id":"W4386024071","doi":"10.1097/01.hs9.0000967904.29417.23","title":"S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Fludarabine; Clinical endpoint; Hematopoietic stem cell transplantation; Population; Oncology; Transplantation; Total body irradiation; Randomized controlled trial; Gastroenterology; Surgery; Adverse effect; Chemotherapy; Cyclophosphamide","score_opus":0.031222843112105225,"score_gpt":0.31141390221384274,"score_spread":0.2801910591017375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909659,0.00006328938,0.0002859533,0.0024226615,0.00019796766,0.0027412008,0.00008596321,0.00036676473,0.0028703217],"genre_scores_gemma":[0.9945917,0.000048820493,0.001518373,0.00018040689,0.00039608707,0.00028758447,0.0005334014,0.00010728786,0.0023362988],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9958684,0.0003610293,0.0007187319,0.0011142491,0.00096207194,0.00097555836],"domain_scores_gemma":[0.99727666,0.0005971416,0.0002901568,0.0008592434,0.00061775994,0.00035901222],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009991932,0.00051012455,0.0012412007,0.0003169658,0.00021913591,0.000075375174,0.00024817596,0.0003590154,0.00035084024],"category_scores_gemma":[0.0008492776,0.00038244957,0.00013167095,0.002493527,0.0004756264,0.00035158775,0.00012599227,0.0013439194,0.000040034265],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84974694,0.0015957484,0.06599729,0.0006592675,0.002212812,0.006374273,0.017385755,0.0010262481,0.04117372,0.00021775148,0.0065050554,0.0071051545],"study_design_scores_gemma":[0.19516017,0.007044882,0.7456954,0.0014646397,0.00018829864,0.00027256657,0.005576326,0.0018366188,0.041366573,0.00016506304,0.00020304245,0.0010263958],"about_ca_topic_score_codex":0.0017060781,"about_ca_topic_score_gemma":0.0013683512,"teacher_disagreement_score":0.67969817,"about_ca_system_score_codex":0.0014039034,"about_ca_system_score_gemma":0.001392393,"threshold_uncertainty_score":0.99986273},"labels":[],"label_agreement":null},{"id":"W4386024076","doi":"10.1097/01.hs9.0000967492.06443.0a","title":"S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Obinutuzumab; Venetoclax; Medicine; Chronic lymphocytic leukemia; Internal medicine; Tolerability; Chlorambucil; Bendamustine; Oncology; Hazard ratio; Interquartile range; Clinical endpoint; Leukemia; Gastroenterology; Randomized controlled trial; Cyclophosphamide; Chemotherapy; Adverse effect; Confidence interval","score_opus":0.023674757635716876,"score_gpt":0.31049292788169774,"score_spread":0.2868181702459809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98256147,0.0011275463,0.000029903578,0.0001612687,0.0003503516,0.011113719,0.000061861734,0.00034259766,0.0042512966],"genre_scores_gemma":[0.9763194,0.00024302842,0.000121383506,0.00005707806,0.00034133223,0.0009795687,0.00008529203,0.000115891125,0.021737035],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99579775,0.00040027362,0.0011107137,0.0007297988,0.0010217818,0.00093966926],"domain_scores_gemma":[0.99578977,0.0016326965,0.00034810803,0.0016304234,0.0003738547,0.00022515758],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001987775,0.00039134888,0.0014027095,0.00012573684,0.00019330376,0.000033472283,0.0005338259,0.00026364365,0.00020691619],"category_scores_gemma":[0.002550913,0.0002526398,0.00063295447,0.0013961946,0.00040670566,0.000069807174,0.0003265354,0.0003130006,0.0002633126],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.71935505,0.0005819807,0.00062859384,0.009697509,0.006417632,0.0010415192,0.01399687,0.044726457,0.006185211,0.0016859003,0.18684804,0.008835256],"study_design_scores_gemma":[0.8672258,0.0014182527,0.00021454082,0.000875882,0.0008360375,0.0001055684,0.0014100833,0.11625435,0.007399514,0.00023362122,0.0037150139,0.00031130668],"about_ca_topic_score_codex":0.0029577913,"about_ca_topic_score_gemma":0.0004925134,"teacher_disagreement_score":0.18313304,"about_ca_system_score_codex":0.121916644,"about_ca_system_score_gemma":0.06929772,"threshold_uncertainty_score":0.9999926},"labels":[],"label_agreement":null},{"id":"W4386024134","doi":"10.1097/01.hs9.0000967716.49281.3f","title":"S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALYSIS OF MURANO: VENETOCLAX-RITUXIMAB (VENR)-TREATED PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Bendamustine; Hazard ratio; Rituximab; Gastroenterology; Confidence interval; Neutropenia; Minimal residual disease; Chronic lymphocytic leukemia; Surgery; Oncology; Leukemia; Chemotherapy; Lymphoma","score_opus":0.02021042823609262,"score_gpt":0.26840182374875443,"score_spread":0.2481913955126618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616706,0.0013926605,0.000008543562,0.000019169567,0.000092115304,0.0011963007,0.00006519183,0.00019941422,0.0008595473],"genre_scores_gemma":[0.9936858,0.00037802698,0.00013302898,0.000026928254,0.00006210385,0.00011340767,0.000525842,0.00010038836,0.0049744826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627405,0.00012400154,0.0006419359,0.00087237987,0.0012521752,0.00083543576],"domain_scores_gemma":[0.99760985,0.00029523254,0.00025656648,0.0011168212,0.0003398581,0.00038165387],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029886828,0.00047664123,0.0012622832,0.00046663903,0.00015895237,0.00003314086,0.0002180017,0.00027844057,0.00073907786],"category_scores_gemma":[0.0001366836,0.00037212204,0.0003036048,0.002911757,0.0003022268,0.00013861916,0.00017137466,0.00029777706,0.00021878674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.017303871,0.0013685585,0.91927326,0.0030026129,0.02315977,0.0026932308,0.00397127,0.007881851,0.0016174917,0.00015246758,0.008070708,0.011504931],"study_design_scores_gemma":[0.2735885,0.008341389,0.5990325,0.0013860019,0.011166625,0.00008490948,0.0014747684,0.0979112,0.0038041223,0.000033184882,0.001999544,0.0011772282],"about_ca_topic_score_codex":0.0032054184,"about_ca_topic_score_gemma":0.00086604693,"teacher_disagreement_score":0.32024074,"about_ca_system_score_codex":0.06528202,"about_ca_system_score_gemma":0.013938612,"threshold_uncertainty_score":0.9998731},"labels":[],"label_agreement":null},{"id":"W4386024385","doi":"10.1097/01.hs9.0000969552.85501.cf","title":"P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Medicine; Internal medicine; Myeloid leukemia; Oncology; Clinical endpoint; Clinical trial; Dasatinib; Imatinib","score_opus":0.01797731521387673,"score_gpt":0.2869151710919347,"score_spread":0.26893785587805796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974923,0.0003379572,0.000016288104,0.00015436253,0.000064443666,0.0013461142,0.0004967162,0.00002339577,0.000068392925],"genre_scores_gemma":[0.9987063,0.00006804325,0.0007130255,0.000026356392,0.00001262069,0.000037230762,0.00032853885,0.00002453973,0.000083380495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975919,0.00037055268,0.00091316,0.00024293932,0.00069970824,0.00018175243],"domain_scores_gemma":[0.9970034,0.0009628058,0.0010058709,0.0006354619,0.0003495395,0.000042917847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034364715,0.00015608442,0.000598155,0.00011668997,0.000053923966,0.0000059217923,0.00013625948,0.00006211622,0.00038068977],"category_scores_gemma":[0.0010352202,0.00009586232,0.00019611065,0.0016536488,0.000094237206,0.00005566921,0.00009208189,0.00009581234,0.0000021697842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1697337,0.010631147,0.30607548,0.0008719227,0.0248854,0.00007318713,0.12092917,0.29305157,0.052328967,0.00015730732,0.0029750788,0.018287057],"study_design_scores_gemma":[0.18551934,0.02033574,0.36100054,0.001390352,0.023719342,0.0000036324282,0.25799328,0.06356399,0.08550485,0.000118966535,0.00017672004,0.00067324383],"about_ca_topic_score_codex":0.0022312847,"about_ca_topic_score_gemma":0.0003682983,"teacher_disagreement_score":0.2294876,"about_ca_system_score_codex":0.00015601669,"about_ca_system_score_gemma":0.00031725966,"threshold_uncertainty_score":0.4168286},"labels":[],"label_agreement":null},{"id":"W4386024401","doi":"10.1097/01.hs9.0000969148.22118.7f","title":"P561: REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Acute leukemia; Leukemia; Internal medicine; Refractory (planetary science); Myeloid leukemia; Compassionate Use; Oncology; Clinical trial","score_opus":0.038907020654257225,"score_gpt":0.3554261701329259,"score_spread":0.31651914947866866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956669,0.000025459982,0.000011711418,0.00030186778,0.000046202196,0.0010281705,0.0000062846007,0.00017718472,0.0027361985],"genre_scores_gemma":[0.9863004,0.00004920217,0.003752008,0.00015143205,0.000032410047,0.00043380752,0.00008238433,0.000026199956,0.009172153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985672,0.000047930032,0.00022674772,0.0002934589,0.00043069082,0.00043392758],"domain_scores_gemma":[0.99922633,0.00010747994,0.000048867496,0.0003223122,0.00011170596,0.00018331046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000117555945,0.00013925417,0.00038427595,0.00007407107,0.000067400826,0.000018995013,0.00009772296,0.00010365075,0.00047117588],"category_scores_gemma":[0.000097049306,0.0000961601,0.000036014797,0.0006212152,0.00014265653,0.0001356315,0.00007199552,0.0002449835,0.0002437401],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061286584,0.0003631729,0.9876002,0.000054700093,0.000059603142,0.00041097356,0.00065437006,0.000002381837,0.000052196185,0.00006283952,0.005735085,0.0043915845],"study_design_scores_gemma":[0.004148357,0.0008764689,0.9855326,0.00027956645,0.00004485427,0.000013208488,0.000408916,0.0007924326,0.00007585518,0.000025502746,0.0076760794,0.00012620143],"about_ca_topic_score_codex":0.000090651665,"about_ca_topic_score_gemma":0.000046492394,"teacher_disagreement_score":0.009366517,"about_ca_system_score_codex":0.00017032347,"about_ca_system_score_gemma":0.00025615998,"threshold_uncertainty_score":0.51590455},"labels":[],"label_agreement":null},{"id":"W4386024479","doi":"10.1097/01.hs9.0000968744.85748.62","title":"P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"NPM1; Medicine; Minimal residual disease; Internal medicine; Oncology; Myeloid leukemia; Bone marrow; Proportional hazards model; Gastroenterology; Karyotype; Biology","score_opus":0.06057304799164782,"score_gpt":0.3564517776467327,"score_spread":0.2958787296550849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955467,0.0010254341,0.00009410341,0.0005813558,0.00023535368,0.0013345664,0.00041666735,0.00046022507,0.0003055853],"genre_scores_gemma":[0.9885607,0.0012031689,0.0022479591,0.00003816485,0.0005903879,0.00025748325,0.00057392125,0.00026472294,0.006263494],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928865,0.0003793328,0.0012413508,0.0014137466,0.0023049256,0.0017741857],"domain_scores_gemma":[0.99508274,0.00022583341,0.00044461625,0.0017467798,0.0005666356,0.0019334229],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007582075,0.0009139193,0.0016031982,0.000632044,0.0005669648,0.00014628514,0.00050264556,0.0002510793,0.0006733008],"category_scores_gemma":[0.0003798604,0.000818469,0.00067839597,0.0024742421,0.00026441424,0.0006111936,0.0004288482,0.00062946614,0.00021543993],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009928079,0.0016671675,0.55754393,0.0025662181,0.0065778615,0.016440133,0.0005865206,0.007042867,0.389136,0.00007105692,0.0016330717,0.00680713],"study_design_scores_gemma":[0.040841516,0.001817913,0.5095147,0.00431213,0.017420407,0.00030331715,0.0053395005,0.07877241,0.33589786,0.0004009498,0.0017907901,0.0035884927],"about_ca_topic_score_codex":0.0016308357,"about_ca_topic_score_gemma":0.00009076894,"teacher_disagreement_score":0.07172955,"about_ca_system_score_codex":0.0058797933,"about_ca_system_score_gemma":0.0031473078,"threshold_uncertainty_score":0.9994266},"labels":[],"label_agreement":null},{"id":"W4386024524","doi":"10.1097/01.hs9.0000968592.70537.d0","title":"P421: TARGETED DISRUPTION OF HUMAN FLT3 ERADICATES LEUKEMIC STEM CELLS WITHOUT HARMING HEALTHY HEMATOPOIETIC STEM CELLS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stem cell; Haematopoiesis; Leukemia; Cancer research; Bone marrow; Myeloid leukemia; Biology; Immunology; Xenotransplantation; Hematopoietic stem cell; Transplantation; Medicine; Internal medicine; Cell biology","score_opus":0.039720430632781134,"score_gpt":0.3205576568430557,"score_spread":0.28083722621027457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99482,0.0010848759,0.00015848558,0.00072937337,0.000259699,0.0012836838,0.000040690767,0.0004989657,0.0011242307],"genre_scores_gemma":[0.98208314,0.0003213886,0.0004766922,0.00020490025,0.00023605436,0.00010053929,0.00007505217,0.00015961645,0.016342591],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99619293,0.00019756057,0.0009248341,0.000735668,0.00096141413,0.0009875942],"domain_scores_gemma":[0.9977915,0.00022196451,0.0003435731,0.00092295994,0.00021966346,0.0005003007],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00072316884,0.0004158459,0.00095335883,0.00026578899,0.0002530139,0.000037343143,0.00036108392,0.00030769434,0.0006564561],"category_scores_gemma":[0.000015520733,0.00037703497,0.00025202025,0.0011444181,0.00023823566,0.00016164573,0.00021220528,0.0007422719,0.0011735328],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034151162,0.00019790455,0.007301355,0.0035096675,0.00017504228,0.00023847121,0.0023904974,0.00010571382,0.95906025,0.00021967114,0.023219936,0.0032399637],"study_design_scores_gemma":[0.0048206444,0.0009934678,0.002167697,0.0010860007,0.00019537311,0.00011869121,0.0067959377,0.005323706,0.9740825,0.000115039205,0.0037182418,0.0005826918],"about_ca_topic_score_codex":0.00017885378,"about_ca_topic_score_gemma":0.000020093168,"teacher_disagreement_score":0.019501694,"about_ca_system_score_codex":0.0007905239,"about_ca_system_score_gemma":0.00058717676,"threshold_uncertainty_score":0.99986815},"labels":[],"label_agreement":null},{"id":"W4386024586","doi":"10.1097/01.hs9.0000968552.93087.6b","title":"P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Internal medicine; Medicine; NPM1; Oncology; Myeloid leukemia; Azacitidine; Cytogenetics; Gastroenterology; Randomization; Bone marrow; Myeloid; Clinical trial; Gene; Biology; Genetics; DNA methylation; Karyotype","score_opus":0.02367151887753247,"score_gpt":0.2916650467869095,"score_spread":0.267993527909377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975046,0.00009857132,0.00007668629,0.0010288678,0.000073891846,0.00047237234,0.000017669874,0.000027009428,0.0007003153],"genre_scores_gemma":[0.99272484,0.00019099812,0.000113440554,0.00003301946,0.00007333199,0.000013516692,0.00010883716,0.000025928735,0.0067160786],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850124,0.00011857594,0.00037459913,0.0002604444,0.00054198975,0.00020312787],"domain_scores_gemma":[0.9989592,0.000079240606,0.00020533212,0.0004964401,0.00016202769,0.00009780275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042604166,0.00011869495,0.00037015197,0.00008035438,0.000070867754,0.0000065259937,0.0001249138,0.00013761109,0.000514319],"category_scores_gemma":[0.00041646496,0.00008160839,0.00011792398,0.00090542936,0.000105208426,0.000053598673,0.00020323425,0.00017032548,0.000022388838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046116747,0.000100121826,0.016795283,0.00028600136,0.0001708727,0.000060453163,0.00017209855,0.0000059937092,0.9743371,0.00012053443,0.0013409309,0.0019989528],"study_design_scores_gemma":[0.04713557,0.0007791506,0.40315932,0.000684996,0.00087108323,0.00009776282,0.0002500043,0.00617316,0.53769094,0.0001465327,0.0026955653,0.00031593908],"about_ca_topic_score_codex":0.000069099195,"about_ca_topic_score_gemma":0.000009145641,"teacher_disagreement_score":0.43664616,"about_ca_system_score_codex":0.00010835562,"about_ca_system_score_gemma":0.00015536459,"threshold_uncertainty_score":0.56314325},"labels":[],"label_agreement":null},{"id":"W4386024691","doi":"10.1097/01.hs9.0000968580.70418.79","title":"P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; Myeloid leukemia; Cancer research; Cytarabine; Leukemia; MCL1; Integrated stress response; Biology; Medicine; Chronic lymphocytic leukemia; Internal medicine; Gene; Genetics; Downregulation and upregulation; Translation (biology)","score_opus":0.03089501745174479,"score_gpt":0.2949990361260349,"score_spread":0.2641040186742901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386024691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943104,0.0005352083,0.0015857237,0.0014136648,0.00008735815,0.0009608354,0.00037313823,0.00017334572,0.000560341],"genre_scores_gemma":[0.9810975,0.00007966819,0.0040313723,0.00043654733,0.00018225025,0.00029771624,0.0005210466,0.00008636045,0.013267547],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981765,0.000036139845,0.00035618307,0.00050486636,0.00038105017,0.0005452233],"domain_scores_gemma":[0.99886376,0.00033329253,0.00007160447,0.0002635077,0.00028385958,0.00018400523],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036481876,0.00022023279,0.00036716173,0.00015202034,0.00010611271,0.00003584799,0.00011428722,0.00019573022,0.00032599535],"category_scores_gemma":[0.0003322891,0.00019762623,0.000074322226,0.0010027607,0.00011854322,0.00009168006,0.00007097868,0.00042211366,0.00005228422],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015538097,0.00079096586,0.0761003,0.006928741,0.0011013714,0.0030095044,0.0067294934,0.0027683626,0.7375064,0.00427511,0.12615491,0.019096758],"study_design_scores_gemma":[0.060890887,0.0020166642,0.07770459,0.008702265,0.00034602705,0.00042387503,0.016919563,0.20525043,0.43116617,0.004421095,0.18942448,0.002733929],"about_ca_topic_score_codex":0.00018873702,"about_ca_topic_score_gemma":0.0004720783,"teacher_disagreement_score":0.3063402,"about_ca_system_score_codex":0.0006088196,"about_ca_system_score_gemma":0.0008361755,"threshold_uncertainty_score":0.80589634},"labels":[],"label_agreement":null},{"id":"W4386052241","doi":"10.1097/01.hs9.0000969572.68411.a2","title":"P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Discontinuation; Medicine; Myeloid leukemia; Internal medicine; Observational study; Clinical endpoint; Cohort; Oncology; Pediatrics; Clinical trial","score_opus":0.028180351054470837,"score_gpt":0.33715202625971846,"score_spread":0.3089716752052476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386052241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947223,0.001069494,0.00003542969,0.000077131175,0.00015758988,0.003590537,0.00017352084,0.000054872755,0.00011910741],"genre_scores_gemma":[0.9975869,0.000118111355,0.0001837551,0.00000804324,0.00014980348,0.00048204628,0.00038327157,0.000047394184,0.001040658],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971887,0.00013898575,0.0009366291,0.00055326486,0.00072472834,0.00045773375],"domain_scores_gemma":[0.99793947,0.00020572133,0.0006463713,0.0008662943,0.00024704778,0.00009507038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004582256,0.00031464166,0.0008836727,0.0002864021,0.00011482207,0.000012475138,0.0002253121,0.00014495614,0.00023680327],"category_scores_gemma":[0.0002997632,0.0002154928,0.00041416058,0.002784287,0.0001265521,0.0001123034,0.00016611133,0.0002517723,0.000014334414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001417642,0.004128883,0.9174122,0.0008704857,0.002308604,0.000025428584,0.0018344697,0.0039612344,0.009409769,0.000026473672,0.002356439,0.056248374],"study_design_scores_gemma":[0.060870692,0.008210506,0.80916816,0.0017464267,0.006524878,0.0000018169038,0.0011401956,0.039627057,0.0714322,0.000054647582,0.0007856061,0.00043782927],"about_ca_topic_score_codex":0.0003781215,"about_ca_topic_score_gemma":0.0018630842,"teacher_disagreement_score":0.10824406,"about_ca_system_score_codex":0.003225323,"about_ca_system_score_gemma":0.0015227984,"threshold_uncertainty_score":0.8787541},"labels":[],"label_agreement":null},{"id":"W4386052329","doi":"10.1097/01.hs9.0000970512.51896.93","title":"P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Carfilzomib; Medicine; Tolerability; Internal medicine; Multiple myeloma; Lenalidomide; Dexamethasone; Adverse effect; Oncology; Gastroenterology","score_opus":0.10469259072811767,"score_gpt":0.41219825223623924,"score_spread":0.3075056615081216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386052329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893883,0.0014747715,0.00008161266,0.002338929,0.00020704576,0.0027663198,0.00087660295,0.00023360139,0.002632851],"genre_scores_gemma":[0.9804574,0.00096787384,0.003581372,0.00040179896,0.0005263924,0.0005622405,0.0013416256,0.00008581524,0.012075459],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99798006,0.00009340203,0.0003978259,0.0006213905,0.00036788176,0.0005394193],"domain_scores_gemma":[0.9980077,0.00085462077,0.00010071064,0.0005367277,0.000106096915,0.00039414715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036911035,0.0002760583,0.0005594388,0.00009059879,0.00012917696,0.00006266641,0.000114824004,0.00015690297,0.0005705675],"category_scores_gemma":[0.0010358538,0.00021230093,0.0001783676,0.00029984393,0.000098944976,0.000096079486,0.00007628425,0.00020390374,0.00027528233],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46400905,0.0022935271,0.000702156,0.000151414,0.0012320937,0.0010377351,0.0020378565,5.991328e-7,0.038727347,0.000085766704,0.06764376,0.4220787],"study_design_scores_gemma":[0.82021606,0.011248103,0.0036937026,0.00032450026,0.00017024619,0.000037720998,0.001787453,0.0014262593,0.035611268,0.0010728467,0.12396225,0.00044958925],"about_ca_topic_score_codex":0.0008749697,"about_ca_topic_score_gemma":0.00009959506,"teacher_disagreement_score":0.42162913,"about_ca_system_score_codex":0.00007538156,"about_ca_system_score_gemma":0.0001741117,"threshold_uncertainty_score":0.8657381},"labels":[],"label_agreement":null},{"id":"W4386052515","doi":"10.1097/01.hs9.0000970592.64148.2c","title":"P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Population; Logistic regression; Multiple myeloma; Inverse probability weighting; Internal medicine; Relative risk; Propensity score matching; Confidence interval; Environmental health","score_opus":0.12420305222523104,"score_gpt":0.4449858585240313,"score_spread":0.32078280629880024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386052515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99224126,0.0006862694,0.00007531207,0.0008932059,0.00007878327,0.0021097693,0.00009415439,0.00012075327,0.0037005164],"genre_scores_gemma":[0.9955618,0.00028381537,0.0024318406,0.000046781774,0.00014614257,0.00017590153,0.00015337166,0.000036331283,0.001164017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973436,0.0006144152,0.0005262269,0.0005015723,0.0007218535,0.00029232854],"domain_scores_gemma":[0.996821,0.001757217,0.0002727024,0.0006521479,0.00031297395,0.00018399586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057003467,0.00024303261,0.00083968445,0.00007325499,0.00017183344,0.000046360565,0.00013246218,0.0000668406,0.0002678418],"category_scores_gemma":[0.00043973816,0.00013676347,0.00013945789,0.0006564416,0.00033926193,0.00013012241,0.0001253754,0.0003725239,0.00005436533],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008988771,0.0012610668,0.9784128,0.000023985878,0.004264537,0.00020149934,0.002898769,0.000019648165,0.00029092262,0.0001693399,0.001492491,0.0019761727],"study_design_scores_gemma":[0.03203022,0.0009510101,0.94038475,0.00012645514,0.0012040146,0.0000028232967,0.023179784,0.0010437864,0.0006177767,0.000104729384,0.00023032917,0.00012434213],"about_ca_topic_score_codex":0.021733519,"about_ca_topic_score_gemma":0.021993171,"teacher_disagreement_score":0.03802807,"about_ca_system_score_codex":0.00006524436,"about_ca_system_score_gemma":0.00016055614,"threshold_uncertainty_score":0.9958529},"labels":[],"label_agreement":null},{"id":"W4386056422","doi":"10.1097/01.hs9.0000972800.74418.67","title":"P1479: COMORBIDITIES AND COMPLICATIONS IN ADULTS WITH PYRUVATE KINASE DEFICIENCY ACCORDING TO HEMOGLOBIN STRATA – A DESCRIPTIVE ANALYSIS FROM THE PEAK REGISTRY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Erythrocyte Function and Pathophysiology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Pyruvate kinase deficiency; Anemia; Internal medicine; Cohort; Hemoglobin; Pediatrics; Pyruvate kinase; Gastroenterology","score_opus":0.031007830066508996,"score_gpt":0.2682154489006635,"score_spread":0.2372076188341545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386056422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99418896,0.00028740498,0.0005347637,0.0021558546,0.000043100958,0.00032319422,0.000102843114,0.00008729163,0.0022765724],"genre_scores_gemma":[0.99793655,0.00007648718,0.0005076896,0.00065563625,0.000051196243,0.00006864258,0.0002405619,0.000013330287,0.0004498806],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990622,0.000052333766,0.00018487887,0.0003516236,0.00013573308,0.00021324267],"domain_scores_gemma":[0.99915576,0.000168273,0.000063620035,0.00043970958,0.00007355837,0.00009908279],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008971221,0.00013644471,0.00027816178,0.000082398314,0.00014255656,0.0000252018,0.00009197834,0.000057282698,0.00011544737],"category_scores_gemma":[0.00007438866,0.0000929772,0.000051764637,0.0013893165,0.00011545376,0.000053848285,0.00006709102,0.00017596204,0.000058573594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017892513,0.00035923911,0.92951316,0.00027831385,0.00055541453,0.0003778464,0.018192457,0.0015798971,0.022084305,0.0027973938,0.018295255,0.0041774637],"study_design_scores_gemma":[0.0012536971,0.00025697544,0.9300058,0.0003297688,0.00025160986,0.000015865293,0.06497131,0.0012536425,0.0003046646,0.00025619465,0.00091685745,0.00018359923],"about_ca_topic_score_codex":0.0015577044,"about_ca_topic_score_gemma":0.004218662,"teacher_disagreement_score":0.046778854,"about_ca_system_score_codex":0.000043941458,"about_ca_system_score_gemma":0.00006568696,"threshold_uncertainty_score":0.37915},"labels":[],"label_agreement":null},{"id":"W4386067267","doi":"10.1097/01.hs9.0000971056.91985.c2","title":"P1040: FACTORS ASSOCIATED WITH THROMBOSIS IN MYELOFIBROSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Polycythemia vera; Internal medicine; Hazard ratio; Thrombosis; Population; Incidence (geometry); Diabetes mellitus; Proportional hazards model; Surgery; Confidence interval; Bone marrow","score_opus":0.06777147028570386,"score_gpt":0.29968683444939304,"score_spread":0.23191536416368919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386067267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99049634,0.00008532175,0.000003802791,0.001095289,0.00005436985,0.00044915415,0.00002431914,0.0002153501,0.007576075],"genre_scores_gemma":[0.99726355,0.00008984297,0.000119864555,0.00018050277,0.000029912137,0.00013819657,0.0001806801,0.000042425923,0.0019550412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987029,0.00004233447,0.00021701929,0.00033516964,0.0003276454,0.00037493953],"domain_scores_gemma":[0.9992834,0.00022009989,0.00006421894,0.00022896488,0.00006584689,0.00013747714],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009625801,0.00022626776,0.00045065433,0.00008802553,0.0000740303,0.00002179373,0.000050592913,0.00011670908,0.00097129465],"category_scores_gemma":[0.000116069226,0.00015303238,0.0000865113,0.00088512205,0.000044804503,0.00007058583,0.00003077381,0.00014742024,0.0002071104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000034412722,0.00035576813,0.99288905,0.000037067486,0.0002145102,0.000084941086,0.0007195272,0.000022502063,0.0004490697,0.00022642703,0.0045520626,0.00041463866],"study_design_scores_gemma":[0.0020673436,0.00044817588,0.9871432,0.0004203486,0.00009158393,0.0000022255938,0.0008411756,0.00008892924,0.0077423365,0.000051821175,0.0009304649,0.00017235686],"about_ca_topic_score_codex":0.00012403452,"about_ca_topic_score_gemma":0.00081725715,"teacher_disagreement_score":0.0072932667,"about_ca_system_score_codex":0.00018232572,"about_ca_system_score_gemma":0.00008917686,"threshold_uncertainty_score":0.99994195},"labels":[],"label_agreement":null},{"id":"W4386067414","doi":"10.1097/01.hs9.0000971928.33191.75","title":"P1260: BIODISTRIBUTION OF LABELED AUTOLOGOUS AND ALLOGENEIC BONE MARROW MESENCHYMAL STROMAL CELLS IN RABBITS AFTER INTRAVENOUS ADMINISTRATION","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Mesenchymal stem cell research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biodistribution; Mesenchymal stem cell; Bone marrow; Spleen; Stromal cell; Transplantation; Chemistry; Pathology; Medicine; Molecular biology; Immunology; Biology; Internal medicine; In vitro","score_opus":0.01974192186846984,"score_gpt":0.28189397711218633,"score_spread":0.2621520552437165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386067414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968821,0.00082728075,0.000037810216,0.0005053216,0.000085092484,0.0006416968,0.00007923887,0.00006909198,0.00087236456],"genre_scores_gemma":[0.9974587,0.00016494322,0.0004212307,0.000024440462,0.000058283567,0.000062465915,0.00016549858,0.000021893336,0.0016225554],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99805635,0.00011948694,0.00046844786,0.0003894055,0.00046569147,0.0005006355],"domain_scores_gemma":[0.9991555,0.00011308637,0.00009770121,0.00027965842,0.00014933903,0.00020469032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000496481,0.00018881164,0.00044251088,0.00013622372,0.000041919124,0.000018002156,0.000072202354,0.00023461264,0.0006427081],"category_scores_gemma":[0.00018944454,0.00017459242,0.000052004172,0.000834071,0.0001443092,0.00006395567,0.0000828268,0.00026284487,0.00010758245],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018167709,0.00038122875,0.08481647,0.0012659937,0.00007419901,0.003096039,0.00047413335,0.000014268987,0.89278907,0.0002644781,0.0016084326,0.013398891],"study_design_scores_gemma":[0.004425286,0.0027273414,0.456491,0.00045529715,0.00009735454,0.00051745115,0.0008442777,0.0015865038,0.53013027,0.00015885217,0.0021300286,0.0004363475],"about_ca_topic_score_codex":0.000087221306,"about_ca_topic_score_gemma":0.00029133595,"teacher_disagreement_score":0.37167454,"about_ca_system_score_codex":0.00009540493,"about_ca_system_score_gemma":0.00030326826,"threshold_uncertainty_score":0.71196723},"labels":[],"label_agreement":null},{"id":"W4386071127","doi":"10.1097/01.hs9.0000971044.20101.d8","title":"P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Internal medicine; Exacerbation; Gastroenterology; Anemia; Bone marrow","score_opus":0.012963645255667799,"score_gpt":0.2547533797614052,"score_spread":0.24178973450573743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386071127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973342,0.00015347774,0.0000078483245,0.00035674454,0.000035630266,0.0010198163,0.00007134265,0.000017812865,0.0010031665],"genre_scores_gemma":[0.9973442,0.00009369574,0.0019357523,0.000018010835,0.000019959754,0.00015435825,0.000092075985,0.000019690942,0.00032225432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99911714,0.000022859347,0.000295868,0.00022764568,0.00018231713,0.00015417383],"domain_scores_gemma":[0.9993396,0.0001094279,0.000114736504,0.00017362165,0.00020306098,0.00005954344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000089750916,0.00012387882,0.0004255393,0.00006392772,0.000030688665,0.0000046031982,0.000025992336,0.00006123562,0.000054149157],"category_scores_gemma":[0.00006108895,0.00009282611,0.00004895837,0.00023653783,0.00008341991,0.00005156794,0.000021096095,0.00004476511,0.000002510846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009853087,0.00047162405,0.9873365,0.00068905135,0.00014495895,0.0000057159136,0.00067034725,0.000004143727,0.0006701293,0.0011751505,0.00092276203,0.0069242725],"study_design_scores_gemma":[0.007600584,0.0018070095,0.96072996,0.00093008793,0.00015370887,0.000006752213,0.0009225365,0.000025592191,0.0272898,0.00013348163,0.00028310245,0.00011738559],"about_ca_topic_score_codex":0.0000558004,"about_ca_topic_score_gemma":0.000040355306,"teacher_disagreement_score":0.02661967,"about_ca_system_score_codex":0.000028713139,"about_ca_system_score_gemma":0.00005813518,"threshold_uncertainty_score":0.37853387},"labels":[],"label_agreement":null},{"id":"W4386074452","doi":"10.1097/01.hs9.0000970600.40043.b8","title":"P924: TREATMENT PATTERNS OF TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM) ACROSS THE UNITED STATES (US), CANADA, AND WESTERN EUROPE: A REAL-WORLD OBSERVATIONAL CHART REVIEW STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Pediatrics","score_opus":0.0849770091517209,"score_gpt":0.35531216676179295,"score_spread":0.27033515761007204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386074452","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938963,0.0009090441,9.518878e-7,0.0019676804,0.00006510081,0.0021671336,0.0005381789,0.00007066639,0.00038493026],"genre_scores_gemma":[0.94034815,0.008534027,0.000019574143,0.0006586087,0.000072044284,0.00032204887,0.0013866293,0.00006066477,0.04859827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755967,0.00023097932,0.0005360613,0.0004298563,0.0007380804,0.0005053492],"domain_scores_gemma":[0.99807566,0.0005137555,0.00019525575,0.0006339857,0.0002973741,0.00028396185],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033425342,0.00031526553,0.0006020257,0.0000652025,0.00020523445,0.000025315541,0.00015456564,0.000039802904,0.00019716118],"category_scores_gemma":[0.00020570183,0.00019685771,0.00008398454,0.00075405533,0.000080086225,0.00007054484,0.0001331945,0.00018108638,0.00003286461],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027780706,0.0005574554,0.98647904,0.00069837604,0.0004929728,0.0005864354,0.000696496,0.0000056049516,0.00006319829,0.000009828792,0.0048244274,0.0053083827],"study_design_scores_gemma":[0.004358725,0.0007590537,0.91766167,0.0007305217,0.00013714499,0.000015440717,0.0007663649,0.00029794715,0.00012866981,0.000002642877,0.07499481,0.00014699029],"about_ca_topic_score_codex":0.39241314,"about_ca_topic_score_gemma":0.7832732,"teacher_disagreement_score":0.3908601,"about_ca_system_score_codex":0.00031973497,"about_ca_system_score_gemma":0.0005045729,"threshold_uncertainty_score":0.80276245},"labels":[],"label_agreement":null},{"id":"W4386074681","doi":"10.1097/01.hs9.0000970832.89903.8f","title":"P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Pomalidomide; Lenalidomide; Dexamethasone; Medicine; Multiple myeloma; Refractory (planetary science); Bortezomib; Internal medicine; Gastroenterology; Oncology","score_opus":0.029152733148670517,"score_gpt":0.30257578674165714,"score_spread":0.27342305359298663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386074681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99754983,0.00075872336,0.000015704882,0.00047598634,0.0000143952775,0.00093705714,0.00002750947,0.000030569496,0.00019020712],"genre_scores_gemma":[0.9957427,0.0007161667,0.0028051955,0.000020199832,0.000013751086,0.000038054655,0.000047561913,0.00002904798,0.0005873321],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984756,0.00013572167,0.0004259776,0.0003502127,0.00031898078,0.00029348192],"domain_scores_gemma":[0.9983729,0.0009856769,0.00013891839,0.00024268938,0.00009676376,0.00016305788],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042207117,0.00018307366,0.00055162964,0.00018789066,0.00003791312,0.000007642125,0.000051233314,0.00012121943,0.00004118807],"category_scores_gemma":[0.0008731886,0.0001366574,0.000023651104,0.00055799703,0.00018347113,0.00009192094,0.00007471309,0.00022174645,0.0000030860604],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036008187,0.0012074689,0.8495439,0.0013804499,0.00016663462,0.00080854783,0.001816017,0.00003058249,0.034147505,0.00006193488,0.00010892123,0.07471982],"study_design_scores_gemma":[0.03968877,0.0017166116,0.9461095,0.0010847453,0.00003554824,0.00004228012,0.0008873795,0.0055742217,0.0045568766,0.000024946996,0.00014984635,0.0001293029],"about_ca_topic_score_codex":0.0007494027,"about_ca_topic_score_gemma":0.0017277085,"teacher_disagreement_score":0.09656554,"about_ca_system_score_codex":0.00007103496,"about_ca_system_score_gemma":0.0001247949,"threshold_uncertainty_score":0.5572727},"labels":[],"label_agreement":null},{"id":"W4386074702","doi":"10.1097/01.hs9.0000971004.26914.cb","title":"P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Discontinuation; Phases of clinical research; Clinical endpoint; Gastroenterology; Oncology; Bone marrow; Clinical trial","score_opus":0.012602810886682003,"score_gpt":0.2505186048097666,"score_spread":0.23791579392308462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386074702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945327,0.00006485655,0.000004501986,0.001107321,0.000037946003,0.003261402,0.0004708402,0.00009066386,0.00042974585],"genre_scores_gemma":[0.99655014,0.00006477155,0.0010817377,0.00007121772,0.00003080164,0.0006307629,0.0006926198,0.00006201811,0.00081590324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99791044,0.00014512421,0.0005295363,0.0006241206,0.00034382907,0.00044695343],"domain_scores_gemma":[0.9982225,0.0006318826,0.00019255714,0.00044036482,0.00028956847,0.00022313371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002451084,0.00040486341,0.00080926734,0.00011963129,0.0001204329,0.000020596115,0.000055753128,0.00013400408,0.00020808025],"category_scores_gemma":[0.00011942468,0.0002631165,0.00008851962,0.00051985716,0.00016894759,0.00010583806,0.00003863361,0.00010507849,0.000016046193],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068550915,0.0028930127,0.92371345,0.00033699,0.00030963638,0.00008417242,0.0008722204,0.000011226671,0.00040225196,0.00026153197,0.0005400909,0.0020244974],"study_design_scores_gemma":[0.030546116,0.015814023,0.9389118,0.00061265274,0.00023527077,0.000013511083,0.000725039,0.0000868588,0.011822958,0.00005204246,0.0009140368,0.00026569684],"about_ca_topic_score_codex":0.0001324024,"about_ca_topic_score_gemma":0.0006513128,"teacher_disagreement_score":0.038004797,"about_ca_system_score_codex":0.00027019763,"about_ca_system_score_gemma":0.00022007793,"threshold_uncertainty_score":0.9999821},"labels":[],"label_agreement":null},{"id":"W4386086931","doi":"10.1097/01.hs9.0000973480.97414.1e","title":"P1652: SAFETY OF DOACS IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Atrial Fibrillation Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; McMaster University","funders":"","keywords":"Medicine; Kidney disease; Internal medicine; Odds ratio; Randomized controlled trial; Atrial fibrillation; Meta-analysis; Regimen; Intensive care medicine","score_opus":0.1055429017719886,"score_gpt":0.3659588355980062,"score_spread":0.2604159338260176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386086931","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.049226e-7,0.99321896,0.000012422971,0.0002329931,0.000015449114,0.006182049,0.0001582761,0.00003494436,0.00014442594],"genre_scores_gemma":[0.00000866331,0.991388,0.0000553891,0.00011146416,0.000032246808,0.00010721084,0.0006782534,0.000052384697,0.007566387],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9972255,0.00024967312,0.0014181423,0.00041047833,0.000501992,0.00019420788],"domain_scores_gemma":[0.9978754,0.00020239703,0.0008827994,0.0007357124,0.000094766845,0.00020893522],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045760896,0.0004121549,0.009520803,0.00023592042,0.000025646174,0.000012346168,0.00011291957,0.000099970624,0.0010769289],"category_scores_gemma":[0.00039014025,0.00022573443,0.0018685849,0.0018422408,0.000036732334,0.000053867803,0.000094410294,0.00014164316,0.0000513686],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014070642,0.000008521182,0.0008190998,0.903747,0.09468177,0.000007798097,0.000003860907,0.0000011609524,2.6086808e-10,0.00007021679,0.00028140898,0.0003650516],"study_design_scores_gemma":[0.00042504023,0.000038455666,0.0004355337,0.14638864,0.80369663,4.295387e-7,0.0000024040164,0.0000023629927,2.1048834e-9,0.0000022756863,0.048830934,0.00017730524],"about_ca_topic_score_codex":0.000008911744,"about_ca_topic_score_gemma":0.00001889926,"teacher_disagreement_score":0.7573584,"about_ca_system_score_codex":0.00013070535,"about_ca_system_score_gemma":0.00024522055,"threshold_uncertainty_score":0.9998362},"labels":[],"label_agreement":null},{"id":"W4386086960","doi":"10.1097/01.hs9.0000974964.49920.9c","title":"PB2039: INFLAMMATORY MARKERS IN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS - A SINGLE CENTRE STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Hemophagocytic lymphohistiocytosis; Cytokine storm; Immunology; Macrophage activation syndrome; Pathological; Interleukin 6; Cytokine; Disease; Internal medicine; Coronavirus disease 2019 (COVID-19)","score_opus":0.02510371736495814,"score_gpt":0.285268429296139,"score_spread":0.26016471193118085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386086960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827894,0.0005300295,0.0000026692207,0.00044209577,0.00010300204,0.0010722263,0.000002891183,0.00030550454,0.014752197],"genre_scores_gemma":[0.98460853,0.0000459527,0.000040439718,0.0001300849,0.000055048255,0.00008683171,0.000025625843,0.00006197123,0.0149455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977219,0.00012265769,0.0005265535,0.00042483394,0.00057282235,0.00063124584],"domain_scores_gemma":[0.9990185,0.000093892726,0.00007583467,0.0005548575,0.00008390458,0.00017301131],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000471849,0.00023525451,0.00047492402,0.00024085164,0.000106114676,0.00003268174,0.00016726633,0.00013023555,0.001906238],"category_scores_gemma":[0.0002553298,0.00022560211,0.00012486885,0.000998314,0.000091614165,0.00013874138,0.00015238098,0.00026978107,0.0021957366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009436556,0.0018702247,0.9262109,0.00080453954,0.00023375517,0.0041728807,0.0043011243,0.00013574697,0.007360237,0.000088150366,0.026852373,0.027026406],"study_design_scores_gemma":[0.014784793,0.00088610826,0.9002953,0.0006223472,0.00011010982,0.00005827204,0.0473739,0.0027318392,0.0022710243,0.00008774076,0.030055774,0.00072276243],"about_ca_topic_score_codex":0.000091856535,"about_ca_topic_score_gemma":0.00015502746,"teacher_disagreement_score":0.043072775,"about_ca_system_score_codex":0.00039957985,"about_ca_system_score_gemma":0.00037461455,"threshold_uncertainty_score":0.99900615},"labels":[],"label_agreement":null},{"id":"W4386086990","doi":"10.1097/01.hs9.0000973548.20044.8c","title":"P1669: DIRECT ORAL ANTICOAGULANTS VS LOW MOLECULAR WEIGHT HEPARIN IN THE MANAGEMENT OF PATIENTS WITH PRIMARY OR METASTATIC BRAIN TUMOURS: A SYSTEMATIC REVIEW AND META-ANALYSIS","year":2023,"lang":"en","type":"review","venue":"HemaSphere","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Meta-analysis; Low molecular weight heparin; Randomized controlled trial; Thrombosis; Malignancy; Internal medicine; Brain metastasis; Heparin; Population; Oncology; Intensive care medicine; Cancer; Metastasis","score_opus":0.06731445474866142,"score_gpt":0.3424315651224318,"score_spread":0.27511711037377035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386086990","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000039819864,0.9889602,0.000033922122,0.00019806183,0.0000103326865,0.010239635,0.00031752,0.00002693783,0.00017357677],"genre_scores_gemma":[0.00010525004,0.9930664,0.0021761477,0.00069034536,0.000004020644,0.0019442906,0.00079696515,0.00009745569,0.0011191766],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9950322,0.0013432587,0.0015616731,0.00072132057,0.0009537273,0.00038780225],"domain_scores_gemma":[0.9969963,0.0005118536,0.00097269646,0.0013094007,0.00008694862,0.00012284327],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015477246,0.0007767026,0.0128286695,0.00023134457,0.000041748655,0.000036778074,0.00029766207,0.00007919895,0.0002719738],"category_scores_gemma":[0.00007234957,0.00031951861,0.0017639474,0.0022478548,0.0000728027,0.00004842796,0.00013358255,0.0002380926,0.000024214612],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003159952,0.00046286554,0.000021284104,0.7530253,0.24345158,0.0014200232,0.000021648315,8.904581e-7,1.7936327e-9,0.000042417287,0.00019888312,0.0013234951],"study_design_scores_gemma":[0.0007624473,0.00025631473,0.00012805204,0.12457833,0.8717964,0.000051213792,0.000039626164,0.0000030234269,1.3273261e-7,0.000005124736,0.0020990698,0.0002802136],"about_ca_topic_score_codex":0.000048385562,"about_ca_topic_score_gemma":0.00006485983,"teacher_disagreement_score":0.628447,"about_ca_system_score_codex":0.00009943016,"about_ca_system_score_gemma":0.000111532085,"threshold_uncertainty_score":0.9999257},"labels":[],"label_agreement":null},{"id":"W4386101054","doi":"10.1097/01.hs9.0000974564.02780.6b","title":"PB1936: IDENTIFYING INEQUITIES IN SUPPORT - GLOBAL SURVEY OF PATIENT ORGANISATIONS DELIVERING SUPPORT SERVICES FOR CLL PATIENTS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Service delivery framework; Medicine; Service (business); Business; Health care; Economic growth; Political science; Marketing","score_opus":0.04832421620977106,"score_gpt":0.34331737036039095,"score_spread":0.2949931541506199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386101054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99738413,0.000048762075,0.000036927766,0.000047774345,0.00018788391,0.00081313687,0.00034477,0.00008313132,0.001053466],"genre_scores_gemma":[0.9978232,0.00004731239,0.0003037294,0.000107329324,0.00003273475,0.00007902276,0.0011472646,0.000037773414,0.00042167702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978022,0.00005323596,0.0006392949,0.0003319359,0.00064605207,0.00052727375],"domain_scores_gemma":[0.99868494,0.00019548282,0.00014773502,0.00035035756,0.00048251648,0.00013897377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004962848,0.00017291712,0.000409175,0.000104036815,0.000067851535,0.000023322962,0.00017273528,0.00011806037,0.00056524324],"category_scores_gemma":[0.00029154355,0.00017046269,0.000083208164,0.0008590762,0.00006328653,0.00016737767,0.000252334,0.00010018808,0.0001218811],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049787626,0.00039433173,0.9787626,0.0035117366,0.00014060258,0.000115713636,0.004551335,0.00021992833,0.00042745803,0.00015711368,0.0062791356,0.0049421503],"study_design_scores_gemma":[0.019922355,0.0011727528,0.95719284,0.0005546829,0.00009352263,0.000038482172,0.0048478683,0.005545855,0.007141942,0.00025973984,0.0027889132,0.0004410549],"about_ca_topic_score_codex":0.00956144,"about_ca_topic_score_gemma":0.008184967,"teacher_disagreement_score":0.021569788,"about_ca_system_score_codex":0.0038019286,"about_ca_system_score_gemma":0.0027627468,"threshold_uncertainty_score":0.99703395},"labels":[],"label_agreement":null},{"id":"W4386101150","doi":"10.1097/01.hs9.0000975152.94267.34","title":"PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Confidence interval; Observational study; MEDLINE; Oncology; Malignancy; Multivariate analysis; Clinical trial; Refractory (planetary science); Intensive care medicine","score_opus":0.03682725364071148,"score_gpt":0.31982114756770513,"score_spread":0.28299389392699364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386101150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6229025,0.35136864,0.00016566274,0.0009565694,0.0005262025,0.020145714,0.0006190187,0.0007272528,0.0025884672],"genre_scores_gemma":[0.9646528,0.022926057,0.001288401,0.00017986678,0.0001247172,0.0013046911,0.0012283784,0.000101009806,0.008194072],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99797904,0.00010221559,0.00057668047,0.00034897582,0.00053404464,0.0004590471],"domain_scores_gemma":[0.9973895,0.0011909235,0.0002051519,0.00057366624,0.00037286684,0.00026787567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033321974,0.0002661146,0.0008887909,0.00011372772,0.00008141246,0.000018073066,0.00013705925,0.00014385257,0.0001784552],"category_scores_gemma":[0.0050835637,0.00017814524,0.00035261104,0.0007278178,0.000049503455,0.00009944198,0.000051761876,0.00019609256,0.00016211746],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002119892,0.00037593732,0.039536662,0.94276834,0.0004708833,0.00029963837,0.00049213704,6.3884437e-7,0.0013642428,0.000084973515,0.013130765,0.001263775],"study_design_scores_gemma":[0.007987758,0.002047181,0.06378498,0.91250145,0.00096150395,0.00014160837,0.0010315656,0.0010307584,0.0050253505,0.00008992395,0.0048812237,0.0005167144],"about_ca_topic_score_codex":0.0000063754674,"about_ca_topic_score_gemma":0.000007490466,"teacher_disagreement_score":0.34175032,"about_ca_system_score_codex":0.00007986255,"about_ca_system_score_gemma":0.00012924896,"threshold_uncertainty_score":0.7264553},"labels":[],"label_agreement":null},{"id":"W4386102508","doi":"10.1097/01.hs9.0000975836.58931.97","title":"PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Obinutuzumab; Medicine; Ibrutinib; Lenalidomide; Rituximab; Internal medicine; Oncology; Follicular lymphoma; Mantle cell lymphoma; Chronic lymphocytic leukemia; Salvage therapy; Phases of clinical research; Idelalisib; Lymphoma; Clinical trial; Chemotherapy; Leukemia; Multiple myeloma","score_opus":0.03128032831111953,"score_gpt":0.3233636286600862,"score_spread":0.2920833003489667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386102508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99531215,0.00028730094,0.00006306699,0.0002206457,0.00028233524,0.002743924,0.000090793335,0.00020035476,0.00079941907],"genre_scores_gemma":[0.9894922,0.0002683053,0.0008767716,0.00011189769,0.00024782843,0.0001418659,0.00027870637,0.0001494524,0.008432989],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949292,0.0002219277,0.0010900098,0.000872205,0.0017659727,0.0011207111],"domain_scores_gemma":[0.9972316,0.0005571602,0.0003877991,0.0011014793,0.00035244267,0.00036953375],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007347649,0.0005419354,0.0017345538,0.000382524,0.0001262041,0.000043840522,0.0003692929,0.0003556925,0.0011281626],"category_scores_gemma":[0.0009648347,0.00036569676,0.00023907212,0.0017391903,0.00040135664,0.00025647876,0.00025631214,0.0003879709,0.00024308915],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9587897,0.006759949,0.0023244848,0.0023598978,0.00066202425,0.010335841,0.0013640784,0.00008516418,0.0006409895,0.000059868238,0.008511226,0.00810676],"study_design_scores_gemma":[0.9699979,0.008523464,0.003528179,0.001734115,0.00025875837,0.00017049574,0.0009382792,0.0049335123,0.0025124692,0.000010715983,0.006859922,0.00053222844],"about_ca_topic_score_codex":0.0011023292,"about_ca_topic_score_gemma":0.00029833688,"teacher_disagreement_score":0.011208143,"about_ca_system_score_codex":0.006687527,"about_ca_system_score_gemma":0.013001374,"threshold_uncertainty_score":0.9998795},"labels":[],"label_agreement":null},{"id":"W4386122831","doi":"10.1097/01.hs9.0000977204.63685.a6","title":"PB2629: LATE DIAGNOSIS OF TWO ADULT SIBLINGS WITH BERNARD SOULIER SYNDROME (BSS)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Platelet Disorders and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Bernard–Soulier syndrome; Medicine; Tranexamic acid; Ristocetin; Von Willebrand disease; Platelet; Von Willebrand factor; Vaginal bleeding; Coagulation; Pediatrics; Desmopressin; Platelet disorder; Bleeding time; Severe bleeding; Surgery; Internal medicine; Pregnancy; Platelet aggregation; Blood loss","score_opus":0.013356147804806491,"score_gpt":0.2661488682950382,"score_spread":0.2527927204902317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386122831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99228346,0.00028261758,0.000007932244,0.0010782833,0.00005131633,0.00031699843,0.000026939275,0.00014361646,0.0058088275],"genre_scores_gemma":[0.9933975,0.0004572527,0.00059374876,0.00025821535,0.000021665272,0.000085000516,0.00006196884,0.000046594658,0.005078103],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99890244,0.000011867658,0.00020846787,0.00026627744,0.00030383377,0.00030711558],"domain_scores_gemma":[0.99933434,0.0000598709,0.00008748923,0.00028121233,0.00010222691,0.00013489062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000042339645,0.00018193762,0.00043797647,0.000073443254,0.000043653505,0.000009792974,0.00006900362,0.000074163094,0.00069339527],"category_scores_gemma":[0.000031235806,0.00013252687,0.000100545,0.0005814098,0.000059080612,0.00007016046,0.00003659662,0.0001176152,0.0005675878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035712158,0.0007257833,0.9656429,0.00052158517,0.0009437047,0.010563566,0.000703839,0.000091147966,0.0006285048,0.00035231953,0.012695104,0.006774389],"study_design_scores_gemma":[0.07077443,0.0092110885,0.80479896,0.0073848795,0.0037559536,0.004854851,0.0038575756,0.0027049852,0.053895008,0.0069551733,0.02920123,0.0026058736],"about_ca_topic_score_codex":0.0002736882,"about_ca_topic_score_gemma":0.0001233517,"teacher_disagreement_score":0.16084398,"about_ca_system_score_codex":0.000025342682,"about_ca_system_score_gemma":0.000049184022,"threshold_uncertainty_score":0.75921917},"labels":[],"label_agreement":null},{"id":"W4386142904","doi":"10.1097/01.hs9.0000969492.96103.aa","title":"P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Observational study; Clinical trial; IGHV@; Chronic lymphocytic leukemia; Demography; Pediatrics; Oncology; Leukemia","score_opus":0.02100252222309458,"score_gpt":0.306741845796958,"score_spread":0.28573932357386345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386142904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956576,0.000032202806,0.0000019116899,0.00021728394,0.00005326491,0.00061553036,0.000027297612,0.00009845541,0.003296452],"genre_scores_gemma":[0.9868637,0.00017243675,0.0000433047,0.00006187938,0.000055598335,0.00011285445,0.00009684118,0.00003805089,0.012555339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99860126,0.000033538887,0.00021573865,0.00031420856,0.00039739851,0.000437851],"domain_scores_gemma":[0.99930686,0.00015039482,0.000040799878,0.0002964479,0.000041207455,0.00016426574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000081133796,0.0001904258,0.0003820979,0.0001153581,0.000053443666,0.00002750628,0.000055012333,0.00006585957,0.00022139224],"category_scores_gemma":[0.0000376568,0.00012772724,0.000046024754,0.00032244023,0.00011094617,0.000086705935,0.000073963034,0.000117404714,0.000053547185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020666132,0.00015258703,0.9946126,0.00016445787,0.00006349715,0.0003054458,0.0005456079,0.0000072865346,9.055301e-7,0.0000699984,0.00042933424,0.0034416323],"study_design_scores_gemma":[0.017141271,0.00030443238,0.9808032,0.0002048353,0.000035877685,0.0000030277322,0.00024068951,0.00050759467,0.00006991711,0.000027950085,0.0005285261,0.00013269055],"about_ca_topic_score_codex":0.024864458,"about_ca_topic_score_gemma":0.06262717,"teacher_disagreement_score":0.03776271,"about_ca_system_score_codex":0.0033676012,"about_ca_system_score_gemma":0.0006186512,"threshold_uncertainty_score":0.9816291},"labels":[],"label_agreement":null},{"id":"W4386143084","doi":"10.1097/01.hs9.0000977400.14880.93","title":"PB2681: GAPS IN THE ASSESSMENT AND MONITORING OF CARDIOVASCULAR RISK AND PSYCHOLOGICAL BURDEN IN POLYCYTHEMIA VERA: LANDMARK 2.0: A WORLDWIDE HEALTH SURVEY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; University of British Columbia","funders":"","keywords":"Medicine; Polycythemia vera; Phlebotomy; Quality of life (healthcare); Internal medicine","score_opus":0.05549516958441596,"score_gpt":0.36432288253758044,"score_spread":0.30882771295316447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386143084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913205,0.006797754,0.000008418711,0.0009035203,0.000049154427,0.0005303003,0.000021270534,0.00001612275,0.00035297076],"genre_scores_gemma":[0.9893913,0.009857806,0.00046824626,0.000046594145,0.00006596207,0.00010184728,0.000018810992,0.000011965413,0.00003743764],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984542,0.00043149074,0.00028319232,0.00031054547,0.00027461848,0.0002459647],"domain_scores_gemma":[0.99908566,0.0004729649,0.000064222804,0.00027333433,0.000023140286,0.00008065746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014617352,0.00014666968,0.0005139019,0.00006559474,0.00005373191,0.000015481997,0.000049665698,0.000064161926,0.000017221784],"category_scores_gemma":[0.0000890057,0.000092500275,0.00006831089,0.0003988894,0.000046721074,0.000026195434,0.000040824303,0.00025316034,0.0000029598218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007336101,0.0001491494,0.9830756,0.000074908196,0.000117291536,0.00011784915,0.00085215917,0.000045573008,0.00001040559,0.00003112537,0.00031801272,0.015134549],"study_design_scores_gemma":[0.0022746476,0.0003338447,0.9954841,0.000267,0.00003780339,0.000024916186,0.00082884374,0.00005449404,0.0000514342,0.00006489754,0.0005051962,0.00007282511],"about_ca_topic_score_codex":0.002788545,"about_ca_topic_score_gemma":0.0006319549,"teacher_disagreement_score":0.015061724,"about_ca_system_score_codex":0.00007574504,"about_ca_system_score_gemma":0.000047981714,"threshold_uncertainty_score":0.42154646},"labels":[],"label_agreement":null},{"id":"W4386170848","doi":"10.1097/01.hs9.0000969780.55126.5b","title":"P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; London Health Sciences Centre","funders":"","keywords":"Medicine; Decitabine; Internal medicine; Regimen; Myelodysplastic syndromes; Dosing; International Prognostic Scoring System; Adverse effect; Oncology; Gastroenterology; Bone marrow","score_opus":0.029238519668841726,"score_gpt":0.35587358611237524,"score_spread":0.3266350664435335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386170848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407655,0.00019216564,0.0009668274,0.00013793542,0.00021958175,0.0037387533,0.00014620778,0.0001311596,0.0003908096],"genre_scores_gemma":[0.99795806,0.00030357414,0.0003822627,0.00004459832,0.000059614747,0.00013624366,0.00023592323,0.000086167274,0.0007935269],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994476,0.00078349654,0.0016125368,0.0010228694,0.0012317856,0.00087330124],"domain_scores_gemma":[0.9942848,0.0033206488,0.00034067893,0.0010576214,0.0004116772,0.00058456935],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025152569,0.00054580776,0.0028580034,0.0009025712,0.0001168875,0.000050493316,0.00035621208,0.0001579442,0.0012432354],"category_scores_gemma":[0.0062203375,0.00044062594,0.00046051823,0.0046282453,0.0002773358,0.00017708205,0.00059930177,0.00048026597,0.000131447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8492634,0.020894557,0.06625139,0.0021595345,0.01128151,0.0034187133,0.0085455645,0.009193239,0.00079818437,0.00009640757,0.00211204,0.025985442],"study_design_scores_gemma":[0.8660176,0.0032231526,0.075369276,0.0008165643,0.0028115057,0.00004001116,0.002692573,0.047938246,0.0002673278,0.000016882323,0.0002292094,0.00057765463],"about_ca_topic_score_codex":0.0012447559,"about_ca_topic_score_gemma":0.00090702943,"teacher_disagreement_score":0.03874501,"about_ca_system_score_codex":0.0028207232,"about_ca_system_score_gemma":0.0014860672,"threshold_uncertainty_score":0.99980456},"labels":[],"label_agreement":null},{"id":"W4386631797","doi":"10.1097/hs9.0000000000000953","title":"Current and Future Perspective in Hematopoietic Stem Progenitor Cell-gene Therapy for Inborn Errors of Metabolism","year":2023,"lang":"en","type":"editorial","venue":"HemaSphere","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Progenitor cell; Genetic enhancement; Stem cell; Haematopoiesis; Hematopoietic stem cell; Perspective (graphical); Bioinformatics; Cancer research; Progenitor; Biology; Gene; Medicine; Genetics; Computer science","score_opus":0.022033403836206403,"score_gpt":0.32982897794331095,"score_spread":0.30779557410710456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386631797","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.060472522,0.25811407,0.000017600652,0.00076693925,0.6730637,0.006380129,0.00072126376,0.00014830423,0.00031547225],"genre_scores_gemma":[0.008474904,0.036250547,0.0006472613,0.000018403856,0.94837105,0.0022695807,0.0006104522,0.0005539216,0.0028038814],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967476,0.000114572555,0.00055634155,0.00082108425,0.0011737124,0.0005866676],"domain_scores_gemma":[0.9976473,0.00049510406,0.00025497892,0.000495938,0.00089276757,0.00021390895],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039663535,0.0004935841,0.0012752946,0.00022400406,0.00006583708,0.000026905785,0.00026125097,0.00083284883,0.00008483862],"category_scores_gemma":[0.00027350834,0.00041209222,0.00031184545,0.00064287614,0.00014205862,0.00006220256,0.00012680805,0.0011069116,0.000015489773],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022600996,0.0010106162,0.00035753794,0.006784275,0.00042661597,0.000102542384,0.0067789652,0.0000011871861,0.0010932789,0.00015037657,0.9678568,0.013177666],"study_design_scores_gemma":[0.0090066325,0.0007318165,0.00029754336,0.00063479895,0.00022769785,0.0000060720604,0.013541267,0.000022249791,0.0054988805,0.00031265614,0.9691598,0.0005606186],"about_ca_topic_score_codex":0.00015757872,"about_ca_topic_score_gemma":0.00009284901,"teacher_disagreement_score":0.27530736,"about_ca_system_score_codex":0.00028363834,"about_ca_system_score_gemma":0.0010539651,"threshold_uncertainty_score":0.9998331},"labels":[],"label_agreement":null},{"id":"W4387899802","doi":"10.1097/hs9.0000000000000966","title":"Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre; University of Toronto","funders":"Sierra Oncology; MorphoSys; Cancer Research UK; Galecto; Incyte; Gilead Sciences; CTI Biopharma; Division of Materials Research; Celgene; Pfizer","keywords":"Myelofibrosis; Medicine; Quality of life (healthcare); Anemia; Ruxolitinib; Clinical endpoint; Danazol; Internal medicine; Physical therapy; Myeloproliferative neoplasm; Janus kinase 2; Clinical trial; Bone marrow","score_opus":0.027577465176416873,"score_gpt":0.2802369706173891,"score_spread":0.25265950544097227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387899802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99747854,0.00017227628,3.0425335e-7,0.0005848573,0.000031426393,0.0014959548,0.00009223584,0.000038458275,0.0001059181],"genre_scores_gemma":[0.99941707,0.000050530827,0.00008365169,0.00012915042,0.000008196891,0.00014824873,0.00009320096,0.00001682425,0.0000531274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828404,0.00012763285,0.00066436833,0.00035110008,0.00039757456,0.00017525721],"domain_scores_gemma":[0.9985554,0.0006299366,0.0002699658,0.00035792426,0.00008138282,0.00010538478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019097717,0.00019169514,0.0005524053,0.00003864834,0.00006034641,0.000016890343,0.000035580695,0.000045854787,0.00002504243],"category_scores_gemma":[0.00038476245,0.0001035562,0.00003052971,0.00026108755,0.00006648348,0.000053653235,0.00006957778,0.00008935711,0.000004291983],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060230226,0.0009108132,0.9920891,0.000067193534,0.0002991456,0.000015338983,0.0048061656,0.0000040446002,0.0000236189,0.0000104644605,0.00022162043,0.0009501867],"study_design_scores_gemma":[0.011567573,0.0009177771,0.9816148,0.0002838148,0.00011845787,5.962089e-7,0.005233482,0.000040875708,0.000089926376,0.000021102152,0.000009531583,0.000102009515],"about_ca_topic_score_codex":0.00104936,"about_ca_topic_score_gemma":0.0007942434,"teacher_disagreement_score":0.010965271,"about_ca_system_score_codex":0.000029554983,"about_ca_system_score_gemma":0.00004514523,"threshold_uncertainty_score":0.42228994},"labels":[],"label_agreement":null},{"id":"W4387969051","doi":"10.1097/hs9.0000000000000963","title":"Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Genentech; Italfarmaco; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Jazz Pharmaceuticals; Yuhan; Gilead Sciences; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer; Constellation Pharmaceuticals","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Post-hoc analysis; Internal medicine; Population; Anemia; Gastroenterology; Bone marrow","score_opus":0.03576256372437367,"score_gpt":0.32653761267776016,"score_spread":0.29077504895338646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387969051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938114,0.00046490168,0.0001117662,0.0011280194,0.00009038929,0.002861096,0.00040967402,0.00013663332,0.0009860937],"genre_scores_gemma":[0.99458885,0.00023931748,0.0015125264,0.00026735157,0.000097008626,0.00077175215,0.0021587096,0.000052923373,0.00031156847],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969019,0.0003882057,0.0009870962,0.0006702258,0.0006209246,0.00043162514],"domain_scores_gemma":[0.9968536,0.0018035652,0.00033607925,0.0005395802,0.00024189739,0.00022527485],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008501992,0.00041299337,0.0034024601,0.00030665164,0.000099193705,0.000060507027,0.00011045724,0.0001541345,0.004374188],"category_scores_gemma":[0.00067189825,0.00025385135,0.0006320605,0.0018864737,0.00010150021,0.0001317576,0.000061639344,0.00018083234,0.00035275292],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17459863,0.0026545927,0.7989403,0.00006746411,0.009269914,0.00025966452,0.0010061953,0.00009927675,0.00022915842,0.00017334762,0.0014977691,0.011203673],"study_design_scores_gemma":[0.49085742,0.0013130528,0.49892554,0.00024287483,0.005423375,0.0000010023931,0.00024353032,0.0005965973,0.0016429992,0.0001688166,0.00025422813,0.00033054917],"about_ca_topic_score_codex":0.00065543654,"about_ca_topic_score_gemma":0.0028776855,"teacher_disagreement_score":0.3162588,"about_ca_system_score_codex":0.00012750216,"about_ca_system_score_gemma":0.0001340249,"threshold_uncertainty_score":0.99999136},"labels":[],"label_agreement":null},{"id":"W4388738295","doi":"10.1097/01.hs9.0000936192.21618.f2","title":"P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Janssen Scientific Affairs; Centre Hospitalier Universitaire de Toulouse; Universitätsklinikum Hamburg-Eppendorf; Syddansk Universitet; Université de Toulouse; Memorial Sloan-Kettering Cancer Center; Karolinska Institutet; University of Texas MD Anderson Cancer Center; Ankara Universitesi; University of Oxford; Université de Lille; Cancer Research Institute","keywords":"Medicine; Lenalidomide; Daratumumab; Quality of life (healthcare); Internal medicine; Multiple myeloma; Population; Dexamethasone; Subgroup analysis; Randomized controlled trial; Surgery; Confidence interval","score_opus":0.04459092877840427,"score_gpt":0.3177322132499836,"score_spread":0.2731412844715793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388738295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994999,0.00041817265,0.00031708396,0.00016594496,0.000022695298,0.0029749526,0.0009332409,0.00009094234,0.00007798779],"genre_scores_gemma":[0.995138,0.0001385375,0.00196356,0.00003210735,0.000020268144,0.00025926423,0.0021385401,0.00005410365,0.00025560657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996879,0.0002466097,0.0009996236,0.0005611717,0.00072947965,0.0005841571],"domain_scores_gemma":[0.996874,0.0012709831,0.0005170922,0.00048523184,0.00035331046,0.0004993964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005387943,0.000341278,0.0017098802,0.00035309058,0.0001303532,0.000015528185,0.00010539834,0.00016092439,0.00012513495],"category_scores_gemma":[0.00045954026,0.00022918366,0.0002576125,0.001965638,0.00019191342,0.000102139566,0.000023458402,0.00016760458,0.0000039701777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18911205,0.00094851607,0.8008282,0.0007590398,0.004805098,0.000036335656,0.00051051134,0.00011286479,0.00028613137,0.000020184092,0.00019405028,0.0023870093],"study_design_scores_gemma":[0.21342877,0.003802303,0.7780473,0.00027439464,0.0011505701,0.000001520208,0.00029256186,0.0016382916,0.0011235214,0.000007599348,0.000029582554,0.0002035848],"about_ca_topic_score_codex":0.005208494,"about_ca_topic_score_gemma":0.0044871406,"teacher_disagreement_score":0.024316717,"about_ca_system_score_codex":0.00007940551,"about_ca_system_score_gemma":0.00031260867,"threshold_uncertainty_score":0.93458384},"labels":[],"label_agreement":null},{"id":"W4388738310","doi":"10.1097/01.hs9.0000936164.84357.ed","title":"P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; Medicine; Daratumumab; Internal medicine; Multiple myeloma; Clinical endpoint; Dexamethasone; Surgery; Phases of clinical research; Minimal residual disease; Progression-free survival; Oncology; Gastroenterology; Chemotherapy; Randomized controlled trial; Bone marrow","score_opus":0.02799922324280263,"score_gpt":0.3080481877675247,"score_spread":0.28004896452472205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388738310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558747,0.0006758022,0.00006517743,0.00027253374,0.00007434004,0.0027088167,0.0003834384,0.000093118615,0.00013930582],"genre_scores_gemma":[0.99761534,0.0002895649,0.0008342122,0.000048671835,0.000030238438,0.00021155493,0.0006370769,0.00007398318,0.00025935125],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99602634,0.00041838884,0.0007556024,0.00091463537,0.0010467661,0.0008382613],"domain_scores_gemma":[0.99704987,0.0011539116,0.00026187766,0.00085044996,0.00022770702,0.0004562094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005611796,0.0005459,0.0014518038,0.0005686247,0.00022620079,0.000059962415,0.00024232015,0.00017493956,0.00020367008],"category_scores_gemma":[0.00048167552,0.00036626525,0.00019417336,0.003455868,0.00029144916,0.00021004208,0.00016663423,0.00044236146,0.000014450251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037945464,0.0024248464,0.94372183,0.00017780063,0.004412899,0.00093155116,0.0020547167,0.00036000446,0.0013031383,0.000004092806,0.00036605517,0.006297625],"study_design_scores_gemma":[0.18018366,0.0018530127,0.80132425,0.000264258,0.0027852398,0.000011901548,0.0022913683,0.0075712465,0.0032346393,0.0000070611627,0.00010239414,0.0003709447],"about_ca_topic_score_codex":0.0033518788,"about_ca_topic_score_gemma":0.013679701,"teacher_disagreement_score":0.14239754,"about_ca_system_score_codex":0.0001873896,"about_ca_system_score_gemma":0.00019369983,"threshold_uncertainty_score":0.99987894},"labels":[],"label_agreement":null},{"id":"W4390458072","doi":"10.1002/j.2572-9241.2019.tb00089.x","title":"PF490 PRESENCE OF BRAFV600E MUTATION IN CHILDHOOD LCH CORRELATES WITH MULTISYSTEM DISEASE AND A POOR SURVIVAL","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"RNA modifications and cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Sanger sequencing; Mutation; Internal medicine; Retrospective cohort study; Disease; Pediatrics; Gastroenterology; Genetics; Biology; Gene","score_opus":0.004188550282559119,"score_gpt":0.21088003522333595,"score_spread":0.20669148494077683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390458072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99730295,0.0015049129,0.0002399335,0.00005496223,0.000040289833,0.00026037745,0.000015594343,0.000004149904,0.0005768112],"genre_scores_gemma":[0.9986741,0.000071746355,0.00018647041,0.000016069926,0.000020265506,0.000026428164,0.00003512121,0.0000105171885,0.00095929886],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99948394,0.000027395005,0.00011577889,0.00020400653,0.00007816158,0.000090708876],"domain_scores_gemma":[0.9996554,0.0000106586895,0.000060098922,0.00018716742,0.00004205537,0.000044608438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000051762854,0.0000737092,0.00009434574,0.000011354017,0.000015374751,0.000008303273,0.000056876775,0.000046071716,0.00002912209],"category_scores_gemma":[0.000018064193,0.000060715494,0.000018449366,0.00006291613,0.00003159251,0.000005316629,0.000023422042,0.00003657924,0.000004403436],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052037335,0.0003292585,0.8229251,0.00040086798,0.00009535209,0.000012109462,0.00059382606,0.002745503,0.16494617,0.0010874409,0.00023289563,0.0061111297],"study_design_scores_gemma":[0.0031687976,0.00043454504,0.9584821,0.00034061825,0.000041507887,0.000020867205,0.001456836,0.0030199557,0.031203408,0.000071031645,0.0013851045,0.00037522308],"about_ca_topic_score_codex":0.000051329327,"about_ca_topic_score_gemma":0.00011164959,"teacher_disagreement_score":0.13555703,"about_ca_system_score_codex":0.000005243095,"about_ca_system_score_gemma":0.000054102366,"threshold_uncertainty_score":0.2475906},"labels":[],"label_agreement":null},{"id":"W4398185210","doi":"10.1002/hem3.69","title":"Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)","year":2024,"lang":"en","type":"review","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Myelodysplastic syndromes; Medicine; Drug development; Clinical trial; Drug; Intensive care medicine; Oncology; Medical physics; Internal medicine; Pharmacology; Bone marrow","score_opus":0.27132309223321066,"score_gpt":0.48313530790035203,"score_spread":0.21181221566714137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398185210","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016674833,0.907046,0.002217546,0.0097697405,0.00453426,0.05233611,0.006709565,0.00032814336,0.00038375767],"genre_scores_gemma":[0.013268566,0.8522329,0.06460399,0.002610309,0.0028311017,0.039090242,0.021062177,0.0010976532,0.0032030593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927267,0.0006433475,0.0035205686,0.0012819275,0.0011391181,0.00068834744],"domain_scores_gemma":[0.97952497,0.017558552,0.0010711966,0.00059429224,0.00089968625,0.000351309],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002193071,0.0007894878,0.0033441812,0.00018525387,0.00017580057,0.00024686722,0.000347524,0.00057679066,0.00049580843],"category_scores_gemma":[0.017915858,0.0004482712,0.0007957525,0.0003631116,0.0002809219,0.00016801238,0.00025696415,0.0015080237,0.000112683985],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009900771,0.005318034,0.0042707445,0.079233736,0.01790131,0.0015843896,0.006952188,0.000011751157,5.3956046e-7,0.0011831536,0.36311534,0.510528],"study_design_scores_gemma":[0.01091401,0.00076831627,0.00016683339,0.03000001,0.004991284,0.00029919387,0.0011282408,0.0004976229,0.000006196016,0.00026439203,0.9501804,0.00078345975],"about_ca_topic_score_codex":0.00002026142,"about_ca_topic_score_gemma":0.00012840591,"teacher_disagreement_score":0.5870651,"about_ca_system_score_codex":0.0010279554,"about_ca_system_score_gemma":0.009329316,"threshold_uncertainty_score":0.9997969},"labels":[],"label_agreement":null},{"id":"W4399045499","doi":"10.1002/hem3.74","title":"First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"Pharmacyclics","keywords":"Ibrutinib; Post-hoc analysis; Chronic lymphocytic leukemia; Medicine; Oncology; Internal medicine; Post hoc; Pooled analysis; Survival analysis; Population; Leukemia; Meta-analysis","score_opus":0.018026519877040136,"score_gpt":0.29915942787016636,"score_spread":0.28113290799312624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399045499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972122,0.00069461216,0.000043528016,0.00019192917,0.00005380187,0.0013667853,0.00014632478,0.00013222627,0.00015862625],"genre_scores_gemma":[0.99534076,0.00005481473,0.0007746082,0.00016377021,0.000118764336,0.00010351447,0.0014716991,0.00010471655,0.0018673344],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9965271,0.00015187444,0.00065980176,0.0008615395,0.0010813146,0.00071840436],"domain_scores_gemma":[0.99812615,0.0002149193,0.00014887008,0.0008121195,0.00031521943,0.00038270117],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027812365,0.00050192344,0.0012312889,0.00036594947,0.00008007365,0.00008411188,0.00018622831,0.00022015446,0.00075181],"category_scores_gemma":[0.00008953889,0.00034954617,0.00022983311,0.002284223,0.00008893957,0.00020471502,0.00007612271,0.00018995533,0.000026427282],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04357077,0.004187282,0.44551477,0.0037932019,0.03193404,0.010325839,0.01624374,0.42893076,0.001347704,0.00027598246,0.0009114895,0.012964423],"study_design_scores_gemma":[0.09174323,0.017396826,0.43607682,0.0025198997,0.0043863207,0.000038050937,0.00029744787,0.44385904,0.0022863445,0.000051131727,0.00028333263,0.001061547],"about_ca_topic_score_codex":0.013825031,"about_ca_topic_score_gemma":0.029441109,"teacher_disagreement_score":0.06541442,"about_ca_system_score_codex":0.07750218,"about_ca_system_score_gemma":0.01208776,"threshold_uncertainty_score":0.99989563},"labels":[],"label_agreement":null},{"id":"W4400982166","doi":"10.1002/hem3.136","title":"Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Pfizer","keywords":"Multiple myeloma; Term (time); Refractory (planetary science); Medicine; Oncology; Internal medicine; Biology; Physics","score_opus":0.016703976176522393,"score_gpt":0.27470621404530243,"score_spread":0.25800223786878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400982166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99584854,0.0017411968,0.000014688821,0.00019117654,0.00009945828,0.0015143016,0.00018094503,0.00004132011,0.00036835024],"genre_scores_gemma":[0.9986615,0.00014826829,0.00024621887,0.000023788512,0.000044938737,0.000046678808,0.00019352172,0.00004016571,0.00059491146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998279,0.00015079348,0.0003200021,0.000417925,0.00054297823,0.00028935514],"domain_scores_gemma":[0.99875635,0.0005034528,0.000052239648,0.00047316318,0.00007299529,0.00014178985],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018788606,0.00021290111,0.0003832835,0.000049259175,0.00006320614,0.00003125143,0.00011424381,0.00007267409,0.0008802231],"category_scores_gemma":[0.00013832418,0.00011045395,0.000042978547,0.00027638255,0.000110301626,0.00012268854,0.00009910022,0.00030878687,0.000033953656],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0081788385,0.0011022183,0.9503298,0.00013270634,0.00034482486,0.0007379151,0.00062982825,6.3070945e-7,0.000032386,0.0000073130036,0.00017349275,0.038330045],"study_design_scores_gemma":[0.017042112,0.0016952277,0.9794263,0.00043548347,0.00011764493,0.000004011418,0.00063971773,0.00007843113,0.000053067502,0.0000062799927,0.0003865188,0.00011516371],"about_ca_topic_score_codex":0.00082957785,"about_ca_topic_score_gemma":0.004976191,"teacher_disagreement_score":0.03821488,"about_ca_system_score_codex":0.00008090527,"about_ca_system_score_gemma":0.00013026601,"threshold_uncertainty_score":0.9637826},"labels":[],"label_agreement":null},{"id":"W4401744308","doi":"10.1002/hem3.116","title":"RNA binding protein‐directed control of leukemic stem cell evolution and function","year":2024,"lang":"en","type":"review","venue":"HemaSphere","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Ontario Institute for Cancer Research; Princess Margaret Cancer Foundation","keywords":"Haematopoiesis; Stem cell; Biology; Myeloid leukemia; RNA-binding protein; Myeloid; Hematopoietic stem cell; Leukemia; Function (biology); Disease; Transcriptome; RNA; Computational biology; Cancer research; Immunology; Gene; Gene expression; Genetics; Medicine; Internal medicine","score_opus":0.01744990871103646,"score_gpt":0.2712963733619915,"score_spread":0.25384646465095506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401744308","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012349016,0.9855736,0.0005329048,0.0000031364561,0.00009084556,0.00078350527,0.000048441176,0.00002742301,0.0005911301],"genre_scores_gemma":[0.0143626,0.96712846,0.0000526557,0.0000027001472,0.00017530337,0.00012346361,0.00010937453,0.000056738587,0.017988686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987464,0.000116789204,0.00032937713,0.00040861036,0.00015306394,0.00024576965],"domain_scores_gemma":[0.9994104,0.000013573663,0.00016930801,0.00025844856,0.00006381804,0.00008447722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018781451,0.00025241115,0.00056640717,0.00006427485,0.000049305865,0.0000271519,0.00010829995,0.0003618016,0.000018163926],"category_scores_gemma":[0.000017707473,0.00019880256,0.00021747517,0.00016985105,0.000045252058,0.0000032954888,0.00008067281,0.0002475571,0.000030947074],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006625237,0.000029817262,0.0000061857104,0.035702333,0.00032421647,0.00000955625,0.0000054960065,0.0000011308989,0.44536704,0.0000818452,0.0017828355,0.5166233],"study_design_scores_gemma":[0.0008955655,0.00073275605,0.000002676075,0.0133436425,0.0011219007,0.00005219145,0.00008820567,0.0001827787,0.014151631,0.000024336961,0.9687836,0.0006207144],"about_ca_topic_score_codex":0.000021700871,"about_ca_topic_score_gemma":0.000008508562,"teacher_disagreement_score":0.9670008,"about_ca_system_score_codex":0.00007245193,"about_ca_system_score_gemma":0.0003119418,"threshold_uncertainty_score":0.8106933},"labels":[],"label_agreement":null},{"id":"W4401745029","doi":"10.1002/hem3.130","title":"Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma","year":2024,"lang":"en","type":"review","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"University of Toronto","keywords":"Chimeric antigen receptor; Chemoimmunotherapy; Medicine; Oncology; Refractory (planetary science); Lymphoma; Internal medicine; CD19; Disease; Immunotherapy; Antigen; Immunology; Rituximab; Cancer; Biology","score_opus":0.06631002535945682,"score_gpt":0.379980524641565,"score_spread":0.3136704992821082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401745029","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016785417,0.9890791,0.0000096612475,0.00002444433,0.00041338615,0.0040462497,0.00019911013,0.00005509227,0.0044943714],"genre_scores_gemma":[0.0006320687,0.983705,0.00021700923,0.000056176443,0.00014399659,0.00032961252,0.00035154072,0.0002614646,0.014303171],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968094,0.00014309953,0.0011260526,0.000670303,0.0005841402,0.0006670092],"domain_scores_gemma":[0.9982049,0.00047108656,0.00028008706,0.00074614503,0.00013483076,0.00016294833],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005888019,0.0005626128,0.0023997459,0.0003354845,0.000035916037,0.00002783687,0.00028971158,0.00052366586,0.0012914473],"category_scores_gemma":[0.000096737924,0.00041953378,0.0012057062,0.00077009003,0.000049504255,0.000042337986,0.00012309276,0.00033829256,0.000106117615],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003987946,0.0013228985,0.0032899221,0.12960947,0.0008833665,0.000056891375,0.00015790525,5.9464323e-8,0.000017478484,0.0000837355,0.004792445,0.85938704],"study_design_scores_gemma":[0.009081463,0.0006797176,0.000094502604,0.013816611,0.00053717836,0.000008410572,0.00009937505,0.000008314863,0.00004747513,0.00003434288,0.97522485,0.00036774803],"about_ca_topic_score_codex":0.00004985653,"about_ca_topic_score_gemma":0.0000676795,"teacher_disagreement_score":0.9704324,"about_ca_system_score_codex":0.0006318236,"about_ca_system_score_gemma":0.00080788723,"threshold_uncertainty_score":0.99982566},"labels":[],"label_agreement":null},{"id":"W4401913715","doi":"10.1002/hem3.146","title":"Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Genentech; F. Hoffmann-La Roche; AbbVie","keywords":"Rituximab; Hypogammaglobulinemia; Medicine; Internal medicine; Chronic lymphocytic leukemia; CD20; Gastroenterology; Venetoclax; Refractory (planetary science); Antibody; Immune system; Immunology; Bendamustine; Leukemia","score_opus":0.011910906799896948,"score_gpt":0.264676162737068,"score_spread":0.2527652559371711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401913715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774057,0.018520782,0.00004001884,0.000057804966,0.00024463507,0.0016736202,0.000011285138,0.00026791243,0.0017781977],"genre_scores_gemma":[0.9929657,0.00043608944,0.00018675059,0.000054256365,0.0002531977,0.0003399459,0.00016610275,0.00018889472,0.0054090912],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99667406,0.00006731395,0.00040277062,0.00088150695,0.00096665515,0.0010077219],"domain_scores_gemma":[0.99846274,0.000162808,0.00008080688,0.0009157386,0.00007947517,0.00029845518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017230157,0.0005525552,0.0008627923,0.0002175571,0.00010472288,0.000097725235,0.00020449689,0.0002470552,0.00052456814],"category_scores_gemma":[0.000022151953,0.00037396266,0.00017302645,0.0007340726,0.00016417357,0.00022859644,0.00009745519,0.00041172854,0.00030584412],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.05933584,0.0038028199,0.1860128,0.033836592,0.016762374,0.1492266,0.022463981,0.016480166,0.0054586786,0.0005552728,0.0034212663,0.5026436],"study_design_scores_gemma":[0.69308317,0.047687065,0.10031217,0.035761625,0.0027315528,0.0016925952,0.00088414934,0.082854405,0.012488263,0.00003868931,0.018948687,0.0035176356],"about_ca_topic_score_codex":0.0025766818,"about_ca_topic_score_gemma":0.0028941508,"teacher_disagreement_score":0.63374734,"about_ca_system_score_codex":0.41068113,"about_ca_system_score_gemma":0.06669948,"threshold_uncertainty_score":0.99987125},"labels":[],"label_agreement":null},{"id":"W4402568580","doi":"10.1002/hem3.70004","title":"Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Servier; Genesis Pharma; Associazione Italiana per la Ricerca sul Cancro; Ministerstvo Zdravotnictví Ceské Republiky; Incyte; BeiGene; Genentech; Sunesis; Gilead Sciences; AbbVie; European Commission; Sanofi; Cilag; TG Therapeutics; Amgen; Ministero della Salute; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Chronic lymphocytic leukemia; Medicine; Oncology; Internal medicine; Leukemia","score_opus":0.09932132477308753,"score_gpt":0.3667572029476041,"score_spread":0.2674358781745166,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402568580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98565096,0.0006127217,0.000004234598,0.000033251075,0.000051890187,0.0011897131,0.0000052060777,0.000038740083,0.012413266],"genre_scores_gemma":[0.9993482,0.00012769598,0.000020993231,0.000025981324,0.000120441364,0.000071269205,0.000015462658,0.000046270863,0.00022368667],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997612,0.0005248803,0.0002669031,0.0004336189,0.0008288567,0.00033376555],"domain_scores_gemma":[0.9988928,0.0003763146,0.000040146744,0.000432275,0.00017482755,0.00008367718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000689881,0.00018474866,0.0002389791,0.00015947678,0.00008470195,0.00012526082,0.00018179246,0.000046029327,0.00008820666],"category_scores_gemma":[0.00003350331,0.00010264794,0.000028065733,0.00045245388,0.00023835641,0.0002630247,0.000085113854,0.00034180912,0.000023288552],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021382237,0.0063963355,0.11678916,0.004373075,0.008593673,0.014072032,0.34192792,0.052018367,0.0029993176,0.01634719,0.0004679047,0.41463277],"study_design_scores_gemma":[0.13415821,0.085085884,0.4389759,0.005552242,0.00042160286,0.00026091194,0.1786366,0.1522554,0.0017867011,0.0007189784,0.001226427,0.00092116],"about_ca_topic_score_codex":0.0026638315,"about_ca_topic_score_gemma":0.0015605774,"teacher_disagreement_score":0.4137116,"about_ca_system_score_codex":0.09392512,"about_ca_system_score_gemma":0.021766042,"threshold_uncertainty_score":0.9837796},"labels":[],"label_agreement":null},{"id":"W4404813541","doi":"10.1002/hem3.70001","title":"Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma","year":2024,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Veterinärmedizinische Universität Wien; Universität Wien; Christian Doppler Forschungsgesellschaft; Vienna Science and Technology Fund; Austrian Science Fund; Medizinische Universität Wien; European Commission; Siemens Medical Solutions USA","keywords":"Myeloid leukemia; Dual (grammatical number); Lymphoma; Block (permutation group theory); Cancer research; Acute leukemia; Leukemia; Medicine; Immunology; Mathematics","score_opus":0.011697156603415188,"score_gpt":0.2629680298935974,"score_spread":0.2512708732901822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404813541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96131426,0.023294086,0.00007687108,0.0015832708,0.0009494402,0.0009406935,0.000028355864,0.0004637429,0.0113492925],"genre_scores_gemma":[0.9583788,0.0020378404,0.0021197759,0.0003304026,0.00064063584,0.00006198692,0.00006455243,0.00015318127,0.036212847],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970646,0.000104935636,0.00035670886,0.00091520476,0.00070038094,0.00085818145],"domain_scores_gemma":[0.99850714,0.00038769786,0.000050023627,0.00048947707,0.0000992352,0.00046642256],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002765403,0.0004752561,0.00056314305,0.0001806985,0.00017593642,0.00018022444,0.00016420151,0.0002796818,0.00041466224],"category_scores_gemma":[0.000046250003,0.00038568454,0.00020866997,0.0006614935,0.00032237888,0.00022947819,0.00021202619,0.00082334393,0.000719256],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023974,0.00042112338,0.0026558186,0.0038248228,0.002097105,0.022093361,0.004521156,0.000018061937,0.18255626,0.0023262443,0.5981347,0.17895396],"study_design_scores_gemma":[0.025509777,0.0025317527,0.051226668,0.0019654597,0.0011882012,0.012847402,0.0050097755,0.011307855,0.14198859,0.0007571976,0.7431186,0.0025487323],"about_ca_topic_score_codex":0.00010949542,"about_ca_topic_score_gemma":0.000018078053,"teacher_disagreement_score":0.17640522,"about_ca_system_score_codex":0.0015790443,"about_ca_system_score_gemma":0.0010277528,"threshold_uncertainty_score":0.9998595},"labels":[],"label_agreement":null},{"id":"W4408845598","doi":"10.1002/hem3.70106","title":"Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; University of British Columbia","funders":"AOP Orphan; Astellas Pharma; Galecto; Sierra Oncology; Incyte; CTI Biopharma; BeiGene; Bristol-Myers Squibb; AstraZeneca; CSL Behring; MPN Research Foundation; Alexion Pharmaceuticals; Gilead Sciences; Sanofi; GlaxoSmithKline; Pfizer; Novartis Pharmaceuticals Corporation; Celgene","keywords":"Medicine; Depression (economics); Myeloproliferative neoplasm; Quality of life (healthcare); Polycythemia vera; Family medicine; Disease; Physical therapy; Emergency medicine; Internal medicine; Myelofibrosis","score_opus":0.01158140979650688,"score_gpt":0.3007316178053178,"score_spread":0.2891502080088109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408845598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98877627,0.0055581336,0.000026918946,0.003437937,0.00006517922,0.00052651105,0.00009977931,0.000022741255,0.0014865216],"genre_scores_gemma":[0.9979233,0.00058678957,0.0001997894,0.00092467933,0.000026736363,0.00013584741,0.00013694621,0.000006731915,0.000059138973],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990907,0.00016695664,0.00020947405,0.00028828258,0.0000807819,0.00016385669],"domain_scores_gemma":[0.9993276,0.0003249229,0.000051666288,0.0001836546,0.000033150678,0.00007900317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000029559365,0.0001606056,0.0003469761,0.000022914059,0.00020205029,0.000025904637,0.000022252767,0.000053472228,0.000020977717],"category_scores_gemma":[0.00003141784,0.000100309604,0.000037111688,0.00017814248,0.000061744075,0.000036351717,0.000030320896,0.00006712091,0.0000056254007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082792474,0.0003132424,0.9787941,0.000012507524,0.00016227465,0.00001246047,0.0037636491,0.0000020348455,0.0000129855225,0.0018968205,0.0012741325,0.013672984],"study_design_scores_gemma":[0.0021299087,0.00029026592,0.9916593,0.00021647509,0.000054009073,0.000011429792,0.004514679,0.00010142439,0.00008689332,0.0003544183,0.00050784025,0.00007334928],"about_ca_topic_score_codex":0.003554589,"about_ca_topic_score_gemma":0.02862161,"teacher_disagreement_score":0.02506702,"about_ca_system_score_codex":0.00025713182,"about_ca_system_score_gemma":0.000151997,"threshold_uncertainty_score":0.9891035},"labels":[],"label_agreement":null},{"id":"W4408884237","doi":"10.1002/hem3.70111","title":"Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Hemophilia Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"European Association for Haemophilia and Allied Disorders; Nemzeti Kutatási Fejlesztési és Innovációs Hivatal; Hungarian Scientific Research Fund; European Hematology Association","keywords":"Haemophilia; Medicine; Clotting factor; Incidence (geometry); Hematology; Internal medicine; Pediatrics; Major bleeding","score_opus":0.11115762673751604,"score_gpt":0.39349760629183156,"score_spread":0.2823399795543155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408884237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7544143,0.002705663,0.0015589067,0.18763477,0.0011234238,0.0045755636,0.00009894533,0.0003157902,0.047572598],"genre_scores_gemma":[0.6514064,0.0013965549,0.003939344,0.014391539,0.00077822193,0.0001914809,0.000033133645,0.00009859501,0.32776475],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99671054,0.00014793489,0.0007681412,0.00087541156,0.0006268936,0.0008710772],"domain_scores_gemma":[0.99770206,0.000521886,0.000080434016,0.0009790079,0.0002744532,0.00044215983],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006243072,0.00045133376,0.0008484977,0.000096005024,0.0004977439,0.00013107974,0.0003958652,0.00033399856,0.005038803],"category_scores_gemma":[0.00036990744,0.00023559754,0.00031330582,0.0009069211,0.00016587676,0.00011518927,0.00031884827,0.0007297575,0.0018901912],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044297013,0.002840194,0.019772585,0.0016734856,0.002321671,0.0006380794,0.0033085505,0.0005306876,0.001397367,0.0017225002,0.8193521,0.10214578],"study_design_scores_gemma":[0.030510342,0.0049509024,0.007586982,0.0039157337,0.001540064,0.00010637593,0.0037035334,0.12339358,0.02846972,0.002361914,0.7914159,0.0020449387],"about_ca_topic_score_codex":0.00013515167,"about_ca_topic_score_gemma":0.00046973382,"teacher_disagreement_score":0.28019217,"about_ca_system_score_codex":0.0001265632,"about_ca_system_score_gemma":0.00072170276,"threshold_uncertainty_score":0.99888694},"labels":[],"label_agreement":null},{"id":"W4410776881","doi":"10.1002/hem3.70145","title":"Characterization of cancer‐associated fibroblasts and their spatial architecture reveals heterogeneity and survival associations in classic Hodgkin lymphoma","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; University Health Network","funders":"Academy of Finland; Helsingin ja Uudenmaan Sairaanhoitopiiri; Helsingin Yliopisto","keywords":"Tumor microenvironment; Stromal cell; Cancer-Associated Fibroblasts; Cancer research; Immune system; Lymphoma; Biology; Cancer; Population; Pathology; Fibroblast activation protein, alpha; Fibroblast; Nodular sclerosis; Immunology; Medicine; Internal medicine; Cell culture; Hodgkin lymphoma; Genetics","score_opus":0.009133015429994338,"score_gpt":0.2374523188488286,"score_spread":0.22831930341883425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410776881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974786,0.0004994872,0.0013174361,0.00013170915,0.000104801395,0.00015112177,0.00018545854,0.0000078903095,0.00012346687],"genre_scores_gemma":[0.99920547,0.00025689282,0.000059680868,0.00007655376,0.0000412574,0.000012816334,0.00019153029,0.000011069712,0.00014472197],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9992694,0.000099867255,0.00020696862,0.00022741185,0.00005361819,0.00014268042],"domain_scores_gemma":[0.9996823,0.000025385578,0.00010181262,0.000109594366,0.000049236573,0.000031678817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000107040316,0.00012637669,0.00021222004,0.000028585579,0.000049522718,0.000014659378,0.000058174035,0.00018395828,0.000003858623],"category_scores_gemma":[0.000056161036,0.000118273376,0.000040749055,0.00011093297,0.000056669574,0.000003571286,0.00004373595,0.00005424691,7.934603e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004745829,0.0000573175,0.20254758,0.00004294712,0.000051825707,3.310318e-7,0.0000828897,0.000015771475,0.78835607,0.000017634547,0.000010409973,0.008769802],"study_design_scores_gemma":[0.0009345268,0.000068064925,0.6638783,0.000095231575,0.000015435331,6.848983e-7,0.000024090798,0.00021956295,0.33427262,0.000114877774,0.00025809545,0.000118497825],"about_ca_topic_score_codex":0.00045016911,"about_ca_topic_score_gemma":0.011728675,"teacher_disagreement_score":0.46133074,"about_ca_system_score_codex":0.000025916155,"about_ca_system_score_gemma":0.000065126,"threshold_uncertainty_score":0.6544876},"labels":[],"label_agreement":null},{"id":"W4412008193","doi":"10.1002/hem3.70352","title":"Preclinical Efficacy of Tasquinimod in Myelodysplastic Neoplasms: Restoring Erythropoiesis and Mitigating Bone Loss","year":2025,"lang":"en","type":"preprint","venue":"HemaSphere","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Aging","funders":"Active Biotech","keywords":"Erythropoiesis; Medicine; Myelodysplastic syndromes; Bone marrow; Cancer research; Anemia; Pharmacology; Oncology; Internal medicine","score_opus":0.03090296219618452,"score_gpt":0.342556286757576,"score_spread":0.3116533245613915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412008193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98855,0.002700364,0.00008901703,0.00057618425,0.0007593345,0.00070540735,0.00003802085,0.00007501381,0.006506675],"genre_scores_gemma":[0.99506676,0.00074941065,0.0021867594,0.00006894994,0.00028795158,0.0001152541,0.000022628154,0.000033251334,0.0014690422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786705,0.000087604494,0.00084203156,0.00063744234,0.00027098486,0.00029490553],"domain_scores_gemma":[0.9981205,0.00076448405,0.00027393954,0.000585331,0.00011377811,0.00014199925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025148698,0.00030268187,0.00096414355,0.00013069602,0.00006239817,0.000021975991,0.000108605294,0.00039642348,0.00020519298],"category_scores_gemma":[0.00067103055,0.0003024411,0.00018722311,0.00027267807,0.00022634724,0.00004339674,0.00049177965,0.0010891745,0.000006676027],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022808441,0.0018534901,0.9207896,0.021934086,0.0010082155,0.0007039168,0.0036869226,0.0035178289,0.0030860074,0.0019010324,0.0031444584,0.036093593],"study_design_scores_gemma":[0.026729608,0.002102175,0.84620994,0.08171168,0.003821388,0.00068343506,0.0034288638,0.0013272405,0.01758349,0.003235241,0.010710289,0.0024566373],"about_ca_topic_score_codex":0.0003570342,"about_ca_topic_score_gemma":0.0003301715,"teacher_disagreement_score":0.07457965,"about_ca_system_score_codex":0.0001644048,"about_ca_system_score_gemma":0.00055813335,"threshold_uncertainty_score":0.9999428},"labels":[],"label_agreement":null},{"id":"W4412371428","doi":"10.1002/hem3.70165","title":"Luspatercept versus mitapivat for non‐transfusion‐dependent β‐thalassemia: Dare to compare?","year":2025,"lang":"en","type":"editorial","venue":"HemaSphere","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; University of Toronto","funders":"","keywords":"Thalassemia; Medicine; Blood transfusion; Internal medicine","score_opus":0.011179993153500262,"score_gpt":0.291936137157545,"score_spread":0.28075614400404475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412371428","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0026528419,0.0018955566,0.00097029255,0.0019632375,0.9546979,0.0037641304,0.001015629,0.0002779212,0.032762468],"genre_scores_gemma":[0.007665182,0.0033982527,0.003279095,0.00087888824,0.8212065,0.0011782196,0.006976108,0.00046398895,0.15495376],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962324,0.000042715626,0.000733591,0.0011042006,0.0010392453,0.00084784825],"domain_scores_gemma":[0.9970567,0.0007032357,0.00015016495,0.00093742996,0.0006534236,0.0004990279],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021529524,0.0007633617,0.0013788833,0.00016182817,0.00026474812,0.00007200443,0.00041995355,0.00166783,0.0010483387],"category_scores_gemma":[0.0006845207,0.0006677307,0.0005897522,0.0003820861,0.0000669289,0.000055247412,0.00018414004,0.0015492705,0.0002759521],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002650669,0.00024241183,0.00006014635,0.0024608655,0.00044562612,0.00011186067,0.00042157917,0.000036882353,0.00026100493,0.000014519466,0.9899724,0.0033220255],"study_design_scores_gemma":[0.010008312,0.00076330476,0.000038274018,0.0028092044,0.0009839655,0.0000060364896,0.0015745031,0.00005843002,0.00045365555,0.000019594665,0.9826333,0.0006513987],"about_ca_topic_score_codex":0.00037266998,"about_ca_topic_score_gemma":0.00065538666,"teacher_disagreement_score":0.13349143,"about_ca_system_score_codex":0.0004960874,"about_ca_system_score_gemma":0.001168701,"threshold_uncertainty_score":0.9998648},"labels":[],"label_agreement":null},{"id":"W4413910826","doi":"10.1002/hem3.70206","title":"Results in pediatric T‐ALL patients treated in trial AIEOP‐BFM ALL 2009: Prognostic factors in the context of modern risk‐adapted therapy","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia","funders":"Ministero della Salute","keywords":"Medicine; Minimal residual disease; Cumulative incidence; Hazard ratio; Internal medicine; Proportional hazards model; Context (archaeology); Prednisone; Incidence (geometry); Oncology; Cohort; Confidence interval; Leukemia","score_opus":0.029965557484606452,"score_gpt":0.30139748465011884,"score_spread":0.2714319271655124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413910826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931689,0.0008089408,0.000008953482,0.0003410108,0.00008955691,0.003280104,0.00008109973,0.000028108218,0.0021933399],"genre_scores_gemma":[0.9984223,0.00058705005,0.000031545304,0.00021650083,0.00004993921,0.0001417976,0.00015578882,0.000028565632,0.0003664644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968699,0.00049624033,0.00097059575,0.00046777187,0.00065331045,0.000542184],"domain_scores_gemma":[0.997435,0.0015919515,0.00022216274,0.0005096269,0.00015570331,0.00008557793],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006669693,0.0002860602,0.0006376368,0.0003764206,0.000023715407,0.00001668591,0.00032540172,0.00028264915,0.000047475038],"category_scores_gemma":[0.002181408,0.0001867188,0.00010951065,0.0014203448,0.000074288684,0.000080646605,0.00006422424,0.00061754975,0.0000111923055],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.049681183,0.002577316,0.92986435,0.00012546474,0.00008421548,0.00011577148,0.005476068,0.00006234258,0.00006491189,0.000021775593,0.0030485513,0.008878024],"study_design_scores_gemma":[0.22109845,0.0017838784,0.7705604,0.00026958555,0.00009454047,0.0000016380852,0.0010539355,0.0038095787,0.00046171772,0.00016470686,0.00047858103,0.00022302249],"about_ca_topic_score_codex":0.0040920028,"about_ca_topic_score_gemma":0.0034755692,"teacher_disagreement_score":0.17141727,"about_ca_system_score_codex":0.000551764,"about_ca_system_score_gemma":0.0006143746,"threshold_uncertainty_score":0.76141715},"labels":[],"label_agreement":null},{"id":"W4414420388","doi":"10.1002/hem3.70224","title":"The impact of reduced dosing frequency of elranatamab on patient‐reported outcomes in patients with relapsed or refractory multiple myeloma: Results from MagnetisMM‐3","year":2025,"lang":"en","type":"letter","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"Pfizer","keywords":"Dosing; Refractory (planetary science); Incidence (geometry); Multiple myeloma; Clinical trial; Quality of life (healthcare)","score_opus":0.021111578107003495,"score_gpt":0.29165523703766494,"score_spread":0.27054365893066146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414420388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98518986,0.00031789034,9.325278e-7,0.007437275,0.00018693165,0.0025357774,0.0021528248,0.000044567438,0.0021339483],"genre_scores_gemma":[0.9903608,0.000069722715,0.0008079605,0.0019882293,0.00010961767,0.00010813446,0.003919007,0.000104153776,0.0025323858],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99516577,0.0003147478,0.0015578448,0.00083594705,0.0014079739,0.0007177436],"domain_scores_gemma":[0.9941827,0.0022053618,0.0011857634,0.0017699806,0.0005031433,0.00015303676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017387743,0.0006710241,0.0014613037,0.00028081,0.000109652756,0.000025244884,0.0003212187,0.00069601636,0.0002463037],"category_scores_gemma":[0.0025824183,0.00034571206,0.0003926644,0.0005417718,0.00022041523,0.000100365614,0.00009670502,0.0016404216,0.000008792497],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04071152,0.0027520387,0.7753924,0.0005287348,0.003756553,0.003217705,0.0005694043,0.000013203629,0.00046045677,0.0000010907552,0.14695986,0.025637044],"study_design_scores_gemma":[0.034437638,0.0054580183,0.9535386,0.0031979815,0.00027866568,0.0000044709295,0.00010132075,0.000031487773,0.0010826428,0.000028304737,0.0014644546,0.0003764429],"about_ca_topic_score_codex":0.010371778,"about_ca_topic_score_gemma":0.0005854767,"teacher_disagreement_score":0.17814618,"about_ca_system_score_codex":0.0006199263,"about_ca_system_score_gemma":0.0010347987,"threshold_uncertainty_score":0.9998995},"labels":[],"label_agreement":null},{"id":"W4415132558","doi":"10.1002/hem3.70216","title":"European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Pharmaceuticals; Kite Pharma; EUSA Pharma; Servier; Adaptive Biotechnologies; Regeneron Pharmaceuticals; BeiGene; European Commission; Sanofi; PharmaMar; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Ministero della Salute; Pfizer; GlaxoSmithKline","keywords":"Multiple myeloma; Risk stratification; Workflow; Genetic testing; DNA sequencing; Statement (logic); MEDLINE","score_opus":0.17092217404667132,"score_gpt":0.3226412180158104,"score_spread":0.1517190439691391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415132558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98990625,0.00027446606,0.0046632765,0.0008374476,0.00011185089,0.0033657143,0.00006506892,0.000040129897,0.00073577143],"genre_scores_gemma":[0.9877605,0.000042138203,0.010891326,0.00014900697,0.00010346479,0.0002364279,0.00029306713,0.000026653273,0.00049742154],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99826276,0.00026248713,0.0005758539,0.00029675412,0.0003049568,0.00029718998],"domain_scores_gemma":[0.9973829,0.0015197636,0.000244825,0.0004635141,0.00030257695,0.000086452674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040612186,0.00018074109,0.00028733915,0.00004980539,0.00014939578,0.000038016464,0.00009165908,0.000052864496,0.000055071956],"category_scores_gemma":[0.0012910154,0.0001258986,0.00011136811,0.00026671684,0.00010106348,0.000060505507,0.00003245809,0.00011063546,0.000007139252],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057846415,0.0023274114,0.16685426,0.0024427758,0.0020220336,0.00022299016,0.0013581099,0.011781956,0.44497573,0.022902751,0.055558015,0.2837693],"study_design_scores_gemma":[0.020242916,0.0049299723,0.45001265,0.0037359293,0.0008020823,0.00001767351,0.0024631014,0.2916213,0.21438468,0.0005916696,0.010572113,0.0006259024],"about_ca_topic_score_codex":0.00016130008,"about_ca_topic_score_gemma":0.00040376963,"teacher_disagreement_score":0.2831584,"about_ca_system_score_codex":0.00013484011,"about_ca_system_score_gemma":0.00020917314,"threshold_uncertainty_score":0.5133996},"labels":[],"label_agreement":null},{"id":"W4415619271","doi":"10.1002/hem3.70232","title":"Choosing words wisely: Language, metaphor, and psychological challenges after pulmonary embolism","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"Clinical Reasoning and Diagnostic Skills","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University","funders":"Wellcome Trust","keywords":"Hypervigilance; Anxiety; Depression (economics); Mental health; Normative; Population; Cohort; Perspective (graphical)","score_opus":0.03149613265867566,"score_gpt":0.35911287236921224,"score_spread":0.32761673971053656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415619271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84080046,0.07571125,0.000055503344,0.006683902,0.0002515507,0.00019954589,0.0000037237896,0.00012589026,0.07616819],"genre_scores_gemma":[0.98689985,0.0040650913,0.0011979572,0.0021250292,0.00019082389,0.000047231708,0.0000071677714,0.000015916776,0.0054509044],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989177,0.000045175177,0.00023095387,0.00040324693,0.00015278261,0.00025014914],"domain_scores_gemma":[0.9979661,0.0014480883,0.00003477815,0.0003343941,0.000039909988,0.00017669245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018454743,0.00016338688,0.00038167194,0.00003926426,0.00004260906,0.00002014937,0.000058693116,0.0001942331,0.0005787225],"category_scores_gemma":[0.0037964254,0.00012287407,0.00010322676,0.00014751672,0.00011015962,0.000032020846,0.00007020709,0.00026664202,0.000049992144],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077882595,0.0014691303,0.03504526,0.00028188239,0.00021124152,0.0016190337,0.0010485334,7.717537e-7,0.0004399109,0.0034841963,0.005819192,0.94980204],"study_design_scores_gemma":[0.002881085,0.00037554442,0.9621759,0.00470212,0.00045355034,0.00033822763,0.0025869103,0.00011317012,0.0003678102,0.0039488766,0.021633666,0.0004231552],"about_ca_topic_score_codex":0.000014829685,"about_ca_topic_score_gemma":0.000009081275,"teacher_disagreement_score":0.94937885,"about_ca_system_score_codex":0.00001675122,"about_ca_system_score_gemma":0.000026480138,"threshold_uncertainty_score":0.63366055},"labels":[],"label_agreement":null},{"id":"W4416734638","doi":"10.1002/hem3.70248","title":"Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Corticosteroid; Hazard ratio; Cumulative dose; Lymphoma; Cytokine release syndrome; Cumulative incidence; Toxicity; Methylprednisolone; Prednisone","score_opus":0.022807049954925034,"score_gpt":0.3072871860336976,"score_spread":0.28448013607877254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416734638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99239045,0.0020791646,0.0016611203,0.00029159457,0.00014902146,0.001400635,0.000051177514,0.000041926236,0.0019348842],"genre_scores_gemma":[0.9787595,0.000744447,0.0005361276,0.00057975645,0.00006007864,0.00008573463,0.00003419461,0.000043677956,0.019156458],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863756,0.000049909555,0.00034242903,0.00033021963,0.00025239165,0.00038749445],"domain_scores_gemma":[0.99892724,0.000320116,0.00006408227,0.0004641994,0.000111330286,0.000113028495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026539413,0.00018185443,0.0004463566,0.00006834121,0.000082735416,0.000030608946,0.00009851616,0.00012624239,0.00059562945],"category_scores_gemma":[0.00006904041,0.00015748637,0.00023995784,0.00018588961,0.000026124735,0.00008601666,0.00007382853,0.000096994,0.0000033705448],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00477338,0.0012367312,0.4539907,0.0012398625,0.0006027192,0.00007349811,0.0009916716,0.0000010813415,0.43312243,0.0004764192,0.001850701,0.10164081],"study_design_scores_gemma":[0.071683735,0.0015449502,0.2364938,0.0011607952,0.00029300965,0.0000343148,0.0019567122,0.0005905639,0.4764916,0.00030397705,0.20890315,0.00054341246],"about_ca_topic_score_codex":0.00015576184,"about_ca_topic_score_gemma":0.00010448846,"teacher_disagreement_score":0.21749689,"about_ca_system_score_codex":0.00008571297,"about_ca_system_score_gemma":0.00015320543,"threshold_uncertainty_score":0.6521725},"labels":[],"label_agreement":null}]}